187

WHO Drug Information Vol. 32, No. 2, 2018

Contents

Regulatory networks

189 Update on the WHO-National Control Laboratory Network for Biologicals

Medicines use

194 The Prescribing Safety Assessment

Safety news

199 Safety warningsAzithromycin ; Tosufloxacin ; Dolutegravir ; Leaking vaccine syringes; Pembrolizumab, atezolizumab ; Filgrastim and other G-CSFs ; Denosumab ; Lamotrigine ; Veterinary ear gel

202 Known risksAnagliptin, linagliptin, teneligliptin ; Selexipag ; Tolvaptan ; Oral benzocaine products

203 Updated recommendationsUlipristal; Antimicrobials ; Dengue vaccine; Daclizumab

205 Other updatesHydroxyethyl starch; Quinolones and fluoro-quinolones

206 Reviews startedOmega-3 fatty acid medicines ; Ulipristal ; Methotrexate; Metamizole; Curcumin-containing supplements

207 FalsifiedmedicinesFalsified hepatitis B vaccines circulating in Uganda

Regulatory news

208 GuidanceEU: Good pharmacogenomic practice; U.S.: Genomic-based tests; UK: Data integrity

209 Pre-market assessmentAustralia: New regulatory pathways ; EU: Two years of PRIME Scheme

210 Medical devicesIMDRF meeting held; Canada: Disinfectants and sterilants reclassified

210 DatabasesJapan: Medicines use in children ; U.S.: Mobile app launched

211 CollaborationTreaty for African Medicines Agency signed ; API inspection programme ; PIC/S updates ; 9th Meeting of World Pharmacopoeias

213 Under discussion214 Approved

Fostamatinib ; Avatrombopag ; Tildrakizumab ; Erenumab ; Lofexidine ; Pegvaliase ; Inotersen

215 New formulationFosnetupitant and palonosetron injection

215 Extensions of indicationsBrentuximab vedotin ; Blinatumomab ; Dabrafenib with trametinib ; Fingolimod ; Tofacitinib

216 BiosimilarsEpoetin alfa ; Trastuzumab ; Pegfilgrastim ; Infliximab ; Adalimumab

217 DiagnosticsMass spectroscopy test for Candida auris

218 Negative opinionsBetrixaban; Abaloparatide; Neratinib

Publications and events

219 Research and development“Disease X” added to WHO research priority list; Vaccines for emerging pathogens

219 Access to medicinesEuropean Parliament resolution ; The role of the pharmacist

220 Pharmaceutical waste managementPharmaceutical pollution and AMR; Medical waste in India increases

221 DiagnosticsFirst WHO essential diagnostics list

222 Disease updatesEbola ; Dengue ; Yellow fever; Cholera ; Hepatitis C; Tuberculosis ; Non-communicable diseases; HTLV-1

225 WHO updates71st World Health Assembly; WHO prequalification updates

228 Upcoming events

Continued

WHO Drug Information

188

WHO Drug Information Vol. 32, No. 2, 2018

Consultation documents

229 The International Pharmacopoeia 229 Atazanavir sulfate233 Atazanavir capsules237 Daclatasvir dihydrochloride245 Daclatasvir tablets 249 Polymorphism255 WHO medicines quality guidelines255 Inquiry regarding production of water for

injections257 Proposal for revision of the WHO Certification

Scheme 275 Other recent WHO consultation documents

ATC/DDDclassification

276 ATC/DDD classification (temporary)279 ATC/DDD classification (final)

International Nonproprietary Names (INN)283 Proposed INN: List 119

Continued

Abbreviations and websitesCHMP Committee for Medicinal Products for Human Use (EMA)EMA European Medicines Agency (www.ema.europa.eu)EU European UnionFDA U.S. Food and Drug Administration (www.fda.gov)Health Canada Federal department responsible for health product regulation in Canada (www.hc-sc.gc.ca)HPRA Health Products Regulatory Authority, Ireland (www.hpra.ie)ICH International Council for Harmonisation of Technical Requirements for Pharmaceuticals for

Human Use (www.ich.org)IGDRP International Generic Drug Regulators Programme (https://www.igdrp.com)MHLW Ministry of Health, Labour and Welfare, JapanMHRA Medicines and Healthcare Products Regulatory Agency, United Kingdom (www.mhra.gov.uk)Medsafe New Zealand Medicines and Medical Devices Safety Authority (www.medsafe.govt.nz)Ph. Int The International Pharmacopoeia (http://apps.who.int/phint/)PIC/S Pharmaceutical Inspection Co-operation SchemePRAC Pharmacovigilance Risk Assessment Committee (EMA)PMDA Pharmaceuticals and Medical Devices Agency, Japan (www.pmda.go.jp/english/index.htm)Ravimiamet Estonian medicines agency, Estonia (www.ravimiamet.ee)Swissmedic Swiss Agency for Therapeutic Products (www.swissmedic.ch)TGA Therapeutic Goods Administration, Australia (www.tga.gov.au)U.S. United States of America WHO World Health Organization (www.who.int)Note:The online version of this issue (freely available at www.who.int/medicines/publications/druginformation) has direct clickable hyperlinks to the documents and websites referenced.

18th International Conference of Drug Regulatory Authorities (ICDRA)

The 18th ICDRA will be hosted by the Health Products Regulatory Authority (HPRA) of Ireland and the World Health Organization

Dublin, Ireland, 3–7 September 2018 http://www.icdra2018.ie/

189

WHO Drug Information Vol. 32, No. 2, 2018

Regulatory networksUpdate on the WHO-National Control Laboratory

Network for Biologicals

WHO prequalifies vaccines for use in Member States. In 2016 WHO initiated the establishment of a Network of national control laboratories (NCLs) that test prequalified vaccines. The Network aims to reduce redundant lot release testing and contribute to more cost-effective testing, thereby improving overall regulatory oversight and reducing regulatory burden. An article about the Network was included in Issue 1 (2017) of this journal.

At the end of 2017 the Network held its First General meeting, which marked the move to the operational stage. This paper provides an update on achievements and next steps.

BackgroundWHO prequalifies vaccines for procurement by UNICEF, the PAHO Revolving Fund and GAVI among others.1 Prequalified vaccines are used to immunize approximately two thirds of the global birth cohort each year.(1) A condition for acceptance of prequalification applications for a vaccine is that the national regulatory authority (NRA) responsible for its oversight has passed a WHO assessment of defined vaccine-related functions,(2) including the evaluation of vaccine batches before they are released onto the market.(3)

Testing of vaccines is complex and expensive. The NCLs responsible for lot release of prequalified vaccines have in-depth experience with regulatory

1 List of prequalified vaccines available at: https://extranet.who.int/gavi/PQ_Web/

testing of the products. Each year they test thousands of lots against approved specifications. Once a lot has been released by the responsible NCL, and provided that it is shipped and stored under appropriate safe conditions, it can be considered to meet its specifications. WHO guidelines therefore recommend that regulatory authorities should use risk-based testing approaches and should consider relying on the outcomes of the lot release done by other regulators.(3)

An example of such reliance is the approach used in Europe, where by law each vaccine lot may be tested only once through the Official Control Authority Batch Release (OCABR) before being marketed in countries of the EU and the European Economic Area2.

2 Council of Europe. Batch Release for Human Biologicals: Vaccines, blood and plasma derivatives. See: https://www.edqm.eu/en/batch-release-human-biologicals-vaccines-blood-and-plasma-derivatives

This update is based on the report of the First General Meeting of the WHO-NNB Network, held in Noida, India, on 31 October –2 November 2017. We thank Mr Mike Ward, Coordinator, WHO Regulatory Systems Strengthening (RSS) Team, for helpful comments on the manuscript.Contact Dr Ute Rosskopf (rosskopfu@who.int) for further information.

Regulatory networks WHO Drug Information Vol. 32, No. 2, 2018

190

Globally however, as the number and capacity of NCLs have increased, the same vaccine batches are often re-tested in multiple recipient countries. This is causing unnecessary delays in supply and sometimes leads to rejection of lots that do actually meet specifications, due to differences in testing methods.

To reduce redundant testing and facilitate access to prequalified vaccines, WHO therefore initiated the establishment of the WHO National Control Laboratory Network for Biologicals in 2016.3 An update on progress is provided below.

Progress update

Advocacy The Network was discussed at the 17th International Conference of Drug Regulatory Authorities (ICDRA), leading to two formal recommendations: • (To WHO:) Establish a global network

of national vaccine control laboratories involved in testing of WHO-prequalified vaccines.

• (To Member States:) For efficient lot release testing of vaccines, consider a risk-based approach or networking (reliance) approach.(4)

Information about the Network was also presented to the WHO Expert Committee on Biological Standardization (ECBS), which sets the global standards that underpin WHO prequalification of vaccines.

Network membershipThe Network’s terms of reference and the participation and confidentiality agreement, were finalized with input from the WHO legal department. The NCLs of the

3 Meeting report available at http://www.who.int/immunization_standards/vaccine_quality/who_rivm2016/en/

following countries have formalized their participation: • Full members (responsible for testing

of one or several prequalified vaccines): Australia, Belgium, Bulgaria, Cuba, Denmark, France, Germany, India, Indonesia, Italy, Senegal, South Africa, Switzerland, Thailand, the Netherlands and the United Kingdom. Agreements with the NCLs of Brazil, Canada, China, the Republic of Korea, Russia and Sweden were pending signature at the time of writing.

• Associate members (importing prequalified vaccines): Bangladesh, Hungary and Sri Lanka. The authority of Bhutan is expected to join in the near future, and the authority of Ghana is considering to become a Network member.

Going forward it is envisaged that regulatory authorities of all WHO Member States will participate in this Network, which offers a pathway for mutual recognition and reliance at the global level.

General Network meetingsOne of the two main routes of Network operations is through regular face-to-face meetings. In 2017 the Network held its First General Meeting in Noida, India. The meeting was hosted by the National Laboratory of Biologicals (NIB) of India and organized by WHO. Representatives from 20 of the 24 NCLs currently testing WHO-prequalified vaccines, manufacturers and other stakeholders participated. The meeting marked the move to the Network’s operational stage. Funding from the Bill & Melinda Gates Foundation for the meeting is gratefully acknowledged.

One day of each general meeting is devoted to technical sessions on sharing best practice. The topics at the First General Meeting were the design and interpretation

Update on the WHO-NCL Network for Biologicals

191

WHO Drug Information Vol. 32, No. 2, 2018 Regulatory networks

of control charts, and handling out-of-specification results.

Preparations are ongoing for the Second General Meeting of the Network, to be held in in Rome, Italy, on 25–27 September 2018. The meeting will be hosted by the Centro Nazionale per il Controllo e la Valutazione dei Farmaci / Istituto Superiore di Sanità (CNCF/ISS).

Information-sharingThe other main route of Network operations is information-sharing through a password-protected platform hosted on a WHO server. An early pilot version was demonstrated at the First General Meeting. Development is ongoing. Once the platform is operational, WHO and NCLs will upload and maintain relevant information on an ongoing basis.

The platform will host the following main types of information:• Laboratory profiles: As agreed in 2016,

the participating NCLs have completed a systematic mapping of their set-up and lot release systems and activities. Twenty such laboratory profiles were sent to WHO ahead of the First General Meeting and were subsequently shared among all contributing NCLs. The laboratory profiles are currently being uploaded to the subsites of the member NCLs on the information-sharing platform (Box 1), for an initial round of validation by test users from NCLs.

• Outcomes of WHO lot testing: WHO tests vaccines as part of the prequalification process and implements a targeted testing plan of prequalified vaccines supplied to UN-funded

Update on the WHO-NCL Network for Biologicals

Box 1: Example of a NCL subsite on the pilot version of the WHO-NNB electronic platform

WHO Online Workspace

Belgium

Scientific Institute of Public Health

Contact/Organogram

Quality of Vaccines and Blood Products

Contracted by WHO for technical testing of vaccinesContracted by WHO for sharing of lot release informationLot release for Belgian and European market Quality Assurance Standard: ISO/IEC 17025 and ISO/IEC 9001Related national regulatory authority: Federal Agency for Medicines and Health Products

www.sciensano.be

+32 2 642 51 11

Prequalified Vaccines

Other Vaccines

Laboratory Activities

Vaccine Test Methods

External Collaboration

3R Program

Lot Release Procedure

Back to main page

Regulatory networks WHO Drug Information Vol. 32, No. 2, 2018

192

programmes. The testing is performed by WHO-contracted laboratories4 that are audited every 3-4 years. Currently the outcomes are reported to procurers—notably UNICEF—and manufacturers. The electronic platform will enable WHO to share this information with the Network members.

• Regulatory lot release outcomes: Over the past few years WHO has established 19 agreements with manufacturers, allowing a total of 10 NCLs to share their lot release data for prequalified vaccines (whether or not supplied to UN-funded programmes) with WHO. This data-sharing is part of the contract between WHO and the respective NCLs (Box 2). WHO is now approaching manufacturers to allow information exchange on lot release outcomes among Network members. The extent of what will be shared will depend on each individual agreement.

Some regulatory lot release information is already publicly available. For example, Swissmedic provides monthly updates on lots 4 See www.who.int/immunization_standards/vaccine_

quality/contracted_labs_vaccines/en/

released either based on its own review, or in recognition of the OCABR process.5 Sharing of the responsible NCLs’ lot release outcomes through the Network will support reliance initiatives in countries importing prequalified vaccines in a more systematic way.

BenefitsThe WHO Network offers some unique benefits in the global context.

Common standardsWHO is well placed to convene a global Network of partners aiming at reliance in vaccine lot release. The NRAs and NCLs found capable to oversee the quality of prequalified vaccines have all passed a comprehensive, stringent WHO assessment. In fact, the WHO indicator tool used for benchmarking regulatory systems is being refined and now also incorporates a classification system that characterizes

5 https://www.swissmedic.ch/swissmedic/en/home/services/laboratories--omcl-/approved-batches.html. A specific batch number can be found through a site-specific search in the browser, e.g.: “AHBVC630A site:swissmedic.ch”

Update on the WHO-NCL Network for Biologicals

Box 2: National lot release data reported to WHO (2016)In 2016 ten NCLs responsible for releasing prequalified vaccines shared lot release data for a total of 2543 batches of prequalified vaccines with WHO, based on agreements with manufacturers. For comparison, 115 lots were tested on behalf of WHO.

Num

ber o

f lot

s

300

250

200

150

100

50

bOPV

1&3

MM

RIP

VH

ib, m

onov

alen

tBC

GPn

eum

ococ

cal

Hep

BD

TaPH

epB-

Hib

-IPV

Men

AC

YW-1

35(c

nj)

Rab

ies

Influ

enza

Teta

nus

DTw

PHep

B-H

ibC

hole

raH

PVYe

llow

feve

rD

TaP

mO

PV2

Hep

A TdJE

(liv

e &

inac

t.) DT

tOPV

Men

AC

193

WHO Drug Information Vol. 32, No. 2, 2018 Regulatory networks

mature regulatory authorities on whose findings WHO and others may choose to rely.6

Common methods and best practiceStandardized vaccine testing methods would be a great help for manufacturers and regulators. WHO has been collaborating with Network partners to develop and implement such methods. A recent example is an assay for the Hib-component in liquid vaccine combinations,(5) which has been widely implemented. A proficiency study is under way, and the pharmacopoeial authorities of both China and India intend to incorporate the method in the next editions of their pharmacopoeias. The Network will provide a platform to encourage the adoption of harmonized methods and best practices.

In addition, some of the partners in the Network have valuable specialized expertise to offer. For example, a pilot project is under way to collaborate with Swissmedic in the framework of the authority’s proteomics project that would enable “profiling” of vaccines to monitor the products circulating on the market.

Facilitating relianceWhile the online information-sharing platform is still under construction, the Network has already stimulated information exchange on an as-needed basis. The NCL of Bulgaria has started to share its lot release data with WHO based on a collaboration agreement.

There is considerable scope for reduction of redundant lot testing both in countries that are full and associate Network members. However, decisions are needed at national level to change the current lot

6 See http://www.who.int/medicines/regulation/benchmarking_tool/en/.

testing policies. The example of Senegal shows that this is achievable: As a result of its Network participation, the NCL is no longer re-testing batches of imported WHO-prequalified vaccines.

ConclusionVaccines and other biological products are essential for public health. In the era of globalization, “big data” and increased challenges faced by regulators, an in-depth understanding of processes is becoming ever more crucial to make good use of data on vaccine quality. By providing an independent global forum for information exchange, the WHO-NNB Network meets an important need.

References

1 Wood D, Dellepiane N. Twenty-five years of the WHO vaccines prequalification programme (1987–2012): Lessons learned and future perspectives. Vaccine 2015;33(1):52–61.doi:10.1016/j.vaccine.2013.11.066.

2 WHO. Procedure for assessing the acceptability, in principle, of vaccines for purchase by United Nations Agencies. WHO Technical Report Series 978, Annex 6. Geneva: World Health Organization, 2010

3 WHO. Guidelines for independent lot release of vaccines by regulatory authorities. Annex 2. In: Technical Report Series No. 978. Geneva: World Health Organization; 2010.

4 17th International Conference of Drug Regulatory Authorities (ICDRA). Cape Town, South Africa, 29 November–2 December 2016. Recommendations. Workshop G: Vaccine regulation. Available at:

5 Rosskopf U, Daas A, Terao E, von Hunolstein C. Collaborative study on saccharide quantification of the Haemophilus influenzae type b component in liquid vaccine presentations. Pharmeur Bio Sci Notes 2017(4):44-68. å

Update on the WHO-NCL Network for Biologicals

194

WHO Drug Information Vol. 32, No. 2, 2018

Medicines useThe Prescribing Safety Assessment

Prescribing is a complex task requiring knowledge of medicines and the diseases they are used to treat, careful judgement of risks and benefits of treatment, and attention to detail. Prescribing can improve health, but also has potential hazards. Studies have found that prescribing is the most challenging area for new graduates, and that errors are common both among trainees and professionals. The Prescribing Safety Assessment (PSA) is an online tool that allows health care professionals to develop and demonstrate their competencies in relation to the safe and effective use of medicines.

The importance of prescribingPrescribing medicines is the primary tool used by all healthcare systems to treat disease, alleviate symptoms and prevent future illness. Although the majority of prescriptions are appropriate, many studies from around the world have drawn attention to the rates of prescribing errors and avoidable adverse drug reactions. In the United Kingdom (UK), errors are found in around 10% of hospital prescriptions and 5% of general practice prescriptions.(1-4) These errors matter because they not only harm patients but present unnecessary costs attributable to failed care, prolonged hospital stays and increasing litigation.

Prescribing is a high-stakes activity for all involved. For patients, medicines are a major factor affecting their health. For doctors and hospitals, prescribing represents a degree of clinical risk and significant cost. Prescribers have to select the correct medicine, dose, and route and frequency

of administration, sometimes in the face of diagnostic uncertainty, while taking into account predicted individual variability in medicine handling and response as a result of comorbidity, genetics, and interacting medicines. Newly graduated doctors write a large proportion of hospital prescriptions (medication orders), and it is therefore unsurprising that widespread evidence exists to show that prescribing by this group is frequently sub-optimum. But senior doctors also make errors, and concerns regarding prescribing skills among all prescribers have been expressed internationally.(5)

We should not be surprised that errors are made since prescribers work under very high-pressured circumstances, full of distractions. They have a heavy burden of administration and require continuous multi-tasking which results in them being more error-prone. The number, age, and vulnerability of hospital patients have

This article was contributed by a team from the Prescribing Safety Assessment, which is delivered jointly by the British Pharmacological Society and MSC Assessment. We thank Professor Simon Maxwell and Dr David James for drafting the manuscript.

195

WHO Drug Information Vol. 32, No. 2, 2018 Medicines use

Figure 1: The structure of the Prescribing Safety Assessment

Clinical settings being assessed are internal medicine, elderly care medicine, paediatrics, psychiatry, obstetrics and gynaecology, and general (family) practice. Further details are available on the Prescribing Safety Assessment website, https://prescribingsafetyassessment.ac.uk/

also progressively increased, as has the complexity of the treatment regimens for common disorders.

In view of this situation it might be expected that new graduates would be well prepared to begin prescribing in these demanding work environments. However, a clear theme from many studies is that students and new graduates often do not feel adequately prepared to carry out their role in prescribing, a concern echoed by their supervisors.

Development of the PSA

Aim and scopeIn response to this situation the British Pharmacological Society (BPS) has collaborated with the UK Medical Schools Council to develop the Prescribing Safety Assessment (PSA),(6) an online training and assessment package to promote better prescribing skills in healthcare. The PSA is a valid and reliable assessment that allows final year medical students to demonstrate that they have the necessary knowledge,

skills and judgement (in relation to the safe and effective use of medicines) to begin their work as independent junior prescribers in UK hospitals. The PSA aims to bridge the gap between traditional pharmacology education and the practical application of that knowledge to patient care in the clinical environment. It presents learners with realistic clinical cases where they are scored on their performance and receive targeted feedback to improve their future performance.

StructureThe PSA is based on an assessment blueprint of eight sections containing item styles that cover different aspects of the clinical activity undertaken by prescribers (Figure 1). The assessment is “open book” but time-limited, with candidates having access to the British National Formulary throughout its duration. The online nature of the assessment offers the advantage of automated marking of candidate prescriptions and provision of feedback.

Prescribing safety assessment (PSA)

Section 1 Prescribing

Section 2 Prescription

review

Section 3 Planning

management

Section 4 Providing

informationSection 5 Calculation

skills

Section 6 Adverse drug

reactions

Section 7 Drug

monitoring

Section 8 Data

interpretation

8 sections – 60 items Total=120 mins

(200 marks)

Medicines use WHO Drug Information Vol. 32, No. 2, 2018

196

Question itemsThe PSA question items have been developed over several years by a team of around 100 trained authors (including clinical pharmacologists, other specialty and trainee doctors, general practitioners and pharmacists) who are mainly based in UK medical schools or National Health Service (NHS) hospitals. Their question items are submitted annually and undergo a strict five-stage quality assurance process overseen by the PSA Assessment Board. Items that survive each stage of review, including a national peer-review meeting, are entered into the PSA item bank, which now includes around 3 000 items. The pass marks for each paper are determined by a Standard-Setting Group comprising representatives from UK medical schools who are selected for their knowledge of the appropriate minimum standard expected of Foundation Year 1 doctors.

Delivery and feedbackThe PSA is delivered online from a cloud-based server located in Mumbai, India. All candidates (final year medical students) are registered on the PSA online system and sent an e-mail requesting them to activate their accounts. After activation of their accounts they have access to general information about the PSA, information videos and 1-hour, 30-item, practice papers with question-specific feedback. Candidates are encouraged to familiarize themselves with the different question types and the assessment environment and to practise finding information in the online version of the British National Formulary.

The detailed feedback associated with each question item enables the student to identify gaps in knowledge and areas for improvement. This feedback is therefore an essential tool in helping students improve

their knowledge and practice in prescribing. Formative feedback means students can take control of their own learning and allows every candidate to assess his or her own work for personal development.

The PSA can be offered formatively or summatively, and has been shown to be suitable as a standardized national prescribing assessment delivered online.(7) It is also delivered to professionals as Continuing Medical Education.

Growth in the PSA

In the UKThe PSA has been a huge success and has now been supported by the UK’s General Medical Council and the Foundation Programme Board to the extent that all new entrants are expected to have passed it in order to continue training as a doctor in the UK, whether they come from UK medical schools or from overseas. Over 50 000 students from the UK and overseas have participated in the training and assessment, and 10 000 medical students sit the PSA each year.

A pilot study has confirmed the feasibility and acceptability of the PSA for pharmacist prescribers and benchmarked their performance against that of final year medical students.(8) For several years the PSA has been delivered to undergraduate and preregistration pharmacists from around 20 pharmacy schools in the UK. Feedback from Health Education England (HEE), students and faculty has been very positive and the number of pharmacy candidates that have taken the PSA has grown to almost 2 000.

InternationallyThe BPS has redeveloped the PSA platform and content to internationalize its appeal and

Prescribing safety assessment (PSA)

197

WHO Drug Information Vol. 32, No. 2, 2018 Medicines use

relevance. This new version of the PSA, the Prescribing Skills Assessment, is delivered to medical schools in Canada, Australia, New Zealand, Malta, and Ireland and has been piloted in India, with further pilots planned for Europe, China and the Middle East.

The BPS and the Royal College of Physicians and Surgeons of Canada have been undertaking an ambitious collaboration to support safer prescribing by doctors in Canada. Representing a significant commitment by both organizations, the partnership has brought experts together to raise the profile of prescribing competency and to promote its importance through the joint development of education and assessment resources in this field. This Prescribing Safely Canada (PSC) initiative is intended to help physicians assess their prescribing skills, identify gaps and help correct unsafe practices and cognitive bias through a feedback loop, while providing analytics of aggregate data that can inform the Royal College of systemic gaps. This initiative is underpinned by the strategic direction of the Royal College, which is to develop a comprehensive agenda for safe prescribing of medications to support specialists that lead and develop high quality, safer care.

There is a mutual benefit for both the Royal College and the BPS to collaborate around medication safety. For the BPS, the Royal College is an attractive partner that is able to utilise the assessment and learning resources formatively as a means of professional development for more experienced clinical staff. The BPS is an equally attractive partner for the Royal College, with a robust technical platform allowing for international collaboration, educationally and psychometrically sound

assessment tools, and global expertise on the dissemination of pharmacological knowledge.

The futureWith the recognition it now enjoys, the PSA represents high standards of quality in medical education and training. The assessment, along with its associated training material, is greatly appreciated by students who recognize the importance of prescribing skills to their future careers. Moreover, the PSA is making a critical contribution to improved patient safety in UK healthcare.

Our future aim is to harness the experience that we have gained from a project that was originally conceived to address a concern in UK healthcare, and to use that knowledge to offer a tool that might enhance the quality of medicines usage globally. We are delighted to be counted as a stakeholder supporting WHO’s Medication Without Harm theme for the third Global Patient Safety Challenge. We intend to develop, and make available, educational case-based materials that will help to embed the prescribing principles outlined in the WHO Guide to Good Prescribing,(9) largely focusing around the Essential Medicines List. To make this a reality, we would like to bring interested stakeholders together as part of an International Advisory Board.

References1 Elliott R, Camacho E, Campbell F, Martyn

St James M, Kaltenthaler E, Wong R et al. Prevalence and economic burden of medication errors in the NHS in England. Rapid evidence synthesis and economic analysis of the prevalence and burden of medication error in the UK. Policy Research Unit in Economic Evaluation of Health and Care Interventions. Universities of Sheffield and York. 2018.

Prescribing safety assessment (PSA)

Medicines use WHO Drug Information Vol. 32, No. 2, 2018

198

2 Dornan T, Ashcroft D, Heathfield H, Lewis P, Miles J, Taylor D et al. An in depth investigation into causes of prescribing errors by foundation trainees in relation to their medical education: EQUIP study. Final report for the GMC, December 2009.

3 Ryan C, Ross S, Davey P, Duncan EM, Francis J, Fielding S et al. Prevalence and causes of prescribing errors: the PRescribing Outcomes for Trainee Doctors Engaged in Clinical Training (PROTECT) study. PLoS ONE 2014; 9(1): e79802.

4 Avery AJ, Ghaleb M, Barber N, Franklin B, Armstrong S, Crowe S et al. The prevalence and nature of prescribing and monitoring errors in English general practice: a retrospective case note review. Br J Gen Pract. 2013 Aug; 63(613): e543–e553.

5 Ross S, Bond C, Rothnie H, Thomas S, Macleod MJ et al. What is the scale of prescribing errors committed by junior doctors? A systematic review. Br. J. Clin, Pharmacol. 2009 Jun; 67(6): 629–640. Published online 16 December 2008.

6 Maxwell SRJ, Cameron IT, Webb DJ. Prescribing safety: ensuring that new graduates are prepared. Lancet. 2015;385:579-581. doi: 10.1016/S0140-6736(14)62339-4.

7 Maxwell SRJ, Coleman JJ, Bollington L et al. Prescribing Safety Assessment 2016: Delivery of a national prescribing assessment to 7343 UK final-year medical students. Br J Clin Pharmacol. 2017;83:2249–2258.

8 Reid F, Power A, Stewart D et al. Piloting the United Kingdom ‘Prescribing Safety Assessment’ with pharmacist prescribers in Scotland. Res Social Adm Pharm. 2018;14:62–68.

9 de Vries TPGM, Henning RH, Hogerzeil HV, Fresle DA. Guide to Good Prescribing. A Practical Manual. Geneva: World Health Organization Action Programme on Essential Drugs; 1994. å

Prescribing safety assessment (PSA)

WHO Drug Information Vol. 32, No. 2, 2018

199

Safety news

Safety warnings

Azithromycin: Long term risks seen in clinical studyI r e l a n d , E s t o n i a – The marketing authorization holder, in agreement with EMA and national regulatory authorities, has informed health professionals about an increased rate of relapses of haematological malignancies and mortality in haematopoietic stem cell transplantation (HSCT) patients treated experimentally with azithromycin. A clinical trial investigating the use of azithromycin to prevent bronchiolitis obliterans syndrome following HSCT was terminated early after an increased risk of relapses was seen compared with placebo. The researchers conclude that long term azithromycin exposure following HSCT may include risks which exceed the anticipated benefits.

► HPRA Safety notice, 2 May 2018.Ravimiamet Safety announcement, 2 May 2018 (in Estonian).

Tosufloxacin:Nephrogenic diabetes insipidusJ a p a n – The PMDA has informed health professionals that cases of nephrogenic diabetes insipidus have been observed with the fluoroquinolone antimicrobial tosufloxacin in Japan. A warning about this adverse effect will be added to the product information.

► PMDA Summary of investigation results and and MHLW Revision of precautions, 19 April 2018.

Dolutegravir: Birth defectsA study involving babies born to 11 558 HIV-positive women in Botswana— the Tsepamo Study— showed that 0.9% of babies (4 of 426) whose mothers became pregnant while taking dolutegravir had a neural tube defect, compared with 0.1% of babies (14 of 11 173) whose mothers took other HIV medicines.

E u r o p e a n U n i o n , A u s t r a l i a , U n i t e d S t a t e s o f A m e r i c a – Regulatory authorities around the world have issued precautionary advice in response to the study findings. The EMA and the TGA have recommended that dolutegravir should not be prescribed to women seeking to become pregnant. Women who can become pregnant should use effective contraception while taking dolutegravir medicines.(1,2) The FDA has recommended that health professionals should exclude pregnancy before starting a dolutegravir-containing regimen in women of childbearing age, and should only prescribe the medicine to women of childbearing age if they decide that its benefits outweigh the risks. In that case, they should reinforce the need for effective contraception.(3) The regulatory authorities will continue to investigate the issue.

► (1) EMA Press release, 18 May 2018.(2) TGA Safety advisory, 31 May 2018. (3) FDA Drug safety communication, 18 May 2018.

G e n e v a – WHO has convened an expert guideline development group meeting and will release updated guidance on the role

Safety news WHO Drug Information Vol. 32, No. 2, 2018

200

of dolutegravir in first‐ and second-line HIV treatment in the coming months. In the interim, WHO advises countries and ministries to follow the 2016 WHO ARV Guidelines, and to consider the following: • Pregnant women who are taking

dolutegravir should not stop their ARV therapy and should speak with their health provider for additional guidance.

• Antiretroviral (ARV) therapy for women of childbearing age, including pregnant women, should be based on drugs for which adequate efficacy and safety data are available; an efavirenz–based regimen is a safe and effective first‐line regimen.

• If other first‐line ARVs cannot be used in women of childbearing age, dolutegravir may be considered in cases where consistent contraception can be assured.

• Programmes should continue strengthening pharmacovigilance including monitoring of birth outcomes.

The WHO Guidelines released in 2016 cautioned that there were insufficient data for using dolutegravir during pregnancy or breastfeeding and recommended efavirenz, in combination with tenofovir and lamivudine or emtricitabine, as the preferred option in pregnancy.

► WHO. Statement on DTG – Geneva 18 May 2018.

Leaking vaccine syringes:Potential underdosingS w i t z e r l a n d , C a n a d a , M a l t a – GlaxoSmithKline (GSK) has provided information on syringe leaks, i.e. escape of fluid between the syringe and needle, that may occur with various vaccines during reconstitution or administration, resulting in a potential risk of underdosing. There are no sterility concerns, given that no leakage problems have been occurring before use.

If a leakage occurs during the reconstitution of lyophilized vaccines, the syringe should be discarded. If leakage is observed during the administration of a vaccine, the doctor must decide whether the individual concerned should be revaccinated. The potential benefit of increasing vaccination protection should be weighed against the risk of adverse events due to administration of a second full dose.

Details of the vaccines affected and further information are found in the regulatory communications referenced below.

► Swissmedic Healthcare professional communication, 13 April 2018 and company information letterHealth Canada Advisory, 1 May 2018.Malta Medicines Authority. Archived Direct Healthcare Professional Communication, 9 March 2018.

Pembrolizumab, atezolizumab: • Use restricted in EU• Reports of sclerosing cholangitis

with pembrolizumab in JapanE u r o p e a n U n i o n – The EMA has restricted the use of pembrolizumab (Keytruda®) and atezolizumab (Tecentriq®) in first-line treatments for urothelial cancer. For this indication the medicines should now only be used in patients with high levels of PD-L1 protein. Early data from two clinical trials have shown reduced survival in patients with low PD-L1 levels. There is no change in the recommended use of the two medicines for second-line treatment, or for treatment of other cancers.(1)

J a p a n – The PMDA has informed health professionals about cases of sclerosing cholangitis reported in patients treated with pembrolizumab in Japan. Sclerosing cholangitis is characterized by swelling due to inflammation, scarring and destruction of

201

WHO Drug Information Vol. 32, No. 2, 2018 Safety news

the bile ducts inside and outside of the liver. The product information will be updated to warn about this risk.

► (1) EMA Press release, 1 June 2018. ► (2) PMDA Summary of investigation results and MHLW Revisions of precautions, 19 April 2018.

Filgrastim and other G-CSFs: AortitisI r e l a n d – The marketing authorization holders, in agreement with HPRA, have informed healthcare professionals that there have been rare reports of aortitis in patients and healthy donors receiving products containing the granulocyte colony-stimulating factors (G-CSFs) filgrastim, lenograstim, lipegfilgrastim or pegfilgrastim. People receiving a G-CSF product should be instructed to seek medical attention if they develop fever, abdominal pain, malaise or back pain.(1)

The EMA’s PRAC had evaluated this safety signal in February 2018 and had recommended that the product information of the G-CSF products on the European market should be updated to reflect the risk of aortitis.(2)

► (1) HPRA Safety notice, 28 May 2018.(2) EMA. PRAC recommendations on signals. Adopted at the 5-8 February 2018 PRAC meeting. 22 February 2018.

Denosumab (indicated in fractures, bone neoplasm metastasis): new malignanciesI r e l a n d , E s t o n i a – The marketing authorization holder, in agreement with EMA and the national regulatory agencies, has informed health professionals of new study findings concerning denosumab (Xgeva®). New primary

malignancies were reported more frequently in clinical studies in patients with advanced malignancies treated with denosumab, compared to zoledronic acid (cumulative incidence at one year: 1.1% versus 0.6%). No treatment-related pattern in individual cancers or cancer groupings was apparent. The product information will be updated to include this information.

► HPRA Safety notice, 17 May 2018.Ravimiamet (Estonian medicines agency). Safety announcement, 9 May 2018 (in Estonian).

Lamotrigine: Rare but serious immune reactionU n i t e d S t a t e s o f A m e r i c a – The FDA has warned that lamotrigine (Lamictal®) can cause haemo phagocytic lymphohistio-cytosis (HLH), a rare but very serious immune system reaction. HLH causes an uncontrolled response by the immune system and typically presents as a persistent fever. It can lead to severe problems with blood cells and organs such as the liver, kidneys, and lungs and can be fatal, especially if it is not diagnosed and treated quickly.

Lamotrigine is used to treat seizures and bipolar disorder. A new warning about this risk has been added to the product information for lamotrigine-containing medicines.

► FDA Drug safety communication, 25 April 2018.

Veterinary ear gel: Eye injuries in pets and ownersE u r o p e a n U n i o n – The EMA has warned that an ear gel for dogs containing terbinafine, florfenicol and betamethasone acetate (Osurnia®) has been causing eye injuries to pets or their owners after

Safety news WHO Drug Information Vol. 32, No. 2, 2018

202

accidental eye exposure. Care should be taken to prevent the ear gel from getting into the eyes of people or dogs. If accidental exposure occurs, the eyes should be thoroughly rinsed with water, and medical care sought. Veterinary healthcare professionals in the EU will be informed in writing of this issue.

► EMA Press release, 20 April 2018.

Known risks

Anagliptin, linagliptin, teneligliptin: Acute pancreatitisJ a p a n – The MHLW has recommended updates to the product information for the antidiabetic medicines anagliptin, linagliptin and teneligliptin following cases of acute pancreatitis reported in patients treated with these medicines in Japan.

A warning about post-marketing reports of acute and potentially fatal pancreatitis is also found in the EMA- and FDA-approved product information for products containing linagliptin and other dipeptidyl peptidase-4 (DPP-4) inhibitors.

► PMDA Summary of investigation results and MHLW Revisions of precautions, 20 March 2018.

Selexipag: Avoid use with CYP2C8 inhibitorsJ a p a n – Based on the results of a drug-drug interaction study involving selexipag (Uptravi®) and gemfibrozil, a strong CYP2C8 inhibitor, the PMDA has recommended that selexipag should be contraindicated in Japan in patients receiving medicines containing clopidogrel, which is also a CYP2C8 inhibitor. Selexipag is used to treat pulmonary hypertension.

Gemfibrozil is not currently approved in Japan.

In the EU and the U.S. selexipag is contraindicated with gemfibrozil but can be used with moderate CYP2C8 inhibitors (such as clopidogrel, deferasirox or teriflunomide), although dose adjustments should be considered.

► PMDA Summary of investigation results and MHLW Revisions of precautions, 20 March 2018.

Tolvaptan: Acute liver failureJ a p a n – The PMDA has informed health professionals that cases of acute liver failure, including several fatal cases, have been reported in patients treated with tolvaptan in Japan. This medicine is used to treat hyponatraemia and – at higher doses – to slow the progression of autosomal dominant polycystic kidney disease, a rare inherited condition. The currently approved product information recommends close monitoring of liver function. The MHLW has requested that a warning about the risk of acute liver failure should be added.

Warnings about serious and potentially life-threatening liver injury are also included in the EMA- and FDA-approved product information.

► PMDA Summary of investigation results and MHLW Revisions of precautions, 20 March 2018.

Oral benzocaine products:Rare but serious blood disorderU n i t e d S t a t e s o f A m e r i c a – In an update to two previous communications the FDA has warned about the risk of methaemoglobinaemia associated with oral benzocaine-containing products. This is

203

WHO Drug Information Vol. 32, No. 2, 2018 Safety news

a serious and potentially life-threatening blood disorder in which the amount of oxygen carried through the blood is greatly reduced.

The FDA has urged manufacturers to stop marketing over-the-counter oral benzocaine products for teething and mouth pain in children under two, and to include certain warnings in the product information of oral benzocaine products for adults and children aged two years and above. The FDA will take action if companies do not comply.

► FDA Drug safety communication, 23 May 2018.

Updated recommendations

UlipristalE u r o p e a n U n i o n – The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed its review of ulipristal acetate (Esmya®), leading to new measures to minimize the risk of rare but serious liver injury. Ulipristal is now contraindicated in women with known liver problems. New treatment courses may be started only if patients are tested and have liver enzyme levels at most 2 times the upper limit of normal. Tests should be repeated once a month during the first two treatment courses and two to four weeks after stopping treatment. If liver enzyme levels rise above 3 times the upper limit of normal, treatment should be stopped and the patient closely monitored. Ulipristal should be used for more than one treatment course only in women who are not eligible for surgery. A card will be included with the medicine to inform women about the need for liver monitoring and for seeking medical help in case of suspected liver problems.

Ulipristal is used to treat moderate to severe symptoms of uterine fibroids. The review was triggered in November 2017 by reports of serious liver injury. In February 2018 the PRAC had issued interim recommendations against starting ulipristal in new patients.

► EMA Press release, 1 June 2018.

Antimicrobials Japan aligns product information J a p a n – The PMDA has recommended that the product information for 164 antimicrobial medicines approved in Japan be updated in line with the national Guidance for Appropriate Use of Antimicrobials. This guidance focuses on the appropriate treatment of patients with acute respiratory tract infections and those with acute diarrhoea. Based on data from Japan and other countries, these two patient groups are believed to be subjected to particularly frequent and unnecessary antimicrobial treatment. The affected medicines are indicated for the treatment of pharyngitis/laryngitis, tonsillitis, acute bronchitis, infectious enteritis or sinusitis.(1)

In other moves to align the product information in Japan with that approved elsewhere, the Agency has recommended that adrenaline can be used for emergency treatment of anaphylaxis in patients receiving alpha blockers, despite the risk of decreased blood pressure induced by adrenaline reversal,(2) and propofol can be given to pregnant women, or women who may be pregnant, provided that the potential

Safety news WHO Drug Information Vol. 32, No. 2, 2018

204

benefits outweigh the risk of neonatal respiratory depression.(3)

► (1) PMDA Report on investigation results, 7 March 2018, and MHLW Revisions of precautions, 27 March 2018.(2) PMDA Report on investigation results, 2 March 2018.(3) PMDA Report on investigation results, 1 March 2018, and MHLW Revision of precautions, 27 March 2018.

Dengue vaccineG e n e v a – WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) has published its revised recommendations on the use of the dengue vaccine CYD-TDV (Dengvaxia®). Results from additional safety studies conducted by the manufacturer had shown that the vaccine is associated with an increased risk of severe dengue in seronegative individuals, starting about 30 months after the first dose.

The SAGE weighed two strategies for achieving high population protection from dengue: consideration of population seroprevalence criteria, and pre-vaccination screening. Acknowledging that both are programmatically difficult, the SAGE expressed its preference for screening and vaccinating only dengue-seropositive persons.

Screening can be done using the dengue IgG ELISA, interpreted in a local context depending on the prevalence of other flaviviruses and past use of flavivirus vaccines (such as Japanese encephalitis and yellow fever vaccines), or—in high transmission settings—rapid tests, although these have a lower sensitivity and specificity than serological testing. Decisions about implementing pre-vaccination screening will require careful assessment of the sensitivity and specificity of available tests, local

priorities, dengue epidemiology, country-specific dengue hospitalization rates, and affordability of both CYD-TDV and screening tests in each country.

Going forward there is a need to develop a highly sensitive and specific rapid diagnostic test, and to simplify immunization schedules.

► WHO. Revised SAGE recommendation on use of dengue vaccine. 19 April 2018.

Daclizumab: Risk outweigh benefitsE u r o p e a n U n i o n – The EMA has confirmed that the multiple sclerosis medicine daclizumab beta (Zinbryta®) poses a risk of serious and potentially fatal immune reactions affecting the brain, liver and other organs. The marketing authorization in the EU was voluntarily withdrawn by the company in March 2018. Healthcare professionals should continue monitoring patients who have been treated with daclizumab in line with recommendations issued in March 2018.(1)

A u s t r a l i a – The TGA has informed health professionals that the marketing authorization holder is coordinating a worldwide withdrawal of daclizumab. To give time for patients to transition off the medicine it will be supplied in Australia until 31 May 2018. (1)

► (1) EMA Press release, 18 March 2018.(2) TGA Alert, 15 March 2018.

205

WHO Drug Information Vol. 32, No. 2, 2018 Safety news

Other updates

Hydroxyethyl starch:Suspension maintained E u r o p e a n U n i o n – Following the recommendation by the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) in January 2018 to suspend the marketing authorizations for hydroxyethyl starch solutions for infusion across the EU, the European Commission had requested the Committee to further consider any possible unmet medical need that could result from the suspension, as well as the feasibility and likely effectiveness of additional risk minimization measures.(1) At its meeting held in May 2018 the PRAC maintained its recommendation. In line with regulatory procedure this recommendation was then sent to the Coordination Group for Mutual Recognition and Decentralized Procedures – Human (CMDh) of the European Heads of Medicines Agencies (HMA) network for its consideration.(2)

► (1) EMA News, 13 April 2018.(2) EMA News, 18 May 2018.

Quinolonesandfluoroquinolones:Public hearingE u r o p e a n U n i o n – Quinolone and fluoro-quinolone antibiotics antibiotics are under review by the PRAC due to the risk of persistent serious side effects mainly affecting muscles, joints and the nervous system. In response to significant public interest, a public hearing was scheduled for 13 June 2018.(1) The EMA received 115 applications to attend, including 55 requests to speak and 60 to participate as observers. Of the former, 23 speakers from 11 EU Member States were selected to share their views directly with the PRAC; the other 22 will provide written contributions that will be considered by the scientific committee and published on the EMA website.(2)

This is the second public hearing during an EMA safety review of a medicine. The first one was held in September 2017 to inform the review of valproate, leading to additional measures to avoid its use in pregnancy.

► (1) EMA Press release, 9 April 2018.(2) EMA Press release, 7 June 2018.

Safety news WHO Drug Information Vol. 32, No. 2, 2018

206

Reviews started

Medicine Use Concerns ReferenceOmega-3 fatty acid medicines

Prevention of recurring heart disease or stroke

An analysis of 10 studies in around 78 000 patients has found that adding omega 3-fatty acid medicines to standard treatment did not significantly reduce heart attacks, stroke or other heart and circulatory problems. These findings were similar to those from 2012 studies.

► EMA. Start of Article 31 referral. 22 March 2018.

Ulipristal acetate (Fibristal®)

Treatment of uterine fibroids

Canadian and European reports of serious adverse events affecting the liver. The EMA has recommended new measures to minimize the risk (see page 203).

► Health Canada Advisory, 15 March 2018.

Methotrexate Treatment of inflammatory diseases, such as arthritis and psoriasis; treatment of certain cancers

Dosing errors, causing continued reports of serious adverse events, including fatalities. Methotrexate is used in higher doses and frequency to treat cancer than to treat inflammatory diseases.

► EMA Press release, 13 April 2018.

Metamizole(also known as dipyrone)

Treatment of severe pain and fever that cannot be controlled with other treatments

Substantial differences between EU member states in recommended maximum daily doses and contraindications during pregnancy or in women who are breastfeeding.

► EMA begins review of medicines containing metamizole. 1 June 2018.

Curcumin-containing supplements(The warning does not apply to turmeric used in food)

Dietary supple-ments for joint, digestive and cardio vascular support

Potential interaction with warfarin that could lead to an increased risk of bleeding. A marked INR increase was reported in a patient on warfarin in New Zealand after starting curcumin supplements.

► Medsafe Monitoring communication, 17 April 2018.

207

WHO Drug Information Vol. 32, No. 2, 2018 Safety news

Falsifiedmedicines

å

FalsifiedhepatitisBvaccinescirculatinginUganda

The WHO Medical Product Alert No. 3/2018 relates to falsified versions of multi-dose (10ml) hepatitis B vaccines (rDNA) that have been identified in Uganda.

WHO was informed by the Uganda National Drug Authority (NDA) that this falsified vaccine was available at patient level in a number of locations in the Central, South-Western and Eastern regions of Uganda. Investigations are ongoing, and samples are being collected for full laboratory analysis. The source of the falsified product has not yet been identified.

The genuine product is manufactured by the Serum Institute of India Pvt Ltd and is WHO-prequalified. Falsified versions of 10 different batch numbers have so far been discovered (see below). Based on label inconsistencies the Serum Institute of India has confirmed that the products with these details are falsified.

No adverse reactions have been reported to WHO at this stage.

Product name: Multi dose (10ml) Hepatitis B Vaccines (rDNA) False manufacturer name stated on the label: Serum Institute of India

Batch number Manufacturing date Expiry Date035L6010 MAY 2016 APR. 2019035L5010 (None indicated) SEP. 2019035L006 MAR. 2016 FEB. 2020035L3004 MAY 2015 SEPT. 2018035L5012 (None indicated) OCT. 2018035L7037 10/2017 09/2020035L6005 (None indicated) 09/2019035L5013 11/2017 01/2020035L5017 (None indicated) Oct 2019035L5007 (None indicated) 07/2018

► WHO Medical Product Alert No. 3/2018, 23 March 2018.PDF version (includes photographs)

Report suspected falsified products to the competent national regulatory authority and/or pharmacovigilance centre, and notify WHO at rapidalert@who.int.

208

WHO Drug Information Vol. 32, No. 2, 2018

Regulatory news

Guidance

EU: Good pharmacogenomic practiceE u r o p e a n U n i o n – The EMA has released its new Guideline on good pharmacogenomic practice, which will come into effect on 1 September 2018. The guideline describes requirements for choosing appropriate genomic methodologies during the development and the life cycle of a medicine. It discusses the characteristics of a robust clinical genomic dataset and highlights the key scientific and technological aspects to consider when determining and interpreting genomic biomarker data and translating them into clinical practice. The guideline is also expected to be a useful reference in the context of future legislation on companion diagnostics, in-house testing and medical devices in Europe.

► EMA Committee for Medicinal Products for Human Use (CHMP). Good pharmacogenomic practice. 22 February 2018.

U.S.: Genomic-based testsU n i t e d S t a t e s o f A m e r i c a – The FDA has finalized two guidance texts to drive the design, development and validation of in vitro diagnostics (IVDs) that use next generation sequencing (NGS) technologies. These diagnostics can look at millions of DNA changes in a single test, and have led to the identification of many new genetic variants. The first guidance relates to the use of FDA-recognized databases to support the clinical validation of new NGS tests, enabling developers to identify an efficient

path for marketing clearance or approval of their products.(1) The second guidance provides recommendations for designing, developing, and validating NGS-based tests intended to aid clinicians in the diagnosis of symptomatic individuals with suspected germline diseases. It does not address tests intended for use in the sequencing of healthy individuals.(2)

► FDA News release, 12 April 2018.(1) FDA. Use of Public Human Genetic Variant Databases to Support Clinical Validity for Genetic and Genomic-Based In Vitro Diagnostics. 13 April 2018.(2) FDA. Considerations for Design, Development, and Analytical Validation of Next Generation Sequencing (NGS) – Based In Vitro Diagnostics (IVDs) Intended to Aid in the Diagnosis of Suspected Germline Diseases. 13 April 2018.

UK: Data integrityU n i t e d K i n g d o m – The MHRA has published its final guidance on data governance systems across all good practice sectors, including good laboratory practice, good clinical practice, good manufacturing practice, good distribution practice and good pharmacovigilance practice. This new guidance was created in response to fundamental failures identified by MHRA and international regulatory partners during inspections, many of which have resulted in regulatory action. It addresses the new technologies used to generate regulatory data—for example electronic data capture, automation of systems and use of remote technologies—and the increased complexity

209

WHO Drug Information Vol. 32, No. 2, 2018 Regulatory news

of supply chains and ways of working, for example via third party service providers.

► MHRA News, 9 April 2018.MHRA. ‘GXP’ Data Integrity Guidance and Definitions. Revision 1: March 2018.

Pre-market assessment

Australia: New regulatory pathways Australia – The TGA has established two new pre-market pathways for medicines, following recommendations of the national medicines and medical devices regulation review.

Firstly, a new provisional approval pathway for prescription medicines has been introduced. Approval through this pathway is on the basis of preliminary clinical data and is limited to six years. The pathway applies to new medicines as well as new uses for existing medicines. To be eligible, a product must target a serious condition, compare favourably with existing medical products and offer a major therapeutic advance. Furthermore there must be evidence of a plan to submit comprehensive clinical data.(1) In April 2018, olaratumab(rmc) (Lartruvo®) was the first medicine to be accepted for evaluation through this pathway.(2)

Secondly, the TGA has published its Assessed listed medicines evidence guidelines, along with guidance for completing applications. This new route sits between the pathways for “listed medicines” (complementary medicines with low risk) and “registered medicines” (fully reviewed products with higher risk). Assessed listed medicines can only contain certain defined low-risk ingredients but are used for at least one “intermediate level indication” requiring some proof of efficacy. Applicants must submit scientific evidence of the product’s efficacy to the TGA for

assessment, whereas they can self-certify the quality and safety of the product.(3)

These initiatives are part of a series of reforms undertaken in response to the regulatory review. Another new pathway for medicines—priority review—came into effect on 1 July 2017, and the first medicine, alectinib (Alecensa®) was registered via this route in February 2018.(4) An expedited approval pathway for needed novel medical devices started in 2018.(5) An overview of changes delivered and upcoming reforms in response to the medicines and medical devices regulation review is available on the TGA website.(6)

► (1) TGA News, 20 March 2018.(2) TGA News, 16 April 2018.(3) TGA. Assessed listed medicines pathway for complementary medicines. 27 March 2018.(4) TGA News, 6 February 2018.(5) Priority review designations medical devices (including IVDs). 13 February 2018.(6) TGA. Medicines and medical devices regulation review [webpage]. Updated 20 March 2018. https://www.tga.gov.au/mmdr

EU: Two years of PRIME SchemeE u r o p e a n U n i o n – The EMA has published a report looking back on two years’ experience with the its PRIME (PRIority Medicines) Scheme, which aims to support and optimize product development for unmet medical needs. Of 177 medicines submitted 36 have been accepted as eligibile to the scheme, including 30 intended to treat rare diseases and 16 intended to treat children. The EMA has provided scientific advice for 22 of the 36 medicines, often with input from health technology assessment bodies that make recommendations on financing or reimbursement of medicines in national healthcare systems.

► EMA News, 7 May 2018.

Regulatory news WHO Drug Information Vol. 32, No. 2, 2018

210

Medical devices

IMDRF meeting heldS h a n g h a i , C h i n a – The International Medical Device Regulators Forum (IMDRF) held its 13th management committee meeting in Shanghai, China, on 20–22 March 2018. The IMDRF is currently working on a unique device identification (UDI) application guide, personalized medical devices, standards for improving the quality of international medical device standards for regulatory use, adverse event terminology, good regulatory review practices, patient registries and regulated product submission. Clinical evaluation of medical devices was adopted as a new work item.

At a one-day open stakeholder forum held on the second meeting day some 500 participants discussed issues of current interest, particularly the use of artificial intelligence in the field of medical devices.

The IMDRF management committee is composed of regulatory representatives of the IMDRF members, i.e. Australia, Brazil, Canada, China, Europe, Japan, Russia, Singapore, South Korea, and the United States of America. WHO and the Regulatory Harmonization Steering Committee of APEC’s Life Sciences Innovation Forum are IMDRF observers. The next committee meeting will be held in Beijing, China, on 18–20 September 2018.

► CFDA News, 23 March 2018.IMDRF Meetings [webpage].

Canada: Disinfectants and sterilantsreclassifiedC a n a d a – Health Canada has announced a reclassification of high-level disinfectant and sterilant solutions (as defined by the Agency on its website) intended for use on medical devices. Only those products that meet the

definition of an antimicrobial agent will continue to be regulated under the Food and Drug Regulations; the others will be subject to the requirements of the Medical Devices Regulations (MDR).

The reclassification is part of Health Canada’s initiatives to align its regulatory requirements with those of the United States. Manufacturers of non-antimicrobial disinfectants and sterilants licensed as medicines have a transition period of 18 months to apply for Class II medical device licences. Health Canada intends to pursue an amendment to the MDR that would reclassify these products under the higher risk Class III category.

► Health Canada Notice, 16 March 2018.

Databases

Japan: Medicines use in children J a p a n – The PMDA has provided an update on the use of its Pediatric Medical Data Collecting System, which was established in 2012 for the collection and analysis of data on the safe use of medicines in children. The system utilizes a large network of institutions and has accumulated electronic medical records of approximately 250 000 patients.

A project started in 2017 to organize and analyse these data alongside information from the literature and from other regulatory authorities. A preliminary analysis focusing on four selected medicines has now been completed. The diuretics spironolactone and furosemide were found to be frequently co-prescribed, and although the package insert states only a dosage for adults they were often used in children as well. The antiepileptic levetiracetam has a dosage specified for children from age four, but was found to be given to younger children too; a clinical investigation of its

211

WHO Drug Information Vol. 32, No. 2, 2018 Regulatory news

use in these children is under way. Aspirin is indicated for Kawasaki disease, a rare condition which affects mainly children under five and is more common in Japan than in other parts of the world. Only 20% of the cases in the database had a diagnosis of Kawasaki disease; about a third of the remaining ones had a diagnosis related to thrombosis.

The analysis will be expanded and refined by inclusion of body weight data, more intensive collection of data on prescribed doses, and extraction of adverse event data.

► PMDA. Pharmaceuticals and Medical Devices Safety Information No. 353, May 2018:3-7.

U.S.: Mobile app launched U n i t e d S t a t e s o f A m e r i c a – The FDA has announced the availability of its Drugs@FDA Express mobile application.

The new mobile app is a streamlined version of the Agency’s Drugs@FDA webpage. It allows users to search on their mobile devices for certain information on FDA-approved medicines based on product name, active ingredient or application number using a single search box. The app will also display the most recent product approvals within seven days, and a number of useful links and contact information.

► FDA In Brief. 22 March 2018.

Collaboration

Treaty for African Medicines Agency signed G e n e v a – The ministers of health of African Union member states have unanimously adopted the Treaty for the establishment of the African Medicines Agency (AMA). This Agency will promote the harmonization of policies, standards and guidelines for

medical products regulation and advocate for the use of the AU Model Law on Medical Products Regulation. The AMA will provide a common framework for regulatory actions, with centres of regulatory excellence that can give guidance and technical assistance to countries that lack regulatory capacity and resources. The Treaty is to be sent to the African Union’s Specialised Technical Committee on Justice and Legal Affairs later in 2018.(1)

The AMA is modelled on the setup of the EMA, a unique regulatory network of national competent authorities in the Member States of the European Economic Area (EEA) working together with the EMA and the European Commission. The future AMA builds on the successes of long-standing efforts for regulatory strengthening, through the WHO-supported African Medicines Regulatory Harmonisation (AMRH) Programme, and through the African Vaccine Regulatory Forum (AVAREF), which was instrumental in coordinating clinical trials for an Ebola vaccine and could be transitioned into a centre for assessment of multi-country clinical trials for a wide range of new medicines and medical devices. These achievements will greatly help the formidable task of setting up a regulatory network among 54 African member states serving a total population of over 1 billion people.(2)

► (1) African Union Press release, 20 May 2018.(2) Intellectual Property Watch. Enter The African Medicines Agency, Continent’s First Super-Regulator? 3 July 2017.

API inspection programme The partners in the International Active Pharmaceutical Ingredient (API) Inspection Programme have published their report

Regulatory news WHO Drug Information Vol. 32, No. 2, 2018

212

on activities in 2011–16. In that period, they conducted 1333 GMP inspections in 20 countries outside their own territories. Between them, the partners inspected a total of 458 sites of common interest, of which 226 (49%) were located in India, and165 (36%) in China. Non-compliances were found at 28% of all sites. Of the 1333 inspections, 131 were conducted by the WHO Prequalification Team.

The collaboration started as a pilot in 2008 and became a full programme in January 2011. It allows the EMA, national regulators of five European countries, the U.S. FDA, Australia’s TGA, Health Canada and Japan’s MHLW and PMDA, as well as the European Directorate for the Quality of Medicines (EDQM) and WHO, to share information on inspections of foreign API manufacturing sites. Since 2011 the membership, the number of sites of common interest, the level of information shared, and overall inspection coverage have all increased. The partners will now seek ways to improve their electronic information exchange platforms and programme reviews further.

► EMA News, 12 April 2018.Report on the International Active Pharmaceutical Ingredient Inspection Programme 2011 – 2016. March 2018.

PIC/S updates G e n e v a – The Pharmaceutical Inspection Co-operation Scheme (PIC/S) held meetings of its Committee and Executive Bureau in Geneva on 16-18 April 2018. The PIC/S Committee adopted a new PIC/S guidance on reliance in GMP inspections of foreign manufacturing sites and revised Chapters 3, 5 and 8 of the PIC/S GMP guide, to enter into force on 1 July 2018. From the same

date PIC/S will also adopt the EU guidelines on GMP excipient risk assessment, exposure limits and good distribution practices for active pharmaceutical ingredients. Furthermore, the Committee has adopted an aide-memoire on cross-contamination in shared facilities. A revised draft guidance on data integrity will be implemented for a trial period while being published for external consultation.

► PIC/S Press release, May 2018.

9th Meeting of World Pharmacopoeias H a n o i , V i e t N a m – Thirteen national, regional and international pharmacopoeias representing 50 pharmacopoeial authorities around the world gathered in Da Nang, Viet Nam on 18–19 April 2018 to attend the 9th International Meeting of World Pharmacopoeias (IMWP). This event has been convened by WHO since 2012, with the first eight meetings focusing on the development of good pharmacopoeial practices. The 2018 meeting focused on creating new collaboration models and improving information-sharing. The participants agreed to establish a pharmacopoeial alert system to exchange information on issues detected with products covered by monographs that necessitate urgent action by a pharmacopeia. The delegations also agreed to use the annual IMWP as a discussion forum to inform each other of recent challenges and to share solutions.

The 10th International Meeting of World Pharmacopoeias meeting will be held in New Delhi, India, in February 2019.

► WHO Representative Office, Viet Nam. International meeting of world pharmacopoeias says collaboration is key to improving access to essential medicines. 11 May 2018.

213

WHO Drug Information Vol. 32, No. 2, 2018 Regulatory news

Under discussion

E u r o p e a n U n i o n – The European Medicines Agency (EMA) has released a draft revised guideline on the clinical evaluation of vaccines. The proposed revision addresses advances in science and technology and adds considerations on priming and boosting strategies and on developing vaccines for emerging pathogens for which it might be problematic to conduct clinical trials outside of outbreaks.

► EMA News, 26 April 2018.Closing date: 30 October 2018.

E u r o p e a n U n i o n – The European Commission has proposed a set of recommendations on strengthening EU cooperation to fight vaccine-preventable diseases. The proposal comes as recent data point to vaccination gaps in Europe, for example with regard to measles and influenza.

► European Commission Press release, 26 April 2018.The Commission’s proposal will be discussed by the European Council, with the aim of seeing a Council recommendation adopted before the end of 2018, with an immediate entry into force.

C a n a d a – The government of Canada has published its proposed pathogens of interest list for public comment. The list largely adopts the Global Priority List of Antibiotic-Resistant Bacteria issued by WHO in 2017. It names the bacterial pathogens that may cause serious, life-threatening infections in the Canadian population and for which new therapies need to be developed.

► Government of Canada. Notice, 17 April 2018.Closing date: 1 July 2018.

U n i t e d S t a t e s o f A m e r i c a – The FDA has released a draft guidance documents on postmarketing safety reporting requirements for combination products, i.e. products composed of two or more different types of medical products (medicine, medical device and/or biological product). In addition, the Agency has published an immediately-in-effect guidance titled Compliance Policy for Combination Product Postmarketing Safety Reporting.

► FDA. Postmarketing Safety Reporting for Combination Products [webpage].FDA Federal Register Notice, 21 March 2018. Closing date: 19 June 2018.

A u s t r a l i a – The TGA has published a proposal that would require medicine sponsors to report all medicines shortages in confidence to the TGA. Shortages classified under a revised protocol as of “extreme” or “high” patient impact would be mandatorily published via the Medicines Shortages Information Initiative on the TGA website.

► TGA Consultation, 27 March 2018.Closing date: 30 April 2018.

E u r o p e a n U n i o n – The European Commission (EC) is seeking comments on a one-health approach to counteracting the threat from infectious diseases. The roadmap document proposes a strategy with three pillars to protect European citizens from emerging and highly pathogenic agents.

► EC Initiative, 26 March 2018.Closing date: 23 April 2018.

Regulatory news WHO Drug Information Vol. 32, No. 2, 2018

214

Approved

Fostamatinib for thrombocytopeniaProduct name: Tavalisse®Dosage form: TabletsClass: Tyrosine kinase inhibitor;

ATC code (temporary): B02BX09Approval: FDAUse: Treatment of adult patients with chronic

immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Benefits: Ability to achieve a stable platelet count to reduce the risk of bleeding.

Safety information: The main adverse effects include hypertension, liver toxicity, diarrhoea and neutropenia. Fostamatinib can cause foetal harm.

► FDA Prescribing information for Tavalisse®. Revised: 04/2018

Avatrombopag to treat thrombocytopenia before procedures in certain patientsProduct name: Doptelet®Dosage form: TabletsClass: Thrombopoietin receptor agonist;

ATC code: B02BX05Approval: FDA (priority review; orphan

designation)Use: Treatment of thrombocytopenia in adults

with chronic liver disease who are scheduled to undergo a medical or dental procedure

Benefits: Ability to increase platelet count, reducing the need for platelet transfusion or rescue therapy.

Safety information: Medicines of this class have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease.

► FDA News release, 21 May 2018.

Tildrakizumab for psoriasisNon-proprietary name in the U.S.:

Tildrakizumab-asmn

Product name: Ilumya®Dosage form: InjectionClass: Interleukin-23 antagonist;

ATC code: L04AC17Approval: FDAUse: Treatment of adults with moderate-to-

severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Benefits: Significant clinical improvement in skin clearance compared to placebo.

Safety information: Tildrakizumab may increase the risk of infections. The medicine should not be administered to patients with active tuberculosis.

► FDA. Prescribing information for Ilumya®. Revised: 03/2018.

Erenumab for prevention of migraineNon-proprietary name in the U.S.: Erenumab-aooeProduct name: Aimovig®Dosage form: Subcutaneous injection for once-

monthly self-administration Class: Calcitonin gene-related peptide receptor

antagonist (first-in-class); ATC code: N02CX07Approval: FDA; EMAUse: Preventive treatment of migraine in adults. In

the EU the medicine is indicated only in adults who have at least 4 migraine days per month.

Benefits: More effective than placebo in reducing the number of days with migraine.

► FDA News release, 17 May 2018.EMA Press release, 1 June 2018.

Lofexidine for opioid use disorderProduct name: Lucemyra®Dosage form: TabletsClass: Central alpha-2 adrenergic agonist;

ATC code: N07BC04Approval: FDA (priority review, fast track

designationUse: Mitigation of opioid withdrawal symptoms

to facilitate abrupt opioid discontinuation

215

WHO Drug Information Vol. 32, No. 2, 2018 Regulatory news

Approved

in adults. The product is only approved for treatment for up to 14 days.

Benefits: Reduces the release of norepinephrine, the actions of which in the autonomic nervous system are believed to play a role in many of the symptoms of opioid withdrawal.

Safety information: The main risks include hypotension, bradycardia, and syncope, QT prolongation, and an increased risk of opioid overdose after opioid discontinuation. Safety and efficacy have not been established in people under 17 years of age.

Note: This is the first FDA-approved non-opioid treatment for the management of opioid withdrawal symptoms.

► FDA News release, 16 May 2018.

Pegvaliase for phenylketonuriaProduct name: Palynziq®Non-proprietary name in the U.S.: Pegvaliase-pqpzDosage form: Injection for subcutaneous useClass: Phenylalanine-metabolizing enzymeApproval: FDAUse: Treatment of adult patients with

phenylketonuria who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management.

Benefits: Ability to reduce blood phenylalanine concentrations.

Safety information: Risk of anaphylaxis, especially during upward titration of the dose within the first year of treatment.

► FDA News release, 24 May 2018.

Inotersen for a rare hereditary deficiency Product name: Tegsedi®Dosage form: Solution for injectionClass: Antisense oligonucleotideApproval: EMA (accelerated assessment; orphan

designation)Use: Treatment of stage 1 or stage 2

polyneuropathy in patients with hereditary transthyretin amyloidosis (hATTR). Efficacy in stage 3 polyneuropathy has not yet been demonstrated.

Benefits: Clinically relevant effects on the neurological manifestations of hATTR and on patients’ quality of life.

Notes: hATTR is diagnosed in about three of every 10 million people in Europe every year. Current therapeutic options are liver transplant, treatment with the nervous system medicine tafamidis, and off-label use of a non-steroidal anti-inflammatory drug.

► EMA Press release, 1 June 2018.

New formulation

Fosnetupitant and palonosetron injectionProduct name: Akynzeo®Newly approved dosage form: Intravenous

injection Approval: FDAUse: Prevention of acute and delayed nausea and

vomiting associated with initial and repeat courses of cancer chemotherapy.

Note: An oral fixed-dose combination of palonosetron and netupitant was approved by the FDA in 2014.

► FDA Product information for Akynzeo®, revised 04/2018.

Extensions of indications

Brentuximab vedotin for Hodgkin lymphomaProduct name: Adcetris®Approval: FDA (priority review, breakthrough

therapy)Newly approved use: Treatment of adult patients

with previously untreated stage III or IV classical Hodgkin lymphoma, in combination with chemotherapy.

Safety information: The product carries a boxed warning highlighting the risk of John Cunningham virus infection resulting in progressive multifocal leukoencephalopathy. Serious risks include peripheral neuropathy; severe allergic (anaphylaxis) or infusion-site

Regulatory news WHO Drug Information Vol. 32, No. 2, 2018

216

Approved

reactions; damage to the blood, lungs and liver; serious or opportunistic infections; metabolic abnormalities (tumour lysis syndrome); serious dermatologic reactions and gastrointestinal complications. The medicine can cause harm to a developing foetus.

► FDA News release, 20 March 2018.

Blinatumomab for acute lymphoblastic leukaemiaProduct name: Blincyto®Approval: FDA(accelerated approval; priority

review, orphan drug designation)Newly approved use: Treatment of adults

and children with B-cell precursor acute lymphoblastic leukaemia (ALL) who are in remission but have minimal residual disease.

Safety information: The medicine carries a boxed warning about cytokine release syndrome and neurological toxicities observed in some clinical trial participants at the start of the first treatment. Serious risks include infections, effects on the ability to drive and use machines, pancreatitis, and adverse events caused by preparation or administration errors. There is a risk of serious adverse reactions in children due to benzyl alcohol preservative; therefore, the drug prepared with preservative-free saline should be used for patients weighing less than 22 kg.

► FDA News release, 29 March 2018.

Dabrafenib with trametinib for certain thyroid cancersProduct name: Tafinlar® in combination with

Mekinist® Approval: FDA (priority review; breakthrough

therapy; orphan drug designation)Newly approved use: Treatment of locally

advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation

Note: This is the first FDA-approved treatment for patients with this aggressive form of thyroid cancer.

► FDA News release, 4 May 2018.

Fingolimod for multiple sclerosis in childrenProduct name: Gilenya®Approval: FDA (priority review, break-through

therapy)Newly approved use: Treatment of relapsing

multiple sclerosis in children and adolescents aged 10 years and older.

Safety information: Fingolimod can cause slowing of the heart rate, especially after the first dose; serious infections, including progressive multifocal leukoencephalopathy (PML); and a number of other adverse effects. Patients should be monitored for infection during treatment and for two months thereafter.

► FDA News release, 11 May 2018.

Tofacitinib for ulcerative colitis Product name: Xeljanz®Approval: FDANewly approved use: Treatment of adults with

moderately to severely active ulcerative colitisSafety information: Increased risk of developing

serious infections that may lead to hospitalization or death; as well as lymphoma and other malignancies, have been observed in patients treated with tofacitinib.

Notes: Tofacitinib is the first FDA-approved oral medicine for chronic use in ulcerative colitis.

► FDA News release, 30 May 2018.

Biosimilars

Epoetin alfa

Non-proprietary name in the U.S.: Epoetin alfa-epbx

Product name: Retacrit®Use: Treatment of anaemia caused by chronic

kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection; reduction of allogeneic red blood cell transfusions in patients undergoing elective, non-cardiac, non-vascular surgery.

► FDA News release, 15 May 2018.

217

WHO Drug Information Vol. 32, No. 2, 2018 Regulatory news

Approved

Trastuzumab

Product name: Kanjinti®Use: Treatment of metastatic breast cancer, early

breast cancer, and metastatic gastric cancer. ► EMA Summary of opinion, 22 March 2018.

Product name: Trazimera®Use: Treatment of metastatic breast cancer, early

breast cancer, and metastatic gastric cancer. ► EMA Summary of opinion, 31 May 2018.

Pegfilgrastim

Non-proprietary name in the U.S.: Pegfilgrastim-jmdb

Product name: Fulphila®Use: To decrease the incidence of infection, as

manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

► FDA News release, 4 June 2018.

Infliximab

Product name: Zessly®Use: Treatment of rheumatoid arthritis, adult

and paediatric Crohn’s disease, adult and paediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.

► EMA Summary of opinion, 22 March 2018.

Adalimumab

Product name: Halimatoz®Use: Treatment of rheumatoid arthritis, juvenile

idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque

psoriasis, hidradenitis suppurativa, uveitis and paediatric uveitis.

► EMA Summary of opinion, 31 May 2018.

Product name: Hefiya®Use: Treatment of juvenile idiopathic arthritis,

axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, uveitis and paediatric uveitis.

► EMA Summary of opinion, 31 May 2018.

Product name: Hyrimoz®Use: Treatment of rheumatoid arthritis, juvenile

idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn’s disease, paediatric Crohn’s disease, ulcerative colitis, uveitis and paediatric uveitis.

► EMA Summary of opinion, 31 May 2018.

Diagnostics

Mass spectroscopy test for Candida aurisU n i t e d S t a t e s o f A m e r i c a – The FDA has authorized the first test to identify Candida auris, an emerging pathogen which can cause serious infections in hospitalized patients and is frequently resistant to multiple antifungal drugs. The approval permits a new use for a mass spectrometry-based diagnostic system that has previously been authorized by the FDA to identify a wide range of pathogen species.

The FDA plans to propose exempting certain mass spectrometry microorganism identification system processes from an additional premarket review once they have achieved initial FDA authorization. This would permit easy updates to device-specific organism databases to expand the capabilities of these devices.

► FDA News release, 20 April 2018.

218

WHO Drug Information Vol. 32, No. 2, 2018

Negative opinions

Three medicines approved in the U.S. have received negative opinions in the European Union. In all three cases the applicants have requested a re-examination of the negative EMA opinion.

BetrixabanProduct name: Dexxience®Dosage form: CapsulesClass: Anticoagulant, Factor Xa inhibitorRegulatory authority: EMA Intended use: Prevention of venous thrombo-

embolism in adults admitted to hospital for the treatment of a recent medical illness.

Reasons for negative opinion: The EMA considered that the pivotal study was not reliable because some results of tests for blood clots were not available. In addition, patients treated with betrixaban had more episodes of bleeding than those treated with the comparator medicine. This was considered an important concern given that the medicine was expected to be used in patients with serious underlying conditions.

► EMA. Refusal of the marketing authorisation for Dexxience (betrixaban). 23 March 2018.FDA approval of betrixaban (BevyxXa®): 23 June 2017.

AbaloparatideProduct name: Eladynos®Dosage form: Injection for subcutaneous useClass: Human parathyroid hormone-related

peptide analogRegulatory authority: EMAUse: Treatment of postmenopausal women with

osteoporosis at high risk for fracture.Reasons for negative opinion: The EMA

considered that the main study did not satisfactorily show the effectiveness of abaloparatide for the intended use. The data from two study sites had to be excluded as the study had not been conducted in compliance with good clinical practice at those sites. From

a safety point of view, the EMA was concerned about the medicine’s effects on the heart, such as increases in heart rate and palpitations. Because most post-menopausal women are at an increased risk of heart problems, the EMA could not identify a group of patients in whom the benefits would outweigh the risks.

► EMA. Refusal of the marketing authorisation for Eladynos (abaloparatide). 23 March 2018.FDA approval of abaloparatide (Tymlos®). 28 April 2017.

NeratinibProduct name: Nerlynx®Dosage form: TabletsClass: Tyrosine kinase inhibitor;

ATC code: L01XE45Regulatory authority: EMAIntended use: For the extended adjuvant

treatment of early-stage, HER2-positive breast cancer in adult patients previously treated with trastuzumab.

Reasons for negative opinion: The EMA considered that, although more women on neratinib than on placebo lived for two years without disease progression than women (94% versus 92% respectively), it is uncertain that this difference would be seen in clinical practice. Furthermore, neratinib causes side effects in the digestive system, particularly diarrhoea, which affected most patients and might be difficult to manage.

► EMA. Refusal of the marketing authorisation for Nerlynx (neratinib). 23 February 2018.FDA approval of neratinib maleate (Nerlynx®). 17 July 2017.

219

WHO Drug Information Vol. 32, No. 2, 2018

Publications and events

Research and development

“Disease X” added to WHO research priority listG e n e v a – In its annual review of its R&D Blueprint, WHO has added “Disease X” to the research priorities for pathogens that could cause serious epidemics and for which there are no or insufficient countermeasures. Disease X represents a known or unknown pathogen that is yet to be found to have potential to cause a serious international epidemic.

The list was first published in December 2015 and is reviewed annually. It now includes (in no particular order) Crimean-Congo haemorrhagic fever (CCHF), Ebola virus disease and Marburg virus disease, Lassa fever, Middle East respiratory syndrome coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS), Nipah and henipaviral diseases, Rift Valley fever (RVF), Zika, and Disease X. The R&D Blueprint explicitly seeks to enable cross-cutting preparedness that is also relevant for a future Disease X.

► WHO. List of Blueprint priority diseases [webpage].

Vaccines for emerging pathogensIn a recent article in JAMA, Dr Anthony Fauci and co-authors provide their views on the development of vaccines for emerging infectious diseases with pandemic potential. The authors conclude that the traditional approach of isolating and growing the pathogen does not support an effective response to these continually emerging

threats. They emphasize that it will be critical to exploit modern-day technological advances, pre-emptively establish detailed information on each family of viral pathogens, and invest in more infrastructure for surveillance in developing countries to expedite pathogen identification and jump-start the process of vaccine development.

► Graham BS, Mascola JR, Fauci AS. Novel Vaccine Technologies. Essential Components of an Adequate Response to Emerging Viral Diseases. JAMA. Published online March 22, 2018. doi:10.1001/jama.2018.0345.

Access to medicines

European Parliament resolution B r u s s e l s – The European Parliament has adopted a resolution calling for national and EU-wide measures to guarantee the right of patients to universal, affordable, effective, safe and timely access to essential and innovative therapies.(1) In its Report on European Union (EU) Options for Improving Access to Medicines the Committee on the Environment, Public Health and Food Safety points to the need for innovation with a clear clinical, social and economic added value, greater transparency of research data and costs; greater public investment in research; improved regulation and mechanisms to monitor conflicts of interest; and patient-oriented research priorities.

Health Action International (HAI) has commended the European Parliament for its report and has urged the European Commission and member states to follow

Publications and events WHO Drug Information Vol. 32, No. 2, 2018

220

up on the recommendations in order to improve access to medicines in the EU.(2)

► (1) European Parliament resolution of 2 March 2017 on EU options for improving access to medicines.(2) HAI Media statement, 3 March 2018.

The role of the pharmacistT h e H a g u e – The International Pharmaceutical Federation (FIP) has published a report that highlights the important role of the pharmacist in ensuring access to safe and effective medicines in a variety of contexts.

Pharmacists are involved at all stages of the life cycle of medicines, from the production of raw materials through to their use by patients. In a landscape of challenges such as substandard and falsified medicines, globalization, and a shortage of human resources in health systems, the pharmacist’s expertise is critical as part of a team approach to the management of medicines. Recognizing that regulation and supply systems have different levels of maturity in countries, the report emphasizes the importance of investments in further training and education to strengthen the competencies of health professionals in ensuring supply chain integrity and rational use of medicines.

► FIP News, 8 May 2018.FIP. Pharmacists in the supply chain: The role of the medicines expert in ensuring quality and availability. The Hague, the Netherlands: International Pharmaceutical Federation, 2018.

Pharmaceutical waste management

Pharmaceutical pollution and AMRB r u s s e l s – The European Public Health Alliance has published the report of a recent

event held to discuss the links between pharmaceutical pollution and antimicrobial resistance (AMR).(1) In Europe, pollution is mainly due to pharmaceutical consumption, while the contribution of manufacturing facilities is considered as negligible.(2) On the other hand, industrial pollution is a major problem in India, where pharmaceutical manufacturing is being stepped up to supply most of the world’s generic medicines.(3) This has significant global impacts as the residues in the environment are becoming a reservoir for the development of resistant pathogens. A 2017 study of samples of effluent discharges in the Hyderabad area were found to have unexpectedly high levels of antibiotic residues and —correlated with this—high levels of resistant pathogens.(4)

The event participants recognized that manufacturing of pharmaceuticals in China and India is a problematic and growing issue that is fuelling AMR. It was proposed that this global issue should be addressed as part of the European strategy on Pharmaceuticals in the Environment (PiE), which is currently under public consultation (5) and is due to be released by May 2018. The participants concluded that, given the high costs of inaction on the closely connected challenges of PiE and AMR, a coherent policy with the right tools and instruments are urgently needed for action to be taken before the European Parliament elections in 2019.

► (1) Joining the dots. Tackling Pharmaceuticals in the environment and AMR in Europe. European Parliament, 30 January 2018. Event Report, March 2018.(2) BIO Intelligence Service. Study on the environmental risks of medicinal products. Final report. Prepared for the Executive Agency for Health and Consumers. 12 December 2013. (3) Changing Markets Foundation. Hyderabad’s pharmaceutical pollution crisis. January 2018.

221

WHO Drug Information Vol. 32, No. 2, 2018 Publications and events

(4) Lübbert C, Baars C, Dayakar A et al. Environmental pollution with antimicrobial agents from bulk drug manufacturing industries in Hyderabad, South India, is associated with dissemination of extended-spectrum beta-lactamase and carbapenemase-producing pathogens. Infection. 2017 Aug;45(4):479-491. (5) European Commission. Public consultation on pharmaceuticals in the environment.

Medical waste in India increasesI n d i a – According to a recent study, India’s medical waste is growing by 7% every year and will reach 775.5 tons by the year 2022. The study outlines the key challenges in biomedical waste management in India: slow data availability at state and central pollution control boards, underreporting of waste generated, limited handling capacity, unauthorized healthcare facility operations, and delays in developing biomedical waste treatment facilities in some states and territories.

The study report was released at a conference on biomedical waste management organized in New Delhi on 22 March 2018 by the Associated Chambers of Commerce & Industry of India (ASSOCHAM) in collaboration with the Directorate of Health Services within the Department of Health and Family Welfare of India. Releasing the report, Dr Kirti Bhushan, Director General of Health Services of the Delhi government stressed that safe and effective management of waste is not only a legal necessity but also a social responsibility.

► India’s medical waste growing at 7% annually: ASSOCHAM. The Times of India. 22 March 2018.

Diagnostics

First WHO essential diagnostics listG e n e v a – WHO has published its first Essential Diagnostics List (EDL). The list focuses on in vitro diagnostics (IVDs) and comprises 113 tests: 58 general IVDs for primary health care, and 55 tests for the detection, diagnosis and monitoring of global priority diseases including HIV, tuberculosis, malaria, hepatitis B and C, human papillomavirus and syphilis. The EDL describes IVDs according to their biological targets, indicating the test purpose, assay format, specimen type, and whether it is appropriate for primary health care or for health facilities with clinical laboratories. The list also provides links to WHO Guidelines or publications and, when available, to prequalified products.

The proposal for the first EDL was agreed by WHO’s new Strategic Advisory Group of Experts on In Vitro Diagnostics (SAGE IVD) in response to a recommendation made by the WHO Expert Committee on the Selection of Essential Medicines at its 2017 meeting. It is intended as a reference for countries to update or develop their own list of essential diagnostics, alongside measures to ensure appropriate and quality-assured supplies, training of health care workers and safe use. WHO will expand the list over the next few years to include tests related to antimicrobial resistance, emerging pathogens, neglected tropical diseases and additional non-communicable diseases.

► WHO News release, 15 May 2018.WHO. Executive summary. World Health Organization Model List of Essential In Vitro Diagnostics. First edition (2018). Report of the first Strategic Advisory Group on In Vitro Diagnostics (SAGE-IVD), WHO headquarters, Geneva, 16–20 April 2018.

Publications and events WHO Drug Information Vol. 32, No. 2, 2018

222

Disease updates

Ebola: Outbreak in DRCG e n e v a , B r a z z a v i l l e , K i n s h a s a – A new Ebola outbreak has been reported from Bikoro in the Democratic Republic of the Congo (DRC). WHO is working with the Government of the DRC and a broad range of partners to rapidly scale up its operations and mobilize health partners, using the model of a successful response to a similar outbreak in 2017.(1)

As at 13 May there were 39 reported Ebola cases, including 2 confirmed, 20 probable (of which 18 were fatal), and 17 suspected cases. WHO has released US$ 2.6 million from its Contingency Fund for Emergencies to support response activities. The estimated budget for an international response is US$ 18 million for a three-month operation.(2)

► (1) WHO News release, 8 May 2018.(2) WHO News release, 13 May 2018.

Dengue: Outbreak in La RéunionG e n e v a – WHO has been notified about a sharp increase of dengue fever in the French overseas territory of La Réunion in the Indian Ocean. As of 23 April, 1816 cases have been confirmed for the year 2018, including 428 probable and confirmed cases reported in the week of 16–23 April 2018 alone. In comparison, less than 100 cases were reported in all of 2017. The western and southern parts of the island are the most affected. The national authorities have stepped up their response and are implementing an emergency plan corresponding to a low level epidemic.

WHO has recommended a range of measures to reduce populations of mosquito

vectors and minimize individual exposure. The Organization advises against any travel or trade restrictions at this stage.

► WHO Disease outbreak news, 1 May 2018.

Yellow fever:Strategy to end epidemicsA b u j a – WHO and the Ministry of Health of Nigeria have launched the “Eliminate Yellow fever Epidemics (EYE) in Africa” strategy, which aims to end yellow fever epidemics in Africa through vaccination campaigns and routine immunization, prevention of international spread, and rapid containment of outbreaks. By 2026, nearly one billion people are to be vaccinated against yellow fever in 27 high-risk African countries. The campaign will be supported by WHO, Gavi – the Vaccine Alliance, UNICEF and more than 50 health partners.

In recent years yellow fever has re-emerged as a serious global public health threat. The ease and speed of population movements, rapid urbanization and a resurgence of mosquitoes due to global warming have significantly increased the risk of urban outbreaks with international spread.

► WHO News release, 10 April 2018.

Cholera: Largest-ever vaccine driveG e n e v a , B r a z z a v i l l e – A spate of cholera outbreaks across Africa has prompted the largest cholera vaccination drive in history, with more than two million people to receive oral cholera vaccine. Major campaigns are under way in Zambia, Uganda, Malawi, South Sudan and Nigeria. The vaccines are sourced from the global stockpile, which is managed by the Global Task Force on Cholera Control (GTFCC) and funded by Gavi, the Vaccine Alliance.(1)

223

WHO Drug Information Vol. 32, No. 2, 2018 Publications and events

A resolution on cholera was endorsed at the 71st World Health Assembly, urging cholera-affected countries to implement a roadmap that aims to reduce deaths from the disease by 90% by 2030.(2)

► (1) WHO News release, 7 May 2018.(2) WHO News release, 24 May 2018.

Hepatitis C:Treatment access increasingG e n e v a – WHO has published an update to its 2016 report on access to treatment of hepatitis C virus (HCV) infection. Access to life-saving direct-acting antivirals (DAA) is still low, but is increasing in champion countries such as Egypt, Pakistan, Brazil, China and Georgia. Drawing on surveys in 23 low- and middle-income countries and among innovator and generic companies, as well as interviews and other new data, the report looks at the key factors that determine access to DAA medicines and highlights areas for action by ministries of health and other government decision-makers, pharmaceutical manufacturers and technical partners.(1)

With the advent of DAAs, HCV infection has become curable. As the cost of the medicines is coming down, treatment becomes cost-saving because it substantially reduces the burden of liver cirrhosis and cancer as well as diseases such as depression and diabetes. New evidence suggests that all people aged 12 or above diagnosed with chronic HCV (with the exception of pregnant women) should be offered treatment. WHO expects to release new HCV treatment guidelines soon.(2)

► (1) WHO. Progress report on access to hepatitis C treatment. Focus on overcoming barriers in low- and middle-income countries. March 2018.(2) WHO. Hepatitis C: simplified curative treat-ments can drive global scale-up. 13 April 2018.

Tuberculosis: World’s biggest infectious killerB r u s s e l s – On the eve of World Tuberculosis Day, four European Commissioners have underlined the EU’s commitment to ending the tuberculosis epidemic by 2030 and have called on governments all over the world to redouble their efforts and make this happen. The EU is also working to address antimicrobial resistance, which is inextricably linked to tuberculosis, as well as the social conditions that encourage the disease to spread.(1)

G e n e v a – WHO and the Stop TB Partnership have launched the first-ever joint advocacy and communications campaign to support thousands of partners, activists and persons affected by tuberculosis. The disease remains among the top 10 causes of death worldwide, and is the major cause of deaths related to antimicrobial resistance and the leading killer of people with HIV. To commemorate World Tuberculosis Day, the partners have provided a joint advocacy and communications toolkit containing practical guidance and information.(2)

G e n e v a – Based on an expedited review of preliminary results from the STREAM Stage 1 randomized controlled trial, WHO has advised national tuberculosis programmes and other stakeholders to continue using the shorter regimens lasting 9–12 months to treat multi-drug-resistant tuberculosis.(3)

WHO has also provided recommendations for the management of isoniazid-resistant tuberculosis.(4) Consolidated guidelines and an update of the Companion Handbook to the WHO guidelines for the management of drug-resistant tuberculosis are planned to be released later in 2018.

Publications and events WHO Drug Information Vol. 32, No. 2, 2018

224

At the 71st World Health Assembly, held in May 2018 in Geneva, delegates agreed on a resolution committing Member States to accelerate their actions to end tuberculosis. The resolution also requests the Secretariat to develop a new global strategy for tuberculosis research and innovation.(5)

► (1) European Commission Statement, 23 March 2018.(2) WHO TB News, 2 March 2018.(3) WHO. Position statement on the continued use of the shorter MDR-TB regimen following an expedited review of the STREAM Stage 1 preliminary results. April 2018.(4) WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis. 2018.(5) WHO News release, 24 May 2018.

Non-communicable diseases:Major health gains from investmentsG e n e v a – A new WHO report shows that even modest investments into actions to address non-communicable diseases (NCDs) generate significant benefits. In low- and lower middle-income countries (LLMICs), where almost half of all premature deaths from NCDs occur, every dollar invested will yield a return to society of at least US$ 7 in increased employment, productivity and longer life. Among the most cost-effective interventions are increasing taxes on tobacco and alcohol, reducing salt content in food products, providing medicinal therapy and counselling to people who have had a heart attack or stroke, vaccinating girls aged 9–13 years against human papillomavirus, and screening women aged 30–49 years for cervical cancer. However, global financing to combat NCDs is severely limited. The report calls on donors to provide kick-start funding

to governments of LLMICs for ambitious scaling-up of “best buy” policies.

► WHO News release, 16 May 2018.WHO. Saving lives, spending less: a strategic response to NCDs. 2018.

HTLV-1: A scourge yet to be addressedSixty representatives from 26 countries have signed an open letter calling for WHO’s support to help prevent the transmission of human T-cell lymphotropic virus type 1 (HTLV-1), a virus similar to HIV and transmitted by the same routes. HTLV-1 is the most potent carcinogenic oncovirus, and potentially the most oncogenic risk factor including chemical carcinogens. Although it was discovered almost 40 years ago, effective intervention strategies have not been actively publicized. The authors warn that HTLV-1 remains a strong threat to individual and community health, and even more so to global health because of the accelerated rate of human migration in recent times.

The letter proposes a WHO vision for the prevention of HTLV-1 transmission, with five intervention strategies to reduce the incidence of HTLV-1 infection. These are based on evidence that transmission can be averted by condom use, by avoiding the transfusion and transplantation of infected blood and organs, by avoiding breastfeeding (if deemed safe) or reducing its duration to 3–6 months, by using sterile needles, and by educating healthcare professionals and the population about prevention strategies.

► Martin F, Tagaya Y, Gallo R. Time to eradicate HTLV-1: an open letter to WHO. The Lancet. 2018; 391 (10133): 1893-4. DOI: https://doi.org/10.1016/S0140-6736(18)30974-7

225

WHO Drug Information Vol. 32, No. 2, 2018 Publications and events

WHO updates

71st World Health AssemblyG e n e v a – The 71st World Health Assembly was held on 21–26 May 2018 in Geneva, Switzerland. Delegates adopted an ambitious strategic “triple billion” five-year plan which aims to ensure that by 2023 one billion more people benefit from universal health coverage; one billion more people are better protected from health emergencies; and one billion more people enjoy better health and wellbeing.(1) Several of the decisions and resolutions agreed upon at the Assembly were related to improving access to quality-assured medical products.

Access to medicinesThe delegates asked WHO to elaborate a five-year roadmap to increase access to safe and effective essential medicines, vaccines and other health products – something that is becoming increasingly challenging across economic settings as medicines prices are rising. Member States also urged stakeholders to implement the recommendations for priority actions under WHO’s Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property, as identified in the review panel’s report.(2)

SpecificmedicalproductsThe Member States adopted a landmark resolution on containment of poliovirus materials under strict biosafety and biosecurity handling and storage conditions in a limited number of facilities that serve critical functions in vaccine production or research.(3) They further agreed on a resolution for a coordinated global response to rheumatic heart disease, including by ensuring a consistent supply of quality-assured antibiotics.(4) Resolutions were also adopted regarding tuberculosis (see page

223–224) and cholera (see page 223), and regarding snakebite, underlining the urgent need to improve access to safe, effective and affordable antivenoms.(4) Resolutions were furthermore adopted to improve access to assistive technology such as wheelchairs or hearing aids, and digital technologies for example to track disease outbreaks or send mobile phone text messages for positive behaviour change.(4)

Public health preparednessDelegates welcomed a proposed five-year global strategic plan to improve public health preparedness and response through the implementation of the International Health Regulations (IHR), a legal instrument introduced in 2007 that is binding on 196 countries and WHO in their work to uphold global public health security.(4) An update was provided on the new Ebola outbreak (see page 222) and on the systems put in place for a faster and more predictable response than during the previous outbreak.(2) Delegates also approved the recommendations of the Review of the Pandemic Influenza Preparedness Framework.(4) On the margins of the Assembly, WHO and the World Bank Group launched the Global Preparedness Monitoring Board as a new mechanism to ensure stringent independent monitoring and regular reporting to tackle outbreaks, pandemics, and other emergencies with health consequences.(5)

► (1) WHO News release, 23 May 2018.(2) WHO News release, 23 May 2018 (2).(3) WHO News release, 26 May 2018.(4) WHO News release, 25 May 2018.(5) WHO News release, 24 May 2018.The meeting documents are available at: http://apps.who.int/gb/e/e_wha71.html

Publications and events WHO Drug Information Vol. 32, No. 2, 2018

226

WHOprequalificationupdates

ICH Q3D introduced for APIs

What is ICH Q3D?The ICH Q3D guideline presents a process to assess and control elemental impurities in drug products using the principles of risk assessment.

Howwillitbeusedinprequalification?The ICH Q3D risk assessment includes consideration of the impurity profile of the active pharmaceutical ingredient (API). Therefore, the WHO Prequalification Team (PQT) has decided to adopt the ICH Q3D guideline for the assessment of the elemental impurities information in new applications for both procedures: the API master file (APIMF) procedure and the procedure for prequalification of APIs. The implementation of ICH Q3D for finished pharmaceutical products (FPPs) is still under consideration within PQT.

Must a risk assessment be provided?Since the ICH Q3D guideline applies to the finished product, providing a risk assessment as part of the APIMF procedure is not a mandatory requirement. However, many API manufacturers may wish to undertake a risk assessment in order that this may then be used in an assessment of the finished pharma-ceutical product with respect to ICH Q3D.

Therefore when submitting an APIMF, either through the APIMF procedure or as part of the API Prequalification procedure, the applicant has two possibilities:• Option 1: Do not provide a risk

management summary (RMS); or• Option 2: Provide a risk management

summary (RMS) for elemental impurities that may be present in the final API.

Applicants should indicate the selected option on the application form.

What will happen during assessment? Ș If no RMS is provided, only the elemental impurities that have been intentionally added will be investigated as part of the assessment, and the need for inclusion of controls for elemental impurities in the API specifications will be determined on this basis. Ș If an RMS is provided then this will be considered as part of an assessment in line with ICH Q3D: For an APIMF participating only in the APIMF procedure, the outcome of the RMS assessment will be recorded in the internal assessment report and remain available if needed for reference as part of an FPP assessment. For APIs seeking prequalification, a statement indicating whether a risk assessment for elemental impurities has been provided will be mentioned on the Confirmation of API Prequalification document (CPQ). In case an RMS is submitted it will be annexed to the CPQ.

What about APIMFs that are already under assessment?For those APIMFs that have already been accepted for assessment, the applicant can submit an RMS for elemental impurities at any time through the amendment procedure. There is no specific change category in the APIMF amendments guideline for such a revision, but applicants should submit such a change as 11 (AIN). However for ongoing applications it should not be provided as part of responses, since these invariably delay the completion of the application.

► WHO/PQT–medicines. Guidance document, 23 May 2018.

227

WHO Drug Information Vol. 32, No. 2, 2018 Publications and events

New WHO stability guideline publishedThe updated WHO stability guideline has now been published in the WHO Technical Report Series (TRS) No. 1010, Annex 10. This guideline replaces the previous stability guideline in TRS 953 Annex 2 (2009) and should be taken into account in preparing the quality part of product dossiers for prequalification.

► WHO Prequalification News, 7 June 2018.

“Firsts”• First flucytosine product prequalified

(HA693). Flucytosine is used to treat cryptococcal disease and other HIV/AIDS-related fungal infections.

• First dispersible ethambutol tablets for children prequalified (TB334). Ethambutol is used in the treatment of tuberculosis.

• First amikacin injection prequalified (TB319). Amikacin is used for second-line treatment of tuberculosis.

► WHO. List of prequalified Medicines/Finished Pharmaceutical Products

• First Quality Control Laboratory (QCL) in sub-Saharan West Africa prequalified: United States Pharmacopoeia (USP) Ghana. This is also a first under the USP banner.

► WHO. List of prequalified Quality Control Laboratories.

• First Medicines Quality Workshop for Manufacturers, held on 4–6 July 2018 in Copenhagen, Denmark. This new type of workshop is aimed at manufacturers that are participating, or intend to participate, in medicines prequalification. The speakers are senior WHO prequalification assessors.

► WHO Prequalification of medicines website. Events. First PQT Medicines Quality Workshop for Manufacturers.

Additional medicines invitedAnti-tuberculosis medicines• Bedaquiline (fumarate), tablet 100mg*• Delamanid, tablet 50mg*• Delamanid, tablet 50mg (dispersible)*• Rifapentine, tablet 300 mg**• Isoniazid 150 mg/rifapentine 150 mg and

Isoniazid 300 mg/rifapentine 300 mg (preferably dispersible or crushable tablets in fixed-dose combination format)**

• Rifapentine, tablet 150 mg (dispersible)**• Rifapentine, tablet 300 mg (scored and

dispersible)** ► * 16th Invitation to Manufacturers of Antituberculosis Medicines, 6 March 2018.** 17th Invitation to Manufacturers of Antituberculosis Medicines, 26 March 2018.

Anti-malarial medicinesAdditional product:• Artesunate/pyronaridine tablet

20mg/60mg (preferably dispersible)Additional product strengths:• Dihydroartemisinin/piperaquine

phosphate tablet 60mg/480mg• Dihydroartemisinin/piperaquine

phosphate tablet 30mg/240mg (preferably dispersible)

► 16th Invitation to Manufacturers of Antimalarial Medicines, 16 March 2018.

Coming soon: Biosimilars

Pakistan joins collaborative registrationThe regulatory authority of Pakistan is the 34th authority to join the WHO’s collaborative registration procedure. The purpose of this procedure is to shorten the time to registration of WHO-prequalified medicines to a target period of 90 days, based on confidential sharing of WHO assessment and inspection reports with permission of the manufacturer.

► WHO Prequalification News, 18 April 2018. WHO Prequalification website. Accelerated Registration of Prequalified FPPs.

Publications and events WHO Drug Information Vol. 32, No. 2, 2018

228

Upcoming events

August

WHO-UMC-HSA Inter-Regional Pharmaco vigilance Training workshop

Singapore, 15–17 August 2018Expert pharmacovigilance trainers from WHO, the Uppsala Monitoring Centre (UMC), and the Health Sciences Authority (HSA) of Singapore will share with participants their expertise and experience over a three-day workshop, jointly organized with the WHO, UMC, HSA, and the Duke-NUS Medical School’s Centre of Regulatory Excellence (CoRE) in Singapore. The workshop is part of a continuation of efforts to enhance pharmacovigilance capabilities in the ASEAN region.

Given this year’s underlying theme of Partnerships to Protect Public Health, the organizers welcome participation from non-regulators, such as people from the industry and non-government organizations (NGOs).

► www.duke-nus.edu.sg/core/event/who-umc-hsa-inter-regional-pharmacovigilance-training-workshop

September

78th FIP World Congress of Pharmacy and Pharmaceutical Sciences

Glasgow, United Kingdom, 2–6 September 2018 The 2018 FIP congress in Glasgow, Scotland, invites pharmacy practitioners and pharmaceutical scientists from around the world to come together to consider ways of extending the role of pharmacists so that they play a full part in ensuring that patients and health systems achieve full benefit from the medicines people take. The one-size-fits-all approach is clearly

failing many patients around the globe for the pharmacological treatment of disease. Pharmacists and pharmaceutical scientists are uniquely trained and qualified health care professionals capable of personalising therapy for improving patient outcomes.

► www.fip.org/glasgow2018/

18th International Conference of Drug Regulatory Authorities (ICDRA)

Dublin, Ireland, 3–7 September 2018The 18th ICDRA will be organized around the theme Smart Safety surveillance: A life-cycle approach to promoting safety of medical products. The pre-ICDRA event on 3–4 September is open to all interested stakeholders. The ICDRA conference will be held on 5–7 September and is open to representatives of governments and national regulatory authorities.

► www.icdra2018.ie/HPRA. Invitation to Exhibit at the HPRA PRE- ICDRA conference 3-4 September 2018.

Joint UNFPA-UNICEF-WHO meetingCopenhagen, Denmark, week of 24 September 2018 The Joint UNICEF-UNFPA-WHO Meeting with manufacturers and suppliers of in vitro diagnostic, vaccines, finished pharmaceutical products, active pharmaceutical ingredients, contraceptive devices and vector control products will provide updates on UN-funded procurement, prequalification and cross-cutting issues. There will be opportunities for one-to-one discussions.

► extranet.who.int/prequal/events/2018-unicef%E2%80%93unfpa%E2%80%93who-meeting-pre-announcement å

229

WHO Drug Information Vol. 32, No. 2, 2018

Consultation documentsTo receive draft monographs by email please contact Mrs Xenia Finnerty (finnertyk@who.int), stating that you wish to be added to the electronic mailing list.

The International Pharmacopoeia

Atazanavir sulfate(Atazanaviri sulfas)

This is a draft proposal of a revised monograph for The International Pharmacopoeia (Working document QAS/17.738, March 2018). The working document with line numbers and tracked changes is available for comment at www.who.int/medicines/areas/quality_safety/quality_assurance/projects.

[Note from the Secretariat: Following laboratory investigations performed to establish Atazanavir sulfate ICRS it is proposed to revise the monograph on Atazanavir sulfate with a view to: • change the recrystallization solvent used in identity test A by IR (from methanol to acetone); and• update the style of the monograph.In the text available at the above-mentioned website, changes from the current monograph are indicated in the text by insert or delete.]

Molecular formula. C38H52N6O7. H2O4S

Relative molecular mass. 802.9

Chemical names. Dimethyl (3S,8S,9S,12S)-9-benzyl-3,12-di-tert-butyl-8-hydroxy-4,11-dioxo-6-{[4-(pyridin-2-yl)phenyl]methyl}-2,5,6,10,13-pentaazatetradecanedioate monosulfate; 2,5,6,10,13-Pentaazatetradecanedioic acid,

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

230

3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-, 1,14-dimethyl ester, (3S,8S,9 S,12S)-, sulfate (1:1); CAS Reg. No. 229975-97-7.

Description. A white to a pale yellow powder.

Solubility. Freely soluble in methanol, practically insoluble in water.

Category. Antiretroviral (protease inhibitor).

Storage. Atazanavir sulfate should be kept in a tightly closed container.

Additional information. Atazanavir sulfate is slightly hygroscopic and may exhibit polymorphism.

RequirementsAtazanavir sulfate contains not less than 98.0% and not more than 102.0% of C38H52N6O7•H2SO4, calculated with reference to the dried substance.

Identity tests• Either test A and D or test B, C and D should be applied.A. Carry out the examination as described under 1.7 Spectrophotometry in the infrared

region. The infrared absorption spectrum is concordant with the spectrum obtained from atazanavir sulfate RS or with the reference spectrum of atazanavir sulfate.

If the spectra thus obtained are not concordant repeat the test using the residues obtained by separately dissolving the test substance and atazanavir sulfate RS in a small amount of acetone R and evaporating to dryness. The infrared absorption spectrum is concordant with the spectrum obtained from atazanavir sulfate RS.

B. Carry out test B.1, or where ultraviolet (UV) detection is not available, test B.2.

B.1 Carry out the test as described under 1.14.1 Thin-layer chromatography using silica gel R6 as the coating substance and a mixture of 9.5 volumes of dichloromethane R and 0.5 volume of 2-propanol R as the mobile phase. Apply separately to the plate 10 μL of each of the following 2 solutions in methanol R. For solution (A) use 1 mg of the test substance per mL. For solution (B) use 1 mg of atazanavir sulfate RS per mL. After removing the plate from the chromatographic chamber allow it to dry exhaustively in air or in a current of air.

Examine the chromatogram in UV light (254 nm). The principal spot obtained with solution (A) corresponds in position, appearance and intensity to that obtained with solution (B).

B.2 Carry out the test as described under 1.14.1 Thin-layer chromatography using the conditions described under test B.1, but using a plate containing silica gel R5 as the coating substance.

Spray the plate with basic potassium permanganate (~5 g/L) TS. Examine the chromatogram in daylight. The principal spot obtained with solution (A) corresponds in position, appearance and intensity to that obtained with solution (B).

Atazanavir sulfate (Ph. Int.)

231

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

C. The absorption spectrum of a 10 µg/mL solution of the test substance in methanol R, when observed between 230 nm and 340 nm, exhibits two maxima at about 250 nm and 280 nm.

D. A 20 mg/mL solution of the test substance yields reaction A described under 2.1 General identification tests as characteristic of sulfates.

Heavy metals. 2.2.3 Limit test for heavy metals

Sulfated ash (2.3). Not more than 2.0 mg/g.

Loss on drying. Dry for 3 hours at 105°C; it loses not more than 10.0 mg/g.

Specificopticalrotation. Use a 10 mg/mL solution in equal volumes of methanol R and water R at 22°C and calculate with reference to the dried substance; the specific optical rotation is between -44° and -48°.

Related substancesCarry out the test as described under 1.14.4 High-performance liquid chromatography using a stainless steel column (150 mm × 4.6 mm) packed with end-capped, base-deactivated particles of silica gel, the surface of which has been modified with chemically-bonded octylsilyl groups (5 μm). Use the following conditions for gradient elution:

mobile phase A: 0.02 M phosphate buffer pH 3.5, acetonitrile R (70:30 v/v);

mobile phase B: 0.02 M phosphate buffer pH 3.5, acetonitrile R (30:70 v/v).

Prepare the 0.02 M phosphate buffer pH 3.5 by dissolving 2.72 g of anhydrous potassium dihydrogen phosphate R in 800 mL of water R, adjust the pH to 3.5 by adding phosphoric acid (~105 g/L) TS and dilute to 1000 mL with water R.

Time (minutes)

Mobile phase A (% v/v)

Mobile phase B (% v/v)

Comments

0–2 100 0 Isocratic2–10 100 to 75 0 to 25 Linear gradient

10–30 75 to 50 25 to 50 Linear gradient30–45 50 to 0 50 to 100 Linear gradient45–50 0 100 Isocratic50–52 0 to 100 100 to 0 Linear gradient52–60 100 0 Isocratic

Prepare the following solutions using as diluent a mixture of equal volumes of water R and acetonitrile R. For solution (1) dissolve about 50 mg of the test substance and dilute to 50.0 mL. For solution (2) dilute 10.0 mL of solution (1) to 200.0 mL. Dilute 10.0 mL of this solution to 100.0 mL. For solution (3) mix 1 mL of solution (1) with 4.5 mL of water R and 0.5 mL of sodium hydroxide (10 g/L) TS and heat the mixture in a water-bath at 85°C for 15 minutes.

Operate with a flow rate of 1.0 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 250 nm. Maintain the column at a temperature of 30°C.

Atazanavir sulfate (Ph. Int.)

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

232

Inject 20 µL of solution (3). The test is not valid unless the resolution between the peak due to atazanavir (retention time about 22 minutes) and the peak with a relative retention of about 1.2 is at least 4.

Inject alternately 20 µL each of solutions (1) and (2).

In the chromatograms obtained with test solution (1):

• the area of any peak, other than the principal peak, is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.5%);

• the sum of the areas of all peaks, other than the principal peak, is not greater than twice the area of the principal peak in the chromatogram obtained with solution (2) (1.0%). Disregard any peak with an area less than 0.1 times the area of the principal peak in the chromatogram obtained with solution (2) (0.05%).

AssayDissolve 0.300 g, accurately weighed, in 30 mL of methanol R by sonication for 10 minutes. Then add 30 mL of water and titrate with sodium hydroxide (0.1 mol/L) VS, determining the end-point potentiometrically. Each mL of sodium hydroxide (0.1 mol/L) VS is equivalent to 40.145 mg of C38H52N6O7•H2SO4.

***

Atazanavir sulfate (Ph. Int.)

233

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

Atazanavir capsules(Atazanaviri capsulae)

This is a draft proposal of a revised monograph for The International Pharmacopoeia (Working document QAS/17.739, March 2018). The working document with line numbers and tracked changes is available for comment at www.who.int/medicines/areas/quality_safety/quality_assurance/projects.

[Note from the Secretariat: Following laboratory investigations performed to establish Atazanavir sulfate ICRS it is proposed to revise the monograph on Atazanavir capsules with a view to: • update the information given under Additional information to reflect the information given in the 20th

WHO Model List of Essential Medicines; and• use the absorptivity value of atazanvir sulfate to calculate the result of the dissolution test and assay

method B.In the text available at the above-mentioned website, changes from the current monograph are indicated in the text by insert or delete.]

Category. Antiretroviral (protease inhibitor).

Storage. Atazanavir capsules should be kept in a tightly closed container.

Additional information. Strength in the current WHO Model List of Essential Medicines (EML): 100 mg, 300 mg of atazanavir (as sulfate). Strength in the current WHO EML for Children: 100 mg of atazanavir (as sulfate).

RequirementsComply with the monograph for Capsules.

DefinitionAtazanavir capsules contain atazanavir sulfate. They contain not less than 90.0% and not more than 110.0% of the amount of atazanavir, C38H52N6O7, stated on the label. Each mg of atazanavir (C38H52N6O7) is equivalent to 1.139 mg of atazanavir sulfate (C38H52N6O7•H2SO4).

Identity testsA. Carry out test A.1, or where UV detection is not available, test A.2.

A.1 Carry out the test as described under 1.14.1 Thin-layer chromatography using silica gel R6 as the coating substance and a mixture of 9.5 volumes of dichloromethane R and 0.5 volume of 2-propanol R as the mobile phase. Apply separately to the plate 10 µL of each of the following 2 solutions in methanol R. For solution (A) disperse a quantity of the content of the capsules containing about 20 mg of atazanavir in 10 mL of methanol R, sonicate for 10 minutes, allow to cool to room temperature, dilute to 20 mL, filter and use the filtrate. For solution (B) use 1.1 mg of atazanavir sulfate RS per mL.

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

234

Atazanavir capsules (Ph. Int.)

After removing the plate from the chromatographic chamber allow it to dry exhaustively in air or a current of air. Examine the chromatogram in ultraviolet light (254 nm).

The principal spot obtained with solution (A) corresponds in position, appearance and intensity to that obtained with solution (B).

A.2 Carry out the test as described under 1.14.1 Thin-layer chromatography using the conditions described above under test A.1 but using a plate containing silica gel R5 as the coating substance. Spray with basic potassium permanganate (~5 g/L) TS. Examine the chromatogram in daylight.

The principal spot obtained with solution (A) corresponds in position, appearance and intensity with that obtained with solution (B).

B. Disperse a quantity of the content of the capsules containing about 20 mg of atazanavir in 10 mL of methanol R, sonicate for 10 minutes, allow to cool to room temperature, dilute to 20 mL and filter. Dilute 1.0 mL of the filtrate to 100.0 mL with methanol R. The absorption spectrum (1.6) of the resulting solution, when observed between 230 and 340 nm, exhibits two maxima at about 250 nm and 280 nm.

C. To a quantity of the content of the capsules equivalent to 0.2 g of atazanavir add 10 mL of a mixture of 1 volume of water R and 1 volume of acetonitrile R, shake and filter. The filtrate yields Reaction A described under 2.1 General identification tests as characteristic of sulfates.

DissolutionCarry out the test as described under 5.5 Dissolution test for solid oral dosage forms using as the dissolution medium 900 mL of dissolution buffer pH 2.5 TS and rotating the paddle at 50 revolutions per minute. At 45 minutes withdraw a sample of 10.0 mL of the medium through an in-line filter. Allow the filtered sample to cool to room temperature. Dilute a suitable volume of the filtrate with dissolution medium to obtain a solution containing 0.10 mg of atazanavir per mL. Measure the absorbance (1.6) of a 1 cm layer of the resulting solution at the maximum at about 250 nm, using the dissolution medium as the blank. For each of the capsules tested, calculate the total amount of atazanavir (C38H52N6O7) in the medium, using an absorptivity value of 11.4 for atazanavir sulfate ( = 114). Each mg of atazanavir sulfate (C38H52N6O7•H2SO4) is equivalent to 1.139 mg of atazanavir (C38H52N6O7).

Evaluate the results as described under 5.5 Dissolution test for solid dosage forms, Acceptance criteria. The amount in solution for each capsule is not less than 75% (Q) of the amount stated on the label.

Related substancesCarry out the test as described under 1.14.4 High-performance liquid chromatography using a stainless steel column (150 mm × 4.6 mm) packed with end-capped base-deactivated particles of silica gel, the surface of which has been modified with chemically-bonded octylsilyl groups (5 μm). Use the following conditions for gradient elution:

235

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

mobile phase A: 0.02 M phosphate buffer pH 3.5, acetonitrile R (70:30 v/v);

mobile phase B: 0.02 M phosphate buffer pH 3.5, acetonitrile R (30:70 v/v).

Prepare the 0.02 M phosphate buffer pH 3.5 by dissolving 2.72 g of anhydrous potassium dihydrogen phosphate R in 800 mL of water R, adjust the pH to 3.5 by adding phosphoric acid (~105 g/L) and dilute to 1000 mL with water R.

Time (minutes)

Mobile phase A (% v/v)

Mobile phase B (% v/v)

Comments

0–2 100 0 Isocratic2–10 100 to 75 0 to 25 Linear gradient

10–30 75 to 50 25 to 50 Linear gradient30–45 50 to 0 50 to 100 Linear gradient45–50 0 100 Isocratic50–52 0 to 100 100 to 0 Linear gradient52–60 100 0 Isocratic

Prepare the following solutions using as diluent a mixture of equal volumes of acetonitrile R and water R. For solution (1) weigh and mix the contents of 20 capsules. Transfer a quantity of the mixed contents equivalent to 20 mg of atazanavir into a 20 mL volumetric flask. Add about 10 mL of the diluent, sonicate for 10 minutes, allow to cool to room temperature, make up to volume and filter. For solution (2) dilute 1.0 mL of solution (1) to 100.0 mL. For solution (3) mix 1 mL of solution (1) with 4.5 mL of water R and 0.5 mL of sodium hydroxide (10 g/L) TS and heat the mixture in a water bath at 85°C for 15 minutes.

Operate with a flow rate of 1.0 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 250 nm. Maintain the column at a temperature of 30°C.

Inject 20 µL of solution (3). The test is not valid unless the resolution between the peak due to atazanavir (retention time about 22 minutes) and the peak with a relative retention of about 1.2 is at least 4.

Inject alternatively 20 µL each of solutions (1) and (2).

In the chromatograms obtained with test solution (1):

• the area of any peak, other than the principal peak, is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (1.0%);

• the sum of the areas of all peaks, other than the principal peak, is not greater than twice the area of the principal peak in the chromatogram obtained with solution (2) (2.0%). Disregard any peak with an area less than 0.1 times the area of the principal peak in the chromatogram obtained with solution (2) (0.1%).

Atazanavir capsules (Ph. Int.)

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

236

Assay• Either test A or test B may be applied.A. Carry out the test as described under 1.14.4 High-performance liquid chromatography

using a stainless steel column (150 mm × 4.6 mm) packed with end-capped base-deactivated particles of silica gel, the surface of which has been modified with chemically-bonded octylsilyl groups (5 μm).

As the mobile phase use a solution prepared as follows: 60 volumes of acetonitrile R and 40 volumes of 0.02 M phosphate buffer pH 3.5. Prepare the 0.02 M phosphate buffer pH 3.5 according to the procedure described in the related substances test.

Prepare the following solutions using as diluent a mixture of equal volumes of acetonitrile R and water R. For solution (1) weigh and mix the contents of 20 capsules. Transfer a quantity equivalent to 20.0 mg of atazanavir, accurately weighed, into a 20 mL volumetric flask. Add about 10 mL of the diluent, sonicate for about 10 minutes, allow to cool to room temperature and make up to volume. Filter a portion of this solution, discarding the first few mL. Dilute 5.0 mL of the filtrate to 50.0 mL with the diluent. For solution (2) use 0.11 mg of atazanavir sulfate RS per mL.

Operate with a flow rate of 1.0 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 250 nm. Maintain the column at a temperature of 30°C.

Inject alternately 20 µL each of solutions (1) and (2) and record the chromatograms for 1.5 times the retention time of atazanavir (about 4 minutes).

Measure the areas of the peak responses obtained in the chromatograms from solutions (1) and (2) and calculate the percentage content of atazanavir, (C38H52N6O7) in the capsules, using the declared content of C38H52N6O7 in atazanavir sulfate RS.

B. Weigh and mix the contents of 20 capsules. Transfer a quantity equivalent to 20 mg of atazanavir, accurately weighed, to a 20 mL volumetric flask. Add about 10 mL of methanol R, sonicate for about 10 minutes, allow to cool to room temperature and make up to volume with methanol R. Filter a portion of this solution, discarding the first few mL of the filtrate. Dilute 1.0 mL of the filtrate to 10.0 mL with methanol R. Measure the absorbance (1.6) of a 1 cm layer of this solution in at the maximum at about 250 nm, using methanol R as a blank. Calculate the percentage content of C38H52N6O7 in the capsules using an absorptivity value of 14.5 for atazanavir sulfate ( = 145). Each mg of atazanavir sulfate (C38H52N6O7 • H2SO4) is equivalent to 1.139 mg of atazanavir (C38H52N6O7).

***

Atazanavir capsules (Ph. Int.)

237

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

Daclatasvir dihydrochloride(Daclatasviri dihydrochloridum)

This is a draft proposal of a monograph for The International Pharmacopoeia (Working document QAS/18.762, May 2018). The working document with line numbers is available for comment at www.who.int/medicines/areas/quality_safety/quality_assurance/projects.

[Note from the Secretariat. The monograph on Daclatasvir dihydrochloride is proposed for inclusion in The International Pharmacopoeia. The methods and specifications were drafted based on information provided by manufacturers and found in the scientific literature and on laboratory investigations.]

Molecular formula. C40H50N8O6·2HCl

Relative molecular mass. 811.81

Graphic formula

Chemical name. Methyl N-[(2S)-1-[(2S)-2-[5-[4-[4’-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate dihydrochloride; CAS Reg. No. 1009119-65-6

Description. A white to a pale yellow powder.

Solubility. Freely soluble in water, soluble in methanol and very slightly soluble in dimethylformamide.

Category. Antiviral (nonstructural protein 5A inhibitor).

Storage. Daclatasvir dihydrochloride should be kept in a tightly closed container.

Additional information. Daclatasvir dihydrochloride may exhibit polymorphism.

RequirementsManufacture. The production method is validated to demonstrate that genotoxic halogenated biphenyl derivatives are adequately controlled in the final product.

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

238

Definition. Daclatasvir dihydrochloride contains not less than 97.0% and not more than 102.0% (“Assay”, method A) or not less than 98.0% and not more than 102.0% (“Assay”, method B) of C40H50N8O6·2HCl, calculated with reference to the anhydrous substance.

Identity tests• Either tests A, E and F or tests D, E and F together with any one of tests B or C may be

applied.A. Carry out the examination as described under 1.7 Spectrophotometry in the infrared

region. The infrared absorption spectrum is concordant with the spectrum obtained from daclatasvir dihydrochloride RS or with the reference spectrum of daclatasvir dihydrochloride.

If the spectra thus obtained are not concordant repeat the test using the residues obtained by separately dissolving the test substance and daclatasvir dihydrochloride RS in a small amount of methanol R and evaporating to dryness. The infrared absorption spectrum is concordant with the spectrum obtained from daclatasvir dihydrochloride RS.

B. Carry out the test as described under 1.14.4 High-performance-liquid chromatography using the conditions given under “Assay”, method A. The retention time of the principal peak in the chromatogram obtained with solution (1) corresponds to the retention time of the peak due to daclatasvir in the chromatogram obtained with solution (2).

C. Carry out test C.1 or, where UV detection is not available, test C.2.

C.1 Carry out test as described under 1.14.1 Thin-layer chromatography using silica gel R4 or similar as the coating substance and a mixture of 77 volumes of ethyl acetate R, 15 volumes of methanol R and 8 volumes of water R as the mobile phase. Apply separately to the plate 2 μL of each of the following 2 solutions in methanol R containing (A) 10 mg of the test substance per mL and (B) 10 mg of daclatasvir dihydrochloride RS per mL. After removing the plate from the chromatographic chamber allow it to dry in air or in a current of cool air. Examine the chromatogram in ultraviolet light (365 nm).

The principal spot obtained with solution (A) corresponds in position, appearance and intensity with that obtained with solution (B).

C.2 Carry out the test as described under 1.14.1 Thin-layer chromatography using the conditions described above under C.1. After drying the plate spray with basic potassium permanganate (5 g/L) TS. Examine the chromatogram in daylight.

The principal spot obtained with solution (A) corresponds in position, appearance and intensity with that obtained with solution (B).

D. The absorption spectrum (1.6) of a 10 µg per mL solution of the test substance in methanol R, when observed between 230 nm and 400 nm, exhibits one maximum at 314 nm.

E. Determine the specific optical rotation (1.4) using a 10 mg per mL solution of the test substance in methanol R. Calculate with reference to the anhydrous substance:  = –92.0 to –102.0.

Daclatasvir dihydrochloride (Ph. Int.)

239

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

F. Dissolve 20 mg of the test substance in 20 mL methanol R; the solution yields reaction A described under 2.1 General identification tests as characteristic of chlorides.

Sulfated ash (2.3). Not more than 1.0 mg/g.

Heavy metals. Use 1.0 g for the preparation of the test solution as described under 2.2.3 Limit test for heavy metals, Procedure 1; determine the heavy metals content according to method A; not more than 20 μg/g.

Water. Determine as described under 2.8 Determination of water by the Karl Fischer method, method A, using 0.2000 g of the substance; the water content is not more than 10 mg/g.

pH value. pH of a 10 mg/mL solution, 2.5–3.5

Impurity A (daclatasvir enantiomer). Carry out test as described under 1.14.4 High-performance liquid chromatography using a stainless steel column (15 cm × 4.6 mm) packed with particles of silica gel, the surface of which has been modified with chemically-bonded cellulose tris (3,5-dichlorophenyl carbamate) (3 µm).1 As mobile phase use a mixture of 30 volumes of 1.58 g per litre ammonium bicarbonate R in water and 70 volumes of acetonitrile R.

Operate at a flow rate of 1.0 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 320 nm. Maintain the column temperature at 40°C.

Prepare the following solutions in mobile phase. For solution (1) dissolve 25.0 mg of the test substance in 50.0 mL. For solution (2) dilute 5.0 mL of solution (1) to 100.0 mL. Dilute 2.0 mL of this solution to 100.0 mL. For solution (3) use a solution containing 0.01 mg daclatasvir impurity A and 0.01 mg daclatasvir dihydrochloride RS per mL.

Inject 10 µL of solution (3). The test is not valid unless the resolution factor between the peaks due to daclatasvir (retention time about 4.5 minutes) and impurity A (daclatasvir enantiomer) (relative retention of about 1.6) is at least 3.0.

Inject alternately 10 µL of solutions (1) and (2).

In the chromatogram obtained with solution (1):

• the area of any peak corresponding to impurity A (daclatasvir enantiomer) is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.1%).

Related substances. Carry out the test as described under 1.14.4 High-performance liquid chromatography.

Use the following conditions for gradient elution:mobile phase A: 0.1% (v/v) solution of trifluoroacetic acid R;mobile phase B: a mixture of 30 volumes of methanol R and 70 volumes of acetonitrile R.

1 A Lux i-Cellulose-5 column or a Chiralpak IC-3 column were found suitable.

Daclatasvir dihydrochloride (Ph. Int.)

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

240

Time (minutes) Mobile phase A (% v/v)

Mobile phase B (% v/v)

Comments

0–1 80 20 Isocratic1–25 80 to 55 20 to 45 Linear gradient25–30 55 to 30 45 to 70 Linear gradient30–35 30 70 Isocratic35–37 30 to 80 70 to 20 Return to initial composition37–45 80 20 Re-equilibration

Operate at a flow rate of 1.0 mL/minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 304 nm. Maintain the column at a temperature of 40°C.

Prepare the following solutions using as diluent a mixture of 80 volumes of mobile phase A and 20 volumes of mobile phase B. For solution (1) dissolve 25.0 mg of the substance to be examined and dilute to 50.0 mL. For solution (2) dilute 1.0 mL of solution (1) to 100.0 mL. Dilute 5.0 mL of this solution to 50.0 mL. For solution (3) use a solution containing 0.5 mg of daclatasvir for peak identification RS (containing daclatasvir and the impurities B, D, F, G, H and I) per mL.

Inject alternatively 10 µL of solutions (1), (2) and (3).

Use the chromatogram obtained with solution (3) and the chromatogram supplied with daclatasvir for peak identification RS to identify the peaks due to the impurities B, D, F, G, H and I in the chromatogram obtained with solution (1). The test is not valid unless the peak-to-valley ration (Hp/Hv) is at least 20, where Hp is the height above the extrapolated baseline of the peak due to the co-eluting impurities B and C and Hv is the height above the extrapolated baseline at the lowest point of the curve separation the peak due to daclatasvir from the peak due to the co-eluting impurities B and C. The impurities, if present, are eluted at the following relative retentions with reference to daclatasvir (retention time about 17 minutes): impurity I about 0.21; impurity H about 0.62; impurity G about 0.76; impurities B and C about 1.12; impurity E about 1.16; impurity D about 1.22; impurity J about 1.39; impurity K about 1.66; and impurity F about 1.82.

In the chromatogram obtained with solution (1):

• the sum of the areas of any peak corresponding to impurities B and C (impurities B and C may co-elute) is not greater than 1.5 times the area of the peak due to daclatasvir obtained with solution (2) (0.15%);

• the area of any peak corresponding to impurities I, H, G, D or F is not greater than 1.5 times the area of the peak due to daclatasvir obtained with solution (2) (0.15%);

• the area of any other impurity peak is not greater than the area of the peak due to daclatasvir obtained with solution (2) (0.10%);

• the sum of the areas of all impurity peaks is not greater than 10 times the area of the principal peak obtained with solution (2) (1.0%). Disregard any peak with an area less than 0.5 times the area of the peak due to daclatasvir obtained with solution (2) (0.05%).

Daclatasvir dihydrochloride (Ph. Int.)

241

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

Assay• Either method A or method B may be applied.A. Carry out test as described under 1.14.4 High-performance liquid chromatography using

a stainless steel column (15 cm x 4.6 mm) packed with base-deactivated particles of silica gel, the surface of which has been modified with chemically-bonded octadecylsilyl groups (3.5 µm).2

Use the following conditions for gradient elution:mobile phase A: 0.1 % (v/v) solution of trifluoroacetic acid R;mobile phase B: a mixture of 50 volumes of methanol R and 50 volumes of acetonitrile R.

Time (minutes) Mobile phase A (% v/v)

Mobile phase B (% v/v)

Comments

0–1 70 30 Isocratic1–13 70 to 60 30 to 40 Linear gradient13–16 60 to 15 40 to 85 Linear gradient16–18 15 85 Isocratic18–20 15 to 70 85 to 30 Return to initial composition20–25 70 30 Re-equilibration

Operate at a flow rate of 1.0 mL/minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 304 nm. Maintain the column at a temperature of 40°C.

Prepare the following solutions using as diluent a mixture of 70 volumes of mobile phase A and 30 volumes of mobile phase B.

For solution (1) dissolve 25.0 mg of the substance to be examined and dilute to 50.0 mL. Dilute 10.0 mL of this solution to 50.0 mL. For solution (2) dissolve 25.0 mg of daclatasvir dihydrochloride RS and dilute to 50.0 mL. Dilute 10.0 mL of this solution to 50.0 mL.

Inject alternately 20 µL each of solutions (1) and (2).

Measure the areas of the peak responses obtained in the chromatograms from solutions (1) and (2) and calculate the percentage content of daclatasvir dihydrochloride (C40H50N8O6·2HCl) using the declared content of C40H50N8O6·2HCl in daclatasvir dihydrochloride RS.

B. Dissolve about 0.3 g, accurately weighed, in 5 mL water and add 20 mL of ethanol (~750 g/L) TS. Titrate with sodium hydroxide (0.1 mol/L) VS, determining the end-point potentiometrically. Each mL of sodium hydroxide (0.1 mol/L) VS is equivalent to 40.59 mg of C40H50N8O6·2HCl.

2 An XBridge C18 column or a Zorbax SB C18 column were found suitable.

Daclatasvir dihydrochloride (Ph. Int.)

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

242

Impurities

A. Methyl N-[(2R)-1-[(2R)-2-[5-[4-[4’-[2-[(2R)-1-[(2R)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate (daclatasvir enantiomer) (synthesis-related impurity)

B. Methyl N-[(2R)-1-[(2S)-2-[5-[4-[4’-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate (RSSS diastereomer) (synthesis-related impurity)

C. Methyl N-[(2S)-1-[(2R)-2-[5-[4-[4’-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate (SRSS diastereomer) (synthesis-related impurity)

Daclatasvir dihydrochloride (Ph. Int.)

243

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

D. Methyl N-[(2R)-1-[(2S)-2-[5-[4-[4’-[2-[(2S)-1-[(2R)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate (RSSR diastereomer) (synthesis-related impurity)

E. Methyl N-[(2S)-1-[(2S)-2-[5-[4-[4’-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]carbamate (synthesis-related impurity)

F. Methyl [(2S)-1-{(2S)-[5-(4’-{2-[(2S)-1- {(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1,3-oxazol-5-yl}biphenyl-4-yl)-1H-imidazol-2-yl] pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate (synthesis-related impurity)

G. Methyl [(2S)-1-{(2S)-2-[5-(4’-{2-(2S)-1-acetylpyrrolidin-2-yl]-1H-imidazol-5-yl}biphenyl-4-yl)-1H-imidazol-2-yl]pynolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate (synthesis-related impurity)

Daclatasvir dihydrochloride (Ph. Int.)

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

244

H. Methyl((1S)-1-(((2S)-2-(5-(4’-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate (synthesis-related impurity)

I. 5,5’-[1,1’-Biphenyl]-4,4’-diylbis[2-(2S)-2-pyrrolidinyl-1H-imidazole] (synthesis-related impurity)

J. (2S,2’S)-2,2’-([1,1’-biphenyl]-4,4’-diyldi-1H-imidazole-5,2-diyl)bis-1-pyrrolidinecarboxylic acid 1,1’-bis(1,1-dimethylethyl) ester (synthesis-related impurity)

K. 4,4’-Diacetylbiphenyl (synthesis-related impurity)

***

Daclatasvir dihydrochloride (Ph. Int.)

245

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

Daclatasvir tablets (Daclatasviri compressi)

This is a draft proposal of a monograph for The International Pharmacopoeia (Working document QAS/18.763, May 2018). The working document with line numbers is available for comment at www.who.int/medicines/areas/quality_safety/quality_assurance/projects.

[Note from the Secretariat. The monograph on Daclatasvir tablets is proposed for inclusion in The International Pharmacopoeia. The methods and specifications were drafted based on information provided by manufacturers, found in the scientific literature and on laboratory investigations. Being the first public specification, this monograph is expected to play an important role in ensuring access to safe, effective and quality-assured daclatasvir tablets worldwide. All manufacturers of these products are therefore invited to provide their feedback to the Secretariat of The International Pharmacopoeia to help ensure that this proposed monograph adequately controls the daclatasvir tablets they manufacture.]

Category. Antiviral (Nonstructural protein 5A inhibitor)

Storage. Daclatasvir tablets should be kept in a well-closed container.

Labelling. The designation of the container should state that the active ingredient is in the dihydrochloride form and the quantity should be indicated in terms of the equivalent amount of daclatasvir.

Additional information. Strength in the current WHO Model List of Essential Medicines (EML): 30 mg and 60 mg daclatasvir.

RequirementsComply with the monograph for Tablets.

Definition. Daclatasvir tablets contain Daclatasvir dihydrochloride. They contain not less than 90.0% and not more than 110.0% of the amount of daclatasvir (C40H50N8O6) stated on the label.

Identity tests• Either tests A and C or tests B and C may be applied.A. Carry out test A.1. or, where UV detection is not available, test A.2.

A.1. Carry out test as described under 1.14.1 Thin-layer chromatography using silica gel R6 or similar as the coating substance and a mixture of 77 volumes of ethyl acetate R, 15 volumes of methanol R and 8 volumes of water R as the mobile phase. Apply separately to the plate 2 μL of each of the following 2 solutions. For solution (A) shake a quantity of the powdered tablets containing 50 mg of daclatasvir with 5 mL of methanol R and filter. For solution (B) use a solution containing 11 mg of daclatasvir dihydrochloride RS per mL methanol R. After removing the plate from the

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

246

chromatographic chamber allow it to dry in air or in a current of cool air. Examine the chromatogram in ultraviolet light (365 nm).

The principal spot obtained with solution (A) corresponds in position, appearance and intensity with that obtained with solution (B).

A.2. Carry out the test as described under 1.14.1 Thin-layer chromatography using the conditions described above under text A.1. After drying the plate spray with basic potassium permanganate (5 g/L) TS. Examine the chromatogram in daylight.

The principal spot obtained with solution (A) corresponds in position, appearance and intensity with that obtained with solution (B).

B. Carry out the test as described under 1.14.4 High-performance liquid chromatography using the conditions and solutions given under “Assay”. The retention time of the principal peak in the chromatogram obtained with solution (1) corresponds to the retention time of the peak due to daclatasvir in the chromatogram obtained with solution (2).

C. To a quantity of powdered tablets containing the equivalent of 10 mg daclatasvir add 40 mL methanol R, sonicate for 5 minutes, allow to cool to room temperature, dilute to 50 mL and filter. Dilute 1 mL of the filtrate to 20 mL with methanol R. The absorption spectrum (1.6) of the resulting solution, when observed between 230 nm and 400 nm, exhibits one maximum at 314 nm.

Dissolution. Carry out the test as described under 5.5 Dissolution test for solid oral dosage forms using as the dissolution medium 500 mL of dissolution buffer pH 6.8 and rotating the paddle at 75 revolutions per minute. At 30 minutes withdraw a sample of 10 mL of the medium through an in-line filter. Allow the filtered sample to cool down to room temperature.

If necessary, dilute a suitable volume of the filtrate with dissolution medium to obtain a solution containing 0.06 mg of daclatasvir per mL. Measure the absorbance (1.6) of a 1 cm layer of the resulting solution at the maximum at about 314 nm, using the dissolution buffer as the blank. Measure at the same time and under the same conditions the absorbance of a suitable solution of daclatasvir dihydrochloride RS in the dissolution buffer.

For each of the tablets tested calculated the amount of daclatasvir (C40H50N8O6) in the medium. Each mg of daclatasvir dihydrochloride is equivalent to 0.910 mg of daclatasvir.

Evaluate the results as described under 5.5 Dissolution test for solid oral dosage forms, Acceptance criteria. The amount of daclatasvir in solution for each tablet is not less than 75% (Q) of the amount declared on the label.

Related substances. Carry out test as described under 1.14.4 High-performance liquid chromatography.

Use the following conditions for gradient elution:mobile phase A: 0.1% (v/v) solution of trifluoroacetic acid; mobile phase B: a mixture of 30 volumes of methanol R and 70 volumes of acetonitrile R.

Daclatasvir tablets (Ph. Int.)

247

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

Time (minutes) Mobile phase A (% v/v)

Mobile phase B (% v/v)

Comments

0–1 80 20 Isocratic1–25 80 to 55 20 to 45 Linear gradient25–30 55 to 30 45 to 70 Linear gradient30–35 30 70 Isocratic35–37 30 to 80 70 to 20 Return to initial composition37–45 80 20 Re-equilibration

Prepare the following solutions using as diluent a mixture of 80 volumes of mobile phase A and 20 volumes of mobile phase B.

For solution (1) transfer a quantity of the powdered tablets containing the equivalent of 25.0 mg of daclatasvir to a 40 mL volumetric flask. Add about 30 mL diluent and sonicate for 5 minutes, cool to room temperature and make up to the volume with the diluent and filter. For solution (2) dilute 1.0 mL of solution (1) to 100.0 mL. Dilute 5.0 mL to this solution to 50.0 mL. For solution (3) use a solution containing 0.5 mg of daclatasvir for peak identification RS (containing daclatasvir and the impurities B, D, F, G, H and I) per mL.

Inject alternatively 10 µL of solutions (1), (2) and (3).

Use the chromatogram supplied with daclatasvir for peak identification to identify the peaks due to the impurities H and G in the chromatogram obtained with solution (3). The test is not valid unless the peak-to-valley ration (Hp/Hv) is at least 20, where Hp is the height above the extrapolated baseline of the peak due to the co-eluting impurities B and C and Hv is the height above the extrapolated baseline at the lowest point of the curve separation the peak due to daclatasvir from the peak due to the co-eluting impurities B and C.

In the chromatogram obtained with solution (1):

• the area of any impurity peak is not greater than 2 times the area of the peak due to daclatasvir in the chromatogram obtained with solution (2) (0.2%);

• the sum of all areas of all impurity peaks is not greater than 15 times the area of the peak due to daclatasvir obtained with solution (2) (1.5%). Disregard any peak with an area less than the area of the peak due to daclatasvir obtained with solution (2) (0.1%).

Assay. Carry out test as described under 1.14.4 High-performance liquid chromatography using a stainless steel column (15 cm x 4.6 mm) packed with base-deactivated particles of silica gel, the surface of which has been modified with chemically-bonded octadecylsilyl groups (3.5 µm).1

Use the following conditions for gradient elution:mobile phase A: 0.1% (v/v) solution of trifluoroacetic acid; mobile phase B: a mixture of 50 volumes of methanol R and 50 volumes of acetonitrile R.

1 An XBridge C18 column or a Zorbax SB C18 column were found suitable.

Daclatasvir tablets (Ph. Int.)

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

248

Time (minutes) Mobile phase A (% v/v)

Mobile phase B (% v/v)

Comments

0–1 70 30 Isocratic1 - 13 70 to 60 30 to 40 Linear gradient13–16 60 to 15 40 to 85 Linear gradient16–18 15 85 Isocratic18–20 15 to 70 85 to 30 Return to initial composition20–25 70 30 Re-equilibration

Operate at a flow rate of 1.0 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 304 nm. Maintain the column temperature at 40°C.

Prepare the following solutions using as diluent a mixture of 70 volumes of mobile phase A and 30 volumes of mobile phase B.

For solution (1) weigh and powder 20 tablets. Transfer a quantity of the powdered tablets containing 100.0 mg of daclatasvir to a 100 mL volumetric flask. Add about 60 mL of diluent and sonicate for 5 minutes, cool to room temperature and make up to volume with diluent. Filter and dilute 5.0 mL of the filtrate to 50.0 mL. For solution (2) dissolve 55.0 mg of daclatasvir dihydrochloride RS and dilute to 50.0 mL. Dilute 5.0 mL of this solution to 50.0 mL.

Inject alternately 20 µL each of solutions (1) and (2).

Measure the areas of the peak responses corresponding to daclatasvir obtained in the chromatograms from solutions (1) and (2) and calculate the percentage content of daclatasvir (C40H50N8O6·) in the tablets using the declared content of C40H50N8O6·2HCl in daclatasvir dihydrochloride RS. Each mg of daclatasvir dihydrochloride is equivalent to 0.910 mg of daclatasvir.

ImpuritiesThe impurities limited by the requirements of this monograph include those listed in the monograph on Daclatasvir dihydrochloride.

***

Daclatasvir tablets (Ph. Int.)

249

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

Polymorphism

This is a draft proposal of a chapter for The International Pharmacopoeia (Working document QAS/17.716/Rev.1, May 2018). The draft has been revised based on the comments received during the public consultation held in July–September 2017. The working document with line numbers is available for comment at www.who.int/medicines/areas/quality_safety/quality_assurance/projects.

[Note from the Secretariat. It is proposed to publish the following chapter on Polymorphism in the Supplementary Information section under “Notes for guidance”.]

Introduction and terminologyThe aim of this chapter is to provide a brief overview of:

• the terminology associated with crystal polymorphism; • some analytical techniques commonly used to characterise polymorphs; • the relevance of polymorphism for active pharmaceutical ingredients (APIs) and finished

pharmaceutical products (FPPs); and• the control strategies for polymorphism employed by The International Pharmacopoeia.

APIs and excipients, in the solid phase, can be classified as either crystalline or non-crystalline solids or a mixture thereof. A crystalline structure implies that the structural units (i.e. the unit cells) are repeated in a long range order. The atoms and/or molecules of an amorphous solid, however, are arranged in a non-ordered, random system, such as in the liquid state, and do not possess a distinguishable crystal lattice. Amorphous solids are classified as non-crystalline solids.

Variation in the crystallization conditions (temperature, pressure, solvent, concentration, rate of crystallization, seeding of the crystallization medium, presence and concentration of impurities, etc.) may cause the formation of different forms.

When the crystalline structure of the same chemical compound (and atomic formula) exhibitstwo or more patterns of the repeated unit cells, these crystalline structures are called polymorphs and the phenomena is referred to as polymorphism. The difference in internal crystal structure could be attributed to differences in molecule packing arrangements and/or different molecular conformations. When a chemical element (e.g. sulfur) exists in different crystalline forms, it is referred to as allotropy, not polymorphism (1). Due to the identical chemical composition of the polymorphic substance it will have the same chemical behaviour in solution, irrespective in the form in which it is presented.

Crystals of the same chemical compound with the same internal structure may exhibit different external shapes or crystal habits.

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

250

Solvates are crystal forms containing stoichiometric or non-stoichiometric quantities of a solvent. When the solvent incorporated into the crystal structure of the compound is water, the molecular adduct formed is referred to as a hydrate. Solvation and hydration products are also sometimes referred to as pseudopolymorphs.(2, 3, 4) However, the term “pseudopolymorphism” is ambiguous because of its use in different circumstances. It is therefore preferable to use only the terms “solvates” and “hydrates”.

Occasionally a compound of a given hydration/solvation state may crystallize into more than one crystalline form; an example of such a compound is nitrofurantoin.(5) Nitrofurantoin can be crystallized as two monohydrate forms (Forms I and II) and two anhydrous forms (designated polymorphs α and β).(5)

Crystal forms are said to be isostructural when they have the same overall crystal packing. Solvates, which have the same overall crystal packing, but differ only in the solvents included in their crystal structures, are termed isostructural solvates ,e.g. hydrate and isopropanolate of hexakis(2,3,6-tri-O-acetyl)-α-cyclodextrin.(6)

The term desolvated solvate (which includes hydrates) has been used to classify a compound that was originally crystallized as a solvate but when the incorporated solvent is removed the crystal lattice of the solvated and desolvated crystal lattices show no or only relatively small differences,(4) for example, desolvated monohydrate of terazosin HCl.(7)

Amorphous forms of APIs and excipients are of substantial interest because they are usually more soluble than their crystalline counterparts but are usually considered to be thermodynamically less stable. Solid-state properties of amorphous forms of the same chemical compound (i.e. thermal behaviour, solubility profile, etc.) may differ; this phenomenon is referred to as polyamorphism.(6)

Traditionally polymorphic forms of an API are classified as either crystalline, amorphous or solvate and hydrate forms. Co-crystals are crystalline materials composed of two or more different molecules, typically an API and co-crystal formers (“conformers”) within the same crystal lattice that are associated by nonionic and noncovalent bonds. An example of a co-crystal is fluoxetine HCl/succinic acid co-crystal.(8) Co-crystals are thus more similar to solvates, in that both contain more than one component in the lattice. However, for co-crystals the conformer is non-volatile.(3)

Pharmaceutical co-crystals have gained considerable attention as alternative forms in an attempt to enhance the bioavailability, stability and processability of the API in the manufacturing process. Another advantage of co-crystals is that they generate a diverse array of solid state forms for APIs that lack ionisable functional groups, which is a prerequisite for salt formation.(3) Guidance and reflection papers on the use and classification of pharmaceutical co-crystals have been published.(3, 9)

Characterization and thermodynamic stability of solid formsCrystalline forms are characterized based on the differences of their physical properties. Table 1 lists some examples of the properties that may differ among different forms.(9)

Polymorphism (Ph. Int.)

251

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

Table 1. Examplesofphysicalpropertiesthatmaydifferamongdifferentforms1. Packing properties

a. Molar volume and densityb. Refractive indexc. Conductivity (electrical and thermal)d. Hygroscopicity

2. Thermodynamic propertiesa. Melting and sublimation temperaturesb. Internal energy (i.e. structural energy)c. Enthalpy (i.e. heat content)d. Heat capacitye. Entropyf. Free energy and chemical potentialg. Thermodynamic activityh. Vapour pressurei. Solubility

3. Spectroscopic propertiesa. Electronic state transitionsb. Vibrational state transitionsc. Nuclear spin state transitions

4. Kinetic propertiesa. Dissolution rateb. Rates of solid state reactionsc. Stability

5. Surface properties a. Surface-free energyb. Interfacial tensionsc. Habit (i.e. shape)

6. Mechanical properties a. Hardnessb. Tensile strengthc. Compatibility, tabletingd. Handling and flow

Table 2 summarizes some of the most commonly used techniques to study and/or classify different forms. These techniques are often complementary and it is indispensable to use several of them. Demonstration of a non-equivalent structure by single crystal X-ray diffraction is currently regarded as the definitive evidence of polymorphism. X-ray powder diffraction can also be used to provide unequivocal proof of polymorphism.(10)

Any technique(s) chosen to confirm the identity of the specific form(s) must be proven to be suitably specific for the identification of the desired form(s). Care must be taken in choosing the appropriate sample preparation technique, as heat generation or exposure to elevated pressure may trigger conversion between different forms.

Table 2. Examples of some techniques that may be used to study and/or classify differentcrystallineforms

1. X-ray powder diffraction2. Single crystal X-ray diffraction3. Microcalorimetry4. Thermal analysis (1.2.1 melting point,* differential scanning calorimetry,

thermogravimetry, thermomicroscopy)5. Moisture sorption analysis6. Microscopy (electronic and optical)7. Solid-state nuclear magnetic resonance;8. Solubility studies9. Spectrophometry: Spectrophotometry in the infrared region (1.7)* and Raman

spectrophotometry10. Intrinsic dissolution rate11. Density measurement

* Methods currently employed by The International Pharmacopoeia

Polymorphism (Ph. Int.)

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

252

Using suitable analytical techniques, the thermodynamic stability of the forms should be investigated. The form with the lowest free energy is the most thermodynamically stable at a given temperature and pressure. The other forms are said to be in a metastable state. At normal temperature and pressure, a metastable form may remain unchanged or may change to a thermodynamically more stable form. In general the more stable the form the less soluble it is. Conversion to a thermodynamically more stable form, may cause changes in some of the physical properties (see Table 1) of the compound that may result in changes to other critical properties such as bioavailability, manufacturability (also referred to as processability), etc.

If there are several crystalline forms one form is thermodynamically more stable at a given temperature and pressure. A given crystalline form may constitute a phase that can reach equilibrium with other solid phases and with the liquid and gas phases.

If each crystalline form is the more stable within a given temperature range the change from one form to another is reversible and is said to be enantiotropic. The change from one phase to another is a univariate equilibrium so that at a given pressure this state is characterized by a transition temperature. However, if only one of the forms is stable over the entire temperature range, the change is irreversible or monotropic.(11)

Relevance of polymorphism for APIs and FPPsPolymorphism of APIs and excipients are of interest as they may affect bioavailability, toxicity and processability. Also the thermodynamic stability of the form included in the FPP is considered important as environmental conditions may compromise the stability thereof. For formulations where the API is dissolved, attention has to be paid to supersaturation with regards to different forms. A formulation might not be supersaturated regarding a metastable polymorph but supersaturated with regards to the thermodynamically stable polymorph. Control of the form by the manufacturer may be required during the processing of APIs and excipients and during the manufacturing of a dosage form to ensure the correct physical characteristics thereof. The control of a specific form is especially critical in the areas where the bioavailability, stability or processability are directly impacted.(4)

The form of a readily soluble API that is incorporated into a solution, for example, an injection, an oral solution or eye drops, is normally non-critical (an exception to this statement might be if the concentration of the solution is such that it is close to the limit of solubility of one of the possible polymorphs – as mentioned above). Similarly, if an API is processed during the manufacturing process to obtain an amorphous form (e.g. hot melt extrusion, spray-dried dispersion, etc.), the original form is considered non-critical, as long as the processability is not influenced.

The form may be critical when the material is included in a solid dosage form or as a suspension in a liquid dosage form. In such cases the characteristics of the different polymorphs may affect the bioavailability or dissolution of the material. The polymorphic form of a biopharmaceutical classification system (BCS) class I or III API in a solid oral dosage form is normally non-critical in terms of dissolution rate or bioavailability as by definition it would be readily soluble, but confirmation thereof by the manufacturer, is recommended. The ICH Harmonised Tripartite Guideline on Specifications: Test procedures and acceptance criteria for

Polymorphism (Ph. Int.)

253

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

new drug substances and new drug products: Chemical substances Q6A, provides guidance on when and how polymorphic forms should be monitored.(4)

The inclusion of potentially harmful solvents in the crystal lattice, which may render APIs or excipients to be toxic or harmful to patients (i.e. solvates), should also be suitably regulated and monitored by the manufacturer.

Polymorphism in The International PharmacopoeiaWhere a monograph indicates that a compound shows polymorphism this may be true crystal polymorphism, occurrence of solvates or occurrence of the amorphous form.

The International Pharmacopoeia controls the forms of a limited number of substances by restricting it to either:• a single form, for example, carbamazepine API (Anhydrous Form III), mebendazole API

(Form C); or• by limiting the presence of unwanted forms, for example, chloramphenicol palmitate API

(should contain at least 90% of polymorph B).

The control of forms specified in The International Pharmacopoeia may be achieved by:• permitting no deviation from the infrared absorption spectrum of the reference substance

prescribed (or reference spectrum supplied) – when the infrared absorption spectrum has been proven to be specific to the preferred form and able to distinguish the undesired form(s), for example, indomethacin API;

• restricting the melting point range, for example, phenobarbital API;• recommending the use of any other suitable methods such as X-ray powder diffractometry,

for example, carbamazepine tablets;• limiting the incorporated solvent (in the case of solvates/hydrates) with a specific limit test,

for example, nevirapine hemihydrate API.

When the infrared identification test is able to detect differences in forms for a specific compound (i.e. polymorphism may be present for this compound), but the control of a specific form is not required by the monograph, the user may be instructed to:

• recrystallize both the test substance and the specified reference substance, in the event where the infrared spectra are found to be not concordant, for example, fluconazole API; and/or

• dry the API and/or specified reference substance to ensure that both forms are in the anhydrous or dehydrated state, for example, nevirapine hemihydrate API.

Whenever the choice of a specific form is critical with regard to bioavailability and/or stability, the method of the manufacturer of the product must be validated to consistently yield the desired polymorph in the final product at release and over its shelf life. The monograph will include a statement under the heading “Manufacturing” to draw attention to the control of a specified form during manufacturing where control is known to be critical, for example, carbamazepine oral suspension.

Polymorphism (Ph. Int.)

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

254

It is the intention of The International Pharmacopoeia to extend the inclusion of explicit statements in monographs, where appropriate, as information on the occurrence of polymorphism becomes available. The Secretariat thus cordially invites the users of The International Pharmacopoeia and manufacturers to share any relevant information that could be included in the monographs.

References

1 Gaskell, DR. 2005. Allotropy and Polymorphism. Reference Module in Materials Science and Materials Engineering. Encyclopedia of Condensed Matter Physics, 8–17.

2 Brittain, HG. 2007. Polymorphism and solvatomorphism 2005. Journal of Pharmaceutical Sciences, 96(4):705–728.

3 US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research. 2013. Guidance to industry: Regulatory classification of pharmaceutical co-crystals.

4 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 1999. ICH Q6A – Specifications: The procedures and acceptance criteria for new drug substances and new drug products: Chemical substances.

5 Caira, M, Pienaar, EW, Lötter, AP. 2006. Polymorphism and pseudopolymorphism of the antibacterial nitrofurantoin. Molecular Crystals and Liquid Crystals, 179(1):241-264.

6 Bettinetti, G., Sorrenti, M., Catenacci, L., Ferrari, F. & Rossi, S. Bettinetti, G, et al. 2006. Polymorphism, pseudopolymorphism, and amorphism of peracetylated α-, β-, and γ-cyclodextrins. Journal of Pharmaceutical and Biomedical Analysis, 41:1205-1211.

7 Bauer, J, et al. 2006. Identification, preparation and characterization of several polymorphs and solvates of terazosin hydrochloride. Journal of Pharmaceutical Sciences, 95(4):917-928.

8 Peterson, ML, et al. 2006. Expanding the scope of crystal form evaluation in pharmaceutical science. Journal of Pharmaceutical Sciences, 9(3):317-326.

9 European Medicines Agency. 2015. Reflection paper on the use of cocrystals of active substances in medicinal products.

10 US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research. 2007. Guidance to industry: ANDAs: Pharmaceutical Solid Polymorphism. Chemistry, Manufacturing and Controls Information.

11 British Pharmacopoeia Commission. 2017. SC I B. Polymorphism. In: British Pharmacopoeia Commission. British Pharmacopoeia 2017. Supplementary chapter. London: TSO.

***

Polymorphism (Ph. Int.)

255

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

WHO medicines quality guidelines

Inquiry regarding production of water for injections

Working document QAS/18.764 (March 2018), reproduced below, relates to a public inquiry on whether to revise the WHO specifications and good manufacturing practices (GMP) for the production of water for injections. The working document with line numbers is available for comment at www.who.int/medicines/areas/quality_safety/quality_assurance/projects.

1. Background Several pharmacopoeias, including the European Pharmacopoeia, during the past years and months adopted revised monographs on water for injections (WFI) allowing production by non-distillation technologies.

Up until now, the production of WFI had been limited to distillation only in many countries. The monograph revisions in the context of several pharmacopoeias were the result of extensive consultations with stakeholders. They newly allow for production of WFI by a purification process equivalent to distillation such as reverse osmosis, coupled with appropriate techniques.

The Japanese Pharmacopoeia and the US Pharmacopeia, for example, allow for production of WFI by distillation or a purification process proven to be equal or superior to distillation, and by distillation or reverse osmosis followed by ultrafiltration, respectively.

In the European context, EDQM conducted a survey in 2010 to gather data on the use of non-distillation technologies for producing WFI and organized an expert workshop in March 2011.The revised monograph in the European Pharmacopoeia foresees that the use of non-distillation technologies for the production of WFI requires that notice is given to the supervisory authority of the manufacturer before implementation.

Any non-distillation technology for producing WFI should be equivalent in quality to that produced by distillation, where equivalence in quality does not simply mean compliance with a specification but also takes into account the robustness of the production method. This is why the ongoing general revision of Annex 1 “Manufacture of sterile medicinal products” to the European Union good manufacturing practices (GMP) guidelines will include new guidance on production methods for WFI. In order to ensure the necessary guidance is available for the newly revised European monograph implementation, a question-and-answer (Q&A) document was prepared by the GMP/GMDP Inspectors Working Group of the European Medicines Agency.

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

256

2. WHO context At an informal WHO consultation on good practices for health products manufacture and inspection held in April 2017, it was noted that new technologies were being adopted for the manufacture of WFI internationally, as outlined above. The monograph on “Water for injections” included in The International Pharmacopoeia and the GMP for water describe a distillation process only when used as WFI, whereas other technologies, such as reverse osmosis, have been included in other pharmacopoeias.

This was reported to the 52nd WHO Expert Committee on Specifications for Pharmaceutical Preparations. The Expert Committee members noted the report and recommended that the WHO Secretariat should collect feedback on whether to revise the WHO specifications and GMP in relation to the production of WFI.

Within the context of the WHO publications the following contain information on the production of WFI by distillation only:

• WHO good manufacturing practices: water for pharmaceutical use (WHO Technical Report Series, No. 970, Annex 2, 2012);

• Monograph on Water for injections in The International Pharmacopoeia: http://apps.who.int/phint/2017/index.html#p/home.

In light of the above, feedback is being sought on whether the WHO specifications and GMP text(s):

• should be revised in relation to the production of WFI allowing other purification processes as well, • and if yes, if details on additional requirements should be added,

• and if yes, which additional requirements should be added.

***

Inquiry regarding production of water for injections

257

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

Proposal for revision of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in

International Commerce

Working document QAS/18.768 (April 2018) relates to a proposed revision of the WHO Certification Scheme, a voluntary agreement among Member States to provide assurance about the quality of pharmaceutical products moving in international commerce. The working document with line numbers and tracked changes is available for comment at www.who.int/medicines/areas/quality_safety/quality_assurance/projects.

1. IntroductionThe WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce (the “Scheme”) is an international voluntary agreement to provide assurance, to countries participating in the Scheme, about the quality of pharmaceutical products moving in international commerce. The primary document of the Scheme is the certificate of a pharmaceutical product (CPP).

The fifty-second WHO Expert Committee on Specifications for Pharmaceutical Preparations (ECSPP) in 2017 was informed about the current situation of the Scheme, including the fact that the forty-third Expert Committee in 2008 had recommended that “the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce should be revised” in line with recent developments. The Expert Committee in 2017 recommended that the “WHO Secretariat should prepare a proposal for revision of the Scheme for public consultation”.

The objective of this working document is to compile key issues on the Scheme and provide a proposed revision of the Scheme for consideration during the upcoming fifty-third ECSPP meeting in 2018.

2. BackgroundThe Scheme has been in operation since 1969 (World Health Assembly resolution WHA 22.50) and was amended in 1975 (WHA 28.65), 1988 (WHA 41.18), 1992 (WHA 45.29) and 1997 (WHA 50.3) (1–5). The current Scheme provides the following three types of certificate:• CPP;• statement of the licensing status of

pharmaceutical product;• batch certificate.In 2007, the forty-second ECSPP discussed and identified a number of perceived problems with the operation of the Scheme (6).

In 2008, a WHO consultation was held to make recommendations for consideration during the forty-third ESPCC, taking account of the WHO working document QAS/07.240 which contains key issues and possible action (7). The forty-third ECSPP in 2008 discussed the report of the consultation (working document QAS/08.279) (8). In light of the changing environment, including the rapid globalization of the pharmaceutical manufacturing sector, coupled with changes in the make-up of both the regulators and the groups involved in procurement, the

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

258

forty-third ECSPP endorsed the following recommendations (9): “1. The WHO Certification Scheme on

the Quality of Pharmaceutical Products Moving in International Commerce should be revised;

2. The proposal for revision of the Scheme and modification of the guidelines should be discussed by the relevant WHO Governing Bodies – the Executive Board and the World Health Assembly – and in consultation with WHO’s Legal Counsel.

3. In the interim a question and answer (Q&A) paper should be prepared on the function of the Scheme.”

Based on the above recommendation, as an interim measure, a Q&A document on the function of the Scheme was developed in 2010 and it was revised in 2015 (10, 11). However, the Scheme itself has not been revised since 1997.

In 2017, the fifty-second ECSPP recommended that the “WHO Secretariat should prepare a proposal for revision of the scheme for public consultation” (12).

The draft working document which includes the proposed revision of the Scheme was prepared by the WHO Secretariat and it will be discussed during an informal consultation planned to be held on 19 to 20 May 2018. In addition, the draft working document will be circulated, including to the Member States and other interested parties, for public consultation to prepare a

version of the working document for possible endorsement by the fifty-third ECSPP.

3. Proposed revision of the SchemeSince the last revision of the Scheme in1997 it has been discussed on various occasions and key issues and possible actions have been identified. These are roughly classified into the following two aspects:(a) issues related to the revision of the Scheme;(b) issues related to implementation/

operational aspects of the Scheme.The objective of this working document is to provide a proposed revision of the scheme for consideration [endorsement/adoption] during the upcoming fifty-third ECSPP. Therefore, possible action related to implementation and operational aspects of the Scheme (e.g. promotion of the Scheme, making use of IT) would be considered after adoption of the revision of the Scheme.

3.1 Summary of key issues and proposed actions related to the revision of the Scheme

The table below outlines key issues and possible actions. These were prepared mainly based on the report of the forty-third ECSPP and on working documents QAS/07.240 and QAS/08.279 and the Q&A document1 as well as comments from the Member States and interested parties during public consultation (6, 7, 9, 12).1 Q16 is “What are the main problem encountered in

the application of the Scheme”

Key issues Proposed actionsa The Scheme is formally at present

directed to individual Member States, whereas regulatory and procurement groupings of multistate organizations also need to be able to operate within the Scheme; this applies to both issuing and receiving parties

The wordings in the Scheme should be changed so that regional organizations such as the European Union can formally participate in the Scheme [Note from Secretariat: Member State(s)” => “Member State(s) and/or regional authority(ies)”.]

(Continued)

Proposal for revision of the WHO Certification Scheme

259

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

(Continued)

Key issues Proposed actionsb The list of competent authorities

is out of date; details of some authorities have changed. The current list of countries that participate in the Scheme in its present form is not readily available

Memberships as “certificate-issuing” countries should be renewed every five years [Note from Secretariat: Added new para. as section 2.5; See below for more detail.]

Member States should inform any update of the name and address of competent authorities to the WHO secretariat [Note from Secretariat: Added new paragraph as section 2.7.]

c Exporting countries that do not fulfil the prerequisites required by the Scheme issue certificates to support export

Memberships as “certificate -issuing” countries should be renewed every five years. Member States intending to continue to participate in the Scheme as “certificate-issuing” countries should resubmit notification to the Director-General of the World Health Organization (WHO) in the same way as section 2.1 [Note from Secretariat: Added new paragraph as section 2.5.]

Member States intending to participate in the Scheme as certificate-–issuing countries should declare that the competent authority meets the requirements in the notification to the WHO Director-General[Note from Secretariat: Added new paragraph as section 2.4.]In case that WHO does not receive the notification for renewal of membership for a long time period, the Director-General may delete such a Member State’s name from the participant list in consultation with the relevant Expert Committee[Note from Secretariat: Added new paragraph as section 2.8.]

d The CPP is no longer provided to substitute the full dossier quality safety and efficacy (QSE) review

CPPs should not be requested in countries that have the capability to conduct full QSE reviews[Note from Secretariat: Added new paragraph as section 3.6.]

e Information on who released the batch for marketing is not disclosed in certificates issued by exporting countries

The certificate should include batch release site information in the CPP as a new option (in section 2A.3, explanatory note 8 in model certificate of the guidelines) (“option c” will become the new “d” and a new “c” will be created)[Note from Secretariat: Added new words in Appendix 1of the Annex.]

f There have been cases in which forged certificates have been supplied to competent authorities of importing countries

Email address, telephone and fax numbers should be provided as contact information so that the requesting authority can request confirmation to the certifying authority countries easily[Note from Secretariat: Added new words in section 2.4.]

g Lead times of the certifying authorities can be very long, sometimes several months

Certifying authority should provide a certificate without undue delay [Note from Secretariat: Added new paragraph as section 4.10.]

h Importing countries require legalization of certificates, additional stamps, etc.

Unnecessary legalization should not be requested[Note from Secretariat: Added new paragraph as section 4.7.]

Proposal for revision of the WHO Certification Scheme

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

260

3.2 Proposed revision of the SchemeThe proposal for revision of the Scheme is attached as an annex. The amendments of the Scheme in the annex are presented in tracked-change mode. Moreover, it should be noted that this revision includes not only an amendment related to 3.1 in this working document but also editorial changes such as:• updating some definitions in “Glossary

and index” in conformity with latest version of relevant guidelines;

• replacing some words (e.g. “license” by “market authorization”).

4. Other issues related to operation of the Scheme

The table below outlines key issues not related to revision of the Scheme. As described in section 3 of this document, possible actions regarding implementation/operation of the Scheme (e.g. promotion of the Scheme, making use of IT) should be considered after adoption of the revision of the Scheme.

Key issuesa Countries not party to the Scheme issue

certificates to support export of pharmaceutical products.

b Not all of certificate-issuing countries adhere to the WHO template

c Member States issue certificates for products not manufactured under their jurisdiction, e.g. for products not authorized for marketing in their countries or not manufactured in their country.

d Exporting countries issue other certificates such as free sale certificates.

e There are inconsistencies in listing the trade name of the product in the recipient country, if different from the certifying country.

f The way of applying for a CPP is not harmonized, with each certifying authority having its own system. (It would be helpful to work towards regional harmonization and a standard electronic submission.)

5. References1 World Health Assembly resolution WHA22.50

(1969).2 World Health Assembly resolution WHA28.65

(1975).3 World Health Assembly resolution WHA41.18

(1988).4 World Health Assembly resolution WHA45.29

(1992).5 World Health Assembly resolution WHA50.3

(1997).6 Forty-second WHO Expert Committee

on Specifications for Pharmaceutical Preparations, Geneva (WHO Technical Report Series, No. 948 (2008)).

7 Proposal for improvement of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce (working document QAS/07.240).

8 Draft report to the forty-third WHO Expert Committee on Specifications for Pharmaceutical Preparations. Recommendations for improvement of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce (QAS/08.279) (2008).

9 Forty-third WHO Expert Committee on Specifications for Pharmaceutical Preparations, Geneva (WHO Technical Report Series, No. 953 (2009)).

10 WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce: Question and Answer (Q&A) (QAS/10.374, 2010)

11 WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce: Questions and Answers (Q & A) (WHO Drug Information Vol. 30, No. 3, 2016)

12 Fifty-second WHO Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series, No. 1010 (2018).

Proposal for revision of the WHO Certification Scheme

261

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

Annex [Note from Secretariat: In the online document posted for comment, the new text based on proposed action on the preceding pages is presented in tracked-change mode.]

Guidelines on the implementation of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce

1. Provisions and objectives1.1 A comprehensive system of quality assurance

must be founded on a reliable system of marketing authorization and independent analysis of the finished pharmaceutical product, as well as upon assurance obtained through independent inspection that all manufacturing operations are carried out in conformity with accepted norms, referred to as good manufacturing practices (GMP).

1.2 In 1969, the Twenty-second World Health Assembly, by resolution WHA22.50, endorsed requirements for Good Practices in the Manufacture and Quality Control of Drugs (1) (referred to henceforth as “GMP as recommended by WHO”). These comprise internationally-recognized and respected standards that all Member States are urged to adopt and to apply. These requirements have since been revised several times.

1.3 These standards provide the basis for the WHO Certification Scheme on the Quality of Pharmaceutical Products moving in International Commerce (referred to henceforth as “the Scheme”) recommended initially in resolution WHA22.50 (1). The Scheme is an administrative instrument that requires each participating Member State or regional authority, upon application by a commercially interested party, to attest to the competent authority of another participating Member State or regional authority that:•a specific product is authorized to be placed

on the market within its jurisdiction or, if it is not thus authorized, the reason why that authorization has not been accorded;

• the plant in which it is produced is subject to inspections at suitable intervals to establish that the manufacturer conforms to GMP as recommended by the World Health Organization (WHO)); and

•all submitted product information, including labelling, is currently authorized in the certifying country.

1.4 The Scheme, as amended in 1975 (2), 1988 (3), 1992 (4) and 1997 (5), by resolutions WHA28.65,

WHA41.18, WHA45.29 and WHA50.3, is applicable to finished dosage forms of pharmaceutical products intended for administration to human beings or to food-producing animals.

1.5 Provision for certification of active pharmaceutical ingredients (APIs) is also included within the scope of the Scheme. This will be the subject of separate guidelines and certificates.

2. Membership[Note from Secretariat: the new text in section 2 includes rearrangement of the order of paragraphs and such change is NOT presented in tracked-change mode in the online document posted for comment, except for the section number.]

2.1 Any Member State as well as regional authority that has legal right to control the regulation of pharmaceutical products are eligible to participate in the Scheme as a certifying member and/or a requesting member if it complies with the requirements stipulated in section 2.2 or 2.3.

2.2 A Member State intending to become a certifying member should possess:•an effective marketing authorization system, not

only for pharmaceutical products, but also for the responsible manufacturers and distributors;

•GMP requirements, consonant with those recommended by WHO, to which all manufacturers of finished pharmaceutical products are required to conform;

•effective controls to monitor the quality of pharmaceutical products registered or manufactured within its country, including access to an independent quality control laboratory;

•a national pharmaceuticals inspectorate, operating as an arm of the national drug regulatory authority, and having the technical competence, experience and resources to assess whether GMP and other controls are being effectively implemented, and the legal power to conduct appropriate investigations to ensure that manufacturers conform to these requirements by, for example, examining premises and records and taking samples;

Proposal for revision of the WHO Certification Scheme

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

262

•administrative capacity to issue the required certificates, to institute inquiries in the case of complaint, and to notify expeditiously both WHO and the competent authority in any Member State known to have imported a specific product that is subsequently associated with a potentially serious quality defect or other hazard.

2.3 A regional authority intending to become a certifying member should possess by itself or through its legal framework:•an effective marketing authorization system, not

only for pharmaceutical products, but also for the responsible manufacturers and distributors;

•GMP requirements, consonant with those recommended by WHO, to which all manufacturers of finished pharmaceutical products are required to conform;

•effective controls to monitor the quality of pharmaceutical products registered or manufactured within its region, including access to an independent quality control laboratory;

•a pharmaceuticals inspectorate, operating as an arm of the drug regulatory authority, and having the technical competence, experience and resources to assess whether GMP and other controls are being effectively implemented, and the legal power to conduct appropriate investigations to ensure that manufacturers conform to these requirements by, for example, examining premises and records and taking samples;

•administrative capacity to issue the required certificates, to institute inquiries in the case of complaint, and to notify expeditiously both WHO and the competent authority in any Member State and regional organization known to have imported a specific product that is subsequently associated with a potentially serious quality defect or other hazard.

2.4 Membership as a certifying member and/or requesting member can be applied by notifying in writing to the WHO Director-General of:• its willingness to participate in the Scheme as a

certifying member and/or a requesting member (Member States and regional authorities may participate only as a certifying member to control the import of pharmaceutical products and APIs);

•any significant reservations it intends to observe relating to this participation;

• the name and address (including email address, telephone and fax numbers) of its drug regulatory authority or other competent authority; and

•declaration to comply with the requirements for a certifying member stipulated in section 2.2 or 2.3, if applicable.

2.5 A Member State and regional authority that has a membership of a certifying member should resubmit the notification in section 2.4 at least once every five years, in order to ensure that it continues to comply with the requirement stipulated in section 2.2 or 2.3 and that contact information keeps updated.

2.6 Consolidated list of information on the notification submitted by Member States and regional authorities in accordance with provision in sections 2.4, 2.5 and 2.7 will be available through WHO’s official website (see also section 3.3).

2.7 A Member State and regional authority should inform WHO of any change of information notified to the WHO Director-General.

2.8 Membership as a certifying member may be disqualified by the Director-General after consultation with the ECSPP in the case that a Member State or regional authority would fail to resubmit a notification in accordance with provision in section 2.5 for a long period.

2.9 Each Member State and regional authority assumes the responsibility to determine, through a process of self-evaluation, whether it satisfies these prerequisites. The Scheme contains no provision, under any circumstance, for external inspection or assessment, either of a competent national authority or of a manufacturing facility. However, should a Member State or regional organization so wish, it could approach WHO, or a well-recognized drug regulatory authority, to occasionally delegate consultants to act as advisers in the course of national inspections and inspector training activities.

3. Requesting a certificate3.1 Three documents can be requested within the scope

of the Scheme:•a certificate of a pharmaceutical product (product

certificate);•a statement of licensing status of pharmaceutical

product(s); and•a batch certificate of a pharmaceutical product.

3.2 Proposed formats for these documents are provided in Appendices 1, 2 and 3 of these guidelines. All participating Member States and regional authorities are henceforth urged to adopt these formats to facilitate interpretation of certified information. Requests for the provision of certificates offering

Proposal for revision of the WHO Certification Scheme

263

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

more limited attestations, for instance, that the manufacturer complies with GMP or that the product is authorized for “free sale” within the country of export are discouraged. Similarly, requests should not be made for certification of information going beyond the scope of this Scheme. When manufacture takes place in a country other than that from which the product certificate is issued, an attestation relevant to compliance of the manufacture with GMP may still be provided (as an attachment to the product certificate) on the basis of inspections undertaken for registration purposes.

The Explanatory Notes attached to the three documents referred to above are very important. Whilst they are not part of the document to be certified, they should always be attached to the certificate.

3.3 A list of addresses of competent national regulatory authorities participating in the Scheme that are responsible for the registration of pharmaceutical and/or veterinary products, together with details of any reservations they have declared regarding their participation in the Scheme will be available at the WHO official website as indicated in section 2.6.

3.4 Each competent authority in certifying members should issue guidelines to all agents responsible for importing pharmaceutical products for human and/or veterinary use that operate under its jurisdiction, including those responsible for public sector purchases, to explain the contribution of certification to the drug regulatory process and the circumstances in which each of the three types of documents will be required.

Certificate of a pharmaceutical product3.5 The Certificate of a pharmaceutical product

(Appendix 1) issued by the competent authority in the exporting country or regional authority (“the certifying authority”), is intended for use by the competent authority in an importing country and regional organization in two situations:•when the product in question is under

consideration for a marketing authorization that will authorize its importation and sale;

•when administrative action is required to renew, extend, vary or review such a marketing authorization.

3.6 The Certificate of a pharmaceutical product should not be required by the Member States or regulatory authorities where they undertake full quality, safety and efficacy review by themselves.

3.7 All requests for certificates should be channeled through the agent in the importing country (see

section 3.4) and the marketing authorization holder or other commercially-interested party in the exporting country (“the applicant”). The applicant should submit the following information for each product to the authority issuing the certificate:•name and dosage form of product•name and amount of active ingredient(s) per unit

dose (International Nonproprietary Name(s) where such exist(s)),

•name and address of marketing authorization holder and/or manufacturing facility,

• formula (complete composition including all excipients; also particularly when no marketing authorization exists or when the formulation differs from that of the authorized product),

•product information for health professionals and for the public (patient information leaflets) as approved by the certifying authority,

For product information to be attached to the certificate see section 4.7

3.8 The certificate is a confidential document. As such, it can be issued by the certifying authority only with the permission of the applicant and, if different, of the marketing authorization holder.

3.9 The certificate is intended to be incorporated into a marketing authorization application in the competent authority in the importing country and regional authority (“the requesting authority”). Once prepared, it is transmitted to the requesting authority through the applicant and, when applicable, the agent in the importing country.

3.10 When any doubt arises about the status or validity of a certificate, the requesting authority should request a copy directly from the certifying authority, as provided for under section 4.9 of these guidelines.

3.11 In the absence of any specific agreement, each certificate will be prepared exclusively in the working language(s) of the certifying authority. The applicant will be responsible for providing any notarized translation that may be required by the requesting authority.

3.12 Since the preparation of certificates imposes a significant administrative load on certifying authorities, the service may need to be financed by charges levied upon applicants.

3.13 Supplementary attestations are obtainable only at the discretion of the certifying authority and with the permission of the applicant. The certifying authority is under no obligation to supply additional information. Requests for supplementary

Proposal for revision of the WHO Certification Scheme

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

264

information should consequently be referred to the applicant, and only in exceptional circumstances to the certifying authority.

Statement of marketing authorization3.14 Model statement of marketing authorization

(Appendix 2). This attests only that a marketing authorization has been issued for a specified product, or products, for use in the exporting country. It is intended for use by importing agents when considering bids made in response to an international tender, in which case it should be requested by the agent as a condition of bidding. It is intended only to facilitate the screening and preparation of information. The importation of any product that is provisionally selected through this procedure should be determined on the basis of a CPP.

Batch certificate3.15 A batch certificate of a pharmaceutical product

(Appendix 3) refers to an individual batch of a pharmaceutical product and is a vital instrument in drug procurement. The provision of a batch certificate is usually a mandatory element in tender and procurement documents.

3.16 A batch certificate is normally issued by the manufacturer and only exceptionally, as in the case of vaccines, sera and some other biological products, by the competent authority in the exporting country or regional authority. The batch certificate is intended to accompany and provide an attestation concerning the quality and expiry date of a specific batch or consignment of a product that has already obtained market authorization in the importing country. The batch certificate should include the specifications of the final product at the time of batch release and the results of a full analysis undertaken on the batch in question. In most circumstances these certificates are issued by the manufacturer to the importing agent (i.e. the marketing authorization holder in the importing country), but they must be made available at the request of – or in the course of any inspection made on behalf of – the competent authority.

4. Issuing a certificate4.1 The certifying authority is responsible for assuring

the authenticity of the certified data. Certificates should not bear the WHO emblem, but a statement should always be included to confirm whether or not the document is issued in the format recommended by WHO.

4.2 When the applicant is the manufacturer of the finished dosage form, the certifying authority

should satisfy itself, before attesting compliance with GMP, that the applicant:•applies identical GMP standards to the

production of all batches of pharmaceutical products manufactured within the facility, including those destined exclusively for export;

•consents, in the event of identification of a quality defect consonant with the criteria set out in section 5.1, to relevant inspection reports being released, in confidence, to the requesting authority, should the latter so require.

4.3 When the applicant is not the manufacturer of the finished dosage form, the certifying authority should similarly satisfy itself – in so far as it has authority to inspect the records and relevant activities of the applicant – that it has the applicant’s consent to release relevant reports on the same basis as described in section 4.2 (b) above.

4.4 GMP as recommended by WHO assigns to the manufacturer of the finished dosage form responsibility for assuring the quality of APIs. National or regional regulations may require that suppliers of APIs be identified in the marketing authorization, but the competent authority may have no power to inspect them.

4.5 Notwithstanding this situation, a certifying authority may agree, on a discretionary and voluntary basis, and at the request of a manufacturer, to undertake an inspection of a manufacturer of APIs to satisfy specific requirements of a requesting authority. Alternatively, pending the development of specific guidelines for APIs, the certifying authority may be able to attest that the manufacturer is an established supplier of the substance in question to manufacturers of finished dosage forms authorized for marketing under its jurisdiction.

4.6 Whenever a product is purchased through a broker or another intermediary, or when more than one set of premises has been involved in the manufacture and packaging of a product, the certifying authority should consider whether it has received sufficient information to satisfy itself that those aspects of the manufacture of the product for which the applicant is not directly responsible have been undertaken in compliance with GMP as recommended by WHO.

4.7 The certifying authority should officially stamp and date all copies of product information submitted to it in support of an application for a certificate and intended to be appended to the certificate.

Every effort should be made to ensure that certificates and all annexed documentation are

Proposal for revision of the WHO Certification Scheme

265

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

consonant with the version of the marketing authorization operative on the date of issue. Nevertheless, requesting authorities should not request unnecessary legalization procedure that may cause undue delay of certificates.

When available, the certifying authority will add a summary basis of approval or any other material the authority deems relevant. Translation by an applicant of these materials into a widely used language, preferably English, shall be deemed to satisfy the provision of 3.11.

4.8 Any additional attachment to a certificate submitted by the applicant, such as price lists of products for which bids are offered, should be clearly identified as not comprising part of the attestation made by the certifying authority.

4.9 To avert potential abuse of the Scheme, to frustrate attempts at falsification, to render routine authentication of certificates by an independent authority superfluous and to enable the certifying authority to maintain comprehensive records of countries to which specific products have been exported, each certificate should identify the importing country and be stamped on each page with the official seal of the certifying authority.

If requested, an identical copy, clearly marked as duplicate, should be forwarded by the certifying authority on demand directly to the requesting authority.

4.10 The certifying authority should establish standard period of time for issue of certificates. It should endeavor to make each issue of certificate completed within this period as far as the applicant submits sufficient documents.

5. Notifying and investigating a quality defect5.1 Each certifying authority undertakes to institute

enquiries into any quality defect reported in a product exported in accordance with the provisions of the Scheme, on the understanding that:• the complaint is transmitted, together with the

relevant facts, through the requesting authority;• the complaint is considered to be of a serious

nature by the latter authority; and• the defect, if it appeared after delivery of the

product into the importing country, is not attributable to local conditions.

5.2 In the case of obvious doubt, a participating national authority may request WHO to assist in identifying

an independent quality control laboratory to carry out tests for the purposes of quality control.

5.3 Each certifying authority undertakes to inform WHO and, as far as is possible, all competent national authorities, of any serious hazard newly associated with a product exported under the provisions of the Scheme or of any criminal abuse of the Scheme directed, in particular, to the export of falsely labelled, substandard or falsified pharmaceutical products. On receipt of such notification, WHO will transmit the message immediately to the competent authority in each Member State and regional organization.

5.4 WHO stands prepared to offer advice should difficulty arise in implementing any aspect of the Scheme or in resolving a complaint, but it cannot be a party to any resulting litigation or arbitration.

References1. Quality control of drugs. In: Twenty-second World

Health Assembly, Boston, Massachusetts, 8-25 July 1969. Part 1: Resolutions and decisions, annexes. Geneva, World Health Organization, 1969: 99-105 (Official Records of the World Health Organization, No. 176).

2. Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce. In: Twenty-eighth World Health Assembly, Geneva, 13-30 May 1975. Part 1: Resolutions and decisions, annexes. Geneva, World Health Organization, 1975: 94-95 (Official Records of the World Health Organization, No. 226).

3. WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce. In: Forty-first World Health Assembly, Geneva, 2-13 May 1988. Resolutions and decisions, annexes. Geneva, World Health Organization, 1988: 53-55 (WHA41/1988/REC/1).

4. Proposed guidelines for implementation of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce. In: Forty-fifth World Health Assembly, Geneva, 4-14 May 1992. Resolutions and decisions, annexes. Geneva, World Health Organization, 1992: 155-165 (Document WHA41/1992/REC/1).

5. Guidelines for implementation of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce. In: Forty-fifth World Health Assembly, Geneva, 5-14 May 1997. Resolutions and decisions, annexes. Geneva, World Health Organization, 1997: 2-3 (WHA50/1997/REC/1).

Proposal for revision of the WHO Certification Scheme

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

266

Appendix 1Model Certificate of a Pharmaceutical Product

Certificate of a pharmaceutical product1

This certificate conforms to the format recommended by the World Health Organization (WHO) (general instructions and explanatory notes attached)

No. of Certificate: Certifying member (certifying country): Requesting member (requesting country):

1. Name and dosage form of the product:

1.1. Active ingredient(s)2 and amount(s) per unit dose3: For complete composition including excipients, see attached.4

1.2. Is this product authorized to be placed on the market for use in the exporting country?5

yes/no (key in as appropriate)

1.3 Is this product actually on the market in the exporting country? yes/no/unknown (key in as appropriate) If the answer to 1.2. is yes, continue with section 2A and omit section 2B. If the answer to 1.2 is no, omit section 2A and continue with section 2B6:

2.A.1. Number of marketing authorization7 and date of issue:

2.A.2. Marketing authorization holder (name and address):

2.A.3. Status of marketing authorization holder8: a/b/c/d (key in appropriate category as defined in note 8)

2.A.3.1. For categories b, c and d, the name and address of the manufacturer producing the dosage form is9:

2.A.3.2. For categories d, the name and address of the manufacturer certifying the finished pharmaceutical product batch is:9

2.A.4. Is a summary basis for approval appended? 10 yes/no (key in as appropriate)

2.A.5. Is the attached, officially approved product information complete and consonant with the market authorization? 11 yes/no/not provided (key in as appropriate)

2.A.6. Applicant for certificate, if different from licence holder (name and address)12:

2.B.1. Applicant for certificate (name and address):

2.B.2. Status of applicant: a/b/c/d (key in appropriate category as defined in footnote 8)

Proposal for revision of the WHO Certification Scheme

267

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

2.B.2.1. For categories b, c and d the name and address of the manufacturer producing the dosage form is:9

2.B.2.2. For categories d, the name and address of the manufacturer certifying the finished pharmaceutical product batch is9

2.B.3. Why is marketing authorization lacking? not required/not requested/under consideration/refused (key in as appropriate)

2.B.4. Remarks13:

3. Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? yes/no/not applicable14 (key in as appropriate)

If not or not applicable, proceed to question 4.

3.1. Periodicity of routine inspections (years):

3.2. Has the manufacture of this type of dosage form been inspected? yes/no (key in as appropriate)

3.3 Do the facilities and operations conform to GMP as recommended by WHO? 15 yes/no/not applicable14 (key in as appropriate)

4. Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product? 16 yes/no (key in as appropriate) If no, explain:

Address of certifying authority: Telephone number: Fax number: Email address: Name of authorized person: Signature: Stamp and date:

General instructionsPlease refer to the guidelines for full instructions on how to complete this form and information on the implementation of the Scheme.Additional sheets should be appended, as necessary, to accommodate remarks and explanations.

Explanatory notes1 This certificate, which is in the format recommended by WHO, establishes the status of the pharmaceutical

product and of the applicant for the certificate in the exporting country. It is for a single product only since manufacturing arrangements and approved information for different dosage forms and different strengths can vary.

2 Use, whenever possible, International Nonproprietary Names (INNs) or national nonproprietary names.3 The formula (complete composition) of the dosage form should be given on the certificate or be appended.4 Details of quantitative composition are preferred but their provision is subject to the agreement of the marketing

authorization holder.5 When applicable, append details of any restriction applied to the sale, distribution or administration of the

product that is specified in the marketing authorization.

Proposal for revision of the WHO Certification Scheme

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

268

6 Sections 2A and 2B are mutually exclusive.7 Indicate, when applicable, if the licence is provisional, or the product has not yet been approved.8 Specify whether the person responsible for placing the product on the market:

(a) manufactures the dosage form; (b) packages and/or labels a dosage form manufactured by an independent company; (c) certifies the finished pharmaceutical product batch; or (d) is involved in none of the above.

9 This information can only be provided with the consent of the marketing authorization holder or, in the case of non-registered products, the applicant. Non-completion of this section indicates that the party concerned has not agreed to inclusion of this information. It should be noted that information concerning the site of production is part of the marketing authorization. If the production site is changed, the marketing authorization has to be updated or it is no longer valid.

10 This refers to the document, prepared by some national regulatory authorities, that summarizes the technical basis on which the product has been licensed.

11 This refers to product information approved by the competent national drug regulatory authority, such as summary product characteristics

12 In this circumstance, permission for issuing the certificate is required from the marketing authorization holder. This permission has to be provided to the authority by the applicant.

13 Please indicate the reason that the applicant has provided for not requesting registration.(a) the product has been developed exclusively for the treatment of conditions – particularly tropical diseases –

not endemic in the country of export;(b) the product has been reformulated with a view to improving its stability under tropical conditions; the product

has been reformulated to exclude excipients not approved for use in pharmaceutical products in the country of import;

(c) the product has been reformulated to meet a different maximum dosage limit for an active ingredient; any other reason, please specify.

14 Not applicable means the manufacture is taking place in a country other than that issuing the product certificate and inspection is conducted under the aegis of the country of manufacture.

15 The requirements for good practices in the manufacture and quality control of drugs referred to in the certificate are those included in the thirty-second report of the Expert Committee on Specifications for Pharmaceutical Preparations, WHO Technical Report Series, No. 823, 1992, Annex 1. Recommendations specifically applicable to biological products have been formulated by the WHO Expert Committee on Biological Standardization (WHO Technical Report Series, No. 822, 1992, Annex 1).

16 This section is to be completed when the marketing authorization holder or applicant conforms to status (b) or (c) as described in note 8 above. It is of particular importance when foreign contractors are involved in the manufacture of the product. In these circumstances the applicant should supply the certifying authority with information to identify the contracting parties responsible for each stage of manufacture of the finished dosage form, and the extent and nature of any controls exercised over each of these parties.

Proposal for revision of the WHO Certification Scheme

269

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

Appendix 2Model Statement of Marketing Authorization Status of Pharmaceutical Product(s)

No. of Statement:

Certifying member (certifying country):

Requesting member (requesting country):

Statement of marketing authorization of pharmaceutical product(s) 1

This statement indicates only whether or not the following products are licensed to be put on the market in the exporting country.

Applicant (name/address):

Name of product Dosage form Active ingredient(s)2 and amount(s) per unit dose:

Marketing authorization no. and date of issue3

The certifying authority undertakes to provide, at the request of the applicant (or, if different, the marketing authorization holder), a separate and complete certificate of a pharmaceutical product (CPP) in the format recommended by the World Health Organization (WHO), for each of the products listed above.

Address of certifying authority:

Telephone number: Fax number:

Email address:

Name of authorized person:

Signature:

Stamp and date:

This statement conforms to the format recommended by WHO.

General instructionsPlease refer to the guidelines for full instructions on how to complete this form and information on the implementation of the Scheme.

Additional sheets should be appended, as necessary, to accommodate remarks and explanations.

Explanatory notes1 This statement is intended for use by importing agents who are required to screen bids made in response to an

international tender and should be requested by the agent as a condition of bidding. The statement indicates that the listed products are authorized to be placed on the market for use in the exporting country. A CPP in the format recommended by WHO will be provided, at the request of the applicant and, if different, the marketing authorization holder, for each of the listed products.

2 Use, whenever possible, International Nonproprietary Names (INNs) or national nonproprietary names.3 If no marketing authorization has been granted, enter “not required”, “not requested”, “under consideration” or

“refused” as appropriate.

Proposal for revision of the WHO Certification Scheme

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

270

Appendix 3Model Batch Certificate of a Pharmaceutical Products

Manufacturers/Official1 Batch Certificate of a Pharmaceutical Product

This certificate conforms to the format recommended by the World Health Organization (WHO) (general instructions and explanatory notes attached).

1. No. of Certificate:

2. Importing (requesting) authority:

3. Name of product:

3.1. Dosage form:

3.2 Active ingredient(s)2 and amount(s) per unit dose:

3.2.1 Is the composition of the product identical to that registered in the country of export? (yes/no/not applicable)3

If no: please attach formula (including excipients) of both products.

4. Marketing authorization holder4 (name and address):

4.1 Marketing authorization number4:

4.2 Date of issue4:

4.3 Marketing authorization issued by4:

4.4 Product certificate number4,5:

5.1 Batch number:

5.2 Date of manufacture:

5.3 Shelf life (years):

5.4 Contents of container:

5.5 Nature of primary container:

5.6 Nature of secondary container/wrapping:

5.7 Specific storage conditions:

5.8 Temperature range:

6. Remarks6:

7. Quality analysis:

7.1 What specifications apply to this dosage form. Either specify the pharmacopoeia or append company specifications.7

7.1.1 In the case of a product registered in the exporting country, have these company specifications7 been accepted by the competent authority? (yes/no)

Proposal for revision of the WHO Certification Scheme

271

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

7.2 Does the batch comply with all parts of the above specifications? yes/no (key in as appropriate)

7.3 Append certificate of analysis8

It is hereby certified that the above declarations are correct and that the results of the analyses and assays on which they are based will be provided on request to the competent authorities in both the importing and exporting countries.

Name and address of authorized person: Telephone number: Fax number: Email address:

Name of authorized person: Signature: Stamp and date:

General instructionsPlease refer to the guidelines for full instructions on how to complete this form and information on the implementation of the Scheme.

Additional sheets should be appended, as necessary, to accommodate remarks and explanations.

Explanatory notesCertification of individual batches of a pharmaceutical product is only undertaken exceptionally by the competent authority of the exporting country. Even then, it is rarely applied other than to vaccines, sera and biologicals. For other products, the responsibility for any requirement to provide batch certificates rests with the marketing authorization holder in the exporting country. The responsibility to forward certificates to the competent authority in the importing country is most conveniently assigned to the importing agent.

Any inquiries or complaints regarding a batch certificate should always be addressed to the competent authority in the exporting country. A copy should be sent to the marketing authorization holder.1 Strike out whichever does not apply.2 Use, whenever possible, International Nonproprietary Names (INNs) or national nonproprietary names.

3 “Not applicable” means that the product is not registered in the country of export.

4 All items under 4 refer to the marketing authorization or the certificate of a pharmaceutical product (CPP) issued in the exporting country.

5 This refers to the CPP as recommended by WHO.

6 Indicate any special storage conditions recommended for the product as supplied.

7 For each of the parameters to be measured, specifications give the values that have been accepted for batch release at the time of product registration.

8 Identify and explain any discrepancies from specifications. Government batch release certificates issued by certain governmental authorities for specific biological products provide additional confirmation that a given batch has been released, without necessarily giving the results of testing. The latter are contained in the manufacturer’s certificate of analysis.

Proposal for revision of the WHO Certification Scheme

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

272

Appendix 4Glossary and index

In order to facilitate understanding, this glossary explains terms in the guidelines and/or refers to relevant sections. It is considered as supplementary information and not as being a formal part of the Scheme.

abuse of Scheme. See section 4.9 and 5.2 of the guidelines.

active pharmaceutical ingredients. Any substance or mixture of substances intended to be used in the manufacture of a pharmaceutical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body.

addresses of competent authorities. See item 2.6 and 3.3 of the guidelines.

applicant. The party applying for a product certificate. This is normally the marketing authorization holder. In all instances, having regard to commercial confidentiality of certain data, the competent authority in the exporting country must obtain permission to release these data from the marketing authorization holder, or, in the absence of a marketing authorization, from the manufacturer.

authentication of certificates. See section 4.9 of the guidelines.

batch (or lot). A defined quantity of a starting material, packaging material, or product processed in a single process or series of processes so that it can be expected to be homogeneous. It may sometimes be necessary to divide a batch into a number of sub-batches, which are later brought together to form a final homogeneous batch. In the case of terminal sterilization, the batch size is determined by the capacity of the autoclave. In continuous manufacture, the batch must correspond to a defined fraction of the production, characterized by its intended homogeneity. The batch size can be defined either as a fixed quality or as the amount produced in a final time interval.

batch certificate. A document containing information, as set out in Annex 3 of the guidelines for use, will normally be issued for each batch by the manufacturer. Furthermore, exceptionally a batch certificate may be validated or issued by the competent authority of the exporting country, particularly for vaccines, sera and other biological products. The batch certificate travels with every major consignment (see also section 3.14 of the guidelines).

batch number (or lot number). A distinctive combination of numbers and/or letters which uniquely identifies a batch on the labels, its batch records and corresponding certificates of analysis, etc.

bulk product. Any product that has completed all processing stages up to, but not including, final packaging.

certifying authority. This is the competent authority that issues product certificates. It shall ensure that it possesses the capacities listed in section 2.2 and 2.3 of the guidelines.

charges for product certificates. See section 3.11 of the guidelines.

competence and evaluation of national authority. See sections 2.2, 2.3, 2.9 and 4.2 of the guidelines.

competent authority. This is the national or regional authority as identified in the formal letter of acceptance in which each Member State or regional authority informs WHO of its intention to participate in the Scheme. The competent authority can issue or receive certificates. The extent of participation should be indicated in the letter of acceptance. (see section 2.1 of the guidelines)

WHO makes available a continuously updated list of addresses of competent authorities and the specific conditions for participation (see section 2.6 of the guideline).

dosage form. The form of the completed pharmaceutical product, e.g. tablet, capsule, elixir, suppository.

drug regulatory authority. A national or regional authority responsible for the registration of and other regulatory activities connecting pharmaceutical products.

Proposal for revision of the WHO Certification Scheme

273

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

expiry date. The date given on the individual container (usually on the label) of a product up to and including which the product is expected to remain within specifications, if stored correctly. It is established for each batch by adding the shelf life to the date of manufacture.

finished pharmaceutical product. A finished dosage form of a pharmaceutical product that has undergone all stages of manufacture, including packaging in its final container and labelling.

free sale certificate. See section 3.2 of the guidelines.

good manufacturing practices. That part of quality assurance which ensures that products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization.

good manufacturibng practices certificate. See section 3.2 of the guidelines.

importing agents, guidelines for. See section 3.4 of the guidelines.

International Nonproprietary Name (INN). The shortened scientific name based on the active ingredient. WHO is responsible for assigning INNs to pharmaceutical substances.

language of product certificates. See section 3.10 of the guidelines.

limits of certification by competent authority. See section 3.12 and 4.8 of the guidelines.

*manufacture. All operations of purchase of materials and products, production, quality control, release, storage, distribution of pharmaceutical products, and related controls.

*manufacturer. A company that carries out operations such as production, packaging, repackaging, labelling and relabelling of pharmaceuticals. (for categories of manufacturer, see Appendix 1, Explanatory Note No. 7).

marketing authorization. A legal document issued by the competent drug regulatory authority for the purpose of marketing or free distribution of a product after evaluation for safety, efficacy and quality. It must set out, inter alia, the name of the product, the pharmaceutical dosage form, the quantitative formula (including excipients) per unit dose (using INNs or national generic names where they exist), the shelf life and storage conditions and packaging characteristics. It specifies the information on which authorization is based (e.g. “The product(s) must conform to all the details provided in your application and as modified in subsequent correspondence.”). It also contains the product information approved for health professionals and the public, the sales category, the name and address of the holder of the authorization and the period of validity of the authorization. Once a product has been given marketing authorization, it is included on a list of authorized products – the register – and is often said to be “registered” or to “have registration”. Market authorization may occasionally also be referred to as a “licence” or “product licence”.

marketing authorization holder. An individual or a corporate entity being in the possession of a marketing authorization of a pharmaceutical product.

pharmaceutical product. Any material and product intended for human or veterinary use presented in its finished dosage form or as a starting material for use in such a dosage form, that is subject to control by pharmaceutical legislation in exporting state and/or the importing state.

product. See pharmaceutical product.

product certificate. A document containing the information as set out in Appendix 1 of the guidelines that is validated and issued for a specific product by the competent authority of the exporting country or regional authority and intended for use by the competent authority in the importing country or – in the absence of such an authority – by the drug procurement authority (see also section 3.5 of the guidelines).

product information. This is the approved product information referred to in section 4.7 of the guidelines and item 2.A.5 of the product certificate. It normally consists of information for health professionals and the public (patient information leaflets) as approved in the exporting country, and when available, a data sheet or a summary of product characteristics approved by the drug regulatory authority.

production. All operations involved in the preparation of a pharmaceutical product, from receipt of materials, through processing, packaging and repackaging, labelling and relabelling, to completion of the finished product.

Proposal for revision of the WHO Certification Scheme

Consultation documents WHO Drug Information Vol. 32, No. 2, 2018

274

registration. Any statutory system of approval required at national or regional level as a precondition for introducing a pharmaceutical product onto the market.

specifications. A list of detailed requirements with which the products or materials used or obtained during manufacture have to conform. They serve as a basis for quality evaluation.

statement of licensing status. See section 3.13 of the guidelines and Annex 2

summary basis of approval. This refers to the document prepared by some national regulatory authorities, that summarizes the technical basis on which the product has been licensed (see section 4.7 of the guidelines and explanatory note 9 of the product certificate contained in Annex 1).

Summary product characteristics (SPC). Product information as approved by the drug regulatory authority. The SPC serves as the basis for production of information for health personnel as well as for consumer information on labels and leaflets of medicinal products and for control of advertising (see also product information).

tenders and brokers. See section 4.6 of the guidelines.

transmission of product certificate. See section 3.8 and 4.9 of the guidelines.

validity of product certificate. See section 3.9 of the guidelines.

when to request a product certificate. See item 3.5 of the guidelines.

WHO responsibility. See item 5.4 of the guidelines.

References1. WHO good distribution practices for pharmaceutical products. In: WHO Expert Committee on Specifications for

Pharmaceutical Preparations. Forty-fourth report. Geneva, World Health Organization, 2010, Annex 5 (WHO Technical Report Series, No. 957).

2. WHO guidelines on quality risk management. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-seventh report. Geneva, World Health Organization, 2013, Annex 2 (WHO Technical Report Series, No. 981).

3. WHO good manufacturing practices for pharmaceutical products: main principles. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-eighth report. Geneva, World Health Organization, 2014, Annex 2 (WHO Technical Report Series, No. 986).

4. Model quality assurance system for procurement agencies. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-eighth report. Geneva, World Health Organization, 2014, Annex 3 (WHO Technical Report Series, No. 986).

***

Proposal for revision of the WHO Certification Scheme

275

WHO Drug Information Vol. 32, No. 2, 2018 Consultation documents

Other recent WHO consultation documents

The following new or revised guidelines have recently been posted for public comment on the WHO website (www.who.int/medicines/areas/quality_safety/quality_assurance/projects).

Revision of WHO GMP for sterile pharmaceutical products – a joint EU, PIC/S, WHO projectWorking document QAS/17.745, December 2017The European Commission (EC), WHO and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), have jointly proposed a revised version of the guidelines on manufacture of sterile medicinal products. The document is subject to parallel public consultation by the three entities.

Good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms: Part 2. Interpretation of part 1 – GMP for HVAC systems.Working document QAS/18.759, February 2018This document represents Part 2 of the heating, ventilation and air-conditioning (HVAC) systems guidelines. It contains non-binding examples, drawings, technical representations and interpretation in support of Part 1 of the HVAC systems guidelines.

Guidelines on import procedures for pharmaceutical products (revision)Working document QAS/18.773, May 2018This is a revision of the WHO guidelines published in 1996. They are intended to promote efficiency in applying relevant regulations, to simplify the checking and handling of consignments of pharmaceutical products in international transit and to provide a basis for collaboration between all parties involved in importation of medicines.

Validation of computerized systems (Appendix 5 to Guidelines on Validation)Working document QAS/16.667/Rev.1, May 2018This is a revision of the 2006 WHO guidance on validation of computerized systems. It applies to systems used in good manufacturing practices (GMP) but may be extended to systems used in all good practice (GXP) activities, as appropriate. å

276

WHO Drug Information Vol. 32, No. 2, 2018

ATC/DDDclassificationThe Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD) as a measuring unit are tools for exchanging and comparing data on drug use at international, national or local levels. The ATC/DDD system has become the gold standard for international drug utilization research. It is maintained by the WHO Collaborating Centre for Drug Statistics Methodology in Oslo, Norway. Visit www.whocc.no/ for more information.

ATC/DDD classification (temporary)

The following ATC codes and DDDs were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology in March 2018.Comments or objections to the decisions from the meeting should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology before 1 September 2018. If no objections are received before this date, the new ATC codes and DDDs will be considered final and included in the January 2019 version of the ATC/DDD Index.

New ATC 5th level codesATC level name/INN ATC codeabemaciclib L01XE50angiotensin II C01CX09apalutamide L02BB05avatrombopag B02BX08candesartan, amlodipine and hydrochlorothiazide C09DX06cannabidiol N03AX24cefpodoxime and beta-lactamase inhibitor J01DD64copanlisib L01XX61doravirine J05AG06edaravone N07XX14fexinidazole P01CA03fostamatinib B02BX09gemigliptin and rosuvastatin A10BH52hydrogen peroxide D11AX25ibalizumab J05AX23lamivudine, tenofovir disoproxil and doravirine J05AR24leuprorelin and bicalutamide L02AE51metformin, saxagliptin and dapagliflozin A10BD25

Continued

277

WHO Drug Information Vol. 32, No. 2, 2018 ATC/DDD classification

Temporary

New ATC 5th level codes (continued)ATC level name/INN ATC codeomidenepag S01EX06prasterone G03XX01talazoparib L01XX60telotristat A16AX15trifarotene D10AD06

New ATC level codes (other than 5th levels)ATC level name/INN ATC codeOther sex hormones and modulators of the genital system G03XX

Change of ATC codeATC level name/INN Previous ATC code New ATC codedimethyl fumarate N07XX09 L04AX07

Changes of ATC level namesPrevious New ATC code

Angiotensin II antagonists, plain Angiotensin II receptor blockers (ARBs), plain C09C

Angiotensin II antagonists, plain Angiotensin II receptor blockers (ARBs), plain C09CA

Angiotensin II antagonists, combinations

Angiotensin II receptor blockers (ARBs), combinations C09D

Angiotensin II antagonists and diuretics

Angiotensin II receptor blockers (ARBs) and diuretics C09DA

Angiotensin II antagonists and calcium channel blockers

Angiotensin II receptor blockers (ARBs) and calcium channel blockers C09DB

Angiotensin II antagonists, other combinations

Angiotensin II receptor blockers (ARBs), other combinations C09DX

fluoromethylcholine (18F) fluorocholine (18F) V09IX07combinations potassium (different salts in combination) A12BA30

New DDDsATC level name/INN DDD unit Adm.R* ATC codeartemether 0.28 g R P01BE02artesunate 0.28 g R P01BE03benralizumab 0.54 mg P R03DX10chenodeoxycholic acid 1 g O A05AA01cladribine 0.34 mg O L04AA40dupilumab 21.4 mg P D11AH05

Continued

ATC/DDD classification WHO Drug Information Vol. 32, No. 2, 2018

278

Temporary

New DDDs (continued)ATC level name/INN DDD unit Adm.R* ATC codeemicizumab 15 mg P B02BX06ertugliflozin 10 mg O A10BK04guselkumab 1.79 mg P L04AC16letermovir 0.48 g O,P J05AX18ocrelizumab 3.29 mg P L04AA36patiromer calcium 8.4 g O V03AE09rolapitant 0.18 g O A04AD14telotristat 0.75 g O A16AX15

* Administration Route: O = oral; P = parenteral.

Changes of DDDsATC level name/INN Previous DDD New DDD ATC code

DDD Unit Adm.R.* DDD Unit Adm.R.*aprepitant1 95 mg P 150 mg P A04AD12aprepitant 95 mg O 165 mg O A04AD12temocillin 2 g P 4 g P J01CA17vasopressin (argipressin) 4 U P 40 U P H01BA01

* Administration Route: P = parenteral.1 expressed as fosaprepitant

WHO Collaborating Centre for Drug Statistics MethodologyOslo, May 2018

279

WHO Drug Information Vol. 32, No. 2, 2018 ATC/DDD classification

ATC/DDD classification (final)

The following ATC codes and DDDs were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology in October 2017.These are considered final and included in the January 2019 version of the ATC/DDD Index.

New ATC 5th level codes

ATC level name/INN ATC codeambrisentan and tadalafil C02KX52atazanavir and ritonavir J05AR23atezolizumab L01XC32avelumab L01XC31caplacizumab B01AX07cefteram J01DD18cladribine1 L04AA40clenbuterol and ambroxol R03CC63crisaborole D11AH06crofelemer A07XA06cytarabine and daunorubicin L01XY01dacomitinib L01XE47dapivirine G01AX17delafloxacin J01MA23doxepin D04AX01emapalumab L04AA39enasidenib L01XX59encorafenib L01XE46enisamium iodide J05AX17epacadostat L01XX58eravacycline J01AA13ertugliflozin A10BK04fexapotide G04CX04floxuridine L01BC09galcanezumab N02CX08glecaprevir and pibrentasvir J05AP57ibandronic acid and colecalciferol M05BB09icotinib L01XE48imidazolyl ethanamide pentandioic acid J05AX21indocyanine green V04CX01ipragliflozin A10BK05isoniazid, sulfamethoxazole, trimethoprim and pyridoxine J04AM08kagocel J05AX22lanadelumab B06AC05

Continued

ATC/DDD classification WHO Drug Information Vol. 32, No. 2, 2018

280

Final

New ATC 5th level codes (continued)ATC level name/INN ATC codeletermovir J05AX18lorlatinib L01XE44lusutrombopag B02BX07medroxyprogesterone and estradiol G03AA17meropenem and vaborbactam J01DH52metformin and ertugliflozin A10BD23naldemedine A06AH05neratinib L01XE45norgestimate and ethinylestradiol G03AB09ozanimod L04AA38patisiran N07XX12peramivir J05AH03riboflavin S01XA26rifampicin, ethambutol and isoniazid J04AM07roxadustat B03XA05sitagliptin and ertugliflozin A10BD24tebipenem pivoxil J01DH06tildrakizumab L04AC17tilorone J05AX19tosufloxacin J01MA22uramustine L01AD08vaginal ring with progestogen G02BB02valbenazine N07XX13valsartan and nebivolol C09DX05

1 Oral formulations indicated for multiple sclerosis. Parenteral formulations are classified in L01BB04.

Change of ATC level namePrevious New ATC codedinutuximab dinutuximab beta L01XC16

New DDDs

ATC level name/INN DDD Unit Adm.R* ATC codeatazanavir and ritonavir 0.3 g1 O J05AR23baricitinib 4 mg O L04AA37cariprazine 3 mg O N05AX15cefroxadine 2.1 g O J01DB11cefteram 0.4 g O J01DD18ceftriaxone and beta-lactamase inhibitor 2 g2 P J01DD63

colistin 9 MU O A07AA10Continued

281

WHO Drug Information Vol. 32, No. 2, 2018 ATC/DDD classification

Final

New DDDs (continued)ATC level name/INN DDD Unit Adm.R* ATC codedelafloxacin delafloxacin

0.9 0.6

g g

O P

J01MA23 J01MA23

delamanid 0.2 g O J04AK06desfesoterodine 3.5 mg O G04BD13droxidopa 1 g O C01CA27eluxadoline 0.2 g O A07DA06enisamium iodide 1.5 g O J05AX17estradiol 1.53 mg TD spray G03CA03faropenem 0.75 g O J01DI03follitropin delta 12 mcg P G03GA10garenoxacin 0.4 g O J01MA19gemifloxacin 0.32 g O J01MA15imidazolyl ethanamide pentandioic acid 90 mg O J05AX21insulin glargine and lixisenatide 40 U3 P A10AE54kagocel 60 mg O J05AX22kanamycin 3 g O A07AA08lomefloxacin 0.4 g O J01MA07mepyramine theophyllinacetate 0.6 g O R03DA12midecamycin 1.2 g O J01FA03misoprostol 0.2 mg O G02AD06naldemedine 0.2 mg O A06AH05nusinersen 0.1 mg P M09AX07pyrimethamine, combinations 75 mg4 P P01BD51reslizumab 7.1 mg P R03DX08rimantadine 0.2 g O J05AC02sarilumab 14.3 mg P L04AC14secnidazole 2 g O P01AB07tebipenem pivoxil 0.56 g O J01DH06thyroid gland preparations 0.1 g O H03AA05tilorone 0.125 g O J05AX19tosufloxacin 0.45 g O J01MA22

* Administration Route: O = oral; P = parenteral.1 refers to atazanavir.2 refers to ceftriaxone.3 refers to insulin glargine.4 refers to pyrimethamine.

ATC/DDD classification WHO Drug Information Vol. 32, No. 2, 2018

282

Final

Changes of DDDsATC level name/INN Previous DDD New DDD ATC code

DDD Unit Adm.R.* DDD Unit Adm.R.*amoxicillin amoxicillin

1 1

g g

O P

1.5 3

g g

O P

J01CA04 J01CA04

amoxicillin and beta-lactamase inhibitor1 1 g O 1.5 g O J01CR02

ampicillin 2 g P 6 g P J01CA01cefepime 2 g P 4 g P J01DE01ciprofloxacin 0.5 g P 0.8 g P J01MA02colistin 3 MU P 9 MU P J01XB01meropenem 2 g P 3 g P J01DH02

* Administration Route: O = oral; P = parenteral.1 New ATC level name valid from 2018.

WHO Collaborating Centre for Drug Statistics MethodologyOslo, May 2018

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

283

International Nonproprietary Names for Pharmaceutical Substances (INN)

Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, the names given in the list on the following pages are under consideration by the World Health Organization as Proposed International Nonproprietary Names. The inclusion of a name in the lists of Proposed International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–117) and Recommended (1–78) International Nonproprietary Names can be found in Cumulative List No. 17, 2017 (available in CD-ROM only). The statements indicating action and use are based largely on information supplied by the manufacturer. This information is merely meant to provide an indication of the potential use of new substances at the time they are accorded Proposed International Nonproprietary Names. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature, these descriptors will neither be revised nor included in the Cumulative Lists of INNs.

Dénominations communes internationales des Substances pharmaceutiques (DCI) Il est notifié que, conformément aux dispositions de l'article 3 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques les dénominations ci-dessous sont mises à l'étude par l'Organisation mondiale de la Santé en tant que dénominations communes internationales proposées. L'inclusion d'une dénomination dans les listes de DCI proposées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–117) et recommandées (1–78) dans la Liste récapitulative No. 17, 2017 (disponible sur CD-ROM seulement). Les mentions indiquant les propriétés et les indications des substances sont fondées sur les renseignements communiqués par le fabricant. Elles ne visent qu'à donner une idée de l'utilisation potentielle des nouvelles substances au moment où elles sont l'objet de propositions de DCI. L'OMS n'est pas en mesure de confirmer ces déclarations ni de faire de commentaires sur l'efficacité du mode d'action ainsi décrit. En raison de leur caractère provisoire, ces informations ne figureront pas dans les listes récapitulatives de DCI.

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI) De conformidad con lo que dispone el párrafo 3 del "Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas", se comunica por el presente anuncio que las denominaciones detalladas en las páginas siguientes están sometidas a estudio por la Organización Mundial de La Salud como Denominaciones Comunes Internacionales Propuestas. La inclusión de una denominación en las listas de las DCI Propuestas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–117) y Recomendadas (1–78) se encuentran reunidas en Cumulative List No. 17, 2017 (disponible sólo en CD-ROM). Las indicaciones sobre acción y uso que aparecen se basan principalmente en la información facilitada por los fabricantes. Esta información tiene por objeto dar una idea únicamente de las posibilidades de aplicación de las nuevas sustancias a las que se asigna una DCI Propuesta. La OMS no está facultada para respaldar esas indicaciones ni para formular comentarios sobre la eficacia de la acción que se atribuye al producto. Debido a su carácter provisional, esos datos descriptivos no deben incluirse en las listas recapitulativas de DCI.

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

284

Proposed International Nonproprietary Names: List 119 Comments on, or formal objections to, the proposed names may be forwarded by any person to the INN Programme of the World Health Organization within four months of the date of their publication in WHO Drug Information, i.e., for List 119 Proposed INN not later than 19 November 2018. Publication date: 19 July 2018

Dénominations communes internationales proposées: Liste 119 Des observations ou des objections formelles à l'égard des dénominations proposées peuvent être adressées par toute personne au Programme des Dénominations communes internationales de l'Organisation mondiale de la Santé dans un délai de quatre mois à compter de la date de leur publication dans WHO Drug Information, c'est à dire pour la Liste 119 de DCI Proposées le 19 novembre 2018 au plus tard. Date de publication: 19 juillet 2018

Denominaciones Comunes Internacionales Propuestas: Lista 119 Cualquier persona puede dirigir observaciones u objeciones respecto de las denominaciones propuestas, al Programa de Denominaciones Comunes Internacionales de la Organización Mundial de la Salud, en un plazo de cuatro meses, contados desde la fecha de su publicación en WHO Drug Information, es decir, para la Lista 119 de DCI Propuestas el 19 de noviembre de 2018 a más tardar. Fecha de publicación: 19 de julio de 2018

Proposed INN (Latin, English, French, Spanish) DCI Proposée DCI Propuesta

Chemical name or description: Action and use: Molecular formula Chemical Abstracts Service (CAS) registry number: Graphic formula Nom chimique ou description: Propriétés et indications: Formule brute Numéro dans le registre du CAS: Formule développée Nombre químico o descripción: Acción y uso: Fórmula molecular Número de registro del CAS: Fórmula desarrollada

abelacimabum # abelacimab immunoglobulin G1-lambda, anti-[Homo sapiens F11

(coagulation factor XI, FXI, plasma thromboplastin antecedent, PTA)], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-452) [Homo sapiens VH (IGHV3-23*01 (93.9%) -(IGHD) -IGHJ4*01 (100%)) [8.8.15] (1-122) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (219) (123-220), hinge (221-235), CH2 D27>A (270), P114>A (334) (236-345), CH3 E12 (361), M14 (363) (346-450), CHS (451-452)) (123-452)], (225-215')-disulfide with lambda light chain (1'-216') [Homo sapiens V-LAMBDA (IGLV1-44*01 (93.5%) -IGLJ2*01 (100%)) [8.3.11] (1'-110') -Homo sapiens IGLC2*01 (111'-216')]; dimer (231-231'':234-234'')-bisdisulfide immunomodulatory, blood coagulation factor inhibitor

abélacimab immunoglobuline G1-lambda, anti-[Homo sapiens F11 (facteur de coagulation XI, FXI, antécédent de la thromboplastine plasmatique, PTA)], Homo sapiens anticorps monoclonal;

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

285

chaîne lourde gamma1 (1-452) [Homo sapiens VH (IGHV3-23*01 (93.9%) -(IGHD) -IGHJ4*01 (100%)) [8.8.15] (1-122) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (219) (123-220), charnière (221-235), CH2 D27>A (270), P114>A (334) (236-345), CH3 E12 (361), M14 (363) (346-450), CHS (451-452)) (123-452)], (225-215')-disulfure avec la chaîne légère lambda (1'-216') [Homo sapiens V-LAMBDA (IGLV1-44*01 (93.5%) -IGLJ2*01 (100%)) [8.3.11] (1'-110') -Homo sapiens IGLC2*01 (111'-216')]; dimère (231-231'':234-234'')-bisdisulfure immunomodulateur, inhibiteur de facteur de la coagulation sanguine

abelacimab inmunoglobulina G1-lambda, anti-[Homo sapiens F11 (factor de coagulación XI, FXI, antecedente de la tromboplastina plasmática, PTA)], Homo sapiens anticuerpo monoclonal; cadena pesada gamma1 (1-452) [Homo sapiens VH (IGHV3-23*01 (93.9%) -(IGHD) -IGHJ4*01 (100%)) [8.8.15] (1-122) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (219) (123-220), bisagra (221-235), CH2 D27>A (270), P114>A (334) (236-345), CH3 E12 (361), M14 (363) (346-450), CHS (451-452)) (123-452)], (225-215')-disulfuro con la cadena ligera lambda (1'-216') [Homo sapiens V-LAMBDA (IGLV1-44*01 (93.5%) -IGLJ2*01 (100%)) [8.3.11] (1'-110') -Homo sapiens IGLC2*01 (111'-216')]; dímero (231-231'':234-234'')-bisdisulfuro immunomodulatory, blood coagulation factor inhibitor

2098724-83-3 Heavy chain / Chaîne lourde / Cadena pesada

QVQLLESGGG LVQPGGSLRL SCAASGFTFS TAAMSWVRQA PGKGLEWVSG 50ISGSGSSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAREL 100SYLYSGYYFD YWGQGTLVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250KPKDTLMISR TPEVTCVVVA VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALAAPIEKT ISKAKGQPRE 350PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450GK 452

Light chain / Chaîne légère / Cadena ligeraQSVLTQPPSA SGTPGQRVTI SCSGSSSNIG SNDVSWYQQL PGTAPKLLIY 50KNYNRPSGVP DRFSGSKSGT SASLAISGLQ SEDEADYYCS AWDQRQFDVV 100FGGGTKLTVL GQPKAAPSVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150AWKADSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT 200HEGSTVEKTV APTECS 216

Post-translational modificationsDisulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 149-205 266-326 372-430

22''-96'' 149''-205'' 266''-326'' 372''-430''Intra-L (C23-C104) 22'-89' 138'-197'

22'''-89''' 138'''-197'''Inter-H-L (h 5-CL 126) 225-215' 225''-215'''Inter-H-H (h 11, h 14) 231-231'' 234-234''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:302, 302''fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennairescomplexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

N-terminal glutamine cyclization to pyroglutamate (pE, 5-oxoproline)H VH Q1: 1, 1''L VL Q1: 1, 1''

C-terminal lysine clippingH CHS K2: 452, 452''

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

286

abivertinibum abivertinib N-[3-({2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-7H-

pyrrolo[2,3-d]pyrimidin-4-yl}oxy)phenyl]prop-2-enamide tyrosine kinase inhibitor, antineoplastic

abivertinib N-[3-({2-[3-fluoro-4-(4-méthylpipérazin-1-yl)anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)phényl]prop-2-énamide inhibiteur de la tyrosine kinase, antinéoplasique

abivertinib N-[3-({2-[3-fluoro-4-(4-metilpiperazin-1-il)anilino]-7H-pirrolo[2,3-d]pirimidin-4-il}oxi)fenil]prop-2-enamida inhibidor de la tirosina kinasa, antineoplásico

C26H26FN7O2

1557267-42-1

adriforantum adriforant N4-(cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-

1-yl]pyrimidine-2,4-diamine histamine H4 receptor antagonist

adriforant N4-(cyclopropylméthyl)-6-[(3R)-3-(méthylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine antagoniste du récepteur H4 de l'histamine

adriforant N4-(ciclopropilmetil)-6-[(3R)-3-(metilamino)pirrolidin- 1-il]pirimidina-2,4-diamina antagonista del receptor H4 de histamina

C13H22N6 943057-12-3

alteminostatum alteminostat N-[7-(hydroxyamino)-7-oxoheptyl]-4-methyl-N-[4-(1-methyl-

1H-indazol-6-yl)phenyl]piperazine-1-carboxamide histone deacetylase inhibitor, antineoplastic

altéminostat N-[7-(hydroxyamino)-7-oxoheptyl]-4-méthyl-N-[4-(1-méthyl-1H-indazol-6-yl)phényl]pipérazine-1-carboxamide inhibiteur de l'histone désacétylase, antinéoplasique

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

287

alteminostat N-[7-(hidroxiamino)-7-oxoheptil]-4-metil-N-[4-(1-metil-1H-indazol-6-il)fenil]piperazina-1-carboxamida inhibidor de la histona desacetilasa, antineoplásico

C27H36N6O3 1246374-97-9

amelparibum amelparib 10-ethoxy-8-[(morpholin-4-yl)methyl]-2,3,4,6-

tetrahydrobenzo[h][1,6]naphthyridin-5(1H)-one poly-ADP-ribose polymerase inhibitor

amelparib 10-éthoxy-8-[(morpholin-4-yl)méthyl]-2,3,4,6-tétrahydrobenzo[h][1,6]naphtyridin-5(1H)-one inhibiteur de poly-ADP-ribose polymérase

amelparib 10-etoxi-8-[(morfolin-4-il)metil]-2,3,4,6-tetrahidrobenzo[h][1,6]naftiridin-5(1H)-ona inhibidor de poli-ADP-ribosa polimerasa

C19H25N3O3

1227156-72-0

amlivirsenum amlivirsen all-P-ambo-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-

2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidine 5'-(1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-13,13-bis{[3-({6-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]hexyl}amino)-3-oxopropoxy]methyl}-8,15,19-trioxo-11-oxa-7,14,20-triazahexacosan-26-yl hydrogen phosphate) antiviral

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

288

amlivirsen 5'-(hydrogénophosphate de 1-[(2-acétamido-2-désoxy-β-D-

galactopyranosyl)oxy]-13,13-bis{[3-({6-[(2-acétamido-2-désoxy-β-D-galactopyranosyl)oxy]hexyl}amino)-3-oxopropoxy]méthyl}-8,15,19-trioxo-11-oxa-7,14,20-triazahexacosan-26-yle) de tout-P-ambo-2'-O-(2-méthoxyéthyl)-P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioadénylyl-(3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')-2'-désoxy-5-méthyl-P-thiocytidylyl-(3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthylcytidine antiviral

amlivirsén 5'-(hidrogenofosfato de 1-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]-13,13-bis{[3-({6-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]hexil}amino)-3-oxopropoxi]metil}-8,15,19-trioxo-11-oxa-7,14,20-triazahexacosan-26-ilo) de todo-P-ambo-2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-P-tioadenilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-5-metilcitidina antiviral

C296H428N96O144P20S19

1637640-12-0

= R1

CH2

OHN

O

HNHO

HO

HO

O

CH3

H

O

= R

NH

OP

OHO

O

NH

OR

R

R 3

O2

R1-moeG=moeCm=moeA=moeG=moeA=dG=dG=dT=dG=dA=dA=dG=dCm=dG=dA=moeA=moeG=moeUm=moeG=moeCm

Legend :

2'-O-(2-methoxyethyl)

5-methyl

P

SHO

2'-deoxy

moe as prefix =

d as prefix =

m as suffix =

5'3'is for

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

289

ampreloxetinum ampreloxetine 4-{2-[(2,4,6-trifluorophenoxy)methyl]phenyl}piperidine

norepinephrine reuptake inhibitor

ampréloxétine 4-{2-[(2,4,6-trifluorophénoxy)méthyl]phényl}pipéridine inhibiteur de la recapture de la norépinéphrine

ampreloxetina 4-{2-[(2,4,6-trifluorofenoxi)metil]fenil}piperidina inhibidor de la recaptación de la norepinefrina

C18H18F3NO

1227056-84-9

HN

O

F F

F

asalhydromorphonum asalhydromorphone 17-methyl-4,5α-epoxy-6,7-didehydromorphinan-3,6-diyl

bis[2-(acetyloxy)benzoate] opioid analgesic

asalhydromorphone bis[2-(acétyloxy)benzoate] de 17-méthyl-4,5α-époxy-6,7-didéshydromorphinane-3,6-diyle analgésique opioïde

asalhidromorfona bis[2-(acetiloxi)benzoato] de 17-metil-4,5α-epoxi-6,7-dideshidromorfinano-3,6-diilo analgésico opioide

C35H31NO9

1431529-94-0

aticaprantum aticaprant 4-(4-{[(2S)-2-(3,5-dimethylphenyl)pyrrolidin-

1-yl]methyl}phenoxy)-3-fluorobenzamide kappa-opioid receptor antagonist

aticaprant 4-(4-{[(2S)-2-(3,5-diméthylphényl)pyrrolidin- 1-yl]méthyl}phénoxy)-3-fluorobenzamide antagoniste des récepteurs opioïdes kappa

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

290

aticaprant 4-(4-{[(2S)-2-(3,5-dimetilfenil)pirrolidin-1-il]metil}fenoxi)- 3-fluorobenzamida antagonista de los receptores de opiáceos kappa

C26H27FN2O2

1174130-61-0

avasopasemum manganesum avasopasem manganese (PBPY-7-11-2344'3')-dichlorido[(11S,12S,71S,72S)-2,6,8,11-

tetraaza-4(2,6)-pyridina-1,7(1,2)-dicyclohexanacycloundecaphane-κ5N2,N1.4,N6,N8,N11]manganese superoxide dismutase mimetic

avasopasem manganèse (PBPY-7-11-2344'3')-dichlorido[(11S,12S,71S,72S)-2,6,8,11-tetraaza-4(2,6)-pyridina-1,7(1,2)-dicyclohexanacycloundécaphane-κ5N2,N1.4,N6,N8,N11]manganèse mimétique de la superoxyde dismutase

avasopasem manganeso (PBPY-7-11-2344'3')-diclorido[(11S,12S,71S,72S)-2,6,8,11-tetraaza-4(2,6)-piridina-1,7(1,2)-diciclohexanacicloundecafano-κ5N2,N1.4,N6,N8,N11]manganeso mimético de superóxido dismutasa

C21H35Cl2MnN5

435327-4-5

avoplacelum avoplacel human culture expanded allogenic adherent

mesenchymal-like stromal cells for cell-based therapy. Cells are of fetal origin and derived from isolated placentae of healthy donors following a cesarean section. Cells express cell surface markers CD29, CD73, and CD105 and exhibit immunomodulatory, and pro-angiogenic and muscle regeneration effects. cell therapy substance (ischemic conditions)

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

291

avoplacel cellules stromales semblables au mésenchyme, humaines,

allogéniques, adhérentes, en culture d'expansion, pour thérapie cellulaire. Les cellules sont d'origine fœtale et dérivent du placenta isolé de donneuses en bonne santé, à la suite d'une césarienne. Les cellules expriment les marqueurs de surface CD29, CD73 et CD105 et montrent des effets immunomodulateurs, pro-angiogéniques et de regénération musculaire. substance de thérapie cellulaire (conditions ischémiques)

avoplacel células similares a mesenquimales, estromales, alogénicas, humanas, expandidas en cultivo para terapia celular. Las células son de origen fetal y derivadas de placentas aisladas de donantes sanas tras una cesárea. Las células expresan los marcadores de superficie CD29, CD73 y CD105, y poseen efectos inmunomoduladores, pro-angiogénicos y de regeneración muscular. sustancia de terapia celular (condiciones isquémicas)

azelapragum azelaprag (2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-

yl)-4H-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide apelin receptor agonist

azélaprag (2S,3R)-N-[4-(2,6-diméthoxyphényl)-5-(5-méthylpyridin-3-yl)-4H-1,2,4-triazol-3-yl]-3-(5-méthylpyrimidin-2-yl)butane-2-sulfonamide agoniste du récepteur de l'apéline

azelaprag (2S,3R)-N-[4-(2,6-dimetoxifenil)-5-(5-metilpiridin-3-il)-4H-1,2,4-triazol-3-il]-3-(5-metilpirimidin-2-il)butano-2-sulfonamida agonista del receptor de apelina

C25H29N7O4S 2049980-18-7

bamadutidum bamadutide L-histidyl-D-seryl-L-glutaminylglycyl-L-threonyl-L-

phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-leucyl-L-seryl-L-lysyl-L-glutaminyl-N6-(N-hexadecanoyl-L-γ-glutamyl)-L-lysyl-L-α-glutamyl-L-seryl-L-lysyl-L-alanyl-L-alanyl-L-glutaminyl-L-α-aspartyl-L-phenylalanyl-L-isoleucyl-L-α-glutamyl-L-tryptophyl-L-leucyl-L-lysyl-L-alanylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-serinamide antidiabetic

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

292

bamadutide L-histidyl-D-séryl-L-glutaminylglycyl-L-thréonyl-L-phénylalanyl-L-thréonyl-L-séryl-L-α-aspartyl-L-leucyl-L-séryl-L-lysyl-L-glutaminyl-N6-(N-hexadécanoyl-L-γ-glutamyl)-L-lysyl-L-α-glutamyl-L-séryl-L-lysyl-L-alanyl-L-alanyl-L-glutaminyl-L-α-aspartyl-L-phénylalanyl-L-isoleucyl-L-α-glutamyl-L-tryptophyl-L-leucyl-L-lysyl-L-alanylglycylglycyl-L-prolyl-L-séryl-L-sérylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-sérinamide hypoglycémiant

bamadutida L-histidil-D-seril-L-glutaminilglicil-L-treonil-L-fenilalanil-L-treonil-L-seril-L-α-aspartil-L-leucil-L-seril-L-lisil-L-glutaminil-N6-(N-hexadecanoil-L-γ-glutamil)-L-lisil-L-α-glutamil-L-seril-L-lisil-L-alanil-L-alanil-L-glutaminil-L-α-aspartil-L-fenilalanil-L-isoleucil-L-α-glutamil-L-triptofil-L-leucil-L-lisil-L-alanilglicilglicil-L-prolil-L-seril-L-serilglicil-L-alanil-L-prolil-L-prolil-L-prolil-L-serinamida hipoglucemiante

C200H313N51O63

1596343-09-7

Sequence / Séquence / Secuencia

HSQGTFTSDL SKQKESKAAQ DFIEWLKAGG PSSGAPPPS 39

Modified residues / Résidus modifiés / Restos modificados

S (2)D-serine

S (39)L-serinamide

K (14)

N6-(N-hexadecanoyl-

-Glu)-Lysine

H2N CO2H

H OH

H2N CONH2

H OH

CO2HH2N

HNH

O

HNH3C

CO2HHO

14

bempegaldesleukinum # bempegaldesleukin human interleukin-2 variant (Ala1 removed, C125>S)

produced in Escherichia coli, in which an average of 6 lysine residues are N6 substituted with [(2,7-bis{[methylpoly(oxyethylene)]carbamoyl}-9H-fluoren-9-yl)methoxy]carbonyl immunomodulator, antineoplastic

bempégaldesleukine variant de l'interleukine 2 humaine (Ala1 supprimée, C125>S), produit par Escherichia coli, dans lequel environ 6 lysines sont N6 substitutées par le radical [(2,7-bis{[méthylpoly(oxyéthylène)]carbamoyl}-9H-fluorén-9-yl)méthoxy]carbonyle immunomodulateur, antinéoplasique

bempegaldesleukina variante de la interleukina 2 humana (Ala1 suprimida, C125>S), producida por Escherichia coli, en la que una media de 6 lisinas son N6 sustituidas por el radical [(2,7-bis{[metilpoli(oxietileno)]carbamoil}-9H-fluoren-9-il)metoxi]carbonilo inmunomodulador, antineoplásico

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

293

C690H1113N177O203S6 (C19H16N2O4 [C2H4O]2n)6

1939126-74-5

bevifimodum # bevifimod staphylococcal protein A (SpA), purified from Staphylococcus

aureus strain A676 culture medium immunomodulator

bévifimod protéine A staphylococcique (SpA), purifiée à partir de milieu de culture de la souche A676 de Staphylococcus aureus immunomodulateur

bevifimod proteína A estafilocócica (SpA), purificada a partir del medio de cultivo de la cepa A676 de Staphylococcus aureus inmunomodulador

2223113-32-2

bintrafuspum alfa # bintrafusp alfa human immunoglobulin G1-lambda, anti-[human programmed

cell death 1 ligand 1 (PD-L1, programmed death ligand 1, PDCD1 ligand 1, B7 homolog 1, B7-H1, CD274)], human monoclonal antibody,anti-(human programmed death ligand 1) immunoglobulin G1, lambda light chain, fused at the C-terminus of both heavy chains via a peptidyl linker (450-471), to a fragment of the mature human extracellular domain of human TGF-beta receptor type-2 (TGFR-2, TGFBR2, transforming growth factor-beta receptor type II)TGFβ type II receptor (472-607), dimer, produced in Chinese hamster ovary (CHO) cells, glycoform alfa;

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

294

gamma1 heavy chain fused to TGFR-2 (1-607) [Homo sapiens VH (IGHV3-23*01 -(IGHD) -IGHJ4*01) [CDRKabatH1: SYIMM (31-35); CDRKabatH2: SIYPSGGITFYADTVKG (50-66); CDRKabatH3: IKLGTVTTVDY (99-109)] (1-120) -Homo sapiens IGHG1*03, (CH1 (121-218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS (449-449, K450del)) (121-449)], (223-215')-disulfide with lambda light chain (1'-216') [Homo sapiens V-LAMBDA (IGLV2-14*01 -IGLJ1*01) [CDRKabatL1: TGTSSDVGGYNYVS (23-36); CDRKabatL2: DVSNRPS (52-58); CDRKabatL3: SSYTSSSTRV (91-100)] (1'-110') -IGLC1*02 (111'-216')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa immunomodulator, antineoplastic

bintrafusp alfa immunoglobuline G1-lambda humaine, anti-[ligand 1 de la protéine 1 de mort cellulaire programmée humain (PD-L1, ligand 1 de mort programmée, ligand 1 PDCD1, homologue 1 de B7, B7-H1, CD274)], anticorps monoclonal humain, fusionnée à l'extrémité C-terminale des deux chaînes lourdes via un linker peptidique (450-471), à un fragment du domaine extracellulaire du récepteur de type-2 du TGF-bêta humain (TGFR-2, TGFBR2, récepteur de type-2 du facteur de croissance transformant-bêta) (472-607), dimère, produit dans des cellules ovariennes de hamsters chinois (CHO), glycoforme alfa; chaîne lourde gamma1 fusionnée au TGFR-2 (1-607) [Homo sapiens VH (IGHV3-23*01 -(IGHD) -IGHJ4*01) [CDRKabatH1: SYIMM (31-35); CDRKabatH2: SIYPSGGITFYADTVKG (50-66); CDRKabatH3: IKLGTVTTVDY (99-109)] (1-120) -Homo sapiens IGHG1*03, (CH1 (121-218), charnière (219-233), CH2 (234-343), CH3 (344-448), CHS (449-449, K450del)) (121-449)], (223-215')-disulfure avec la chaîne légère lambda (1'-216') [Homo sapiens V-LAMBDA (IGLV2-14*01 -IGLJ1*01) [CDRKabatL1: TGTSSDVGGYNYVS (23-36); CDRKabatL2: DVSNRPS (52-58); CDRKabatL3: SSYTSSSTRV (91-100)] (1'-110') -IGLC1*02 (111'-216')]; dimère (229-229'':232-232'')-bisdisulfure, produit dans des cellules ovariennes de hamsters chinois (CHO), glycoforme alfa immunomodulateur, antinéoplasique

bintrafusp alfa inmunoglobulina G1-lambda, anti-[ligando 1 de la proteína 1 de muerte celular programadahumana (PD-L1, ligando 1 de muerte programada, ligando 1 PDCD1, homólogo 1 de B7, B7-H1, CD274)], anticuerpo monoclonal humano,anti-(human programmed death ligand 1) immunoglobulin G1, lambda light chain, fusionado en el extremo C-terminal de las diez cadenas pesadas mediante un conector peptídico (451-471), a un fragmento del dominio mature human extracelular del receptor tipo-2 del TGF-beta humano (TGFR-2, TGFBR2, receptor tipo-2 del factor de crecimiento transformante-beta )TGFβ type II receptor (472-607), dímero, producido en las células ováricas de hamsters chinos (CHO), glicoforma alfa;

cadena pesada gamma1 fusionada al TGFR-2 (1-607) [Homo sapiens VH (IGHV3-23*01 -(IGHD) -IGHJ4*01) [CDRKabatH1: SYIMM (31-35); CDRKabatH2: SIYPSGGITFYADTVKG (50-66); CDRKabatH3: IKLGTVTTVDY (99-109)] (1-120) -Homo sapiens IGHG1*03, (CH1 (121-218), bisagra (219-233), CH2 (234-343), CH3 (344-448), CHS (449-449, K450del)) (121-449)], (223-215')-disulfuro con la cadena ligera lambda (1'-216') [Homo sapiens V-LAMBDA (IGLV2-14*01 -IGLJ1*01) [CDRKabatL1: TGTSSDVGGYNYVS (23-36); CDRKabatL2: DVSNRPS (52-58); CDRKabatL3: SSYTSSSTRV (91-100)] (1'-110') -IGLC1*02 (111'-216')]; dímero (229-229'':232-232'')-bisdisulfuro, producido en las células ováricas de hamsters chinos (CHO), glicoforma alfa inmunomodulador, antineoplásico

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

295

1918149-01-5

birtamimabum # birtamimab immunoglobulin G1-kappa, anti-[Homo sapiens serum

amyloid A (AA) and immunoglobulin amyloid light chain (AL)], monoclonal antibody; gamma1 heavy chain (1-449) [VH (Mus musculus IGHV10-1*02 (89.8%)/Homo sapiens IGHV3-72*01 (84.0%) -(IGHD) -Homo sapiens IGHJ4*01 (92.9%)) [8.10.10] (1-119) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (216) (120-217), hinge (218-232), CH2 (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120-449)], (222-219')-disulfide with kappa light chain (1'-219') [V-KAPPA (Mus musculus IGKV1-110*01 (91.0%)/Homo sapiens IGKV2-30*02 (87.0%) -Homo sapiens IGKJ4*01 (91.7%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3A45.1 (158), V101 (196)(113'-219')]; dimer (228-228'':231-231'')-bisdisulfide immunomodulator

birtamimab immunoglobuline G1-kappa, anti-[Homo sapiens amyloïde A sérique (AA) et chaîne légère amyloïde (AL) d'immunoglobuline)], anticorps monoclonal; chaîne lourde gamma1 (1-449) [VH (Mus musculus IGHV10-1*02 (89.8%)/Homo sapiens IGHV3-72*01 (84.0%) -(IGHD) -Homo sapiens IGHJ4*01 (92.9%)) [8.10.10] (1-119) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (216) (120-217), charnière (218-232), CH2 (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120-449)], (222-219') -disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA (Mus musculus IGKV1-110*01 (91.0%)/Homo sapiens IGKV2-30*02 (87.0%) -Homo sapiens IGKJ4*01 (91.7%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3A45.1 (158), V101 (196)(113'-219')]; dimère (228-228'':231-231'')-bisdisulfure immunomodulateur

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

296

birtamimab inmunoglobulina G1-kappa, anti-[Homo sapiens amiloide A

sérica (AA) y cadena ligera amiloide (AL) de inmunoglobulina)], anticuerpo monoclonal; cadena pesada gamma1 (1-449) [VH (Mus musculus IGHV10-1*02 (89.8%)/Homo sapiens IGHV3-72*01 (84.0%) -(IGHD) -Homo sapiens IGHJ4*01 (92.9%)) [8.10.10] (1-119) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (216) (120-217), bisagra (218-232), CH2 (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120-449)], (222-219') -disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA (Mus musculus IGKV1-110*01 (91.0%)/Homo sapiens IGKV2-30*02 (87.0%) -Homo sapiens IGKJ4*01 (91.7%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3A45.1 (158), V101 (196)(113'-219')]; dímero (228-228'':231-231'')-bisdisulfuro inmunomodulador

1608108-91-3

brilaroxazinum brilaroxazine 6-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-2H-1,4-

benzoxazin-3(4H)-one anxiolytic

brilaroxazine 6-{4-[4-(2,3-dichlorophényl)pipérazin-1-yl]butoxy}-2H-1,4-benzoxazin-3(4H)-one anxiolytique

brilaroxazina 6-{4-[4-(2,3-diclorofenil)piperazin-1-il]butoxi}-2H-1,4-benzoxazin-3(4H)-ona ansiolítico

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

297

C22H25Cl2N3O3

1239729-06-6

budigalimabum # budigalimab immunoglobulin G1-kappa, anti-[Homo sapiens PDCD1

(programmed cell death 1, PD-1, PD1, CD279)], monoclonal antibody; gamma1 heavy chain (1-448) [VH (Homo sapiens IGHV1-46*01 (76.5%) -(IGHD) -IGHJ6*03 (90.9%)) [8.8.11] (1-118) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (215) (119-216), hinge (217-231), CH2 L1.3>A (235), L1.2>A (236) (232-341), CH3 E12 (357), M14 (359) (342-446), CHS (447-448)) (119-448)], (221-219')-disulfide with kappa light chain (1'-219') [V-KAPPA (Mus musculus IGKV1-117*01 (89.0%)/Homo sapiens IGKV2-28*01 or IGKV2-29*02 (85.0%) -Homo sapiens IGKJ2*01 (100%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (227-227":230-230")-bisdisulfide immunomodulator, antineoplastic

budigalimab immunoglobuline G1-kappa, anti-[Homo sapiens PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal; chaîne lourde gamma1 (1-448) [VH (Homo sapiens IGHV1-46*01 (76.5%) -(IGHD) -IGHJ6*03 (90.9%)) [8.8.11] (1-118) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (215) (119-216), charnière (217-231), CH2 L1.3>A (235), L1.2>A (236) (232-341), CH3 E12 (357), M14 (359) (342-446), CHS (447-448)) (119-448)], (221-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA (Mus musculus IGKV1-117*01 (89.0%)/Homo sapiens IGKV2-28*01 or IGKV2-29*02 (85.0%) -Homo sapiens IGKJ2*01 (100%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimère (227-227":230-230")-bisdisulfure immunomodulateur, antinéoplasique

budigalimab inmunoglobulina G1-kappa, anti-[Homo sapiens PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal; cadena pesada gamma1 (1-448) [VH (Homo sapiens IGHV1-46*01 (76.5%) -(IGHD) -IGHJ6*03 (90.9%)) [8.8.11] (1-118) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (215) (119-216), bisagra (217-231), CH2 L1.3>A (235), L1.2>A (236) (232-341), CH3 E12 (357), M14 (359) (342-446), CHS (447-448)) (119-448)], (221-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA (Mus musculus IGKV1-117*01 (89.0%)/Homo sapiens IGKV2-28*01 or IGKV2-29*02 (85.0%) -Homo sapiens IGKJ2*01 (100%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dímero (227-227":230-230")-bisdisulfuro inmunomodulador, antineoplásico

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

298

2098225-93-3 Heavy chain / Chaîne lourde / Cadena pesada

EIQLVQSGAE VKKPGSSVKV SCKASGYTFT HYGMNWVRQA PGQGLEWVGW 50VNTYTGEPTY ADDFKGRLTF TLDTSTSTAY MELSSLRSED TAVYYCTREG 100EGLGFGDWGQ GTTVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPEAAGGPS VFLFPPKPKD 250TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK 448

Light chain / Chaîne légère / Cadena ligeraDVVMTQSPLS LPVTPGEPAS ISCRSSQSIV HSHGDTYLEW YLQKPGQSPQ 50LLIYKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSHIP 100VTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200VTHQGLSSPV TKSFNRGEC 219

Post-translational modificationsDisulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 145-201 262-322 368-426

22''-96'' 145''-201'' 262''-322'' 368''-426''Intra-L (C23-C104) 23'-93' 139'-199'

23'''-93''' 139'''-199'''Inter-H-L (h 5-CL 126) 221-219' 221''-219'''Inter-H-H (h 11, h 14) 227-227'' 230-230''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:298, 298''Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennairescomplexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

camsirubicinum camsirubicin (8R,10S)-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-

hexopyranosyl)oxy]-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-7,9,10,12-tetrahydrotetracen-5(8H)-one antineoplastic

camsirubicine (8R,10S)-10-[(3-amino-2,3,6-tridésoxy-α-L-lyxo-hexopyranosyl)oxy]-6,8,11-trihydroxy-8-(2-hydroxyéthyl)-12-imino-1-méthoxy-7,9,10,12-tétrahydrotétracén-5(8H)-one antinéoplasique

camsirubicina (8R,10S)-10-[(3-amino-2,3,6-tridesoxi-α-L-lixo-hexopiranosil)oxi]-6,8,11-trihidroxi-8-(2-hidroxietil)-12-imino-1-metoxi-7,9,10,12-tetrahidrotetracen-5(8H)-ona antineoplásico

C27H32N2O9 236095-26-4

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

299

cemiplimabum # cemiplimab immunoglobulin G4-kappa, anti-[Homo sapiens PDCD1 (programmed cell

death 1, PD-1, PD1, CD279)], Homo sapiens monoclonal antibody; gamma4 heavy chain (1-444) [Homo sapiens VH (IGHV3-23*01 (86.7%) -(IGHD) -IGHJ4*01 (100%)) [8.8.10] (1-117) -Homo sapiens IGHG4*01 (CH1 (118-215), hinge S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-214')-disulfide with kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV1-39*01 (86.3%) -IGKJ3*01 (75.0%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (223-223'':226-226'')-bisdisulfide immunomodulator, antineoplastic

cémiplimab immunoglobuline G4-kappa, anti-[Homo sapiens PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], Homo sapiens anticorps monoclonal; chaîne lourde gamma4 (1-444) [Homo sapiens VH (IGHV3-23*01 (86.7%) -(IGHD) -IGHJ4*01 (100%)) [8.8.10] (1-117) -Homo sapiens IGHG4*01 (CH1 (118-215), charnière S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-39*01 (86.3%) -IGKJ3*01 (75.0%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (223-223'':226-226'')-bisdisulfure immunomodulateur, antinéoplasique

cemiplimab inmunoglobulina G4-kappa, anti-[Homo sapiens PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], Homo sapiens anticuerpo monoclonal; cadena pesada gamma4 (1-444) [Homo sapiens VH (IGHV3-23*01 (86.7%) -(IGHD) -IGHJ4*01 (100%)) [8.8.10] (1-117) -Homo sapiens IGHG4*01 (CH1 (118-215), bisagra S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-39*01 (86.3%) -IGKJ3*01 (75.0%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (223-223'':226-226'')-bisdisulfuro inmunomodulador, antineoplásico

1801342-60-8 Heavy chain / Chaîne lourde / Cadena pesada

EVQLLESGGV LVQPGGSLRL SCAASGFTFS NFGMTWVRQA PGKGLEWVSG 50ISGGGRDTYF ADSVKGRFTI SRDNSKNTLY LQMNSLKGED TAVYYCVKWG 100NIYFDYWGQG TLVTVSSAST KGPSVFPLAP CSRSTSESTA ALGCLVKDYF 150PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTKTYTC 200NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF PPKPKDTLMI 250SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTYRVV 300SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP REPQVYTLPP 350SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS 400FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTQKSLSL SLGK 444

Light chain / Chaîne légère / Cadena ligeraDIQMTQSPSS LSASVGDSIT ITCRASLSIN TFLNWYQQKP GKAPNLLIYA 50ASSLHGGVPS RFSGSGSGTD FTLTIRTLQP EDFATYYCQQ SSNTPFTFGP 100GTVVDFRRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214

Post-translational modificationsDisulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 144-200 258-318 364-422

22''-96'' 144''-200'' 258''-318'' 364''-422''Intra-L (C23-C104) 23'-88' 134'-194'

23'''-88''' 134'''-194'''Inter-H-L (CH1 10-CL 126) 131-214' 131''-214'''Inter-H-H (h 8, h 11) 223-223'' 226-226''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:294, 294''C-terminal lysine clipping:H CHS K2: 444, 444''Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennairescomplexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

300

cenupatidum cenupatide N2-acetyl-L-arginyl-2-methylalanyl-L-arginyl-α-methyl-

L-phenylalaninamide urokinase plasminogen activator receptor (uPAR) inhibitor

cénupatide N2-acétyl-L-arginyl-2-méthylalanyl-L-arginyl-α-méthyl- L-phénylalaninamide inhibiteur du récepteur activateur du plasminogène de type urokinase (uPAR)

cenupatida N2-acetil-L-arginil-2-metilalanil-L-arginil-α-metil- L-fenilalaninamida inhibidor del receptor activador del plasminógeno tipo uroquinasa (uPAR)

C28H47N11O5

1006388-38-0

ceralasertibum ceralasertib (R)-imino(methyl)(1-{6-[(3R)-3-methylmorpholin-4-yl]-2-

(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl}cyclopropyl)-λ6-sulfanone antineoplastic

céralasertib (R)-imino(méthyl)(1-{6-[(3R)-3-méthylmorpholin-4-yl]-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl}cyclopropyl)-λ6-sulfanone antinéoplasique

ceralasertib (R)-imino(metil)(1-{6-[(3R)-3-metilmorfolin-4-il]-2-(1H-pirrolo[2,3-b]piridin-4-il)pirimidin-4-il}ciclopropil)-λ6-sulfanona antineoplásico

C20H24N6O2S 1352226-88-0

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

301

cimlanodum cimlanod N-hydroxy-5-methylfuran-2-sulfonamide

HNO donor

cimlanod N-hydroxy-5-méthylfurane-2-sulfonamide donneur de HNO

cimlanod N-hidroxi-5-metilfurano-2-sulfonamida donantes de HNO

C5H7NO4S

1620330-72-4

cintirorgonum cintirorgon 3-{(2S)-6-[3-(difluoromethoxy)-5-fluorophenyl]-4-[3-

(trifluoromethyl)benzene-1-sulfonyl]-3,4-dihydro-2H-1,4-benzoxazin-2-yl}-2,2-dimethylpropanoic acid antineoplastic

cintirorgon ide 3-{(2S)-6-[3-(difluorométhoxy)-5-fluorophényl]-4-[3-(trifluorométhyl)ben-zène-1-sulfonyl]-3,4-dihydro-2H-1,4-benzoxazin-2-yl}-2,2-diméthylpropanoïque antinéoplasique

cintirorgón ácido 3-{(2S)-6-[3-(difluorometoxi)-5-fluorofenil]-4-[3-(trifluorometil)ben-ceno-1-sulfonil]-3,4-dihidro-2H-1,4-benzoxazin-2-il}-2,2-dimetilpropanoico antineoplásico

C27H23F6NO6S 1227156-72-0

coblopasvirum coblopasvir methyl {(2S)-1-[(2S)-2-(4-{4-[7-(2-[(2S)-1-{(2S)-2-

[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-4-yl)-2H-1,3-benzodioxol-4-yl]phenyl}-1H-imidazol-2-yl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate antiviral

coblopasvir {(2S)-1-[(2S)-2-(4-{4-[7-(2-[(2S)-1-{(2S)-2-[(méthoxycarbonyl)amino]-3-méthylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-4-yl)-2H-1,3-benzodioxol-4-yl]phényl}-1H-imidazol-2-yl)pyrrolidin-1-yl]-3-méthyl-1-oxobutan-2-yl}carbamate de méthyle antiviral

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

302

coblopasvir {(2S)-1-[(2S)-2-(4-{4-[7-(2-[(2S)-1-{(2S)-2-[(metoxicarbonil)amino]-3-metilbutanoil}pirrolidin-2-il]-1H-imidazol-4-il)-2H-1,3-benzodioxol-4-il]fenil}-1H-imidazol-2-il)pirrolidin-1-il]-3-metil-1-oxobutan-2-il}carbamato de metilo antiviral

C41H50N8O8 1312608-46-0

cotadutidum cotadutide L-histidyl-L-seryl-L-glutaminylglycyl-L-threonyl-L-

phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-N6-(N-hexadecanoyl-L-γ-glutamyl)-L-lysyl-L-seryl-L-α-glutamyl-L-tyrosyl-L-leucyl-L-α-aspartyl-L-seryl-L-α-glutamyl-L-arginyl-L-alanyl-L-arginyl-L-α-aspartyl-L-phenylalanyl-L-valyl-L-alanyl-L-tryptophyl-L-leucyl-L-α-glutamyl-L-alanylglycylglycine antidiabetic

cotadutide L-histidyl-L-séryl-L-glutaminylglycyl-L-thréonyl-L-phénylalanyl-L-thréonyl-L-séryl-L-α-aspartyl-N6-(N-hexadécanoyl-L-γ-glutamyl)-L-lysyl-L-séryl-L-α-glutamyl-L-tyrosyl-L-leucyl-L-α-aspartyl-L-séryl-L-α-glutamyl-L-arginyl-L-alanyl-L-arginyl-L-α-aspartyl-L-phénylalanyl-L-valyl-L-alanyl-L-tryptophyl-L-leucyl-L-α-glutamyl-L-alanylglycylglycine hypoglycémiant

cotadutida L-histidil-L-seril-L-glutaminilglicil-L-treonil-L-fenilalanil-L-treonil-L-seril-L-α-aspartil-N6-(N-hexadecanoil-L-γ-glutamil)-L-lisil-L-seril-L-α-glutamil-L-tirosil-L-leucil-L-α-aspartil-L-seril-L-α-glutamil-L-arginil-L-alanil-L-arginil-L-α-aspartil-L-fenilalanil-L-valil-L-alanil-L-triptofil-L-leucil-L-α-glutamil-L-alanilglicilglicina hipoglucemiante

C167H252N42O55

1686108-82-6

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

303

crovalimabum # crovalimab immunoglobulin G1-kappa, anti-[Homo sapiens C5

(complement 5)], monoclonal antibody; gamma1 heavy chain (1-451) [VH (Vicugna pacos IGHV3S1*01 (70.4%)/Homo sapiens IGHV3-66*01 (69.4%) -(IGHD)-Homo sapiens IGHJ4*01 (100%)) [9.8.15] (1-123) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (220) (124-221), hinge (222-236), CH2 L1.2>R (241), G1.1>R (242), S3>K (245), A110>G (333), A115>S (336), P116>S (337) (237-346), CH3 E12 (362), M14 (364), M107>L (434), N114>A (440), Q118>R (444), S120>E (446) (347-451), CHS G1>del, K2>del) (124-451)], (226-217')-disulfide with kappa light chain (1'-217') [V-KAPPA (Homo sapiens IGKV1-13*02 or IGKV1D-13*01 (94.3%) -IGKJ4*01 (100%)) [6.3.12] (1'-110') -Homo sapiens IGKC*01, Km3 A45.1 (156), V101 (194) (111'-217')]; dimer (232-232":235-235")-bisdisulfide immunomodulator

crovalimab immunoglobuline G1-kappa, anti-[Homo sapiens C5 (complément 5)], anticorps monoclonal; chaîne lourde gamma1 (1-451) [VH (Vicugna pacos IGHV3S1*01 (70.4%)/Homo sapiens IGHV3-66*01 (69.4%) -(IGHD)-Homo sapiens IGHJ4*01 (100%)) [9.8.15] (1-123) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (220) (124-221), charnière (222-236), CH2 L1.2>R (241), G1.1>R (242), S3>K (245), A110>G (333), A115>S (336), P116>S (337) (237-346), CH3 E12 (362), M14 (364), M107>L (434), N114>A (440), Q118>R (444), S120>E (446) (347-451), CHS G1>del, K2>del) (124-451)], (226-217')-disulfure avec la chaîne légère kappa (1'-217') [V-KAPPA (Homo sapiens IGKV1-13*02 or IGKV1D-13*01 (94.3%) -IGKJ4*01 (100%)) [6.3.12] (1'-110') -Homo sapiens IGKC*01, Km3 A45.1 (156), V101 (194) (111'-217')]; dimère (232-232":235-235")-bisdisulfure immunomodulateur

crovalimab inmunoglobulina G1-kappa, anti-[Homo sapiens C5 (complemento 5)], anticuerpo monoclonal; cadena pesada gamma1 (1-451) [VH (Vicugna pacos IGHV3S1*01 (70.4%)/Homo sapiens IGHV3-66*01 (69.4%) -(IGHD)-Homo sapiens IGHJ4*01 (100%)) [9.8.15] (1-123) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (220) (124-221), bisagra (222-236), CH2 L1.2>R (241), G1.1>R (242), S3>K (245), A110>G (333), A115>S (336), P116>S (337) (237-346), CH3 E12 (362), M14 (364), M107>L (434), N114>A (440), Q118>R (444), S120>E (446) (347-451), CHS G1>del, K2>del) (124-451)], (226-217')-disulfuro con la cadena ligera kappa (1'-217') [V-KAPPA (Homo sapiens IGKV1-13*02 or IGKV1D-13*01 (94.3%) -IGKJ4*01 (100%)) [6.3.12] (1'-110') -Homo sapiens IGKC*01, Km3 A45.1 (156), V101 (194) (111'-217')]; dímero (232-232":235-235")-bisdisulfuro inmunomodulador

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

304

1917321-26-6

Heavy chain / Chaîne lourde / Cadena pesadaQVQLVESGGG LVQPGRSLRL SCAASGFTVH SSYYMAWVRQ APGKGLEWVG 50AIFTGSGAEY KAEWAKGRVT ISKDTSKNQV VLTMTNMDPV DTATYYCASD 100AGYDYPTHAM HYWGQGTLVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL RRGPKVFLFP 250PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR 350EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVLHEALHA HYTRKELSLS 450P 451

Light chain / Chaîne légère / Cadena ligeraDIQMTQSPSS LSASVGDRVT ITCRASQGIS SSLAWYQQKP GKAPKLLIYG 50ASETESGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQN TKVGSSYGNT 100FGGGTKVEIK RTVAAPSVFI FPPSDEQLKS GTASVVCLLN NFYPREAKVQ 150WKVDNALQSG NSQESVTEQD SKDSTYSLSS TLTLSKADYE KHKVYACEVT 200HQGLSSPVTK SFNRGEC 217

Post-translational modificationsDisulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-97 150-206 267-327 373-431

22''-97'' 150''-206'' 267''-327'' 373''-431''Intra-L (C23-C104) 23'-88' 137'-197'

23'''-88''' 137'''-197'''Inter-H-L (h 5-CL 126) 226-217' 226''-217'''Inter-H-H (h 11, h 14) 232-232'' 235-235''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:303, 303''Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennairescomplexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

danicopanum danicopan (2S,4R)-1-{[3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-

1-yl]acetyl}-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine- 2-carboxamide complement factor D inhibitor

danicopan (2S,4R)-1-{[3-acétyl-5-(2-méthylpyrimidin-5-yl)-1H-indazol-1-yl]acétyl}-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine- 2-carboxamide inhibiteur du facteur D du complément

danicopán (2S,4R)-1-{[3-acetil-5-(2-metilpirimidin-5-il)-1H-indazol- 1-il]acetil}-N-(6-bromopiridin-2-il)-4-fluoropirrolidina- 2-carboxamida inhibidor del factor D del complemento

C26H23BrFN7O3

1903768-17-1

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

305

dersimelagonum dersimelagon 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-

methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid melanocortin receptor agonist

dersimélagon acide 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-méthoxyphényl)pyrrolidine-3-carbonyl]-4-(méthoxyméthyl)pyrrolidin-3-yl]-5-(trifluorométhyl)phényl}pipéridine-4-carboxylique agoniste du récepteur de la mélanocortine

dersimelagón ácido 1-{2-[(3S,4R)-1-[(3R,4R)-1-ciclopentil-3-fluoro-4-(4-metoxifenil)pirrolidina-3-carbonil]-4-(metoximetil)pirrolidin-3-il]-5-(trifluorometil)fenil}piperidina-4-carboxílico agonista del receptor de melanocortina

C36H45F4N3O5 1835256-48-8

dilanubicelum dilanubicel Allogeneic umbilical cord CD34+ enriched blood cells. The drug

substance consists of the total progeny generated from culture of enriched CD34+ umbilical cord blood cells that have been cultured ex vivo in the presence of immobilised engineered Notch ligand Delta1ext -IgG (DXI) and recombinant cytokines. Cell phenotype distribution: CD3, CD7, CD14, CD15, CD16+CD56+ (both stained together), CD34, CD41, CD45RA, CD56, and CD90. Cells are intended to enhance reconstitution in hematopoietic stem cell transplantation patients with high risk of iatrogenic conditioning-related prolonged pancytopenia. cell therapy substance (adjuvant to chemotherapy / radiotherapy)

dilanubicel cellules du sang de cordon ombilical, allogéniques, enrichies en CD34+. Le principe actif consiste en la totalité de la descendance générée par la culture des cellules de sang de cordon ombilical enrichies en CD34+ mises en culture ex vivo en présence de ligand Notch Delta1ext -IgG (DXI) immobile et de cytokines recombinantes. Distribution du phénotype cellulaire: CD3, CD7, CD14, CD15, CD16+CD56+ (les deux teintés ensemble), CD34, CD41, CD45RA, CD56, et CD90. Les cellules sont destinées à accroitre la récupération après une transplantation de cellules souches hématopoïétiques, des patients avec un fort risque de pancytopénie prolongée lié à la condition iatrogénique. substance de thérapie cellulaire (adjuvant à une chimio- ou radiothérapie)

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

306

dilanubicel Células de sangre de cordón umbilical, alogénicas, enriquecidas en CD34+. El principio activo consta del total de la progenie generada en el cultivo de células de sangre de cordón umbilical enriquecidas en CD34+ que se han cultivado ex vivo en presencia del ligando ingenierizado de Notch Delta1ext -IgG (DXI) inmovilizado y de citoquinas recombinantes. Distribución del fenotipo celular: CD3, CD7, CD14, CD15, CD16+CD56+ (ambos teñidos juntos), CD34, CD41, CD45RA, CD56 y CD90. Las células se pretenden usar para potenciar la reconstitución en pacientes sometidos a trasplante de células troncales hematopoyéticas con alto riesgo de pancitopenia prolongada, relacionada con el acondicionamiento iatrogénico. sustancia de terapia celular (adyuvante a quimio- o radioterapia)

dilpacimabum # dilpacimab immunoglobulin G1-kappa, anti-[Homo sapiens DLL4 (delta-like 4)] and

anti-[Homo sapiens VEGFA (vascular endothelial growth factor A,VEGF-A, VEGF)], dual-variable domain humanized monoclonal antibody, bispecific; dual-variable gamma1 heavy chain (1-577) [humanized VH anti-DLL4 (Homo sapiens IGHV3-48*01 (89.8%) -(IGHD)-IGHJ4*01 (92.9%)) [8.8.11] (1-118) -6-mer linker (119-124) -humanized VH anti-VEGFA (Homo sapiens IGHV3-23*03 or IGHV3-30*02 (76.8%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.16] (125-247) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (344) (248-345), hinge (346-360), CH2 L1.3>A (364), L1.2>A (365) (361-470), CH3 E12 (486), M14 (488) (471-575), CHS (576-577)) (248-577)], (350-334')-disulfide with dual-variable kappa light chain (1'-334') [humanized V-KAPPA anti-DLL4 (Homo sapiens IGKV1D-13*01 (88.3%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -13-mer linker (108-120) -humanized V-KAPPA anti-VEGFA (Homo sapiens IGKV1-16*01 (88.4%) -IGKJ1*01 (100%)) [6.3.9] (121-227) -Homo sapiens IGKC*01, Km3 A45.1 (273), V101 (311)(228'-334')]; dimer (356-356":359-359")-bisdisulfide immunomodulator, antineoplastic

dilpacimab immunoglobuline G1-kappa, anti-[Homo sapiens DLL4 (delta-like 4)] et anti-[Homo sapiens VEGFA (facteur de croissance A de l'endothélium vasculaire, VEGF-A, VEGF)], anticorps monoclonal humanisé double-variable domaine, bispécifique; chaîne lourde gamma1 avec double-variable (1-577) [VH humanisé anti-DLL4 (Homo sapiens IGHV3-48*01 (89.8%) -(IGHD)-IGHJ4*01 (92.9%)) [8.8.11] (1-118) -6-mer linker (119-124) -VH humanisé anti-VEGFA (Homo sapiens IGHV3-23*03 orIGHV3-30*02 (76.8%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.16] (125-247) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (344) (248-345), charnière (346-360), CH2 L1.3>A (364), L1.2>A (365) (361-470), CH3 E12 (486), M14 (488) (471-575), CHS (576-577)) (248-577)], (350-334')-disulfure à la chaîne légère kappa avec double-variable (1'-334') [V-KAPPA humanisé anti-DLL4 (Homo sapiens IGKV1D-13*01 (88.3%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -13-mer linker (108-120) -V-KAPPA humanisé anti-VEGFA (Homo sapiens IGKV1-16*01 (88.4%) -IGKJ1*01 (100%)) [6.3.9] (121-227) -Homo sapiens IGKC*01, Km3 A45.1 (273), V101 (311) (228'-334')]; dimère (356-356":359-359")-bisdisulfure immunomodulateur, antinéoplasique

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

307

dilpacimab inmunoglobulina G1-kappa, anti-[Homo sapiens DLL4 (delta-like 4)] y anti-[Homo sapiens VEGFA (factor de crecimiento A del endotelio vascular, VEGF-A, VEGF)], anticuerpo monoclonal humanizado doble-variable dominio, biespecífico; cadena pesada gamma1 con doble-variable (1-577) [VH humanizado anti-DLL4 (Homo sapiens IGHV3-48*01 (89.8%) -(IGHD)-IGHJ4*01 (92.9%)) [8.8.11] (1-118) -6-mer espaciador (119-124) -VH humanizado anti-VEGFA (Homo sapiens IGHV3-23*03 orIGHV3-30*02 (76.8%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.16] (125-247) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (344) (248-345), bisagra (346-360), CH2 L1.3>A (364), L1.2>A (365) (361-470), CH3 E12 (486), M14 (488) (471-575), CHS (576-577)) (248-577)], (350-334')-disulfuro con la cadena ligera kappa con doble-variable (1'-334') [V-KAPPA humanizado anti-DLL4 (Homo sapiens IGKV1D-13*01 (88.3%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -13-mer espaciador (108-120) -V-KAPPA humanizado anti-VEGFA (Homo sapiens IGKV1-16*01 (88.4%) -IGKJ1*01 (100%)) [6.3.9] (121-227) -Homo sapiens IGKC*01, Km3 A45.1 (273), V101 (311) (228'-334')]; dímero (356-356":359-359")-bisdisulfuro inmunomodulador, antineoplásico

1791420-09-1

dostarlimabum # dostarlimab immunoglobulin G4-kappa, anti-[Homo sapiens PDCD1

(programmed cell death 1, PD-1, PD1, CD279)], humanized monoclonal antibody;

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

308

gamma4 heavy chain (1-443) [humanized VH (Homo sapiens IGHV3-23*01 (93.8%) -(IGHD) -IGHJ4*01 (92.3%)) [8.8.9] (1-116) -Homo sapiens IGHG4*01 (CH1 (117-214), hinge S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (117-443)], (130-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-9*01 (85.3%) -IGKJ2*02 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (222-222'':225-225'')-bisdisulfide immunomodulator, antineoplastic

dostarlimab immunoglobuline G1-kappa, anti-[Homo sapiens PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-443) [ VH humanisé (Homo sapiens IGHV3-23*01 (93.8%) -(IGHD) -IGHJ4*01 (92.3%)) [8.8.9] (1-116) -Homo sapiens IGHG4*01 (CH1 (117-214), charnière S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (117-443)], (130-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV1-9*01 (85.3%) -IGKJ2*02 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (222-222'':225-225'')-bisdisulfure immunomodulateur, antinéoplasique

dostarlimab inmunoglobulina G1-kappa, anti-[Homo sapiens PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-443) [ VH humanizado (Homo sapiens IGHV3-23*01 (93.8%) -(IGHD) -IGHJ4*01 (92.3%)) [8.8.9] (1-116) -Homo sapiens IGHG4*01 (CH1 (117-214), bisagra S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (117-443)], (130-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (Homo sapiens IGKV1-9*01 (85.3%) -IGKJ2*02 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (222-222'':225-225'')-bisdisulfuro inmunomodulador, antineoplásico

2022215-59-2

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

309

durlobactamum durlobactam (1R,2S,5R)-2-carbamoyl-3-methyl-7-oxo-1,6-

diazabicyclo[3.2.1]oct-3-en-6-yl hydrogen sulfate beta-lactamase inhibitor

durlobactam hydrogénosulfate de (1R,2S,5R)-2-carbamoyl-3-méthyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-én-6-yle inhibiteur de la bêta-lactamase

durlobactam hidrogenosulfato de (1R,2S,5R)-2-carbamoil-3-metil-7-oxo-1,6-diazabiciclo[3.2.1]oct-3-en-6-ile inhibidor de la beta-lactamasa

C8H11N3O6S

1467829-71-5

eftozanermin alfa # eftozanermin alfa Gln1-human single-chain tumor necrosis factor ligand

superfamily member 10 (TNFSF10, tumor necrosis factor-related apoptosis-inducing ligand, TRAIL) receptor binding domain fragment, repeat of three identical chains (2-161, 171-330, 340-499) fused together via glycosylated linkers (162-170 connecting chain I to chain II and 331-339 connecting chain II to chain III), fused via linker (500-511) to an Fc fragment of human immunoglobulin G1 (512-740) [Homo sapiens IGHG1*03 (CH2 (524-633 (Asn590>Ser)), CH3 (634-738),CHS (739-740))], dimer, produced in Chinese hamster ovary (CHO) cells, glycoform alfa antineoplastic

eftozanermine alfa Gln1-chaîne unique du membre 10 de la superfamille des ligands du facteur de nécrose tumorale humain (TNFSF10, ligand inducteur d'apoptose apparenté au TNF, TRAIL) fragment du domaine se liant au récepteur, répétition de trois chaînes identiques, (2-161, 171-330, 340-499) fusionnées via des linkers glycosylés (162-170 liant la chaîne I à la chaîne II et 331-339 liant la chaîne II à la chaîne III), fusionné via un linker (500-511) au fragment Fc de l'immunoglobuline G1 humaine (512-740) [Homo sapiens IGHG1*03 (CH2 (524-633 (Asn590>Ser)), CH3 (634-738),CHS (739-740))], dimère, produit par des cellules ovariennes de hamster chinois (CHO), glycoforme alfa antinéoplasique

eftozanermina alfa Gln1-cadena única del miembro 10 de la superfamilia de los ligandos del factor de necrosis tumoral humano (TNFSF10, ligando inductor de la apoptosis relacionado con el TNF, TRAIL) fragmento del dominio que se une al

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

310

receptor, repetición de tres cadenas idénticas, (2-161, 171-

330, 340-499) fusionadas mediante los conectores glicosilados (162-170 que une la cadena I a la cadena II y 331-339 que une la cadena II a la cadena III), fusionado mediante un enlace (500-511) al fragmento Fc de la inmunoglobulina G1 humana (512-740) [Homo sapiens IGHG1*03 (CH2 (524-633 (Asn590>Ser)), CH3 (634-738),CHS (739-740))], dímero, producido en las células ováricas de hamster chinos (CHO), glicoforma alfa antineoplásico

1820660-69-2

eladocagenum exuparvovecum # eladocagene exuparvovec a recombinant non-replicating adeno-associated virus

serotype 2 (AAV2) vector comprising a dopa decarboxylase (DDC, AADC) variant 2 cDNA transcript, which encodes human aromatic-L-amino-acid decarboxylase isoform 1, under the control of the cytomegalovirus (CMV) intermediate-early (IE) promoter and SV40 poly A transcription terminator. gene therapy substance (aromatic L-amino acid decarboxylase (AADC) deficiency)

éladocagène exuparvovec vecteur viral adéno-associé de sérotype 2 (AAV2) non-répliquant recombinant contenant une transcription ADNc du variant 2 de la dopa décarboxylase (DDC, AADC) codant pour l'isoforme 1 de l'acide L-aminé aromatique décarboxylase humaine, sous le contrôle d'un promoteur intermédiaire précoce de cytomegalovirus (CMV) et une séquence poly-A de SV40 de terminaison de la transcription substance pour thérapie génique (déficience en acide L-aminé aromatique décarboxylase)

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

311

eladocagén exuparvovec Un vector de virus adenoasociado recombinante no replicativo de serotipo 2 (AAV2) que consta de un tránscrito cDNA de la variante 2 de la dopa descarboxilasa, que codifica para la isoforma 1 de la L-aminoácido aromático descarboxilasa humana, bajo el control del promotor intermedio temprano del citomegalovirus y un terminador de la transcripción poli A de SV40. sustancia de terapia genica (deficiencia en L-aminoácido aromático descarboxilasa)

2098615-91-7

elopultidum elopultide L-isoleucyl-L-prolyl-L-seryl-L-seryl-L-prolyl-L-valyl-L-histidyl-L-leucyl-L-lysyl-

L-arginyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-isoleucyl-L-leucyl-L-leucyl-L-leucyl-L-isoleucyl-L-leucylglycyl-L-alanyl-L-leucyl-L-leucyl-L-leucylglycyl-L-leucine pulmonary surfactant

élopultide L-isoleucyl-L-prolyl-L-séryl-L-séryl-L-prolyl-L-valyl-L-histidyl-L-leucyl-L-lysyl-L-arginyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-isoleucyl-L-leucyl-L-leucyl-L-leucyl-L-isoleucyl-L-leucylglycyl-L-alanyl-L-leucyl-L-leucyl-L-leucylglycyl-L-leucine surfactant pulmonaire

elopultida L-isoleucil-L-prolil-L-seril-L-seril-L-prolil-L-valil-L-histidil-L-leucil-L-lisil-L-arginil-L-leucil-L-lisil-L-leucil-L-leucil-L-leucil-L-leucil-L-leucil-L-leucil-L-leucil-L-leucil-L-isoleucil-L-leucil-L-leucil-L-leucil-L-isoleucil-L-leucilglycil-L-alanil-L-leucil-L-leucil-L-leucilglicil-L-leucina surfactante pulmonar

C178H320N40O36

1018791-84-8

eluforsenum eluforsen all-P-ambo-[1-33]tritriaconta-2'-O-methyl-[1-32]dotriaconta-P-thio-

AUCAUAGGAA ACACCAAAGA UGAUAUUUUC UUU; all-P-ambo-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methyl-P-thiocytidylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thioguanylyl-(3'→5')-2'-O-methyl-P-thioguanylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thiocytidylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thiocytidylyl-(3'→5')-2'-O-methyl-P-thiocytidylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thioguanylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methyl-P-thioguanylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methyl-P-thiocytidylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methyluridine functional cystic fibrosis transmembrane regulator (CFTR) synthesis promotion

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

312

éluforsen tout-P-ambo-[1-33]tritriaconta-2'-O-méthyl-[1-32]dotriaconta-P-thio-AUCAUAGGAA

ACACCAAAGA UGAUAUUUUC UUU; tout-P-ambo-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-méthyl-P-thiocytidylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thioguanylyl-(3'→5')-2'-O-méthyl-P-thioguanylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thiocytidylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thiocytidylyl-(3'→5')-2'-O-méthyl-P-thiocytidylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thioguanylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-méthyl-P-thioguanylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-méthyl-P-thiocytidylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-méthyluridine promoteur de la synthèse de la protéine régulatrice de la perméabilité transmembranaire impliquée dans la mucoviscidose (CFTR) fonctionnelle

eluforsén todo-P-ambo-[1-33]tritriaconta-2'-O-metil-[1-32]dotriaconta-P-tio-AUCAUAGGAA ACACCAAAGA UGAUAUUUUC UUU; todo-P-ambo-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tiocitidilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tiocitidilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tiocitidilil-(3'→5')-2'-O-metil-P-tiocitidilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tiocitidilil-(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metiluridina promotor de la síntesis de la proteína reguladora de la conductancia transmembrana de la fibrosis quística (CFTR) funcional

C347H452N122O195P32S32

2101868-82-8

encequidarum encequidar N-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl]phenyl}-2H-

tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4H-1-benzopyran-2-carboxamide antineoplastic

encéquidar N-[2-(2-{4-[2-(6,7-diméthoxy-3,4-dihydroisoquinoléin-2(1H)-yl)éthyl]phényl}-2H-tétrazol-5-yl)-4,5-diméthoxyphényl]-4-oxo-4H-1-benzopyrane-2-carboxamide antinéoplasique

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

313

encequidar N-[2-(2-{4-[2-(6,7-dimetoxi-3,4-dihidroisoquinolein-2(1H)-il)etil]fenil}-2H-tetrazol-5-il)-4,5-dimetoxifenil]-4-oxo-4H-1-benzopirano-2-carboxamida antineoplásico

C38H36N6O7

849675-66-7

ensifentrinum ensifentrine N-(2-{(2E)-9,10-dimethoxy-4-oxo-2-[(2,4,6-

trimethylphenyl)imino]-6,7-dihydro-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl}ethyl)urea phosphodiesterase inhibitor

ensifentrine N-(2-{(2E)-9,10-diméthoxy-4-oxo-2-[(2,4,6-triméthylphényl)imino]-6,7-dihydro-2H-pyrimido[6,1-a]isoquinoléin-3(4H)-yl}éthyl)urée inhibiteur de phosphodiestérase

ensifentrina N-(2-{(2E)-9,10-dimetoxi-4-oxo-2-[(2,4,6-trimetilfenil)imino]-6,7-dihidro-2H-pirimido[6,1-a]isoquinolein-3(4H)-il}etil)urea inhibidor de fosfodiesterasa

C26H31N5O4

1884461-72-6

exicorilantum exicorilant [(4aR,8aS)-1-(4-fluorophenyl)-6-(2-methyl-2H-1,2,3-

triazole-4-sulfonyl)-1,4,5,6,7,8,8a,9-octahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl][4-(trifluoromethyl)pyridin-2-yl]methanone glucocorticoid receptor antagonist

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

314

exicorilant [(4aR,8aS)-1-(4-fluorophényl)-6-(2-méthyl-2H-1,2,3-triazole-4-sulfonyl)-1,4,5,6,7,8,8a,9-octahydro-4aH-pyrazolo[3,4-g]isoquinoléin-4a-yl][4-(trifluorométhyl)pyridin-2-yl]méthanone antagoniste des récepteurs glucocorticoïdes

exicorilant [(4aR,8aS)-1-(4-fluorofenil)-6-(2-metil-2H-1,2,3-triazol-4-sulfonil)-1,4,5,6,7,8,8a,9-octahidro-4aH-pirazolo[3,4-g]isoquinolein-4a-il][4-(trifluorometil)piridin-2-il]metanona antagonista de los receptores glucocorticoides

C26H23F4N7O3S

1781244-77-6

fosgemcitabinum palabenamidum fosgemcitabine palabenamide benzyl N-[(P5'S)-2'-deoxy-2',2'-difluoro-OP-phenyl-

5'-cytidylyl]-L-alaninate antineoplastic

fosgemcitabine palabénamide N-[(P5'S)-2'-désoxy-2',2'-difluoro-OP-phényl-5'-cytidylyl]- L-alaninate de benzyle antinéoplasique

fosgemcitabina palabenamida N-[(P5'S)-2'-desoxi-2',2'-difluoro-OP-fenil-5'-citidilil]- L-alaninato de bencilo antineoplásico

C25H27F2N4O8P

1562406-27-2

fosifloxuridinum nafalbenamidum fosifloxuridine nafalbenamide benzyl N-[P-ambo-2'-deoxy-5-fluoro-OP-(naphthalen-1-yl)-

5'-uridylyl]-L-alaninate antineoplastic

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

315

fosifloxuridine nafalbénamide N-[P-ambo-2'-désoxy-5-fluoro-OP-(naphtalén-1-yl)-

5'-uridylyl]-L-alaninate de benzyle antinéoplasique

fosifloxuridina nafalbenamida N-[P-ambo-2'-desoxi-5-fluoro-OP-(naftalen-1-il)-5'-uridilil]- L-alaninato de bencilo antineoplásico

C29H29FN3O9P

1332837-31-6

foslinanibum foslinanib 2-(3-fluorophenyl)-6-methoxy-4-oxo-1,4-dihydroquinolin-

5-yl dihydrogen phosphate antineoplastic

foslinanib dihydrogénophosphate de 2-(3-fluorophényl)-6-méthoxy- 4-oxo-1,4-dihydroquinoléin-5-yle antinéoplasique

foslinanib dihidrogenofosfato de 2-(3-fluorofenil)-6-metoxi-4-oxo- 1,4-dihidroquinolein-5-ilo antineoplásico

C16H13FNO6P

1256037-60-1

fosmanogepixum fosmanogepix [12-amino-6-oxa-1(3),7(2)-dipyridina-2(5,3)-[1,2]oxazola-

4(1,4)-benzenaheptaphan-11-ium-11-yl]methyl hydrogen phosphate antifungal

fosmanogépix hydrogénophosphate de [12-amino-6-oxa-1(3),7(2)-dipyridina-2(5,3)-[1,2]oxazola-4(1,4)-benzénaheptaphan-11-ium-11-yl]méthyle antifongique

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

316

fosmanogepix hidrogenofosfato de [12-amino-6-oxa-1(3),7(2)-dipiridina-2(5,3)-[1,2]oxazola-4(1,4)-bencenaheptafan-11-ium-11-il]metilo antifúngico

C22H21N4O6P

2091769-17-2

frovocimabum # frovocimab immunoglobulin G4-kappa, anti-[Homo sapiens PCSK9

(proprotein convertase subtilisin/kexin type 9, neural apoptosis-regulated convertase 1, NARC1, NARC-1, proprotein convertase 9, PC9) catalytic domain], humanized monoclonal antibody; gamma4 heavy chain (1-451) [humanized VH (Homo sapiens IGHV3-21*01 (88.8%) -(IGHD)-IGHJ4*01 (100%)) [8.8.18] (1-125) -Homo sapiens IGHG4*01 (CH1 (126-223), hinge S10>P (233) (224-235), CH2 F1.3>A (239), L1.2>A (240) (236-345), CH3 (346-450), CHS K2>del (451)) (126-451)], (139-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (Homo sapiens IGKV2-28*01 (87.00%) -IGKJ1*01 (100%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (231-231":234-234")-bisdisulfide antihyperlipidaemic

frovocimab immunoglobuline G4-kappa, anti-[Homo sapiens PCSK9 (proprotéine convertase subtilisine/kexine type 9, convertase 1 régulée par l'apoptose neuronale, NARC1, NARC-1, proprotéine convertase 9, PC9)], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-451) [VH humanisé (Homo sapiens IGHV3-21*01 (88.8%) -(IGHD)-IGHJ4*01 (100%)) [8.8.18] (1-125) -Homo sapiens IGHG4*01 (CH1 (126-223), charnière S10>P (233) (224-235), CH2 F1.3>A (239), L1.2>A (240) (236-345), CH3 (346-450), CHS K2>del (451)) (126-451)], (139-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (Homo sapiens IGKV2-28*01 (87.00%) -IGKJ1*01 (100%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimère (231-231":234-234")-bisdisulfure antihyperlipidémiant

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

317

frovocimab inmunoglobulina G4-kappa, anti-[Homo sapiens PCSK9 (proproteína convertasa subtilisina/kexina tipo 9, convertasa 1 regulada por la apoptosa neuronal, NARC1, NARC-1, proproteína convertasa 9, PC9)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-451) [VH humanizado (Homo sapiens IGHV3-21*01 (88.8%) -(IGHD)-IGHJ4*01 (100%)) [8.8.18] (1-125) -Homo sapiens IGHG4*01 (CH1 (126-223), bisagra S10>P (233) (224-235), CH2 F1.3>A (239), L1.2>A (240) (236-345), CH3 (346-450), CHS K2>del (451)) (126-451)], (139-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (Homo sapiens IGKV2-28*01 (87.00%) -IGKJ1*01 (100%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dímero (231-231":234-234")-bisdisulfuro antihiperlipémico

1643672-70-1

futibatinibum futibatinib 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-

1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one antineoplastic

futibatinib 1-[(3S)-3-{4-amino-3-[(3,5-diméthoxyphényl)éthynyl]- 1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-én-1-one antinéoplasique

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

318

futibatinib 1-[(3S)-3-{4-amino-3-[(3,5-dimetoxifenil)etinil]-1H-pirazolo[3,4-d]pirimidin-1-il}pirrolidin-1-il]prop-2-en-1-ona antineoplásico

C22H22N6O3

1448169-71-8

galicaftorum galicaftor 4-[(2R,4R)-4-[1-(2,2-difluoro-1,3-benzodioxol-

5-yl)cyclopropane-1-carboxamido]-7-(difluoromethoxy)- 3,4-dihydro-2H-1-benzopyran-2-yl]benzoic acid cystic fibrosis transmembrane regulator (CFTR) channel modulator

galicaftor acide 4-[(2R,4R)-4-[1-(2,2-difluoro-1,3-benzodioxol- 5-yl)cyclopropane-1-carboxamido]-7-(difluorométhoxy)- 3,4-dihydro-2H-1-benzopyran-2-yl]benzoïque modulateur de la protéine régulatrice de la perméabilité transmembranaire impliquée dans la mucoviscidose (CFTR)

galicaftor ácido 4-[(2R,4R)-4-[1-(2,2-difluoro-1,3-benzodioxol- 5-il)ciclopropano-1-carboxamido]-7-(difluorometoxi)- 3,4-dihidro-2H-1-benzopiran-2-il]benzoico modulador de la proteína reguladora de la conductancia transmembrana de la fibrosis quística (CFTR)

C28H21F4NO7 1918143-53-9

gancotamabum # gancotamab immunoglobulin scFv, anti-[Homo sapiens ERBB2

(epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], Homo sapiens monoclonal antibody single chain;

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

319

scFv (1-251) [Homo sapiens VH (IGHV3-23*04 (94.9%) -(IGHD) -IGHJ4*01 (100%)) [8.8.12] (1-119) -15-mer tris(tetraglycyl-seryl) linker (120-134) -Homo sapiens V-LAMBDA (IGLV1-40*01(97.0%) -IGLJ3*02 (100%)) [9.3.11] (135-245) -6-mer bisglycyl-seryl-bisglycyl-cysteinyl (246-251)] antineoplastic

gancotamab immunoglobuline scFv, anti-[Homo sapiens ERBB2 (récepteur 2 du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], Homo sapiens anticorps monoclonal à chaîne unique; scFv (1-251) [Homo sapiens VH (IGHV3-23*04 (94.9%) -(IGHD) -IGHJ4*01 (100%)) [8.8.12] (1-119) -15-mer tris(tétraglycyl-séryl) linker (120-134) -Homo sapiens V-LAMBDA (IGLV1-40*01(97.0%) -IGLJ3*02 (100%)) [9.3.11] (135-245) -6-mer bisglycyl-séryl-bisglycyl-cystéinyl (246-251)] antinéoplasique

gancotamab inmunoglobulina scFv, anti-[Homo sapiens ERBB2 (receptor 2 del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], Homo sapiens anticuerpo monoclonal con cadena única; scFv (1-251) [Homo sapiens VH (IGHV3-23*04 (94.9%) -(IGHD) -IGHJ4*01 (100%)) [8.8.12] (1-119) -15-mer tris(tetraglicil-seril) conector (120-134) -Homo sapiens V-LAMBDA (IGLV1-40*01(97.0%) -IGLJ3*02 (100%)) [9.3.11] (135-245) -6-mer bisglicil-seril-bisglicil-cisteinil (246-251)] antineoplásico

1509928-00-0

golexanolonum golexanolone (17E)-3α-ethynyl-17-(hydroxyimino)-5α-androstan-3β-ol

GABA-A receptor modulating steroid antagonist

golexanolone (17E)-3α-éthynyl-17-(hydroxyimino)-5α-androstan-3β-ol antagoniste de la modulation positive par les stéroïdes des récepteurs GABA-A

golexanolona (17E)-3α-etinil-17-(hidroxiimino)-5α-androstan-3β-ol antagonista de modulación positiva por los esteroides de los receptores GABA-A

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

320

C21H31NO2

2089238-18-4

gosuranemabum # gosuranemab immunoglobulin G4-kappa, anti-[Homo sapiens MAPT

(microtubule-associated protein tau, tau)], monoclonal antibody; gamma4 heavy chain (1-443)[VH (Mus musculus IGHV5-6*01 (85.6%)/Homo sapiens IGHV3-11*01 (84.5%) -(IGHD) -Homo sapiens IGHJ6*01 (92.9%)) [8.8.10] (1-117) -Homo sapiens IGHG4*01 (CH1 (118-215), hinge S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS K2>del (443)) (118-443)], (131-219')-disulfide with kappa light chain (1'-219') [V-KAPPA (Mus musculus IGKV1-117*01 (89.0%)/Homo sapiens IGKV2-30*02 (84.0%) -Homo sapiens IGKJ4*01 (100%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (223-223'':226-226'')-bisdisulfide tau protein inhibitor

gosuranémab immunoglobuline G4-kappa, anti-[Homo sapiens MAPT (protéine tau associée aux microtubules, tau)], anticorps monoclonal; chaîne lourde gamma4 (1-443) [VH (Mus musculus IGHV5-6*01 (85.6%)/Homo sapiens IGHV3-11*01 (84.5%) -(IGHD) -Homo sapiens IGHJ6*01 (92.9%)) [8.8.10] (1-117) -Homo sapiens IGHG4*01 (CH1 (118-215), charnière S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS K2>del (443)) (118-443)], (131-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA (Mus musculus IGKV1-117*01 (89.0%)/Homo sapiens IGKV2-30*02 (84.0%) -Homo sapiens IGKJ4*01 (100%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimère (223-223'':226-226'')-bisdisulfure inhibiteur de la protéine tau

gosuranemab inmunoglobulina G4-kappa, anti-[Homo sapiens MAPT (proteína tau asociada con microtúbulos, tau)], anticuerpo monoclonal; cadena pesada gamma4 (1-443) [VH (Mus musculus IGHV5-6*01 (85.6%)/Homo sapiens IGHV3-11*01 (84.5%) -(IGHD) -Homo sapiens IGHJ6*01 (92.9%)) [8.8.10] (1-117) -Homo sapiens IGHG4*01 (CH1 (118-215), bisagra S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS K2>del (443)) (118-443)], (131-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA (Mus musculus IGKV1-117*01 (89.0%)/Homo sapiens IGKV2-30*02 (84.0%) -Homo sapiens IGKJ4*01 (100%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dímero (223-223'':226-226'')-bisdisulfuro inhibidor de la próteina tau

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

321

1788032-39-2

hydromethylthioninum hydromethylthionine N3,N3,N7,N7-tetramethyl-10H-phenothiazine-3,7-diamine

neuroprotectant

hydrométhylthionine N3,N3,N7,N7-tétraméthyl-10H-phénothiazine-3,7-diamine neuroprotecteur

hidrometiltionina N3,N3,N7,N7-tetrametil-10H-fenotiazina-3,7-diamina neuroprotector

C16H19N3S

613-11-6

iadademstatum iadademstat trans-N1-[(1R,2S)-2-phenylcyclopropyl]cyclohexane-

1,4-diamine lysine-specific histone demethylase (LSD1) inhibitor

iadademstat trans-N1-[(1R,2S)-2-phénylcyclopropyl]cyclohexane- 1,4-diamine inhibiteur de l'histone déméthylase-1 spécifique de la lysine (LSD1)

iadademstat trans-N1-[(1R,2S)-2-fenilciclopropil]ciclohexano-1,4-diamina inhibidor de la histona demetilasa-1 específica de la lisina (LSD1)

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

322

C15H22N2

1431304-21-0

idecabtagenum vicleucelum # idecabtagene vicleucel human culture expanded genetically modified autologous T cells for

cell-based gene therapy. Cells are derived from isolated blood of the patient and are transduced with non-replicative self-inactivating (SIN) human immunodeficiency virus type 1 (HIV-1) based lentiviral vector (LVV) pseudotyped with the vesicular stomatitis virus glycoprotein G (VSV-G) envelope protein, and encoding the C11D5.3 anti-TNF receptor superfamily member 17 (TNFRSF17, BCMA) single chain variable fragment (scFv) CD8/4-1BB/CD3zeta chimeric antigen receptor (CAR) under the transcriptional control of the myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted (MND) promoter. Cells exhibit anti-tumoral activity in patients with multiple myeloma. genetically modified cell (antineoplastic)

idécabtagène vicleucel lymphocytes T humains, autologues, génétiquement modifiés, en culture d'expansion pour thérapie génique avec cellules. Les cellules sont dérivées du sang prélevé chez le patient et sont transduites avec un vecteur lentiviral basé sur le virus de l'immunodéficience humaine de type 1 (VIH-1) non-répliquant auto-inactivant, pseudotypé avec la glycoprotéine G de l'enveloppe de du virus de la stomatite vésiculaire (VSV-G) et codant pour le récepteur de l'antigène chimérique (CAR) consistant en un fragment variable de la chaîne unique de l’anticorps CD11D5.3 anti-membre 17 de la superfamille des récepteurs du TNF (TNFRSF17, BCMA)/CD8/4-1BB/CD3zêta sous le contrôle transcriptionnel d'un promoteur du virus du sarcome myéloprolifératif dont la région de contrôle négatif a été supprimée, et le site de liaison de l'amorce substitué par dl587rev (MND). Les cellules montrent une activité anti-tumorale chez de patients atteints de multiples myélomes. cellule génétiquement modifiée (antinéoplasique)

idecabtagén vicleucel Linfocitos T autólogos, modificados genéticamente, humanos, expandidos en cultivo para terapia génica con células. Las células se derivan de sangre aislada del paciente y se transducen con un vector lentiviral basado en el virus de la inmunodeficiencia humana tipo 1 (HIV-1) no replicativo y autoinactivante, seudotipado con la glicoproteina G de la envuelta del virus de la estomatitis vesicular (VSV-G), y que codifica para el receptor de antígeno quimérico (CAR) consistente en un fragmento variable de cadena sencilla (scFv) del anticuerpo CD11D5.3 anti-miembro 17 de la superfamilia de receptores de TNF (TNFRSF17, BCMA)/CD8/4-1BB/CD3zeta bajo el control transcripcional del enhancer del virus del sarcoma mieloproliferativo, y el promotor con la región de control negativo delecionada y el sitio de unión del cebador dl587rev sustituido (MND). Las células poseen actividad antitumoral en pacientes con mieloma múltiple. célula modificada genéticamente (antineoplásico)

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

323

ilginatinibum ilginatinib N2-[(1S)-1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-

(pyrazin-2-yl)pyridine-2,6-diamine tyrosine kinase inhibitor

ilginatinib N2-[(1S)-1-(4-fluorophényl)éthyl]-4-(1-méthyl-1H-pyrazol-4-yl)-N6-(pyrazin-2-yl)pyridine-2,6-diamine inhibiteur de la tyrosine kinase

ilginatinib N2-[(1S)-1-(4-fluorofenil)etil]-4-(1-metil-1H-pirazol-4-il)-N6-(pirazin-2-il)piridina-2,6-diamina inhibidor de la tirosina kinasa

C21H20FN7

1239358-86-1

iodinum (131I) apamistamabum # iodine (131I) apamistamab immunoglobulin G1-kappa, anti-[Homo sapiens PTPRC (protein

tyrosine phosphatase receptor type C, GP180, LCA, T200, CD45)], Mus musculus monoclonal antibody, conjugated on six tyrosyl, to iodine (131I); gamma1 heavy chain (1-444) [Mus musculus VH (IGHV4-1*02 (95.9%) -(IGHD) -IGHJ4*01 (100%)) [8.8.14] (1-121) -Mus musculus IGHG1*02 (CH1 Q100>E (199) (122-218), hinge (219-231), CH2 K81>Q (288), I84.3>F (294) (232-338), CH3 N27>D (369) (339-443), CHS (444-445)) (122-445)], (223-218')-disulfide with kappa light chain (1'-218') [Mus musculus V-KAPPA (IGKV3-12*01 (98.0%) -IGKJ4*01 (100%)) [10.3.9] (1'-111') -Mus musculus IGKC*01 (100%) (112'-218')]; dimer (225-225'':228-228'':230-230'')-trisdisulfide; conjugated on 6 tyrosyl (2 per H chain and 1 per L chain), to iodine (131I) immunomodulator, antineoplastic

iodine (131I) apamistamab immunoglobuline G1-kappa, anti-[Homo sapiens PTPRC (protéine tyrosine phosphatase de type récepteur C, GP180, LCA, T200, CD45)], Mus musculus anticorps monoclonal, conjugué sur 6 tyrosyl, à l'iode (131I); chaîne lourde gamma1 (1-444) [Mus musculus VH (IGHV4-1*02 (95.9%) -(IGHD) -IGHJ4*01 (100%)) [8.8.14] (1-121) -Mus musculus IGHG1*02 (CH1 Q100>E (199) (122-218), charnière (219-231), CH2 K81>Q (288), I84.3>F (294) (232-338), CH3 N27>D (369) (339-443), CHS (444-445)) (122-445)], (223-218')-disulfure avec la chaîne légère kappa (1'-218') [Mus musculus V-KAPPA (IGKV3-12*01 (98.0%) -IGKJ4*01 (100%)) [10.3.9] (1'-111') -Mus musculus IGKC*01 (100%) (112'-218')]; dimère (225-225'':228-228'':230-230'')-trisdisulfure; conjugué sur 6 tyrosyl (2 par chaîne H et 1 par chaîne L) à l'iode (131I) immunomodulateur, antinéoplasique

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

324

iodo (131I) apamistamab inmunoglobulina G1-kappa, anti-[Homo sapiens PTPRC

(proteína tirosina fosfatasa de tipo receptor C, GP180, LCA, T200, CD45)], Mus musculus anticuerpo monoclonal, conjugado con 6 restos tirosil, al iodo (131I); cadena pesada gamma1 (1-444) [Mus musculus VH (IGHV4-1*02 (95.9%) -(IGHD) -IGHJ4*01 (100%)) [8.8.14] (1-121) -Mus musculus IGHG1*02 (CH1 Q100>E (199) (122-218), bisagra (219-231), CH2 K81>Q (288), I84.3>F (294) (232-338), CH3 N27>D (369) (339-443), CHS (444-445)) (122-445)], (223-218')-disulfuro con la cadena ligera kappa (1'-218') [Mus musculus V-KAPPA (IGKV3-12*01 (98.0%) -IGKJ4*01 (100%)) [10.3.9] (1'-111') -Mus musculus IGKC*01 (100%) (112'-218')]; dímero (225-225'':228-228'':230-230'')-trisdisulfuro; conjugado con 6 restos tirosil (2 por cadena H y 1 por cadena L) al iodo (131I) inmunomodulador, antineoplásico

2097132-02-8

CO2H

NH2HHO

[131I]

Heavy chain / Chaîne lourde / Cadena pesadaEVKLLESGGG LVQPGGSLKL SCAASGFDFS RYWMSWVRQA PGKGLEWIGE 50INPTSSTINF TPSLKDKVFI SRDNAKNTLY LQMSKVRSED TALYYCARGN 100YYRYGDAMDY WGQGTSVTVS SAKTTPPSVY PLAPGSAAQT NSMVTLGCLV 150KGYFPEPVTV TWNSGSLSSG VHTFPAVLQS DLYTLSSSVT VPSSTWPSET 200VTCNVAHPAS STKVDKKIVP RDCGCKPCIC TVPEVSSVFI FPPKPKDVLT 250ITLTPKVTCV VVDISKDDPE VQFSWFVDDV EVHTAQTQPR EEQFNSTFRS 300VSELPIMHQD WLNGKEFKCR VNSAAFPAPI EKTISKTKGR PKAPQVYTIP 350PPKEQMAKDK VSLTCMITDF FPEDITVEWQ WNGQPAENYK NTQPIMDTDG 400SYFVYSKLNV QKSNWEAGNT FTCSVLHEGL HNHHTEKSLS HSPGK 445

Light chain / Chaîne légère / Cadena ligeraDIALTQSPAS LAVSLGQRAT ISCRASKSVS TSGYSYLHWY QQKPGQPPKL 50LIYLASNLES GVPARFSGSG SGTDFTLNIH PVEEEDAATY YCQHSRELPF 100TFGSGTKLEI KRADAAPTVS IFPPSSEQLT SGGASVVCFL NNFYPKDINV 150KWKIDGSERQ NGVLNSWTDQ DSKDSTYSMS STLTLTKDEY ERHNSYTCEA 200THKTSTSPIV KSFNRNEC 218

Post-translational modificationsDisulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 148-203 259-319 365-423

22''-96'' 148''-203'' 259''-319'' 365''-423''Intra-L (C23-C104) 23'-92' 138'-198'

23'''-92''' 138'''-198'''Inter-H-L (h 5-CL 126) 223-218' 223''-218'''Inter-H-H (h7, h 10, h 12) 225-225'' 228-228'' 230-230''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:295, 295''Mus musculus hybridoma-type glycans / glycanes de type hybridome de Mus musculus /glicanos de tipo hibridoma de Mus musculus

Iodination sites / Sites d'iodation / Posiciones de yodaciónradiolabeled 3-[131I]iodotyrosineH VH Y109, Y110: 101 or 102, 101'' or 102''

H CH3 Y85.2, Y86: 402 or 405, 402'' or 405''L V-KAPPA Y36, Y38, Y42: 334' or 36' or 40',

34''' or 36''' or 40'''

lenzumestrocelum lenzumestrocel human culture expanded autologous mesenchymal stromal

cells for cell-based therapy. Cells are derived from isolated bone marrow of the patient. Cells express surface markers CD29, CD44, CD73, CD105 and CD49 and are intended to mediate immunomodulatory and neuroprotective effects cell therapy substance (immunomodulator)

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

325

lenzumestrocel cellules mésenchymales stromales humaines, autologues, expansées pour thérapie cellulaire. Les cellules sont dérivées de la moelle osseuse du patient. Les cellules expriment les marqueurs de surface CD29, CD44, CD73, CD105 et CD49, et sont destinées à avoir des effets immunomodulateurs et neuroprotecteurs. substance de thérapie cellulaire (immunomodulateur)

lenzumestrocel células mesenquimales estromales, autólogas, humanas, expandidas en cultivo para terapia celular. Las células derivan de médula ósea aislada del paciente. Las células expresan los marcadores de superficie CD29, CD44, CD73, CD105 y CD49, y se pretende que medien en efectos inmunomoduladores y neuroprotectores. sustancia de terapia celular (inmunomodulador)

leriglitazonum leriglitazone rac-(5R)-5-{[4-(2-{5-[(1RS)-1-hydroxyethyl]pyridin-2-

yl}ethoxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione peroxisome proliferator activated receptor (PPAR) gamma agonist

lériglitazone rac-(5R)-5-{[4-(2-{5-[(1RS)-1-hydroxyéthyl]pyridin-2-yl}éthoxy)phényl]méthyl}-1,3-thiazolidine-2,4-dione agoniste des récepteurs gamma activés par les proliférateurs de peroxysomes

leriglitazona rac-(5R)-5-{[4-(2-{5-[(1RS)-1-hidroxietil]piridin-2-il}etoxi)fenil]metil}-1,3-tiazolidina-2,4-diona agonista de los receptores gamma activados por los factores de proliferación de peroxisomas

C19H20N2O4S

146062-44-4

linrodostatum linrodostat (2R)-N-(4-chlorophenyl)-2-[cis-4-(6-fluoroquinolin-4-

yl)cyclohexyl]propanamide antineoplastic

linrodostat (2R)-N-(4-chlorophényl)-2-[cis-4-(6-fluoroquinoléin-4-yl)cyclohexyl]propanamide antinéoplasique

linrodostat (2R)-N-(4-clorofenil)-2-[cis-4-(6-fluoroquinolein-4-il)ciclohexil]propanamida antineoplásico

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

326

C24H24ClFN2O

1923833-60-6

lisocabtagenum maraleucelum # lisocabtagene maraleucel human culture expanded genetically modified autologous T

cells for cell-based gene therapy. CD4+ CD8+ T Cells are derived from isolated blood of the patient and are transduced with non-replicative self-inactivating (SIM) lentiviral vector encoding an FMC63 anti-CD19 single chain variable fragment (scFv) lgG4 hinge region/CD28/CD137 (4-1BB)/CD3zeta chimeric antigen receptor (CAR) and a truncated form of the human epidermal growth factor receptor (EGFRt) under the control of the elongation factor 1-alpha (EF1-alpha)/R region from the human T cell leukaemia virus 1 (HTLV-1 R) composite promoter. Cells exhibit anti-tumoral activity in patients with CD19-expressing B cell malignancies. cell genetically modified (antineoplastic)

lisocabtagène maraleucel lymphocytes T humains autologues en culture d'expansion et génétiquement modifiés pour thérapie génique avec cellules. Les lymphocytes T CD4+ et CD8+ sont dérivés du sang prélevé chez le patient et sont transduits avec un vecteur lentiviral non-répliquant et auto-inactivant codant pour un récepteur de l'antigène chimérique (CAR) consistant en un fragment variable de la chaîne unique (scFv) de l’anticorps FMC63 anti-CD-19, une région charnière de IgG4/CD28/CD137 (4-1BB)/CD3zêta et une forme tronquée du récepteur du facteur de croissance épidermique humain (EGFRt) sous le contrôle d'un promoteur composé du facteur d'élongation 1-alpha (EF1-alfa)/région R du virus T-lymphotrope humain (HTLV-1 R). Les cellules montrent une activité anti-tumorale chez les patients atteints de tumeurs malignes des lymphocytes B exprimant le CD-19. cellule génétiquement modifiée (antinéoplasique)

lisocabtagén maraleucel Linfocitos T autólogos, modificados genéticamente, humanos, expandidos en cultivo para terapia génica con células. Los linfocitos T CD4+ y CD8+ se derivan de sangre aislada del paciente y se transducen con un vector lentiviral no replicativo y autoinactivante que codifica para un receptor de antígeno quimérico (CAR) consistente en un fragmento variable de cadena sencilla (scFv) del anticuerpo FMC63 anti-CD19, una región bisagra de

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

327

IgG4/CD28/CD137 (4-1BB)/CD3zeta y una forma truncada del receptor del factor de crecimiento epidérmico humano (EGFRt) bajo el control de un promotor compuesto del factor de elongación 1-alfa (EF1-alfa)/región R del virus de la leucemia humana de linfocitos T (HTLV-1 R). Las células poseen actividad anti-tumoral en pacientes con cánceres de linfocitos B que expresan CD19. célula modificada genéticamente (antineoplásico)

marstacimabum # marstacimab immunoglobulin G1-lambda, anti-[Homo sapiens TFPI

(tissue factor pathway inhibitor, extrinsic pathway inhibitor, EPI, lipoprotein-associated coagulation inhibitor, LACI)], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV3-23*01 (100%) -(IGHD) -IGHJ3*02 (100%)) [8.8.13] (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), hinge (219-233), CH2 L1.4>A (237), L1.3>A (238), G1>A (240) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-217')-disulfide with lambda light chain (1'-218') [Homo sapiens V-LAMBDA (IGLV1-40*01 (100%) -IGLJ2*01 (100%)) [9.3.12] (1'-112') -Homo sapiens IGLC2*01 (113-218')]; dimer (229-229'':232-232'')-bisdisulfide haemostatic

marstacimab immunoglobuline G1-lambda, anti-[Homo sapiens TFPI (inhibiteur de la voie du facteur tissulaire, inhibiteur de la voie extrinsèque, EPI, inhibiteur de la coagulation associé aux lipoprotéines, LACI)], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-449) [Homo sapiens VH (IGHV3-23*01 (100%) -(IGHD) -IGHJ3*02 (100%)) [8.8.13] (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), charnière (219-233), CH2 L1.4>A (237), L1.3>A (238), G1>A (240) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-217')-disulfure avec la chaîne légère lambda (1'-218') [Homo sapiens V-LAMBDA (IGLV1-40*01 (100%) -IGLJ2*01 (100%)) [9.3.12] (1'-112') -Homo sapiens IGLC2*01 (113-218')]; dimère (229-229'':232-232'')-bisdisulfure hémostatique

marstacimab inmunoglobulina G1-lambda, anti-[Homo sapiens TFPI (inhibidor de la vía del factor tisular, inhibidor de la vía extrínseca, EPI, inhibidor de la coagulación asociado a las lipoproteínas, LACI)], Homo sapiens anticuerpo monoclonal; cadena pesada gamma1 (1-449) [Homo sapiens VH (IGHV3-23*01 (100%) -(IGHD) -IGHJ3*02 (100%)) [8.8.13] (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), bisagra (219-233), CH2 L1.4>A (237), L1.3>A (238), G1>A (240) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-217')-disulfuro con la cadena ligera

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

328

lambda (1'-218') [Homo sapiens V-LAMBDA (IGLV1-40*01 (100%) -IGLJ2*01 (100%)) [9.3.12] (1'-112') -Homo sapiens IGLC2*01 (113-218')]; dímero (229-229'':232-232'')-bisdisulfuro hemostático

1985638-39-8 Heavy chain / Chaîne lourde / Cadena pesada

EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSA 50ISGSGGSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAILG 100ATSLSAFDIW GQGTMVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPEAAGA PSVFLFPPKP 250KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG 449

Light chain / Chaîne légère / Cadena ligeraQSVLTQPPSV SGAPGQRVTI SCTGSSSNIG AGYDVHWYQQ LPGTAPKLLI 50YGNSNRPSGV PDRFSGSKSG TSASLAITGL QAEDEADYYC QSYDSSLSGS 100GVFGGGTKLT VLGQPKAAPS VTLFPPSSEE LQANKATLVC LISDFYPGAV 150TVAWKADSSP VKAGVETTTP SKQSNNKYAA SSYLSLTPEQ WKSHRSYSCQ 200VTHEGSTVEK TVAPTECS 218

Post-translational modificationsDisulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 147-203 264-324 370-428

22''-96'' 147''-203'' 264''-324'' 370''-428''Intra-L (C23-C104) 22'-90' 140'-199'

22'''-90''' 140'''-199'''Inter-H-L (h5-CL 126) 223-217' 223''-217'''Inter-H-H (h11, h 14) 229-229'' 232-232''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:300, 300''Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennairescomplexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

masupirdinum masupirdine 1-(2-bromobenzene-1-sulfonyl)-5-methoxy-3-[(4-

methylpiperazin-1-yl)methyl]-1H-indole serotonin receptor antagonist

masupirdine 1-(2-bromobenzène-1-sulfonyl)-5-méthoxy-3-[(4-méthylpipérazin-1-yl)méthyl]-1H-indole antagoniste des récepteurs de la sérotonine

masupirdina 1-(2-bromobenceno-1-sulfonil)-5-metoxi-3-[(4-metilpiperazin-1-il)metil]-1H-indol antagonista del receptor de la serotonina

C21H24BrN3O3S

701205-60-9

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

329

miricorilantum miricorilant 6-(trans-4-phenylcyclohexyl)-5-{[3-

(trifluoromethyl)phenyl]methyl}pyrimidine-2,4(1H,3H)-dione glucocorticoid receptor antagonist

miricorilant 6-(trans-4-phénylcyclohexyl)-5-{[3-(trifluorométhyl)phényl]méthyl}pyrimidine-2,4(1H,3H)-dione antagoniste des récepteurs glucocorticoïdes

miricorilant 6-(trans-4-fenilciclohexil)-5-{[3-(trifluorometil)fenil]metil}pirimidina-2,4(1H,3H)-diona antagonista de los receptores glucocorticoides

C24H23N2O2F3 1400902-13-7

mivavotinibum mivavotinib 6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-

4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one tyrosine kinase inhibitor, antineoplastic

mivavotinib 6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-méthyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one inhibiteur de la tyrosine kinase, antinéoplasique

mivavotinib 6-{[(1R,2S)-2-aminociclohexil]amino}-7-fluoro-4-(1-metil-1H-pirazol-4-il)-1,2-dihidro-3H-pirrolo[3,4-c]piridin-3-ona inhibidor de la tirosina kinasa, antineoplásico

C17H21FN6O 1312691-33-0

murlentamabum # murlentamab immunoglobulin G1-kappa, anti-[Homo sapiens AMHR2 (anti-Müllerian

hormone (AMH) receptor type 2, Müllerian inhibiting substance type II receptor, MISRII, MISR2)], humanized monoclonal antibody; gamma1 heavy chain (1-445) [humanized VH (Homo sapiens IGHV1-3*01 (90.8%) -(IGHD)-IGHJ4*01 (92.9%)) [8.8.8] (1-115) -Homo sapiens IGHG1*01, G1m17,1 (CH1 K120 (212) (116-213), hinge (214-228), CH2 (229-338), CH3 D12 (354), M14 (356) (339-443), CHS (444-445)) (116-445)], (218-213')-disulfide with kappa light chain (1'-213') [humanized V-KAPPA (Homo sapiens IGKV1-5*01 (86.2%) -IGKJ4*01 (100%)) [5.3.9] (1'-106') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191)(107'-213')]; dimer (224-224":227-227")-bisdisulfide immunomodulator, antineoplastic

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

330

murlentamab immunoglobuline G1-kappa, anti-[Homo sapiens AMHR2 (récepteur de

type 2 de l'hormone anti- müllérienne, récepteur de type II de la substance inhibitrice müllérienne, MISRII, MISR2)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-445) [VH humanisé (Homo sapiens IGHV1-3*01 (90.80%) -(IGHD)-IGHJ4*01 (92.9%)) [8.8.8] (1-115) -Homo sapiens IGHG1*01, G1m17,1 (CH1 K120 (212) (116-213), charnière (214-228), CH2 (229-338), CH3 D12 (354), M14 (356) (339-443), CHS (444-445)) (116-445)], (218-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA humanisé (Homo sapiens IGKV1-5*01 (86.2%) -IGKJ4*01 (100%)) [5.3.9] (1'-106') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (107'-213')]; dimère (224-224":227-227")-bisdisulfure immunomodulateur, antinéoplasique

murlentamab inmunoglobulina G1-kappa, anti-[Homo sapiens AMHR2 (receptor de tipo 2 de la hormona anti- müllériana, receptor de tipo II de la sustancia inhibidora mülleriana, MISRII, MISR2)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-445) [VH humanizado (Homo sapiens IGHV1-3*01 (90.80%) -(IGHD)-IGHJ4*01 (92.9%)) [8.8.8] (1-115) -Homo sapiens IGHG1*01, G1m17,1 (CH1 K120 (212) (116-213), bisagra (214-228), CH2 (229-338), CH3 D12 (354), M14 (356) (339-443), CHS (444-445)) (116-445)], (218-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizado (Homo sapiens IGKV1-5*01 (86.2%) -IGKJ4*01 (100%)) [5.3.9] (1'-106') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (107'-213')]; dímero (224-224":227-227")-bisdisulfuro inmunomodulador, antineoplásico

2058047-65-5

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

331

neluxicaponum neluxicapone 4,5-dihydroxy-2-[(4-methylphenyl)methyl]benzene-1,3-

dicarbonitrile antiparkinsonian

néluxicapone 4,5-dihydroxy-2-[(4-méthylphényl)méthyl]benzène-1,3-dicarbonitrile antiparkinsonien

neluxicapona 4,5-dihidroxi-2-[(4-metilfenil)metil]benzeno-1,3-dicarbonitrilo antiparkinsoniano

C16H12N2O2

1498323-18-4

nerinetidum nerinetide L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-

glutaminyl-L-arginyl-L-arginyl-L-arginyl-L-lysyl-L-leucyl-L-seryl-L-seryl-L-isoleucyl-L-α-glutamyl-L-seryl-L-α-aspartyl-L-valine neurological agent

nérinétide L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-arginyl-L-lysyl-L-leucyl-L-séryl-L-séryl-L-isoleucyl-L-α-glutamyl-L-séryl-L-α-aspartyl-L-valine agent neurologique

nerinetida L-tirosilglicil-L-arginil-L-lisil-L-lisil-L-arginil-L-arginil-L-glutaminil-L-arginil-L-arginil-L-arginil-L-lisil-L-leucil-L-seril-L-seril-L-isoleucil-L-α-glutamil-L-seril-L-α-aspartil-L-valina agente neurológico

C105H188N42O30

500992-11-0

nevanimibum nevanimibe N-({1-[4-(dimethylamino)phenyl]cyclopentyl}methyl)-

N'-[2,6-di(propan-2-yl)phenyl]urea acyl CoA:cholesterol acyltransferase (ACAT) inhibitor

névanimibe N-({1-[4-(diméthylamino)phényl]cyclopentyl}méthyl)- N'-[2,6-di(propan-2-yl)phényl]urée inhibiteur de l'acyl CoA:cholestérol acyltransférase

nevanimiba N-({1-[4-(dimetilamino)fenil]ciclopentil}metil)-N'-[2,6-di(propan-2-il)fenil]urea inhibidor de l'acyl CoA:colesterolo aciltransferasa

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

332

C27H39N3O

133825-80-6

nirsevimabum # nirsevimab immunoglobulin G1-kappa, anti-[human respiratory virus (RSV)

fusion glycoprotein F], monoclonal antibody; gamma1 heavy chain (1-456) [VH (Homo sapiens IGHV1-69*01 (82.5%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.19] (1-126) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (223) (127-224), hinge (225-239), CH2 M15.1>Y (261), S16>T (263), T18>E (265) (240-349), CH3 E12 (365), M14 (367) (350-454), CHS (455-456)) (127-456)], (229-214')-disulfide with kappa light chain (1'-214') [V-KAPPA (Homo sapiens IGKV1-33*01 (93.7%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (235-235'':238-238'')-bisdisulfide immunomodulator, antiviral

nirsévimab immunoglobuline G1-kappa, anti-[glycoprotéine de fusion F du virus respiratoire syncytial (VRS) humain], anticorps monoclonal; chaîne lourde gamma1 (1-456) [VH (Homo sapiens IGHV1-69*01 (82.5%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.19] (1-126) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (223) (127-224), charnière (225-239), CH2 M15.1>Y (261), S16>T (263), T18>E (265) (240-349), CH3 E12 (365), M14 (367) (350-454), CHS (455-456)) (127-456)], (229-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA (Homo sapiens IGKV1-33*01 (93.7%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (235-235'':238-238'')-bisdisulfure immunomodulateur, antiviral

nirsevimab inmunoglobulina G1-kappa, anti-[glicoproteína de fusión F del virus respiratorio sincitial (VRS) humano], anticuerpo monoclonal; cadena pesada gamma1 (1-456) [VH (Homo sapiens IGHV1-69*01 (82.5%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.19] (1-126) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (223) (127-224), bisagra (225-239), CH2 M15.1>Y (261), S16>T (263), T18>E (265) (240-349), CH3 E12 (365), M14 (367) (350-454), CHS (455-456)) (127-456)], (229-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA (Homo sapiens IGKV1-33*01 (93.7%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (235-235'':238-238'')-bisdisulfuro inmunomodulador, antiviral

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

333

1989556-22-0

nomacopanum # nomacopan complement inhibitor from Ornithodoros moubata (soft tick

or Argasid tick), produced in Escherichia coli complement factor C5 inhibitor

nomacopan inhibiteur du complément de Ornithodoros moubata (tique molle ou Argasidé), produit dans Escherichia coli inhibiteur du facteur C5 du complément

nomacopán inhibidor del complemento de Ornithodoros moubata (garrapata o Argásido), producido en Escherichia coli inhibidor del factor C5 del complemento

C720H1107N197O244S11

875125-19-2

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

334

obexelimabum # obexelimab immunoglobulin G1-kappa, anti-[Homo sapiens CD19 (B

lymphocyte surface antigen B4, Leu-12)], monoclonal antibody; gamma1 heavy chain (1-451) [VH (Mus musculus IGHV1-14*01 (77.6%)/Homo sapiens IGHV1-3*01 (73.5%) -(IGHD)-Homo sapiens IGHJ4*01 (100%)) [8.8.14] (1-121) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (218) (122-219), hinge (220-234), CH2 S29>E (271), L113>F (332) (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122-451)], (224-219')-disulfide with kappa light chain (1'-219') [V-KAPPA (Mus musculus IGKV2-137*01 (75.0%)/Homo sapiens IGKV3D-11*03 (73.7%) -Homo sapiens IGKJ2*01 (90.9%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (230-230":233-233")-bisdisulfide immunomodulator

obéxélimab immunoglobuline G1-kappa, anti-[Homo sapiens CD19 (antigène de surface B4 des lymphocytes B, Leu-12)], anticorps monoclonal; chaîne lourde gamma1 (1-451) [VH (Mus musculus IGHV1-14*01 (77.6%)/Homo sapiens IGHV1-3*01 (73.5%) -(IGHD)-Homo sapiens IGHJ4*01 (100%)) [8.8.14] (1-121) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (218) (122-219), charnière (220-234), CH2 S29>E (271), L113>F (332) (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122-451)], (224-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA (Mus musculus IGKV2-137*01 (75.0%)/Homo sapiens IGKV3D-11*03 (73.7%) -Homo sapiens IGKJ2*01 (90.9%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimère (230-230":233-233")-bisdisulfure immunomodulateur

obexelimab inmunoglobulina G1-kappa, anti-[Homo sapiens CD19 (antígeno de superficie B4 de los linfocitos B, Leu-12)], anticuerpo monoclonal; cadena pesada gamma1 (1-451) [VH (Mus musculus IGHV1-14*01 (77.6%)/Homo sapiens IGHV1-3*01 (73.5%) -(IGHD)-Homo sapiens IGHJ4*01 (100%)) [8.8.14] (1-121) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (218) (122-219), bisagra (220-234), CH2 S29>E (271), L113>F (332) (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122-451)], (224-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA (Mus musculus IGKV2-137*01 (75.0%)/Homo sapiens IGKV3D-11*03 (73.7%) -Homo sapiens IGKJ2*01 (90.9%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dímero (230-230":233-233")-bisdisulfuro inmunomodulador

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

335

1690307-05-1 Heavy chain / Chaîne lourde / Cadena pesada

EVQLVESGGG LVKPGGSLKL SCAASGYTFT SYVMHWVRQA PGKGLEWIGY 50INPYNDGTKY NEKFQGRVTI SSDKSISTAY MELSSLRSED TAMYYCARGT 100YYYGTRVFDY WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250PKDTLMISRT PEVTCVVVDV EHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK AFPAPIEKTI SKAKGQPREP 350QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450K 451

Light chain / Chaîne légère / Cadena ligeraDIVMTQSPAT LSLSPGERAT LSCRSSKSLQ NVNGNTYLYW FQQKPGQSPQ 50LLIYRMSNLN SGVPDRFSGS GSGTEFTLTI SSLEPEDFAV YYCMQHLEYP 100ITFGAGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200VTHQGLSSPV TKSFNRGEC 219

Post-translational modificationsDisulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 148-204 265-325 371-429

22''-96'' 148''-204'' 265''-325'' 371''-429''Intra-L (C23-C104) 23'-93' 139'-199'

23'''-93''' 139'''-199'''Inter-H-L (h 5-CL 126) 224-219' 224''-219'''Inter-H-H (h 11, h 14) 230-230'' 233-233''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:301, 301''Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennairescomplexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

odevixibatum odevixibat (2S)-2-[(2R)-2-(2-{[3,3-dibutyl-7-(methylsulfanyl)-1,1-

dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-1λ6,2,5-benzothiadiazepin-8-yl]oxy}acetamido)-2-(4-hydroxyphenyl)acetamido]butanoic acid ileal bile acid transporter inhibitor

odévixibat acide (2S)-2-[(2R)-2-(2-{[3,3-dibutyl-7-(méthylsulfanyl)-1,1-dioxo-5-phényl-2,3,4,5-tétrahyd-ro-1H-1λ6,2,5-benzothiadiazépin-8-yl]oxy}acétamido)-2-(4-hydroxyphényl)acétamido]butanoïque inhibiteur du transporteur iléal d'acides biliaire

odevixibat ácido (2S)-2-[(2R)-2-(2-{[3,3-dibutil-7-(metilsulfanil)-1,1-dioxo-5-fenil-2,3,4,5-tetrahid-ro-1H-1λ6,2,5-benzotiadiazepin-8-il]oxi}acetamido)-2-(4-hidroxifenil)acetamido]butanoico inhibidor del transportador ilíaco de ácidos biliares

C37H48N4O8S2 501692-44-0

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

336

olacaftorum olacaftor N-(benzenesulfonyl)-6-[3-fluoro-5-(2-

methylpropoxy)phenyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide cystic fibrosis transmembrane regulator (CFTR) protein modulator

olacaftor N-(benzènesulfonyl)-6-[3-fluoro-5-(2-méthylpropoxy)phényl]-2-[(4S)-2,2,4-triméthylpyrrolidin-1-yl]pyridine-3-carboxamide modulateur de la protéine régulatrice de la perméabilité transmembranaire impliquée dans la mucoviscidose (CFTR)

olacaftor N-(bencenosulfonil)-6-[3-fluoro-5-(2-metilpropoxi)fenil]-2-[(4S)-2,2,4-trimetilpirrolidin-1-il]piridina-3-carboxamida modulador de la proteína reguladora de la conductancia transmembrana de la fibrosis quística (CFTR)

C29H34FN3O4S

1897384-89-2

olenasufligenum relduparvovecum # olenasufligene relduparvovec A recombinant non-replicating adeno-associated virus

serotype rh.10 (AAVrh.10) vector, comprised of a recombinant genome with the AAV2 Inverted Terminal Repeats (ITR) packaged into an AAVrh.10 capsid, expressing the human N-sulfoglucosamine sulfohydrolase (hSGSH) cDNA, under the control of the CMV immediate early enhancer/chicken β actin (CAG) promoter and a bovine hGH polyA transcription termination site. gene therapy substance (mucopolysaccharidosis III)

olénasufligène relduparvovec vecteur viraladéno-associé de sérotype rh.10 recombinant non-répliquant (AAVrh.10), comprenant un génome fait de séquences inverses terminales répétées (ITR) de AAV2 empaquetées dans une capside de AAVrh.10, exprimant l'ADNc de la N-sulfoglucosamine sulfohydrolase humaine (hSGSH), sous le contrôle du promoteur du CMV (cytomégalovirus) immédiat précoce / du promoteur de l'actine β du poulet et une séquence poly A de la hGH bovine comme terminaison de la transcription. substance pour thérapie génique (mucopolysaccharidose III)

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

337

olenasufligén relduparvovec Un vector de virus adenoasociado recombinante no replicativo de serotipo rh.10 (AAVrh.10), compuesto por un genoma recombinante con las Repeticiones Terminales Invertidas (ITR) empaquetadas en una cápside de AAVrh.10, expresando el cDNA de la N-sulfoglucosamina sulfohidrolasa humana, bajo el control del enhancer inmediato temprano del CMV/promotor de la b actina de pollo y un sitio poli A de la hGH bovina como terminación de la transcripción. sustancia de terapia genica (mucopolisacaridosis III)

2096510-84-6

olinvacimabum # olinvacimab immunoglobulin G1_V-lambda-C-kappa, anti-[Homo

sapiens KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, VEGF-R2, FLK1, CD309)], monoclonal antibody; gamma1 heavy chain (1-462) [N-terminal 6-mer (1-6) -VH (Homo sapiens IGHV1-3*01 (84.7%) -(IGHD) -IGHJ4*01 (100%)) [8.8.14] (7-127) -5-mer linker (128-132) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (229) (133-230), hinge(231-245), CH2(246-355), CH3E12 (371), M14 (373) (356-460), CHS (461-462)) (133-462)], (235-227')-disulfide with V-lambda-C-kappa light chain (1'-227') [N-terminal 5-mer (1'-5') - V-LAMBDA (Homo sapiens IGLV3-21*01 (81.2%) -IGLJ1*01 (100%)) [6.3.10] (6'-112') -8-mer linker(113'-120') -Homo sapiens IGKC*01 T1.3>S (122), Km3 A45.1 (166), V101 (204) (121'-227')]; dimer (241-241'':244-244'')-bisdisulfide immunomodulator, antineoplastic

olinvacimab immunoglobuline G1_V-lambda-C-kappa, anti-[Homo sapiens KDR (récepteur à domaine insert kinase, récepteur 2 du facteur de croissance endothélial vasculaire, VEGFR2, VEGF-R2, FLK1, CD309)], anticorps monoclonal; chaîne lourde gamma1 (1-462) [6-mer N-terminal (1-6) -VH (Homo sapiens IGHV1-3*01 (84.7%) -(IGHD) -IGHJ4*01 (100%)) [8.8.14] (7-127) -5-mer linker (128-132) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (229) (133-230), charnière (231-245), CH2(246-355), CH3E12 (371), M14 (373) (356-460), CHS (461-462)) (133-462)], (235-227')-disulfure avec la chaîne légère V-lambda-C-kappa (1'-227') [5-mer N-terminal (1'-5') -V-LAMBDA (Homo sapiens IGLV3-21*01 (81.2%) -IGLJ1*01 (100%)) [6.3.10] (6'-112') -8-mer linker (113'-120') -Homo sapiens IGKC*01 T1.3>S (122), Km3 A45.1 (166), V101 (204) (121'-227')]; dimère (241-241'':244-244'')-bisdisulfure immunomodulateur, antinéoplasique

olinvacimab inmunoglobulina G1_V-lambda-C-kappa, anti-[Homo sapiens KDR (receptor con dominio inserto kinasa, receptor 2 del factor de crecimiento endotelial vascular, VEGFR2, VEGF-R2, FLK1, CD309)], anticuerpo monoclonal;

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

338

cadena pesada gamma1 (1-462) [6-mer N-terminal (1-6) -VH (Homo sapiens IGHV1-3*01 (84.7%) -(IGHD) -IGHJ4*01 (100%)) [8.8.14] (7-127) -5-mer ligante (128-132) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (229) (133-230), bisagra(231-245), CH2(246-355), CH3E12 (371), M14 (373) (356-460), CHS (461-462)) (133-462)], (235-227')-disulfuro con la cadena ligera V-lambda-C-kappa (1'-227') [5-mer N-terminal (1'-5') -V-LAMBDA (Homo sapiens IGLV3-21*01 (81.2%) -IGLJ1*01 (100%)) [6.3.10] (6'-112') -8-mer ligante (113'-120') -Homo sapiens IGKC*01 T1.3>S (122), Km3 A45.1 (166), V101 (204) (121'-227')]; dímero (241-241'':244-244'')-bisdisulfuro inmunomodulador, antineoplásico

2095504-49-5

olorinabum olorinab 3-[(4aS,5aS)-3-{[(2S)-1-hydroxy-3,3-dimethylbutan-

2-yl]carbamoyl}-4,4a,5,5a-tetrahydro-1H-cyclopropa[4,5]cyclopenta[1,2-c]pyrazol-1-yl]pyrazine 1-oxide cannabinoid CB2 receptor agonist

olorinab 1-oxyde de 3-[(4aS,5aS)-3-{[(2S)-1-hydroxy- 3,3-diméthylbutan-2-yl]carbamoyl}-4,4a,5,5a-tétrahydro- 1H-cyclopropa[4,5]cyclopenta[1,2-c]pyrazol-1-yl]pyrazine agoniste des récepteurs CB2 aux cannabinoïdes

olorinab 1-óxido de 3-[(4aS,5aS)-3-{[(2S)-1-hidroxi-3,3-dimetilbutan-2-il]carbamoil}-4,4a,5,5a-tetrahidro-1H-ciclopropa[4,5]ciclopenta[1,2-c]pirazol-1-il]pirazina agonista del receptor CB2 de cannabinoides

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

339

C18H23N5O3 1268881-20-4

omburtamabum # omburtamab immunoglobulin G1-kappa, anti-[Homo sapiens CD276

(B7H3, B7-H3, B7RP-2)], Mus musculus monoclonal antibody; gamma1 heavy chain (1-442) [Mus musculus VH (IGHV1-85*01 (88.8%) -(IGHD) -IGHJ3*01 (100%)) [8.8.11] (1-118) -Mus musculus IGHG1*02 (CH1 Q100>E (196) (119-215), hinge (216-228), CH2 K81>Q (285), I84.3>F (291) (229-335), CH3 N27>D (366) (336-440), CHS (441-442)) (119-442)], (220-214')-disulfide with kappa light chain (1'-214') [Mus musculus V-KAPPA (IGKV5-39*01 (100%) -IGKJ5*01 (100%)) [6.3.9] (1'-107') -Mus musculus IGKC*01 (100%) (108'-214')]; dimer (222-222'':225-225'':227-227'')-trisdisulfide immunomodulator, antineoplastic

omburtamab immunoglobuline G1-kappa, anti-[Homo sapiens CD276 (B7H3, B7-H3, B7RP-2)], Mus musculus anticorps monoclonal; chaîne lourde gamma1 (1-442) [Mus musculus VH (IGHV1-85*01 (88.8%) -(IGHD) -IGHJ3*01 (100%)) [8.8.11] (1-118) -Mus musculus IGHG1*02 (CH1 Q100>E (196) (119-215), charnière (216-228), CH2 K81>Q (285), I84.3>F (291) (229-335), CH3 N27>D (366) (336-440), CHS (441-442)) (119-442)], (220-214')-disulfure avec la chaîne légère kappa (1'-214') [Mus musculus V-KAPPA (IGKV5-39*01 (100%) -IGKJ5*01 (100%)) [6.3.9] (1'-107') -Mus musculus IGKC*01 (100%) (108'-214')]; dimère (222-222'':225-225'':227-227'')-trisdisulfure immunomodulateur, antinéoplasique

omburtamab inmunoglobulina G1-kappa, anti-[Homo sapiens CD276 (B7H3, B7-H3, B7RP-2)], Mus musculus anticuerpo monoclonal; cadena pesada gamma1 (1-442) [Mus musculus VH (IGHV1-85*01 (88.8%) -(IGHD) -IGHJ3*01 (100%)) [8.8.11] (1-118) -Mus musculus IGHG1*02 (CH1 Q100>E (196) (119-215), bisagra (216-228), CH2 K81>Q (285), I84.3>F (291) (229-335), CH3 N27>D (366) (336-440), CHS (441-442)) (119-442)], (220-214')-disulfuro con la cadena ligera kappa (1'-214') [Mus musculus V-KAPPA (IGKV5-39*01 (100%) -IGKJ5*01 (100%)) [6.3.9] (1'-107') -Mus musculus IGKC*01 (100%) (108'-214')]; dímero (222-222'':225-225'':227-227'')-trisdisulfuro inmunomodulador, antineoplásico

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

340

1895083-75-6

Heavy chain / Chaîne lourde / Cadena pesadaQVQLQQSGAE LVKPGASVKL SCKASGYTFT NYDINWVRQR PEQGLEWIGW 50IFPGDGSTQY NEKFKGKATL TTDTSSSTAY MQLSRLTSED SAVYFCARQT 100TATWFAYWGQ GTLVTVSAAK TTPPSVYPLA PGSAAQTNSM VTLGCLVKGY 150FPEPVTVTWN SGSLSSGVHT FPAVLQSDLY TLSSSVTVPS STWPSETVTC 200NVAHPASSTK VDKKIVPRDC GCKPCICTVP EVSSVFIFPP KPKDVLTITL 250TPKVTCVVVD ISKDDPEVQF SWFVDDVEVH TAQTQPREEQ FNSTFRSVSE 300LPIMHQDWLN GKEFKCRVNS AAFPAPIEKT ISKTKGRPKA PQVYTIPPPK 350EQMAKDKVSL TCMITDFFPE DITVEWQWNG QPAENYKNTQ PIMDTDGSYF 400VYSKLNVQKS NWEAGNTFTC SVLHEGLHNH HTEKSLSHSP GK 442

Light chain / Chaîne légère / Cadena ligeraDIVMTQSPAT LSVTPGDRVS LSCRASQSIS DYLHWYQQKS HESPRLLIKY 50ASQSISGIPS RFSGSGSGSD FTLSINSVEP EDVGVYYCQN GHSFPLTFGA 100GTKLELKRAD AAPTVSIFPP SSEQLTSGGA SVVCFLNNFY PKDINVKWKI 150DGSERQNGVL NSWTDQDSKD STYSMSSTLT LTKDEYERHN SYTCEATHKT 200STSPIVKSFN RNEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 145-200 256-316 362-420

22''-96'' 145''-200'' 256''-316'' 362''-420''Intra-L (C23-C104) 23'-88' 134'-194'

23'''-88''' 134'''-194'''Inter-H-L (h 5-CL 126) 220-214' 220''-214'''Inter-H-H (h 7, h 10, h 12) 222-222'' 225-225'' 227-227''N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:292, 292''Mus musculus hybridoma-type glycans / glycanes de type hybridome de Mus musculus /glicanos de tipo hibridoma de Mus musculusC-terminal lysine clipping:H CHS K2:442, 442''(14.7% of H chain without the C-terminal lysine)

ontamalimabum # ontamalimab immunoglobulin G2-kappa, anti-[Homo sapiens MADCAM1 (mucosal

vascular addressin cell adhesion molecule 1, mucosal addressin cell adhesion molecule-1, MAdCAM-1, MACAM1)], Homo sapiens monoclonal antibody; gamma2 heavy chain (1-450) [Homo sapiens VH (IGHV1-18*01 (93.9%) -(IGHD) -IGHJ6*01 (100%)) [8.8.17] (1-124) -Homo sapiens IGHG2*01, G2m.. (CH1 (125-222), hinge (223-234), CH2 V45.1 (285) (235-343), CH3 (344-448), CHS (449-450)) (125-450)], (138-219')-disulfide with kappa light chain (1'-219') [Homo sapiens V-KAPPA (IGKV2D-29*1 (96.0%) -IGKJ1*01 (100%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (226-226":227-227":230-230":233-233")-tetrakisdisulfide immunomodulator

ontamalimab immunoglobuline G2-kappa, anti-[Homo sapiens MADCAM1 (molécule 1 d'adhésion cellulaire adressine de muqueuse vasculaire, molécule-1 d'adhésion cellulaire adressine de muqueuse, MAdCAM-1, MACAM1)], Homo sapiens anticorps monoclonal; chaîne lourde gamma2 (1-450) [Homo sapiens VH (IGHV1-18*01 (93.9%) -(IGHD) -IGHJ6*01 (100%)) [8.8.17] (1-124) -Homo sapiens IGHG2*01, G2m.. (CH1 (125-222), charnière (223-234), CH2 V45.1 (285) (235-343), CH3 (344-448), CHS (449-450)) (125-450)], (138-219')-disulfure avec la chaîne légère kappa (1'-219') [Homo sapiens V-KAPPA (IGKV2D-29*1 (96.0%) -IGKJ1*01 (100%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimère (226-226":227-227":230-230":233-233")-tétrakisdisulfure immunomodulateur

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

341

ontamalimab inmunoglobulina G2-kappa, anti-[Homo sapiens MADCAM1 (molécula 1 de adhesión celular adresina de mucosa vascular, molécula-1 de adhesión celular adresina de mucosa, MAdCAM-1, MACAM1)], Homo sapiens anticuerpo monoclonal; cadena pesada gamma2 (1-450) [Homo sapiens VH (IGHV1-18*01 (93.9%) -(IGHD) -IGHJ6*01 (100%)) [8.8.17] (1-124) -Homo sapiens IGHG2*01, G2m.. (CH1 (125-222), bisagra (223-234), CH2 V45.1 (285) (235-343), CH3 (344-448), CHS (449-450)) (125-450)], (138-219')-disulfuro con la cadena ligera kappa (1'-219') [Homo sapiens V-KAPPA (IGKV2D-29*1 (96.0%) -IGKJ1*01 (100%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dímero (226-226":227-227":230-230":233-233")-tetrakisdisulfuro inmunomodulador

2098790-40-8

Heavy chain / Chaîne lourde / Cadena pesadaQVQLVQSGAE VKKPGASVKV SCKASGYTFT SYGINWVRQA PGQGLEWMGW 50ISVYSGNTNY AQKVQGRVTM TADTSTSTAY MDLRSLRSDD TAVYYCAREG 100SSSSGDYYYG MDVWGQGTTV TVSSASTKGP SVFPLAPCSR STSESTAALG 150CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSNF 200GTQTYTCNVD HKPSNTKVDK TVERKCCVEC PPCPAPPVAG PSVFLFPPKP 250KDTLMISRTP EVTCVVVDVS HEDPEVQFNW YVDGVEVHNA KTKPREEQFN 300STFRVVSVLT VVHQDWLNGK EYKCKVSNKG LPAPIEKTIS KTKGQPREPQ 350VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPM 400LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450

Light chain / Chaîne légère / Cadena ligeraDIVMTQTPLS LSVTPGQPAS ISCKSSQSLL HTDGTTYLYW YLQKPGQPPQ 50LLIYEVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGI YYCMQNIQLP 100WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200VTHQGLSSPV TKSFNRGEC 219

Post-translational modificationsDisulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 151-207 264-324 370-428

22''-96'' 151''-207'' 264''-324'' 370''-428''Intra-L (C23-C104) 23'-93' 139'-199'

23'''-93''' 139'''-199'''Inter-H-L (CH1 10-CL 126) 138-219' 138''-219'''Inter-H-H (h 4, h 5, h 8, h 11) 226-226'' 227-227'' 230-230'' 233-233''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:300, 300''Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennairescomplexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

orilanolimabum # orilanolimab immunoglobulin G4-kappa, anti-[Homo sapiens FCGRT (Fc

fragment of IgG receptor and transporter, neonatal Fc receptor, FcRn, transmembrane alpha chain of the neonatal receptor)], monoclonal antibody; gamma4 heavy chain (1-444) [VH (Mus musculus IGHV1-81*01 (92.9%)/Homo sapiens IGHV1-18*01 (77.6%) -(IGHD) -Homo sapiens IGHJ3*02 (83.3%)) [8.8.11] (1-118) -Homo sapiens IGHG4*01 (CH1 (119-216), hinge S10>P (226) (217-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444)) (119-444)], (132-214')-disulfide with kappa light chain (1'-214') [V-KAPPA (Mus musculus IGKV13-85*01 (88.4%)/Homo sapiens IGKV1-NL1*01 (83.2%) -Homo sapiens IGKJ4*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191)(108'-214')]; dimer (224-224'':227-227'')-bisdisulfide immunomodulator

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

342

orilanolimab immunoglobuline G4-kappa, anti-[Homo sapiens FCGRT (transporteur et récepteur du fragment Fc des IgG, récepteur Fc néonatal, FcRn, chaîne alpha transmembranaire du récepteur néonatal)], anticorps monoclonal; chaîne lourde gamma4 (1-444) [VH (Mus musculus IGHV1-81*01 (92.9%)/Homo sapiens IGHV1-18*01 (77.6%) -(IGHD) -Homo sapiens IGHJ3*02 (83.3%)) [8.8.11] (1-118) -Homo sapiens IGHG4*01 (CH1 (119-216), charnière S10>P (226) (217-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444)) (119-444)], (132-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA (Mus musculus IGKV13-85*01 (88.4%)/Homo sapiens IGKV1-NL1*01 (83.2%) -Homo sapiens IGKJ4*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191)(108'-214')]; dimère (224-224'':227-227'')-bisdisulfure immunomodulateur

orilanolimab inmunoglobulina G4-kappa, anti-[Homo sapiens FCGRT (transportador y receptor del fragmento Fc de las IgG, receptor Fc neonatal, FcRn, cadena alfa transmembranaria del receptor neonatal)], anticuerpo monoclonal; cadena pesada gamma4 (1-444) [VH (Mus musculus IGHV1-81*01 (92.9%)/Homo sapiens IGHV1-18*01 (77.6%) -(IGHD) -Homo sapiens IGHJ3*02 (83.3%)) [8.8.11] (1-118) -Homo sapiens IGHG4*01 (CH1 (119-216), bisagra S10>P (226) (217-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444)) (119-444)], (132-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA (Mus musculus IGKV13-85*01 (88.4%)/Homo sapiens IGKV1-NL1*01 (83.2%) -Homo sapiens IGKJ4*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191)(108'-214')]; dímero (224-224'':227-227'')-bisdisulfuro inmunomodulador

2066544-85-0

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

343

osocimabum # osocimab immunoglobulin G1-kappa, anti-[Homo sapiens F11

(coagulation factor XI, FXI, plasma thromboplastin antecedent, PTA) activated], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV3-23*01 (90.8%) -(IGHD) -IGHJ6*01 (100%)) [8.8.13] (1-120) -Homo sapiens IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), hinge (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS K2>del (449)) (120-449)], (223-214')-disulfide with kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV1-33*01 (96.8%) -IGKJ4*01 (91.7%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide anticoagulant

osocimab immunoglobuline G1-kappa, anti-[Homo sapiens F11 (facteur de coagulation XI, FXI, antécédent de la thromboplastine plasmatique, PTA) activé], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-449) [Homo sapiens VH (IGHV3-23*01 (90.8%) -(IGHD) -IGHJ6*01 (100%)) [8.8.13] (1-120) -Homo sapiens IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), charnière (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS K2>del (449)) (120-449)], (223-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-33*01 (96.8%) -IGKJ4*01 (91.7%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (229-229'':232-232'')-bisdisulfure anticoagulant

osocimab inmunoglobulina G1-kappa, anti-[Homo sapiens F11

(factor de coagulación XI, FXI, antecedente de la tromboplastina plasmática, PTA) activada], Homo sapiens anticuerpo monoclonal; cadena pesada gamma1 (1-449) [Homo sapiens VH (IGHV3-23*01 (90.8%) -(IGHD) -IGHJ6*01 (100%)) [8.8.13] (1-120) -Homo sapiens IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), bisagra (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS K2>del (449)) (120-449)], (223-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-33*01 (96.8%) -IGKJ4*01 (91.7%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (229-229'':232-232'')-bisdisulfuro anticoagulante

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

344

2056878-75-0 Heavy chain / Chaîne lourde / Cadena pesada

EVQLLESGGG LVQPGGSLRL SCAASGFTFS QYGMDWVRQA PGKGLEWVSG 50IGPSGGSTVY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCTRGG 100PYYYYGMDVW GQGTTVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG 449

Light chain / Chaîne légère / Cadena ligeraDIQMTQSPSS LSASVGDRVT ITCQASQDIS NYLNWYQQKP GKAPKLLIYD 50ASNLETGVPS RFSGSGSGTD FTFTISSLQP EDIATYYCQQ ADSFPVTFGG 100GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214

Post-translational modificationsDisulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 147-203 264-324 370-428

22''-96'' 147''-203'' 264''-324'' 370''-428''Intra-L (C23-C104) 23'-88' 134'-194'

23'''-88''' 134'''-194'''Inter-H-L (h5-CL 126) 223-214' 223''-214'''Inter-H-H (h 11, h 14) 229-229'' 232-232''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:300, 300''Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennairescomplexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

otilimabum # otilimab immunoglobulin G1-lambda, anti-[Homo sapiens CSF2

(colony stimulating factor 2 (granulocyte-macrophage), granulocyte-macrophage colony stimulating factor, GM-CSF)], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-447) [Homo sapiens VH (IGHV3-NL1*01 (88.1%) -(IGHD) -IGHJ1*01 (100%)) [8.10.8] (1-117) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (214) (118-215), hinge (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS (446-447)) (118-447)], (220-209')-disulfide with lambda light chain (1'-210') -[Homo sapiens V-LAMBDA (IGLV3-1*01 (85.2%) -IGLJ3*02 (100%)) [6.1.9] (1'-104') -Homo sapiens IGLC2*01 (105'-210')]; dimer (226-226'':229-229'')-bisdisulfide immunomodulator

otilimab immunoglobuline G1-lambda, anti-[Homo sapiens CSF2 (facteur 2 stimulant de colonies (granulocyte-macrophage), facteur stimulant des colonies de granulocytes et macrophages, GM-CSF)], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-447) [Homo sapiens VH (IGHV3-NL1*01 (88.1%) -(IGHD) -IGHJ1*01 (100%)) [8.10.8] (1-117) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (214) (118-215), charnière (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS (446-447)) (118-447)], (220-209')-disulfure avec la chaîne légère lambda (1'-210') -[Homo sapiens V-LAMBDA (IGLV3-1*01 (85.2%) -IGLJ3*02 (100%)) [6.1.9] (1'-104') -Homo sapiens IGLC2*01 (105'-210')]; dimère (226-226'':229-229'')-bisdisulfure immunomodulateur

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

345

otilimab inmunoglobulina G1-lambda, anti-[Homo sapiens CSF2 (factor 2 estimulante de colonias (granulocito-macrófago), factor estimulante de las colonias de granulocitos y macrófagos, GM-CSF)], Homo sapiens anticuerpo monoclonal; cadena pesada gamma1 (1-447) [Homo sapiens VH (IGHV3-NL1*01 (88.1%) -(IGHD) -IGHJ1*01 (100%)) [8.10.8] (1-117) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (214) (118-215), bisagra (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS (446-447)) (118-447)], (220-209')-disulfuro con la cadena ligera lambda (1'-210') -[Homo sapiens V-LAMBDA (IGLV3-1*01 (85.2%) -IGLJ3*02 (100%)) [6.1.9] (1'-104') -Homo sapiens IGLC2*01 (105'-210')]; dímero (226-226'':229-229'')-bisdisulfuro inmunomodulador

1638332-55-4 Heavy chain / Chaîne lourde / Cadena pesada

QVQLVESGGG LVQPGGSLRL SCAASGFTFS SYWMNWVRQA PGKGLEWVSG 50IENKYAGGAT YYAASVKGRF TISRDNSKNT LYLQMNSLRA EDTAVYYCAR 100GFGTDFWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK 447

Light chain / Chaîne légère / Cadena ligeraDIELTQPPSV SVAPGQTARI SCSGDSIGKK YAYWYQQKPG QAPVLVIYKK 50RPSGIPERFS GSNSGNTATL TISGTQAEDE ADYYCSAWGD KGMVFGGGTK 100LTVLGQPKAA PSVTLFPPSS EELQANKATL VCLISDFYPG AVTVAWKADS 150SPVKAGVETT TPSKQSNNKY AASSYLSLTP EQWKSHRSYS CQVTHEGSTV 200EKTVAPTECS 210

Post-translational modificationsDisulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-98 144-200 261-321 367-425

22''-98'' 144''-200'' 261''-321'' 367''-425''Intra-L (C23-C104) 22'-85' 132'-191'

22'''-85''' 132'''-191'''Inter-H-L (h5-CL 126) 220-209' 220''-209'''Inter-H-H (h 11, h 14) 226-226'' 229-229''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:297, 297''Fucosylated complex bi-antennary PER.C6-type glycans / glycanes de type PER.C6 bi-antennairescomplexes fucosylés / glicanos de tipo PER.C6 biantenarios complejos fucosilados

prademagenum zamikeracelum # prademagene zamikeracel human culture expanded genetically modified autologous

keratinocytes for cell-based gene therapy. Cells are isolated from skin of the patient, expanded and transduced with replication incompetent and non-self-inactivating Moloney murine leukemia virus (MMLV) derived retroviral vector encoding the functional collagen type VII alpha 1 chain (COL7A1) under the control of the mouse phosphoglycerol kinase-1 (mPGK-1) promoter. genetically modified cell (functionnal collagene synthesis promotion)

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

346

pradémagène zamikéracel kératinocytes humains, autologues, en culture d'expansion et

génétiquement modifiés pour thérapie génique avec cellules. Les cellules sont isolées à partir de la peau du patient et sont expansées et transduites avec un vecteur rétroviral non-répliquant et auto-inactivant dérivé du virus de la leucémie murine de Moloney (MMLV) codant pour la chaîne fonctionnelle alpha 1 du collagène de type VII (COL7A1) sous le contrôle du promoteur de la phosphoglycérol kinase-1 murine (mPGK-1). cellule génétiquement modifiée (promotion de la synthèse de collagène fonctionnel)

prademagén zamikeracel Queratinocitos autólogos, modificados genéticamente, humanos, expandidos en cultivo para terapia génica con células. Las células se aíslan de la piel del paciente, se expanden y transducen con un vector retroviral incompetente para replicación y no autoinactivante derivado del virus de la leucemia murina de Moloney (MMLV), que codifica para la cadena funcional alfa 1 del colágeno tipo VII (COL7A1) bajo el control del promotor de la fosfoglicerol cinasa-1 de ratón (mPGK-1). célula modificada genéticamente (promoción de la sintesis del colágeno funcional)

prolgolimabum # prolgolimab immunoglobulin G1_V-lambda-C-kappa, anti-[Homo sapiens

PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], monoclonal antibody; gamma1 heavy chain (1-459) [VH (Vicugna pacos IGHV3S1*01 (89.8%)/Homo sapiens IGHV3-23*04 or IGHV3-64*04 (85.7%) -(IGHD) -Homo sapiens IGHJ1*01 (100%)) [8.8.22] (1-129) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (226) (130-227), hinge (228-242), CH2 L1.3>A (246), L1.2>A (247) (243-352), CH3 E12 (368), M14 (370) (353-457), CHS (458-459)) (130-459)], (232-214')-disulfide with V-lambda-C-kappa light chain (1'-214') [V-LAMBDA (IGLV3-9*01 (100%) -IGLJ1*01 (90.9%)) [6.3.9] (1'-106') -1-mer glutaminyl linker (107') -Homo sapiens IGKC1*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (238-238'':241-241'')-bisdisulfide immunomodulator, antineoplastic

prolgolimab immunoglobuline G1_V-lambda-C-kappa, anti-[Homo sapiens PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal; chaîne lourde gamma1 (1-459) [VH (Vicugna pacos IGHV3S1*01 (89.8%)/Homo sapiens IGHV3-23*04 or IGHV3-64*04 (85.7%) -(IGHD) -Homo sapiens IGHJ1*01 (100%)) [8.8.22] (1-129) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (226) (130-227), charnière (228-242), CH2 L1.3>A (246), L1.2>A (247) (243-352), CH3 E12 (368), M14 (370) (353-457), CHS (458-459)) (130-459)], (232-214')-disulfure avec la chaîne légère V-lambda-C-kappa (1'-214') [V-LAMBDA (IGLV3-9*01 (100%) -IGLJ1*01 (90.9%)) [6.3.9] (1'-106') -1-mer glutaminyl linker (107') -Homo sapiens IGKC1*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (238-238'':241-241'')-bisdisulfure immunomodulateur, antinéoplasique

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

347

prolgolimab inmunoglobulina G1_V-lambda-C-kappa, anti-[Homo sapiens

PDCD1 (proteína 1 de muerrte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal; cadena pesada gamma1 (1-459) [VH (Vicugna pacos IGHV3S1*01 (89.8%)/Homo sapiens IGHV3-23*04 or IGHV3-64*04 (85.7%) -(IGHD) -Homo sapiens IGHJ1*01 (100%)) [8.8.22] (1-129) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (226) (130-227), bisagra (228-242), CH2 L1.3>A (246), L1.2>A (247) (243-352), CH3 E12 (368), M14 (370) (353-457), CHS (458-459)) (130-459)], (232-214')-disulfuro con la cadena ligera V-lambda-C-kappa (1'-214') [V-LAMBDA (IGLV3-9*01 (100%) -IGLJ1*01 (90.9%)) [6.3.9] (1'-106') -1-mer glutaminil linker (107') -Homo sapiens IGKC1*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (238-238'':241-241'')-bisdisulfuro inmunomodulador, antineoplásico

2093956-19-3

Heavy chain / Chaîne lourde / Cadena pesadaQVQLVQSGGG LVQPGGSLRL SCAASGFTFS SYWMYWVRQV PGKGLEWVSA 50IDTGGGRTYY ADSVKGRFAI SRVNAKNTMY LQMNSLRAED TAVYYCARDE 100GGGTGWGVLK DWPYGLDAWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG 150TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV 200PSSSLGTQTY ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPEAAGGP 250SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK 300TKPREEQYNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK 350AKGQPREPQV YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE 400NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ 450KSLSLSPGK 459

Light chain / Chaîne légère / Cadena ligeraQPVLTQPLSV SVALGQTARI TCGGNNIGSK NVHWYQQKPG QAPVLVIYRD 50SNRPSGIPER FSGSNSGNTA TLTISRAQAG DEADYYCQVW DSSTAVFGTG 100TKLTVLQRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214

Post-translational modificationsDisulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 156-212 273-333 379-437

22''-96'' 156''-212'' 273''-333'' 379''-437''Intra-L (C23-C104) 22'-87' 134'-194'

22'''-87''' 134'''-194'''Inter-H-L (h 5-CL 126) 232-214' 232''-214'''Inter-H-H (h 11, h 14) 238-238'' 241-241''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:309, 309''Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennairescomplexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

redipultidum redipultide L-cysteinyl-L-tryptophyl-L-leucyl-L-cysteinyl-L-arginyl-L-alanyl-

L-leucyl-L-isoleucyl-L-lysyl-L-arginyl-L-isoleucyl-L-glutaminyl- L-alanyl-L-leucyl-L-isoleucyl-L-prolyl-L-lysylglycylglycyl-L-arginyl-L-leucyl-L-leucyl-L-prolyl-Lglutaminyl-L-leucyl-L-valyl-L-cysteinyl- L-arginyl-L-leucyl-L-valyl-L-leucyl-L-arginyl-L-cysteinyl-L-serine, cyclic (1-33:4-27)-bisdisulfide pulmonary surfactant

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

348

rédipultide bisdisulfure cyclique (1-33:4-27) de L-cystéinyl-L-tryptophyl- L-leucyl-L-cystéinyl-L-arginyl-L-alanyl-L-leucyl-L-isoleucyl- L-lysyl-L-arginyl-L-isoleucyl-L-glutaminyl-L-alanyl-L-leucyl- L-isoleucyl-L-prolyl-L-lysylglycylglycyl-L-arginyl-L-leucyl- L-leucyl-L-prolyl-Lglutaminyl-L-leucyl-L-valyl-L-cystéinyl- L-arginyl-L-leucyl-L-valyl-L-leucyl-L-arginyl-L-cystéinyl- L-sérine surfactant pulmonaire

redipultida bisdisulfuro cíclico (1-33:4-27) de L-cisteinil-L-triptofil-L-leucil-L-cisteinil-L-arginil-L-alanil-L-leucil-L-isoleucil-L-lisil-L-arginil- L-isoleucil-L-glutaminil-L-alanil-L-leucil-L-isoleucil-L-prolil- L-lisilglicilglicil-L-arginil-L-leucil-L-leucil-L-prolil-Lglutaminil- L-leucil-L-valil-L-cisteinil-L-arginil-L-leucil-L-valil-L-leucil- L-arginil-L-cisteinil-L-serina surfactante pulmonar

C174H302N54O38S4

2056154-08-4

relatlimabum # relatlimab immunoglobulin G4-kappa, anti-[Homo sapiens LAG3

(lymphocyte activating 3, lymphocyte-activation 3, CD223)], Homo sapiens monoclonal antibody; gamma4 heavy chain (1-447) [Homo sapiens VH (IGHV4-34*01 (92.7%) -(IGHD) -IGHJ5*02 (100%)) [8.7.14] (1-120) -Homo sapiens IGHG4*01 (CH1 (121-218), hinge S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (121-447)], (134-214')-disulfide with kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.9%) -IGKJ2*01 (90.9%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191)(108'-214')]; dimer (226-226'':229-229'')-bisdisulfide immunomodulator, antineoplastic

rélatlimab immunoglobuline G4-kappa, anti-[Homo sapiens LAG3 (activateur 3 des lymhocytes, lymphocyte-activation 3, CD223)], Homo sapiens anticorps monoclonal; chaîne lourde gamma4 (1-447) [Homo sapiens VH (IGHV4-34*01 (92.7%) -(IGHD) -IGHJ5*02 (100%)) [8.7.14] (1-120) -Homo sapiens IGHG4*01 (CH1 (121-218), charnière S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (121-447)], (134-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.9%) -IGKJ2*01 (90.9%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (226-226'':229-229'')-bisdisulfure immunomodulateur, antinéoplasique

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

349

relatlimab inmunoglobulina G4-kappa, anti-[Homo sapiens LAG3 (activador 3 de los linfocitos, linfocito-activación 3, CD223)], Homo sapiens anticuerpo monoclonal; cadena pesada gamma4 (1-447) [Homo sapiens VH (IGHV4-34*01 (92.7%) -(IGHD) -IGHJ5*02 (100%)) [8.7.14] (1-120) -Homo sapiens IGHG4*01 (CH1 (121-218), bisagra S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (121-447)], (134-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.9%) -IGKJ2*01 (90.9%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (226-226'':229-229'')-bisdisulfuro inmunomodulador, antineoplásico

1673516-98-7

Heavy chain / Chaîne lourde / Cadena pesadaQVQLQQWGAG LLKPSETLSL TCAVYGGSFS DYYWNWIRQP PGKGLEWIGE 50INHRGSTNSN PSLKSRVTLS LDTSKNQFSL KLRSVTAADT AVYYCAFGYS 100DYEYNWFDPW GQGTLVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT 200YTCNVDHKPS NTKVDKRVES KYGPPCPPCP APEFLGGPSV FLFPPKPKDT 250LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY 300RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT 350LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLGK 447

Light chain / Chaîne légère / Cadena ligeraEIVLTQSPAT LSLSPGERAT LSCRASQSIS SYLAWYQQKP GQAPRLLIYD 50ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPLTFGQ 100GTNLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-95 147-203 261-321 367-425

22''-95'' 147''-203'' 261''-321'' 367''-425''Intra-L (C23-C104) 23'-88' 134'-194'

23'''-88''' 134'''-194'''Inter-H-L (CH1 10-CL 126) 134-214' 134''-214'''Inter-H-H (h 8, h 11) 226-226'' 229-229''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:297, 297''Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennairescomplexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

reldesemtivum reldesemtiv 1-[2-({[trans-3-fluoro-1-(3-fluoropyridin-2-

yl)cyclobutyl]methyl}amino)pyrimidin-5-yl]-1H-pyrrole-3-carboxamide troponin activator

reldésemtiv 1-[2-({[trans-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]méthyl}amino)pyrimidin-5-yl]-1H-pyrrole-3-carboxamide activateur de la troponine

reldesemtiv 1-[2-({[trans-3-fluoro-1-(3-fluoropiridin-2-il)ciclobutil]metil}amino)pirimidin-5-il]-1H-pirrol-3-carboxamida activador de la troponina

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

350

C19H18F2N6O

1345410-31-2

reproxalapum reproxalap 2-(3-amino-6-chloroquinolin-2-yl)propan-2-ol

immunomodulator

réproxalap 2-(3-amino-6-chloroquinoléin-2-yl)propan-2-ol immunomodulateur

reproxalap 2-(3-amino-6-cloroquinolein-2-il)propan-2-ol inmunomodulador

C12H13ClN2O

916056-79-6

resmetiromum resmetirom 2-(3,5-dichloro-4-{[6-oxo-5-(propan-2-yl)-1,6-

dihydropyridazin-3-yl]oxy}phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile antihyperlipidaemic

resmétirom 2-(3,5-dichloro-4-{[6-oxo-5-(propan-2-yl)-1,6-dihydropyridazin-3-yl]oxy}phényl)-3,5-dioxo-2,3,4,5-tétrahydro-1,2,4-triazine-6-carbonitrile antihyperlipidémiant

resmetirom 2-(3,5-dicloro-4-{[6-oxo-5-(propan-2-il)-1,6-dihidropiridazin-3-il]oxi}fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazina- 6-carbonitrilo antihiperlipémico

C17H12Cl2N6O4

920509-32-6

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

351

ripretinibum ripretinib N-{4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-

1,6-naphthyridin-3-yl]-2-fluorophenyl}-N'-phenylurea tyrosine kinase inhibitor, antineoplastic

riprétinib N-{4-bromo-5-[1-éthyl-7-(méthylamino)-2-oxo-1,2-dihydro-1,6-naphtyridin-3-yl]-2-fluorophényl}-N'-phénylurée inhibiteur de la tyrosine kinase, antinéoplasique

ripretinib N-{4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro- 1,6-naftiridin-3-il]-2-fluorofenil}-N'-fenilurea inhibidor de la tirosina kinasa, antineoplásico

C24H21BrFN5O2

1442472-39-0

rocacetrapibum rocacetrapib (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-

2-methoxy-5-(propan-2-yl)phenyl]-5,5-dimethylcyclohex- 1-en-1-yl}methyl)-4-methyl-1,3-oxazolidin-2-one antihyperlipidaemic

rocacétrapib (4S,5R)-5-[3,5-bis(trifluorométhyl)phényl]-3-({2-[4-fluoro- 2-méthoxy-5-(propan-2-yl)phényl]-5,5-diméthylcyclohex- 1-én-1-yl}méthyl)-4-méthyl-1,3-oxazolidin-2-one antihyperlipidémiant

rocacetrapib (4S,5R)-5-[3,5-bis(trifluorometil)fenil]-3-({2-[4-fluoro- 2-metoxi-5-(propan-2-il)fenil]-5,5-dimetilciclohex-1-en- 1-il}metil)-4-metil-1,3-oxazolidin-2-ona antihiperlipémico

C31H34F7NO3

1402796-27-3

OCH3

F

H3C CH3

H3C

H3C

N

O

HH

F3C

CF3

CH3

O

rodatristatum rodatristat ethyl (3S)-8-{2-amino-6-[(1R)-1-(5-chloro[1,1'-biphenyl]-

2-yl)-2,2,2-trifluoroethoxy]pyrimidin-4-yl}- 2,8-diazaspiro[4.5]decane-3-carboxylate tryptophan hydroxylase inhibitor

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

352

rodatristat (3S)-8-{2-amino-6-[(1R)-1-(5-chloro[1,1'-biphényl]-2-yl)-2,2,2-trifluoroéthoxy]pyrimidin-4-yl}- 2,8-diazaspiro[4.5]décane-3-carboxylate d'éthyle inhibiteur de la tryptophane hydroxylase

rodatristat (3S)-8-{2-amino-6-[(1R)-1-(5-cloro[1,1'-bifenil]-2-il)- 2,2,2-trifluoroetoxi]pirimidin-4-il}-2,8-diazaspiro[4.5]decano-3-carboxilato de etilo inhibidor de la triptófano hidroxilasa

C29H31ClF3N5O3

1673571-51-1

rolinsatamabum # rolinsatamab immunoglobulin G1-kappa, anti-[Homo sapiens PRLR

(prolactin receptor)], monoclonal antibody; gamma1 heavy chain (1-450) [VH (Mus musculus IGHV1-69*02 (82.70%)/Homo sapiens IGHV1-46*01 (79.6%) -(IGHD)-Homo sapiens IGHJ6*01 (90.9%)) [8.8.13] (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), hinge (219-233), CH2 S3>C (242) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain (1'-214') [V-KAPPA (Mus musculus IGKV6-13*01 (82.10%)/Homo sapiens IGKV1-12*01 (81.1%) -Homo sapiens IGKJ4*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229":232-232")-bisdisulfide antineoplastic

rolinsatamab immunoglobuline G1-kappa, anti-[Homo sapiens PRLR (récepteur de la prolactine)], anticorps monoclonal; chaîne lourde gamma1 (1-450) [VH (Mus musculus IGHV1-69*02 (82.70%)/Homo sapiens IGHV1-46*01 (79.6%) -(IGHD)-Homo sapiens IGHJ6*01 (90.9%)) [8.8.13] (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), charnière (219-233), CH2 S3>C (242) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA (Mus musculus IGKV6-13*01 (82.10%)/Homo sapiens IGKV1-12*01 (81.1%) -Homo sapiens IGKJ4*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (229-229":232-232")-bisdisulfure antinéoplasique

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

353

rolinsatamab inmunoglobulina G1-kappa, anti-[Homo sapiens PRLR (receptor de la prolactina)], anticuerpo monoclonal; cadena pesada gamma1 (1-450) [VH (Mus musculus IGHV1-69*02 (82.70%)/Homo sapiens IGHV1-46*01 (79.6%) -(IGHD)-Homo sapiens IGHJ6*01 (90.9%)) [8.8.13] (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), bisagra (219-233), CH2 S3>C (242) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA (Mus musculus IGKV6-13*01 (82.10%)/Homo sapiens IGKV1-12*01 (81.1%) -Homo sapiens IGKJ4*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (229-229":232-232")-bisdisulfuro antineoplásico

2095467-30-2

rolinsatamabum talirinum # rolinsatamab talirine immunoglobulin G1-kappa, anti-[Homo sapiens PRLR

(prolactin receptor)], monoclonal antibody, conjugated to the pyrrolobenzodiazepine (PDB) dimer SGD-1882;

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

354

gamma1 heavy chain (1-450) [VH (Mus musculus IGHV1-69*02 (82.7%)/Homo sapiens IGHV1-46*01 (79.6%) -(IGHD)-Homo sapiens IGHJ6*01 (90.9%)) [8.8.13] (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), hinge (219-233), CH2 S3>C (242) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain (1'-214') [V-KAPPA (Mus musculus IGKV6-13*01 (82.10%)/Homo sapiens IGKV1-12*01 (81.1%) -Homo sapiens IGKJ4*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229":232-232")-bisdisulfide; conjugated, on two site-specific drug attachment engineered cysteines (C242, C242''), to a maximum of two pyrrolobenzodiazepine (PDB) dimers SGD-1882, each via a cleavable (valine-alanine dipeptide as cathepsine B cleavage site) maleimidocaproyl type linker antineoplastic

rolinsatamab talirine immunoglobuline G1-kappa, anti-[Homo sapiens PRLR (récepteur de la prolactine)], anticorps monoclonal, conjugué à deux pyrrolobenzodiazépine (PDB) dimères SGD-1882; chaîne lourde gamma1 (1-450) [VH (Mus musculus IGHV1-69*02 (82.7%)/Homo sapiens IGHV1-46*01 (79.6%) -(IGHD)-Homo sapiens IGHJ6*01 (90.9%)) [8.8.13] (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), charnière (219-233), CH2 S3>C (242) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA (Mus musculus IGKV6-13*01 (82.10%)/Homo sapiens IGKV1-12*01 (81.1%) -Homo sapiens IGKJ4*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (229-229":232-232")-bisdisulfure; conjugué, sur deux cystéines sites de fixation spécifique du linker-produit actif (C242, C242''), à un maximum de deux pyrrolobenzodiazépine (PDB) dimères SGD-1882, chacun via un linker clivable (dipeptide valine-alanine clivable par la cathepsine B) de type maléimidocaproyl antinéoplasique

rolinsatamab talirina inmunoglobulina G1-kappa, anti-[Homo sapiens PRLR (receptor de la prolactina)], anticuerpo monoclonal, conjugado con diez pirrolobenzodiazepinas (PDB) dímeros SGD-1882; cadena pesada gamma1 (1-450) [VH (Mus musculus IGHV1-69*02 (82.7%)/Homo sapiens IGHV1-46*01 (79.6%) -(IGHD)-Homo sapiens IGHJ6*01 (90.9%)) [8.8.13] (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), bisagra (219-233), CH2 S3>C (242) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA (Mus musculus IGKV6-13*01 (82.10%)/Homo sapiens IGKV1-12*01 (81.1%) -Homo sapiens IGKJ4*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (229-229":232-232")-bisdisulfuro;

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

355

conjugado, en diez cisteinas sitios de fijación específicos del linker-producto activo (C242, C242''), con un máximo de diez dímeros de pirrolobenzodiazepina (PDB) SGD-1882, cada uno mediante un espaciador escindible (dipéptido valina-alanina escindible por la catepsina B) del tipo maleimidocaproil antineoplásico

2095467-44-8

O

O

N

NH

O

OCH3

H3CO

N

NH

O

OCH3

NH

AlaVal

O

H2N CO2H

H S H

N

O

O

and epimer at C*et l'épimère en C*y el epímero al C*

H CH2 S3>C:242, 242''

Heavy chain / Chaîne lourde / Cadena pesadaEVQLVQSGAE VKKPGSSVKV SCKASGYTFT TYWMHWVRQA PGQGLEWIGE 50IDPSDSYSNY NQKFKDRATL TVDKSTSTAY MELSSLRSED TAVYYCARNG 100GLGPAWFSYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PCVFLFPPKP 250KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450

Light chain / Chaîne légère / Cadena ligeraDIQMTQSPSS VSASVGDRVT ITCKASQYVG TAVAWYQQKP GKSPKLLIYS 50ASNRYTGVPS RFSDSGSGTD FTLTISSLQP EDFATYFCQQ YSSYPWTFGG 100GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214

Post-translational modificationsDisulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 147-203 264-324 370-428

22''-96'' 147''-203'' 264''-324'' 370''-428''Intra-L (C23-C104) 23'-88' 134'-194'

23'''-88''' 134'''-194'''Inter-H-L (h 5-CL 126) 223-214' 223''-214'''Inter-H-H (h 11, h 14) 229-229'' 232-232''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:300, 300''Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennairescomplexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

Modified residues / résidus modifiés / restos modificados

roluperidonum roluperidone 2-({1-[2-(4-fluorophenyl)-2-oxoethyl]piperidin-4-yl}methyl)-

2,3-dihydro-1H-isoindol-1-one antipsychotic

rolupéridone 2-({1-[2-(4-fluorophényl)-2-oxoéthyl]pipéridin-4-yl}méthyl)-2,3-dihydro-1H-isoindol-1-one antipsychotique

roluperidona 2-({1-[2-(4-fluorofenil)-2-oxoetil]piperidin-4-il}metil)- 2,3-dihidro-1H-isoindol-1-ona antipsicótico

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

356

C22H23FN2O2 359625-79-9

rovafovirum etalafenamidum rovafovir etalafenamide ethyl (2S)-2-{[(S)-({[(2R,5R)-5-(6-amino-9H-purin-9-yl)-

4-fluoro-2,5-dihydrofuran-2-yl]oxy}methyl)phenoxyphosphonoyl]amino}propanoate antiviral

rovafovir étalafénamide (2S)-2-{[(S)-({[(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy}méthyl)phénoxyphosphonoyl]amino}propanoate d'éthyle antiviral

rovafovir etalafenamida (2S)-2-{[(S)-({[(2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il]oxi}metil)fenoxifosfonoil]amino}propanoato de etilo antiviral

C21H24FN6O6P

912809-27-9

ruxotemitidum ruxotemitide L-lysyl-L-lysyl-L-tryptophyl-L-tryptophyl-L-lysyl-L-lysyl-

L-tryptophyl-β-phenyl-L-phenylalanyl- L-lysinamide antineoplastic

ruxotémitide L-lysyl-L-lysyl-L-tryptophyl-L-tryptophyl-L-lysyl-L-lysyl- L-tryptophyl-β-phényl-L-phénylalanyl- L-lysinamide antinéoplasique

ruxotemitida L-lisil-L-lisil-L-triptopfil-L-triptopfil-L-lisil-L-lisil-L-triptopfil- β-fenil-L-fenilalanil- L-lisinamida antineoplásico

C78H106N18O9

1345407-05-7

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

357

selatogrelum selatogrel [(2R)-3-[4-(butoxycarbonyl)piperazin-1-yl]-2-{6-[(3S)-3-

methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carboxamido}-3-oxopropyl]phosphonic acid platelet aggregation inhibitor

sélatogrel acide [(2R)-3-[4-(butoxycarbonyl)pipérazin-1-yl]-2-{6-[(3S)-3-méthoxypyrrolidin-1-yl]-2-phénylpyrimidine-4-carboxamido}-3-oxopropyl]phosphonique antiagrégant plaquettaire

selatogrel ácido [(2R)-3-[4-(butoxicarbonil)piperazin-1-il]-2-{6-[(3S)-3-metoxipirrolidin-1-il]-2-fenilpirimidina-4-carboxamida}-3-oxopropil]fosfónico inhibidor de la agregación plaquetaria

C28H39N6O8P

1159500-34-1

setogepramum setogepram (3-pentylphenyl)acetic acid

anti-inflammatory, antifibrotic

sétogépram acide (3-pentylphényl)acétique anti-inflammatoire, antifibrotique

setogepram ácido (3-pentilfenil)acético antiinflamatorio, antifibrótico

C13H18O2

1002101-19-0

sintilimabum # sintilimab immunoglobulin G4-kappa, anti-[Homo sapiens PDCD1

(programmed cell death 1, PD-1, PD1, CD279)], Homo sapiens monoclonal antibody;

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

358

gamma4 heavy chain (1-447) [Homo sapiens VH (IGHV1-69*01 (93.9%) -(IGHD) -IGHJ4*01 (100%)) [8.8.13] (1-120) -Homo sapiens IGHG4*01 (CH1 (121-218), hinge S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (121-447)], (134-214')-disulfide with kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (96.8%) -IGKJ4*01 (91.7%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (226-226'':229-229'')-bisdisulfide immunomodulator

sintilimab immunoglobuline G4-kappa, anti-[Homo sapiens PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], Homo sapiens anticorps monoclonal; chaîne lourde gamma4 (1-447) [Homo sapiens VH (IGHV1-69*01 (93.9%) -(IGHD) -IGHJ4*01 (100%)) [8.8.13] (1-120) -Homo sapiens IGHG4*01 (CH1 (121-218), charnière S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (121-447)], (134-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (96.8%) -IGKJ4*01 (91.7%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (226-226'':229-229'')-bisdisulfure immunomodulateur

sintilimab inmunoglobulina G4-kappa, anti-[Homo sapiens PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], Homo sapiens anticuerpo monoclonal; cadena pesada gamma4 (1-447) [Homo sapiens VH (IGHV1-69*01 (93.9%) -(IGHD) -IGHJ4*01 (100%)) [8.8.13] (1-120) -Homo sapiens IGHG4*01 (CH1 (121-218), bisagra S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (121-447)], (134-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (96.8%) -IGKJ4*01 (91.7%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (226-226'':229-229'')-bisdisulfuro inmunomodulador

2072873-06-2 Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAISWVRQA PGQGLEWMGL 50IIPMFDTAGY AQKFQGRVAI TVDESTSTAY MELSSLRSED TAVYYCARAE 100HSSTGTFDYW GQGTLVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT 200YTCNVDHKPS NTKVDKRVES KYGPPCPPCP APEFLGGPSV FLFPPKPKDT 250LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY 300RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT 350LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLGK 447

Light chain / Chaîne légère / Cadena ligeraDIQMTQSPSS VSASVGDRVT ITCRASQGIS SWLAWYQQKP GKAPKLLISA 50ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ ANHLPFTFGG 100GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214

Post-translational modificationsDisulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 147-203 261-321 367-425

22''-96'' 147''-203'' 261''-321'' 367''-425''Intra-L (C23-C104) 23'-88' 134'-194'

23'''-88''' 134'''-194'''Inter-H-L (CH1 10-CL 126) 134-214' 134''-214'''Inter-H-H (h 8, h 11) 226-226'' 229-229''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4: 297, 297''Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennairescomplexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosiladosN-terminal glutamine cyclization to pyroglutamate (pE, 5-oxoproline)H VH Q1:1, 1''C-terminal lysine clippingH CHS K2: 447, 447''

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

359

siremadlinum siremadlin (6S)-5-(5-chloro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-6-

(4-chlorophenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-1-(propan-2-yl)-5,6-dihydropyrrolo[3,4-d]imidazol-4(1H)-one antineoplastic

sirémadline (6S)-5-(5-chloro-1-méthyl-2-oxo-1,2-dihydropyridin-3-yl)-6-(4-chlorophényl)-2-(2,4-diméthoxypyrimidin-5-yl)-1-(propan-2-yl)-5,6-dihydropyrrolo[3,4-d]imidazol-4(1H)-one antinéoplasique

siremadlina (6S)-5-(5-cloro-1-metil-2-oxo-1,2-dihidropiridin-3-il)-6-(4-clorofenil)-2-(2,4-dimetoxipirimidin-5-il)-1-(propan-2-il)-5,6-dihidropirrolo[3,4-d]imidazol-4(1H)-ona antineoplásico

C26H24Cl2N6O4

1448867-41-1

soticlestatum soticlestat (4-benzyl-4-hydroxypiperidin-1-yl)([2,4'-bipyridin]-3-

yl)methanone hydroxylase inhibitor

soticlestat (4-benzyl-4-hydroxypipéridin-1-yl)([2,4'-bipyridin]-3-yl)méthanone inhibiteur de l'hydroxylase

soticlestat (4-bencil-4-hidroxipiperidin-1-il)([2,4'-bipiridin]-3-il)metanona inhibidor de la hidroxilasa

C23H23N3O2 1429505-03-2

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

360

spesolimabum # spesolimab immunoglobulin G1-kappa, anti-[Homo sapiens IL1RL2

(interleukin 1 receptor like 2, interleukin 36 receptor, IL1R-rp2, IL1RRP2)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-449) [ VH (Homo sapiens IGHV1-2*02 (81.20%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.12] (1-119) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (216) (120-217), hinge (218-232), CH2 L1.3>A (236), L1.2>A (237) (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120-449)], (222-215')-disulfide with kappa light chain humanized (1'-215') [V-KAPPA (Homo sapiens IGKV3-20*01 (79.2%)-Homo sapiens IGKJ2*01 (90.9%)) [7.3.9] (1'-108') -Homo sapiens IGKC*01, Km3 A45.1 (154), V101 (192)(109'-215')]; dimer (228-228'':231-231'')-bisdisulfide immunomodulator

spésolimab immunoglobuline G1-kappa, anti-[Homo sapiens IL1RL2

(récepteur like 2 de l'interleukine 1, récepteur de l'interleukine 36, IL1R-rp2, IL1RRP2), anticorps monoclonal humanisé ; chaîne lourde gamma1 humanisée (1-449) [VH (Homo sapiens IGHV1-2*02 (81.20%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.12] (1-119) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (216) (120-217), charnière (218-232), CH2 L1.3>A (236), L1.2>A (237) (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120-449)], (222-215')-disulfure avec la chaîne légère kappa humanisée (1'-215') [V-KAPPA (Homo sapiens IGKV3-20*01 (79.2%)-Homo sapiens IGKJ2*01 (90.9%)) [7.3.9] (1'-108') -Homo sapiens IGKC*01, Km3 A45.1 (154), V101 (192)(109'-215')]; dimère (228-228'':231-231'')-bisdisulfure immunomodulateur

espesolimab inmunoglobulina G1-kappa, anti-[Homo sapiens IL1RL2

(receptor like 2 de la interleukina 1, receptor de la interleukina 36, IL1R-rp2, IL1RRP2), anticuerpo monoclonal humanizado; cadena pesada gamma1 humanizada (1-449) [VH (Homo sapiens IGHV1-2*02 (81.20%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.12] (1-119) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (216) (120-217), bisagra (218-232), CH2 L1.3>A (236), L1.2>A (237) (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120-449)], (222-215')-disulfuro con la cadena ligera kappa humanizada (1'-215') [V-KAPPA (Homo sapiens IGKV3-20*01 (79.2%)-Homo sapiens IGKJ2*01 (90.9%)) [7.3.9] (1'-108') -Homo sapiens IGKC*01, Km3 A45.1 (154), V101 (192)(109'-215')]; dímero (228-228'':231-231'')-bisdisulfuro inmunomodulador

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

361

2097104-58-8

tabituximabum # tabituximab immunoglobulin G1-kappa, anti-[Homo sapiens FZD10

(frizzled class receptor 10, frizzled family receptor 10, Frizzled-10, CD350)], chimeric monoclonal antibody; gamma1 heavy chain chimeric (1-448) [Mus musculus VH (IGHV14-3*02 (99.0%) -(IGHD) -IGHJ3*01 (100%)) [8.8.11] (1-118) -Homo sapiens IGHG1*01, G1m17,1 (CH1 K120 (215) (119-216), hinge (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-214')-disulfide with kappa light chain chimeric (1'-214') [Mus musculus V-KAPPA (IGKV12-46*01 (98.9%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (227-227'':230-230'')-bisdisulfide immunomodulator, antineoplastic

tabituximab immunoglobuline G1-kappa, anti-[Homo sapiens FZD10 (récepteur 10 de la classe frizzled, récepteur 10 de la famille frizzled, Frizzled-10, CD350)], anticorps monoclonal chimérique; chaîne lourde gamma1 chimérique (1-448) [Mus musculus VH (IGHV14-3*02 (99.0%) -(IGHD) -IGHJ3*01 (100%)) [8.8.11] (1-118) -Homo sapiens IGHG1*01, G1m17,1 (CH1 K120 (215) (119-216), charnière (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-214')-disulfure avec la chaîne légère kappa chimérique (1'-214') [Mus musculus V-KAPPA (IGKV12-46*01 (98.9%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (227-227'':230-230'')-bisdisulfure immunomodulateur, antinéoplasique

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

362

tabituximab inmunoglobulina G1-kappa, anti-[Homo sapiens FZD10 (receptor 10 de la clase frizzled, receptor 10 de la familia frizzled, Frizzled-10, CD350)], anticuerpo monoclonal quimérico; cadena pesada gamma1 quimérica (1-448) [Mus musculus VH (IGHV14-3*02 (99.0%) -(IGHD) -IGHJ3*01 (100%)) [8.8.11] (1-118) -Homo sapiens IGHG1*01, G1m17,1 (CH1 K120 (215) (119-216), bisagra (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-214')-disulfuro con la cadena ligera kappa quimérica (1'-214') [Mus musculus V-KAPPA (IGKV12-46*01 (98.9%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (227-227'':230-230'')-bisdisulfuro inmunomodulador, antineoplásico

1644134-10-0 Heavy chain / chaîne lourde / cadena pesada

EVQLQQSGAE LVKPGASVKL SCTASGFNIN DTYMHWVKQR PEQGLEWIGR 50 IDPANGNTKY DPKFQGKATI TADTSSNTAY LQLSSLTSED TAVYYCARGA 100 RGSRFAYWGQ GTLVTVSAAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150 FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200 CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250 TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300 YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350 TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400 SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK 448

Light chain / chaîne légère / cadena ligeraDIQMTQSPAS LSVSVGETVT ITCRASENIY SNLAWYQQKQ GKSPQLLVYV 50 ATNLADGVPS RFSGSGSGTQ YSLKINSLQS EDFGSYYCQH FWGTPYTFGG 100 GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEC 214

Post-translational modificationsDisulfide bridges location / positions des ponts disulfure / posiciones de les puentos disulfuroIntra-H (C23-C104) 22-96 145-201 262-322 368-426

22''-96'' 145''-201'' 262''-322'' 368''-426''Intra-L (C23-C104) 23'-88' 134'-194'

23'''-88''' 134'''-194'''Inter-H-L (h 5-CL 126) 221-214' 221''-214'''Inter-H-H (h 11, h 14) 227-227'' 230-230''N-glycosylation sites / sites de N-glycosylation / posiciones de N-gicosilaciónH VH N35:30, 30''H CH2 N84.4:298, 298''Fucosylated complex bi-antennary CHO-type glycans/ glycanes de type CHO bi-antennairescomplexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

tabituximabum barzuxetanum # tabituximab barzuxetan immunoglobulin G1-kappa, anti-[Homo sapiens FZD10 (frizzled

class receptor 10, frizzled family receptor 10, Frizzled-10, CD350)], chimeric monoclonal antibody conjugated to barzuxetan, a DPTA chelator derivative; gamma1 heavy chain chimeric (1-448) [Mus musculus VH (IGHV14-3*02 (99.0%) -(IGHD) -IGHJ3*01 (100%)) [8.8.11] (1-118) -Homo sapiens IGHG1*01, G1m17,1 (CH1 K120 (215) (119-216), hinge (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-214')-disulfide with kappa light chain chimeric (1'-214') [Mus musculus V-KAPPA (IGKV12-46*01 (98.9%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (227-227'':230-230'')-bisdisulfide; conjugated, on an average of 2 to 4 lysyl, to barzuxetan, p-SCN-Bn-CHX-A”-DPTA, a DPTA chelator derivative For the barzuxetan part, please refer to the annex « Names for radicals and groups ». immunomodulator, antineoplastic

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

363

tabituximab barzuxétan immunoglobuline G1-kappa, anti-[Homo sapiens FZD10 (récepteur 10 de la

classe frizzled, récepteur 10 de la famille frizzled, Frizzled-10, CD350)], anticorps monoclonal chimérique conjugué au barzuxétan, un dérivé du chélateur DPTA ; chaîne lourde gamma1 chimérique (1-448) [Mus musculus VH (IGHV14-3*02 (99.0%) -(IGHD) -IGHJ3*01 (100%)) [8.8.11] (1-118) -Homo sapiens IGHG1*01, G1m17,1 (CH1 K120 (215) (119-216), charnière (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-214')-disulfure avec la chaîne légère kappa chimérique (1'-214') [Mus musculus V-KAPPA (IGKV12-46*01 (98.9%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (227-227'':230-230'')-bisdisulfure; conjugué, sur une moyenne de 2 à 4 lysyl, au barzuxétan, p-SCN-Bn-CHX-A”-DPTA, un dérivé du chélateur DPTA Pour la partie barzuxétan, veuillez-vous référer à l’annexe « Noms pour radicaux et groupes». immunomodulateur, antinéoplasique

tabituximab barzuxetán inmunoglobulina G1-kappa, anti-[Homo sapiens FZD10 (receptor 10 de la clase frizzled, receptor 10 de la familia frizzled, Frizzled-10, CD350)], anticuerpo monoclonal quimérico conjugado al barzuxetán, un derivado del DPTA; cadena pesada gamma1 quimérica (1-448) [Mus musculus VH (IGHV14-3*02 (99.0%) -(IGHD) -IGHJ3*01 (100%)) [8.8.11] (1-118) -Homo sapiens IGHG1*01, G1m17,1 (CH1 K120 (215) (119-216), bisagra (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-214')-disulfuro con la cadena ligera kappa quimérica (1'-214') [Mus musculus V-KAPPA (IGKV12-46*01 (98.9%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (227-227'':230-230'')-bisdisulfuro; conjugado, en 2 - 4 restos lisil, por término medio, al barzuxetán, p-SCN-Bn-CHX-A"-DPTA, un derivado de un agente quelante DPTA Por la parte barzuxetán, por favor vaya al anexo « Denominaciones para Radicales y Grupos ». inmunomodulador, antineoplásico

1612758-88-9 Heavy chain / chaîne lourde / cadena pesada

EVQLQQSGAE LVKPGASVKL SCTASGFNIN DTYMHWVKQR PEQGLEWIGR 50 IDPANGNTKY DPKFQGKATI TADTSSNTAY LQLSSLTSED TAVYYCARGA 100 RGSRFAYWGQ GTLVTVSAAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150 FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200 CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250 TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300 YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350 TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400 SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK 448

Light chain / chaîne légère / cadena ligeraDIQMTQSPAS LSVSVGETVT ITCRASENIY SNLAWYQQKQ GKSPQLLVYV 50 ATNLADGVPS RFSGSGSGTQ YSLKINSLQS EDFGSYYCQH FWGTPYTFGG 100 GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEC 214

Post-translational modificationsDisulfide bridges location / positions des ponts disulfure / posiciones de les puentos disulfuroIntra-H (C23-C104) 22-96 145-201 262-322 368-426

22''-96'' 145''-201'' 262''-322'' 368''-426''Intra-L (C23-C104) 23'-88' 134'-194'

23'''-88''' 134'''-194'''Inter-H-L (h 5-CL 126) 221-214' 221''-214'''Inter-H-H (h 11, h 14) 227-227'' 230-230''conjugated, on an average of 2 to 4 lysyl, to barzuxetan / conjugué, sur une moyenne de 2 à 4lysyl, au barzuxétan / conjugado en 2 - 4 restos lisil, por término medio, al barzuxetánN-glycosylation sites / sites de N-glycosylation / posiciones de N-gicosilaciónH VH N35:30, 30''H CH2 N84.4:298, 298''Fucosylated complex bi-antennary CHO-type glycans/ glycanes de type CHO bi-antennairescomplexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

364

tafasitamabum # tafasitamab immunoglobulin G1-G2-kappa, anti-[Homo sapiens CD19

(B lymphocyte surface antigen B4, Leu-12)], monoclonal antibody; gamma1-gamma2 heavy chain (1-451) [VH (Mus musculus IGHV1-14*01 (77.6%)/Homo sapiens IGHV1-3*01 (73.5%) -(IGHD) -Homo sapiens IGHJ4*01 (100%)) [8.8.14] (1-121) -Homo sapiens IGHG1*01 (CH1 G1m17, K120 (218) (122-219) -hinge (220-234) -CH2 1.6-1.1 (235-240)) (122-240) -Homo sapiens IGHG2*01 (CH2 1-125, S3>D (243), G2m.. V45.1 (286), G110>A (331), I117>E (336) (241-344) -CH3 nG1m1 E12 (360) M14 (362) (345-449) -CHS (450-451)) (241-451)], (224-219')-disulfide with kappa light chain (1'-219') [V-KAPPA (Mus musculus IGKV2-137*01 (75.0%)/Homo sapiens IGHV3D-11*03 (73.7%) -Homo sapiens IGKJ2*01 (90.9%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (230-230":233-233")-bisdisulfide immunomodulator, antineoplastic

tafasitamab immunoglobuline G1-G2-kappa, anti-[Homo sapiens CD19 (antigène de surface B4 des lymphocytes B, Leu-12)], anticorps monoclonal; chaîne lourde gamma1-gamma2 (1-451) [VH (Mus musculus IGHV1-14*01 (77.6%)/Homo sapiens IGHV1-3*01 (73.5%) -(IGHD) -Homo sapiens IGHJ4*01 (100%)) [8.8.14] (1-121) -Homo sapiens IGHG1*01 (CH1 G1m17, K120 (218) (122-219) -charnière (220-234) -CH2 1.6-1.1 (235-240)) (122-240) -Homo sapiens IGHG2*01 (CH2 1-125, S3>D (243), G2m.. V45.1 (286), G110>A (331), I117>E (336) (241-344) -CH3 nG1m1 E12 (360) M14 (362) (345-449) -CHS (450-451)) (241-451)], (224-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA (Mus musculus IGKV2-137*01 (75.0%)/Homo sapiens IGHV3D-11*03 (73.7%) -Homo sapiens IGKJ2*01 (90.9%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimère (230-230":233-233")-bisdisulfure immunomodulateur, antinéoplasique

tafasitamab inmunoglobulina G1-G2-kappa, anti-[Homo sapiens CD19 (antígeno de superficie B4 de los linfocitos B, Leu-12)], anticuerpo monoclonal; cadena pesada gamma1-gamma2 (1-451) [VH (Mus musculus IGHV1-14*01 (77.6%)/Homo sapiens IGHV1-3*01 (73.5%) -(IGHD) -Homo sapiens IGHJ4*01 (100%)) [8.8.14] (1-121) -Homo sapiens IGHG1*01 (CH1 G1m17, K120 (218) (122-219) -bisagra(220-234) -CH2 1.6-1.1 (235-240)) (122-240) -Homo sapiens IGHG2*01 (CH2 1-125, S3>D (243), G2m.. V45.1 (286), G110>A (331), I117>E (336) (241-344) -CH3 nG1m1 E12 (360) M14 (362) (345-449) -CHS (450-451)) (241-451)], (224-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA (Mus musculus IGKV2-137*01 (75.0%)/Homo sapiens IGHV3D-11*03 (73.7%) -Homo sapiens IGKJ2*01 (90.9%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dímero (230-230":233-233")-bisdisulfuro inmunomodulador, antineoplásico

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

365

1422527-84-1

Heavy chain / Chaîne lourde / Cadena pesadaEVQLVESGGG LVKPGGSLKL SCAASGYTFT SYVMHWVRQA PGKGLEWIGY 50INPYNDGTKY NEKFQGRVTI SSDKSISTAY MELSSLRSED TAMYYCARGT 100YYYGTRVFDY WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG GPDVFLFPPK 250PKDTLMISRT PEVTCVVVDV SHEDPEVQFN WYVDGVEVHN AKTKPREEQF 300NSTFRVVSVL TVVHQDWLNG KEYKCKVSNK ALPAPEEKTI SKTKGQPREP 350QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400MLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450K 451

Light chain / Chaîne légère / Cadena ligeraDIVMTQSPAT LSLSPGERAT LSCRSSKSLQ NVNGNTYLYW FQQKPGQSPQ 50LLIYRMSNLN SGVPDRFSGS GSGTEFTLTI SSLEPEDFAV YYCMQHLEYP 100ITFGAGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200VTHQGLSSPV TKSFNRGEC 219

Post-translational modificationsDisulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 148-204 265-325 371-429

22''-96'' 148''-204'' 265''-325'' 371''-429''Intra-L (C23-C104) 23'-93' 139'-199'

23'''-93''' 139'''-199'''Inter-H-L (h 5-CL 126) 224-219' 224''-219'''Inter-H-H (h 11, h 14) 230-230'' 233-233''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4: 301, 301''Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennairescomplexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.C-terminal lysine clipping:H CHS K2: 451, 451''

talditerceptum alfa # talditercept alfa human immunoglobulin G1 Fc fragment (1-225) fused via a

peptidyl linker (226-243) to a human fibronectin tenth type III domain variant anti-[human myostatin (MSTN, growth differentiation factor 8, GDF8)](244-340), dimer, produced in Chinese hamster ovary (CHO) cells, glycoform alfa; gamma1 chain H-CH2-CH3 fragment [Homo sapiens IGHG1*01 (CH2 (11-120), CH3 (121-225))] (1-225); dimer (6-6':9-9')-bisdisulfide-linker (226-243)-human fibronectin tenth type III domain fibronectin variant anti-[human myostatin (MSTN, growth differentiation factor 8, GDF8)] (244-340), produced in Chinese hamster ovary (CHO) cells, glycoform alfa myostatin inhibitor

talditercept alfa fragment Fc d'immunoglobuline G1 humaine (1-225) fusionné via un peptide (226-243) au variant du dixième domaine de la fibronectine humaine de type III anti-[myostatine humaine (MSTN, facteur 8 de différentiation de croissance, GDF8)] (244-340), dimère, produit dans des cellules ovariennes de hamsters chinois (CHO), glycoforme alfa; chaîne gamma1 fragment H-CH2-CH3 [Homo sapiens IGHG1*01 (CH2 (11-120), CH3 (121-225))] (1-225); dimère (6-6':9-9')-bisdisulfure-linker (226-243)-variant du dixième domaine de la fibronectine humaine de type III anti-[myostatine humaine (MSTN, facteur 8 de différentiation de croissance, GDF8)] (244-340), produit dans des cellules ovariennes de hamsters chinois (CHO), glycoforme alfa inhibiteur de la myostatine

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

366

talditercept alfa fragmento Fc de inmunoglobulina G1 humana (1-225) fusionada mediante un péptido (226-243) a la variante del décimo dominio de la fibronectina humana del tipo III anti-[miostatina humana (MSTN, factor 8 de diferenciación de crecimiento, GDF8)] (244-340), dímero, producido en las células ováricas de hamsters chinos (CHO), glicoforma alfa; cadena gamma1 fragmento H-CH2-CH3 [Homo sapiens IGHG1*01 (CH2 (11-120), CH3 (121-225))] (1-225); dímero (6-6':9-9')-bisdisulfuro-conector (226-243)-variante del décimo dominio de la fibronectina humana del tipo III anti-[miostatina humana (MSTN, factor 8 de diferenciación de crecimiento, GDF8)] (244-340), producido en las célulass ováricas de hamsters chinos (CHO), glicoforma alfa inhibidor de la miostatina

1580555-23-2

taniborbactamum taniborbactam (3R)-3-(2-{trans-4-[(2-

aminoethyl)amino]cyclohexyl}acetamido)-2-hydroxy-3,4-dihydro-2H-1,2-benzoxaborinine-8-carboxylic acid beta-lactamase inhibitor

taniborbactam acide (3R)-3-(2-{trans-4-[(2-aminoéthyl)amino]cyclohexyl}acétamido)-2-hydroxy-3,4-dihydro-2H-1,2-benzoxaborinine-8-carboxylique inhibiteur de la bêta-lactamase

taniborbactam ácido (3R)-3-(2-{trans-4-[(2-aminoetil)amino]ciclohexil}acetamido)-2-hidroxi-3,4-dihidro-2H-1,2-benzoxaborinina-8-carboxílico inhibidor de la beta-lactamasa

C19H28BN3O5

1613267-49-4

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

367

tavapadonum tavapadon (-)-(6Ξ)-1,5-dimethyl-6-(2-methyl-4-{[3-

(trifluoromethyl)pyridin-2-yl]oxy}phenyl)pyrimidine-2,4(1H,3H)-dione dopamine receptor partial agonist

tavapadon (-)-(6Ξ)-1,5-diméthyl-6-(2-méthyl-4-{[3-(trifluorométhyl)pyridin-2-yl]oxy}phényl)pyrimidine-2,4(1H,3H)-dione agoniste partiel des récepteurs dopaminergiques

tavapadón (-)-(6Ξ)-1,5-dimetil-6-(2-metil-4-{[3-(trifluorometil)piridin- 2-il]oxi}fenil)pirimidina-2,4(1H,3H)-diona agonista parcial de los receptores dopaminergicos

C19H16F3N3O3

1643489-24-0

telaglenastatum telaglenastat N-[6-(4-{5-[2-(pyridin-2-yl)acetamido]-1,3,4-thiadiazol-

2-yl}butyl)pyridazin-3-yl]-2-[3-(trifluoromethoxy)phenyl]acetamide antineoplastic

télaglénastat N-[6-(4-{5-[2-(pyridin-2-yl)acétamido]-1,3,4-thiadiazol- 2-yl}butyl)pyridazin-3-yl]-2-[3-(trifluorométhoxy)phényl]acétamide antinéoplasique

telaglenastat N-[6-(4-{5-[2-(piridin-2-il)acetamido]-1,3,4-tiadiazol- 2-il}butil)piridazin-3-il]-2-[3-(trifluorometoxi)fenil]acetamida antineoplásico

C26H24F3N7O3S

1439399-58-2

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

368

temelimabum # temelimab immunoglobulin G4-kappa, anti-[Homo sapiens

endogenous retrovirus (HERV) family W multiple sclerosis-associated retrovirus (MRSV) envelope protein], humanized monoclonal antibody; gamma4 heavy chain (1-443) [humanized VH (Homo sapiens IGHV1-46*01 (81.2%) -(IGHD)-IGHJ4*01 (92.9%)) [8.8.9] (1-116) -Homo sapiens IGHG4*01 (CH1 (117-214), hinge S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (117-443)], (130-213')-disulfide with kappa light chain (1'-213') [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (81.9%) -IGKJ4*01 (100%)) [5.3.9] (1'-106') -Homo sapiens IGKC*01, Km3 A45.1 (152), V101 (190) (107'-213')]; dimer (222-222":225-225")-bisdisulfide immunomodulator

témélimab immunoglobuline G4-kappa, anti-[protéine d'enveloppe du

rétrovirus associé à la sclérose en plaques (MRSV) de la famille W des rétrovirus endogènes (HERV) d'Homo sapiens], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-443) [VH humanisé (Homo sapiens IGHV1-46*01 (81.2%) -(IGHD)-IGHJ4*01 (92.9%)) [8.8.9] (1-116) -Homo sapiens IGHG4*01 (CH1 (117-214), charnière S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (117-443)], (130-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA humanisé (Homo sapiens IGKV1-39*01 (81.9%) -IGKJ4*01 (100%)) [5.3.9] (1'-106') -Homo sapiens IGKC*01, Km3 A45.1 (152), V101 (190) (107'-213')]; dimère (222-222":225-225")-bisdisulfure immunomodulateur

temelimab inmunoglobulina G4-kappa, anti-[proteína de la envoltura

del retrovirus asociado a la esclerosis en placas (MRSV) de la familia W de los retrovirus endógenos (HERV) d'Homo sapiens], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-443) [VH humanizado (Homo sapiens IGHV1-46*01 (81.2%) -(IGHD)-IGHJ4*01 (92.9%)) [8.8.9] (1-116) -Homo sapiens IGHG4*01 (CH1 (117-214), bisagra S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (117-443)], (130-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizado (Homo sapiens IGKV1-39*01 (81.9%) -IGKJ4*01 (100%)) [5.3.9] (1'-106') -Homo sapiens IGKC*01, Km3 A45.1 (152), V101 (190) (107'-213')]; dímero (222-222":225-225")-bisdisulfuro inmunomodulador

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

369

1393641-34-3 Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGSSVKV SCKASGYTFT DYEMHWVRQA PGQGLEWIGA 50VAPETGGTAY NQKFKGRATI TADKSTSTAY MELSSLRSED TAVYYCTSTV 100VPFAYWGQGT LVTVSSASTK GPSVFPLAPC SRSTSESTAA LGCLVKDYFP 150EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTKTYTCN 200VDHKPSNTKV DKRVESKYGP PCPPCPAPEF LGGPSVFLFP PKPKDTLMIS 250RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTYRVVS 300VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR EPQVYTLPPS 350QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF 400FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTQKSLSLS LGK 443

Light chain / Chaîne légère / Cadena ligeraQIQLTQSPSS LSASVGDRVT ITCSASSSVS YMYWYQQKPG KAPKAWIYRT 50SNLASGVPSR FSGSGSGTDY TLTISSLQPE DFATYYCQQY QSLPLTFGGG 100TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200SSPVTKSFNR GEC 213

Post-translational modificationsDisulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 143-199 257-317 363-421

22''-96'' 143''-199'' 257''-317'' 363''-421''Intra-L (C23-C104) 23'-87' 133'-193'

23'''-87''' 133'''-193'''Inter-H-L (CH1 10-CL 126) 130-213' 130''-213'''Inter-H-H (h 8, h 11) 222-222'' 225-225''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:293, 293''Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennairescomplexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

teserpaturevum # teserpaturev A conditionally-replicating oncolytic Herpes simplex virus

type 1 (HSV-1) strain F that has genetically engineered deletions within both copies of the γ34.5 gene and within the α47 gene, and further modified by insertion of an expressible beta-galactosidase (LacZ) gene in the ICP6 locus. antineoplastic

téserpaturev souche F du virus Herpes simplex type 1 (HSV-1), oncolytique, dont la réplication est conditionnée, avec délétions par génie génétique dans les deux copies du gène γ34.5 et dans le gène α47 et avec des modifications par insertion du gène expressible de la bêta-galactosidase (LacZ) dans le locus ICP6 antinéoplasique

teserpaturev Un virus Herpes simplex de tipo 1 (VHS-1) de la cepa F oncolítico, con replicación condicionada, que tiene deleciones introducidas por ingeniería genética en ambas copias del gen γ34.5 y en el gen α47, y con modificaciones adicionales mediante inserción de un gén expresable de beta-galactosidasa (LacZ) en el locus ICP6. antineoplásico

1802360-34-4

tildacerfontum tildacerfont 3-[4-chloro-2-(morpholin-4-yl)-1,3-thiazol-5-yl]-

2,5-dimethyl-7-(pentan-3-yl)pyrazolo[1,5-a]pyrimidine corticotropin releasing factor (CRF) antagonist

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

370

tildacerfont 3-[4-chloro-2-(morpholin-4-yl)-1,3-thiazol-5-yl]-

2,5-diméthyl-7-(pentan-3-yl)pyrazolo[1,5-a]pyrimidine antagoniste du facteur de libération de la corticotropine (CRF)

tildacerfont 3-[4-cloro-2-(morfolin-4-il)-1,3-tiazol-5-il]-2,5-dimetil- 7-(pentan-3-il)pirazolo[1,5-a]pirimidina antagonista del factor de liberación de la corticotropina (CRF)

C20H26ClN5OS

1014983-00-6

tirbanibulinum tirbanibulin N-benzyl-2-(5-{4-[2-(morpholin-4-yl)ethoxy]phenyl}pyridin-

2-yl)acetamide antineoplastic

tirbanibuline N-benzyl-2-(5-{4-[2-(morpholin-4-yl)éthoxy]phényl}pyridin-2-yl)acétamide antinéoplasique

tirbanibulina N-bencil-2-(5-{4-[2-(morfolin-4-il)etoxi]fenil}piridin- 2-il)acetamida antineoplásico

C26H29N3O3

897016-82-9

tirzepatidum tirzepatide L-tyrosyl-2-methylalanyl-L-α-glutamylglycyl-L-threonyl-L-

phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-tyrosyl-L-seryl-L-isoleucyl-2-methylalanyl-L-leucyl-L-α-aspartyl-L-lysyl-L-isoleucyl-L-alanyl-L-glutaminyl-N6-[(22S)-22,42-dicarboxy-10,19,24-trioxo-3,6,12,15-tetraoxa-9,18,23-triazadotetracontan-1-oyl]-L-lysyl-L-alanyl-L-phenylalanyl-L-valyl-L-glutaminyl-L-tryptophyl-L-leucyl-L-isoleucyl-L-alanylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-serinamide antidiabetic

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

371

tirzépatide L-tyrosyl-2-méthylalanyl-L-α-glutamylglycyl-L-thréonyl-L-phénylalanyl-L-thréonyl-L-séryl-L-α-aspartyl-L-tyrosyl-L-séryl-L-isoleucyl-2-méthylalanyl-L-leucyl-L-α-aspartyl-L-lysyl-L-isoleucyl-L-alanyl-L-glutaminyl-N6-[(22S)-22,42-dicarboxy-10,19,24-trioxo-3,6,12,15-tétraoxa-9,18,23-triazadotétracontan-1-oyl]-L-lysyl-L-alanyl-L-phénylalanyl-L-valyl-L-glutaminyl-L-tryptophyl-L-leucyl-L-isoleucyl-L-alanylglycylglycyl-L-prolyl-L-séryl-L-sérylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-sérinamide hypoglycémiant

tirzepatida L-tirosil-2-metilalanil-L-α-glutamilglicil-L-treonil-L-fenilalanil-L-treonil-L-seril-L-α-aspartil-L-tirosil-L-seril-L-isoleucil-2-metilalanil-L-leucil-L-α-aspartil-L-lisil-L-isoleucil-L-alanil-L-glutaminil-N6-[(22S)-22,42-dicarboxi-10,19,24-tetraoxo-3,6,12,15-trioxa-9,18,23-triazadotetracontan-1-oil]-L-lisil-L-alanil-L-fenilalanil-L-valil-L-glutaminil-L-triptofil-L-leucil-L-isoleucil-L-alanilglicilglicil-L-prolil-L-seril-L-serilglicil-L-alanil-L-prolil-L-prolil-L-prolil-L-serinamida hipoglucemiante

C225H348N48O68

2023788-19-2

tofersenum tofersen all-P-ambo-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-

(3'→5')-2'-O-(2-methoxyethyl)adenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)guanylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)guanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyluridine superoxide dismutase 1 (SOD1) synthesis inhibitor

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

372

tofersen tout-P-ambo-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)adénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)guanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioadénylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-2'-désoxy-5-méthyl-P-thiocytidylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-désoxy-5-méthyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthylcytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)guanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyluridine inhibiteur de la synthèse de la superoxide dismutase 1 (SOD1)

tofersén todo-P-ambo-2'-O-(2-metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)adenilil-(3'→5')-2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)guanilil-(3'→5')-2'-O-(2-metoxietil)-P-tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metilcitidilil-(3'→5')-2'-O-(2-metoxietil)-P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)guanilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-5-metiluridina inhibidor de la sintesis de la superóxido dismutasa 1 (SOD1)

C230H317N72O123P19S15

2088232-70-4

toripalimabum # toripalimab immunoglobulin G4-kappa, anti-[Homo sapiens PDCD1

(programmed cell death 1, PD-1, PD1, CD279)], monoclonal antibody; gamma4 heavy chain (1-452) [VH (Homo sapiens IGHV1-46*01 (80.6%) -(IGHD)-IGHJ3*01 (92.9%)) [8.8.18] (1-125) -Homo sapiens IGHG4*01 (CH1 (126-223), hinge S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (126-452)], (139-219')-disulfide with kappa light chain (1'-219') [V-KAPPA (Mus musculus IGKV1-117*01 (93.0%)/Homo sapiens IGKV2-30*02 (88.0%) -Homo sapiens IGKJ2*01 (100%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (231-231":234-234")-bisdisulfide immunomodulator, antineoplastic

toripalimab immunoglobuline G4-kappa, anti-[Homo sapiens PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal;

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

373

chaîne lourde gamma4 (1-452) [VH (Homo sapiens IGHV1-46*01 (80.6%) -(IGHD)-IGHJ3*01 (92.9%)) [8.8.18] (1-125) -Homo sapiens IGHG4*01 (CH1 (126-223), charnière S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (126-452)], (139-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA (Mus musculus IGKV1-117*01 (93.0%)/Homo sapiens IGKV2-30*02 (88.0%) -Homo sapiens IGKJ2*01 (100%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimère (231-231":234-234")-bisdisulfure immunomodulateur, antinéoplasique

toripalimab inmunoglobulina G4-kappa, anti-[Homo sapiens PDCD1

(proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal; cadena pesada gamma4 (1-452) [VH (Homo sapiens IGHV1-46*01 (80.6%) -(IGHD)-IGHJ3*01 (92.9%)) [8.8.18] (1-125) -Homo sapiens IGHG4*01 (CH1 (126-223), bisagra S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (126-452)], (139-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA (Mus musculus IGKV1-117*01 (93.0%)/Homo sapiens IGKV2-30*02 (88.0%) -Homo sapiens IGKJ2*01 (100%)) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dímero (231-231":234-234")-bisdisulfuro inmunomodulador, antineoplásico

1924598-82-2 Heavy chain / Chaîne lourde / Cadena pesada

QGQLVQSGAE VKKPGASVKV SCKASGYTFT DYEMHWVRQA PIHGLEWIGV 50IESETGGTAY NQKFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCAREG 100ITTVATTYYW YFDVWGQGTT VTVSSASTKG PSVFPLAPCS RSTSESTAAL 150GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS 200LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPEFL GGPSVFLFPP 250KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ 300FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE 350PQVYTLPPSQ EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400PVLDSDGSFF LYSRLTVDKS RWQEGNVFSC SVMHEALHNH YTQKSLSLSL 450GK 452

Light chain / Chaîne légère / Cadena ligeraDVVMTQSPLS LPVTLGQPAS ISCRSSQSIV HSNGNTYLEW YLQKPGQSPQ 50LLIYKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSHVP 100LTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200VTHQGLSSPV TKSFNRGEC 219

Post-translational modificationsDisulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 152-208 266-326 372-430

22''-96'' 152''-208'' 266''-326'' 372''-430''Intra-L (C23-C104) 23'-93' 139'-199'

23'''-93''' 139'''-199'''Inter-H-L (CH1 10-CL126) 139-219' 139''-219'''Inter-H-H (h 8, h 11) 231-231'' 234-234''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:302, 302''Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennairescomplexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

374

umibecestatum umibecestat N-{6-[(3R,6R)-5-amino-3,6-dimethyl-6-(trifluoromethyl)-3,6-

dihydro-2H-1,4-oxazin-3-yl]-5-fluoropyridin-2-yl}-3-chloro-5-(trifluoromethyl)pyridine-2-carboxamide beta-secretase inhibitor

umibécestat N-{6-[(3R,6R)-5-amino-3,6-diméthyl-6-(trifluorométhyl)-3,6-dihydro-2H-1,4-oxazin-3-yl]-5-fluoropyridin-2-yl}-3-chloro-5-(trifluorométhyl)pyridine-2-carboxamide inhibiteur de la secrétase bêta

umibecestat N-{6-[(3R,6R)-5-amino-3,6-dimetil-6-(trifluorometil)-3,6-dihidro-2H-1,4-oxazin-3-il]-5-fluoropiridin-2-il}-3-cloro-5-(trifluorometil)piridina-2-carboxamida inhibidor de la secretasa beta

C19H15ClF7N5O2

1387560-01-1

vafidemstatum vafidemstat (41R,42S)-6-oxa-3-aza-1(2)-[1,3,4]oxadiazola-5(1,4),8(1)-

dibenzena-4(1,2)-cyclopropanaoctaphan-15-amine lysine-specific histone demethylase (LSD1) inhibitor

vafidemstat (41R,42S)-6-oxa-3-aza-1(2)-[1,3,4]oxadiazola-5(1,4),8(1)-dibenzéna-4(1,2)-cyclopropanaoctaphan-15-amine inhibiteur de l'histone déméthylase-1 spécifique de la lysine (LSD1)

vafidemstat (41R,42S)-6-oxa-3-aza-1(2)-[1,3,4]oxadiazola-5(1,4),8(1)-dibencena-4(1,2)-ciclopropanaoctafan-15-amina inhibidor de la histona demetilasa-1 específica de la lisina (LSD1)

C19H20N4O2

1357362-02-7

valecobulinum valecobulin (2S)-2-amino-3-methyl-N-{4-[3-(1H-1,2,4-triazol-1-yl)-

4-(3,4,5-trimethoxybenzoyl)phenyl]-1,3-thiazol- 2-yl}butanamide beta-tubulin polymerization inhibitor, antineoplastic

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

375

valécobuline (2S)-2-amino-3-méthyl-N-{4-[3-(1H-1,2,4-triazol-1-yl)-

4-(3,4,5-triméthoxybenzoyl)phényl]-1,3-thiazol- 2-yl}butanamide inhibiteur de la polymérisation de la bêta-tubuline, antinéoplasique

valecobulina (2S)-2-amino-3-metil-N-{4-[3-(1H-1,2,4-triazol-1-il)- 4-(3,4,5-trimetoxibenzoil)fenil]-1,3-tiazol-2-il}butanamida inhibidor de la polimerización de la beta-tubulina, antineoplásico

C26H28N6O5S

1188371-47-2

zampilimabum # zampilimab immunoglobulin G4-kappa, anti-[Homo sapiens TGM2

(transglutaminase 2, transglutaminase-2 (TG2), protein-glutamine-gamma-glutamyltransferase C polypeptide, TGC)], humanized and chimeric monoclonal antibody; gamma4 heavy chain (1-441) [humanized VH (Homo sapiens IGHV3-23*03 (89.8%) -(IGHD) -IGHJ4*01 (100%)) [8.8.7] (1-114) -Homo sapiens IGHG4*01 (CH1 (115-212), hinge S10>P (222) (213-224), CH2 (225-334), CH3 (335-439), CHS (440-441)) (115-441)], (128-214')-disulfide with kappa light chain chimeric (1'-214') [V-KAPPA (Mus muculus IGKV14-111*01 (82.1%)/Homo sapiens IGKV1-16*01 (78.9%) -Homo sapiens IGKJ1*01 (91.7%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (220-220":223-223")-bisdisulfide immunomodulator

zampilimab immunoglobuline G4-kappa, anti-[Homo sapiens TGM2 (transglutaminase 2, transglutaminase-2, TG2, protéine-glutamine-gamma-glutamyltransférase polypeptide C, TGC)], anticorps monoclonal humanisé et chimérique; chaîne lourde gamma4 (1-441) [VH humanisé (Homo sapiens IGHV3-23*03 (89.8%) -(IGHD) -IGHJ4*01 (100%)) [8.8.7] (1-114) -Homo sapiens IGHG4*01 (CH1 (115-212), charnière S10>P (222) (213-224), CH2 (225-334), CH3 (335-439), CHS (440-441)) (115-441)], (128-214')-disulfure avec la chaîne légère kappa chimérique (1'-214') [V-KAPPA (Mus muculus IGKV14-111*01 (82.1%)/Homo sapiens IGKV1-16*01 (78.9%) -Homo sapiens IGKJ1*01 (91.7%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (220-220":223-223")-bisdisulfure immunomodulateur

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

376

zampilimab inmunoglobulina G4-kappa, anti-[Homo sapiens TGM2

(transglutaminasa 2, transglutaminasa-2, TG2, proteína-glutamina-gamma-glutamiltransferasa polipéptido C, TGC)], anticuerpo monoclonal humanizado y quimérico; cadena pesada gamma4 (1-441) [VH humanizado (Homo sapiens IGHV3-23*03 (89.8%) -(IGHD) -IGHJ4*01 (100%)) [8.8.7] (1-114) -Homo sapiens IGHG4*01 (CH1 (115-212), bisagra S10>P (222) (213-224), CH2 (225-334), CH3 (335-439), CHS (440-441)) (115-441)], (128-214')-disulfuro con la cadena ligera kappa quimérica (1'-214') [V-KAPPA (Mus muculus IGKV14-111*01 (82.1%)/Homo sapiens IGKV1-16*01 (78.9%) -Homo sapiens IGKJ1*01 (91.7%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (220-220":223-223")-bisdisulfuro inmunomodulador

2098280-42-1 Heavy chain / Chaîne lourde / Cadena pesada

EVQLLESGGG LVQPGGSLRL SCAASGFTLS THAMSWVRQA PGKGLEWVAT 50ISSGGRSTYY PDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYFCARLI 100STYWGQGTLV TVSSASTKGP SVFPLAPCSR STSESTAALG CLVKDYFPEP 150VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL GTKTYTCNVD 200HKPSNTKVDK RVESKYGPPC PPCPAPEFLG GPSVFLFPPK PKDTLMISRT 250PEVTCVVVDV SQEDPEVQFN WYVDGVEVHN AKTKPREEQF NSTYRVVSVL 300TVLHQDWLNG KEYKCKVSNK GLPSSIEKTI SKAKGQPREP QVYTLPPSQE 350EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL 400YSRLTVDKSR WQEGNVFSCS VMHEALHNHY TQKSLSLSLG K 441

Light chain / Chaîne légère / Cadena ligeraDITMTQSPSS LSASVGDRVT ITCKASQDIN SYLTWFQQKP GKAPKILIYL 50VNRLVDGVPS RFSGSGSGQD YALTISSLQP EDFATYYCLQ YDDFPYTFGQ 100GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214

Post-translational modificationsDisulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 141-197 255-315 361-419

22''-96'' 141''-197'' 255''-315'' 361''-419''Intra-L (C23-C104) 23'-88' 134'-194'

23'''-88''' 134'''-194'''Inter-H-L (CH1 10-CL 126) 128-214' 128''-214'''Inter-H-H (h 8, h 11) 220-220'' 223-223''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:291, 291''Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennairescomplexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

# Electronic structure available on Mednet: http://mednet.who.int/ # Structure électronique disponible sur Mednet: http://mednet.who.int/ # Estructura electrónica disponible en Mednet: http://mednet.who.int/ * http://www.who.int/medicines/services/inn/publication/en/

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

377

Names for Radicals and Groups Some substances for which a proposed international nonproprietary name has been established may be used in the form of salts or esters. The radicals or groups involved may be of complex composition and it is then inconvenient to refer to them in a systematic chemical nomenclature. Consequently, shorter nonproprietary names for some radicals and groups have been devised or selected, and they are suggested for use with the proposed international nonproprietary names. Dénominations applicables aux radicaux et groupes Certaines substances pour lesquelles une dénomination commune internationale proposée a été établie sont parfois utilisées sous forme de sels ou d'esters. Les radicaux ou groupes correspondants sont alors quelques fois si complexes qu'il est malcommode de les désigner conformément à la nomenclature chimique systématique. Des dénominations communes abrégées ont donc été formées ou choisies pour certains d'entre eux et il est suggéré de les employer avec les dénominations communes internationales proposées. Denominaciones para Radicales y Grupos Ciertas sustancias para las cuales hay establecidas una denominación común internacional pueden usarse en forma de sales o de ésteres. Los radicales o grupos correspondientes pueden llegar a tener una composición tan compleja que resulte incómodo referirse a ellos mediante la nomenclatura química sistemática. Las siguientes denominaciones comunes abreviadas han sido ideadas o elegidas para algunos de estos radicales y grupos y se sugiere que se empleen con las denominaciones comunes internacionales propuestas

barzuxetanum barzuxetan (4-{(2R)-2-[bis(carboxymethyl)amino]-3-[{(1S,2S)-2-

[bis(carboxymethyl)amino]cyclohexyl}(carboxymethyl) amino]propyl}phenyl)carbamothioyl

barzuxétan (4-{(2R)-2-[bis(carboxyméthyl)amino]-3-[{(1S,2S)-2-[bis(carboxyméthyl)amino]cyclohexyl}(carboxyméthyl) amino]propyl}phényl)carbamothioyle

barzuxetán (4-{(2R)-2-[bis(carboximetil)amino]-3-[{(1S,2S)-2-[bis(carboximetil)amino]ciclohexil}(carboximetil)amino] propil}fenil)carbamotioil

C26H35N4O10S

157380-45-5

HO2C NN

CO2H

HO2C

H

NHC

S

H

NH

CO2HHO2C

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

378

AMENDMENTS TO PREVIOUS LISTS MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES

MODIFICACIONES A LAS LISTAS ANTERIORES Proposed International Nonproprietary Names (Prop. INN): List 104 Dénominations communes internationales proposées (DCI Prop.): Liste 104 Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 104 (WHO Drug Information, Vol. 24, No. 4, 2010) p. 389 pracinostatum pracinostat replace the chemical name by the following one pracinostat sustitúyase el nombre químico por el siguiente

(2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-

N-hydroxyprop-2-enamide

(2E)-3-{2-butil-1-[2-(dietilamino)etil]-1H-benzimidazol-5-il}- N-hidroxiprop-2-enamida

Proposed International Nonproprietary Names (Prop. INN): List 108 Dénominations communes internationales proposées (DCI Prop.): Liste 108 Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 108 (WHO Drug Information, Vol. 26, No. 4, 2012) p. 448 turoctocogum alfa pegolum # turoctocog alfa pegol replace the description by the following one turoctocog alfa pégol remplacer la description par la suivante turoctocog alfa pegol sustitúyase la descripción por la siguiente

human coagulation factor VIII-(1-750)-(1638-1648)-peptide

compound with human coagulation factor VIIIa light chain, glycosylated and pegylated;

O3.750-[α-methylpoly(oxyethylene) 5-(acetamido)-3,5-dideoxy-D-glycero-α-D-galacto-non-2-ulopyranosylonate-(2→4)-α-D-galactopyranosyl-(1→4)-2-(acetamido)-2-deoxy-α-D-galactopyranosyl]-des-(751-1637)-human coagulation factor VIII-(1-1648)-peptide containing 92 kDa factor VIIIa heavy chain compound with human coagulation factor VIIIa light chain glycosylated (glycoform alfa produced in CHO cells)

facteur VIII de coagulation humain-(1-750)-(1638-1648)-peptide associé à la chaîne légère du facteur VIIIa de coagulation humain glycosylés et pégylés;

O3.750-[5-(acétamido)-3,5-didésoxy-D-glycéro-α-D-galacto-non-2-ulopyranosylonate de α-méthylpoly(oxyéthylène)-(2→4)-α-D-galactopyranosyl-(1→4)-2-(acétamido)-2-déoxy-α-D-galactopyranosyl]-dès-(751-1637)-facteur VIII de coagulation humain-(1-1648)-peptide contenant la chaîne lourde de 92 kDa du factor VIIIa associé à la chaîne légère du facteur VIIIa de coagulation humain glycosylés (glycoforme alfa produit par des cellules CHO)

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

379

factor VIII de coagulación humano-(1-750)-(1638-1648)-péptido

asociado a la cadena ligera del factor VIIIa de coagulación humano glicosilados y pegilados;

O3.750-[5-(acetamido)-3,5-didesoxi-D-glicero-β-D-galacto-non-2-ulopiranosilonato de α-metilpoli(oxietileno)-(2→4)-α-D-galactopiranosil-(1→4)-2-(acetamido)-2-desoxi-α-D-galactopiranosil]-des-(751-1637)-factor VIII de coagulación humano-(1-1648)-péptido que contiene la cadena pesada de 92 kDa del factor VIIIa asociado a la cadena ligera del factor VIIIa de coagulación humano glicosilados (glicoforma alfa producido por células CHO)

Proposed International Nonproprietary Names (Prop. INN): List 114 Dénominations communes internationales proposées (DCI Prop.): Liste 114 Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 114 (WHO Drug Information, Vol. 29, No. 4, 2015) p. 655 pibrentasvirum pibrentasvir replace the molecular formula by the following one pibrentasvir remplacer la formule moléculaire brute par la suivante pibrentasvir sustitúyase la fómula molecular por la siguiente

C57H65F5N10O8 Proposed International Nonproprietary Names (Prop. INN): List 117 Dénominations communes internationales proposées (DCI Prop.): Liste 117 Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 117 (WHO Drug Information, Vol. 31, No. 2, 2017)

p. 243 delete/supprimer/suprimáse insert/insérer/insertese adavivintum lorecivivintum

adavivint lorecivivint adavivint lorécivivint

adavivint lorecivivint

p. 297 delete/supprimer/suprimáse insert/insérer/insertese loxicodegolum oxycodegolum

loxicodegol oxycodegol loxicodégol oxycodégol

loxicodegol oxicodegol

p. 352-354 delete/supprimer/suprimáse insert/insérer/insertese votrisiranum vutrisiranum

votrisiran vutrisiran votrisiran vutrisiran

votrisirán vutrisirán

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

380

Proposed International Nonproprietary Names (Prop. INN): List 118 Dénominations communes internationales proposées (DCI Prop.): Liste 118 Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 118 (WHO Drug Information, Vol. 31, No. 4, 2017)

p. 645 belvarafenibum belvarafenib replace the structure by the following one belvarafénib remplacer la structure par la suivante belvarafenib sustitúyase la estructura por la siguiente

NH

N

OH3C

S

N

N

HN

F

Cl

H2N

p. 655 cilofexorum cilofexor replace the structure by the following one cilofexor remplacer la structure par la suivante cilofexor sustitúyase la estructura por la siguiente

p. 663 efinopegdutidum # - 664 efinopegdutide replace the description and structure by the following ones éfinopégdutide remplacer la description et structure par les suivantes efinopegdutida sustitúyase la descripción y la estructura por las siguientes

oxyntomodulin analogue, conjugated by a 10 kDa polyethylene glycol (PEG) linker

(n ~ 225) to an Fc portion dimer of human immunoglobulin G4 (IgG4): N1.1-{3-[α-(3-{3-[(3RS)-3-({16,20-anhydro-[Ser2>Aib,Ser16>Glu,Arg17>Lys,Gln20>Lys,Asp21>Glu,Lys30> Cys]-oxyntomodulin (1-30)-peptide 30-amide}-S3.30-yl)-2,5-dioxopyrrolidin-1-yl]propanamido}propyl) poly(oxyethylene)-ω-yloxy]propyl}[immunoglobulin G4 heavy chain constant region C-terminal 221-peptide dimer disulfide], non-glycosylated, immunoglobulin fragment dimer produced in Escherichia coli

analogue de l' oxyntomoduline (GLP-1), conjugué par un linker polyéthylène glycol (PEG) de 10 kDa (n ~ 225) à un dimère de fragment Fc d'immunoglobuline G4 (IgG4) humaine: N1.1-{3-[α-(3-{3-[(3RS)-3-({16,20-anhydro-[Ser2>Aib,Ser16>Glu,Arg17>Lys,Gln20>Lys,Asp21>Glu,Lys30> Cys]-oxyntomodulin (1-30)-peptide 30-amide}-S3.30-yl)-2,5-dioxopyrrolidin-1-yl]propanamido}propyl) poly(oxyéthylène)-ω-yloxy]propyl}[peptide de 221 acides aminés de la région constante C-terminale de la chaîne lourde G4 d'immunoglobuline, dimère disulfure], non-glycosylé, dimère du fragment d'immunoglobuline produit par Escherichia coli

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

381

análogo de la oxintomodulina (GLP-1), conjugado por un enlace polietileno glicol

(PEG) de 10 kDa (n ~ 225) a un dímero del fragmento Fc de la inmunoglobulina G4 (IgG4) humana: N1.1-{3-[α-(3-{3-[(3RS)-3-({16,20-anhidro-[Ser2>Aib,Ser16>Glu,Arg17>Lys,Gln20>Lys,Asp21>Glu,Lys30> Cys]-oxintomodulin (1-30)-péptido 30-amida}-S3.30-il)-2,5-dioxopirrolidin- 1-il]propanamido}propil)poli(oxietileno)-ω-iloxi]propil}[péptido de 221 aminoácidos de la región constante C-terminal de la cadena pesada G4 de la inmunoglobulina, dímero disulfuro], no glicosilado, dímero del fragmento de la inmunoglobulina producido por Escherichia coli

p. 670 etidaligidum etidaligide replace the structure by the following one étidaligide remplacer la structure par la suivante etidaligida sustitúyase la estructura por la siguiente

GSCSTSG-T-G-C-C-C-A-C-A-A-C-C-C-A-G-C-A-A-A-C-A-A-G-C-C-T-A-G-A• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •CSGSASC-A-C-G-G-G-T-G-T-T-G-G-G-T-C-G-T-T-T-G-T-T-C-G-G-A-T-C-THO

HOP

O

O

O5’ [5] [10] [15] [20] [25] [30]

3’

[5’][10’][15’][20’][25’][30’]OH

PO

O

O

5’

OHP

O

O

3’

CH3

H

CH3

H

H

CH3

CH3H CH3

HH

OHNO

O3

O

O

H

HO

NHO

O

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

382

p. 697 delete insert

opigolixum opigolixum opigolix

p. 703 revosimelinum revosimeline replace the action and use by the following one révosiméline remplacer le mécanisme d’action par le suivant revosimelina sustitúyase el acción por el siguiente

muscarinic receptor antagonist antagoniste des récepteurs muscariniques antagonista de los receptores muscarinicos p. 726-727 delete/supprimer/suprimáse insert/insérer/insertese vanalimabum mitazalimabum

vanalimab mitazalimab vanalimab mitazalimab

vanalimab mitazalimab

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

383

ANNEX 1

PROCEDURE FOR THE SELECTION OF RECOMMENDED

INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES1

The following procedure shall be followed by the World Health Organization (hereinafter also

referred to as “WHO”) in the selection of recommended international nonproprietary names for pharmaceutical substances, in accordance with resolution WHA3.11 of the World Health Assembly, and in the substitution of such names. Article 1 - Proposals for recommended international nonproprietary names and proposals for substitution of such names shall be submitted to WHO on the form provided therefore. The consideration of such proposals shall be subject to the payment of an administrative fee designed only to cover the corresponding costs of the Secretariat of WHO (“the Secretariat”). The amount of this fee shall be determined by the Secretariat and may, from time to time, be adjusted. Article 2 - Such proposals shall be submitted by the Secretariat to the members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations designated for this purpose, such designated members hereinafter referred to as “the INN Expert Group”, for consideration in accordance with the “General principles for guidance in devising International Nonproprietary Names for Pharmaceutical Substances”, annexed to this procedure2. The name used by the person discovering or first developing and marketing a pharmaceutical substance shall be accepted, unless there are compelling reasons to the contrary. Article 3 - Subsequent to the examination provided for in article 2, the Secretariat shall give notice that a proposed international nonproprietary name is being considered. a) Such notice shall be given by publication in WHO Drug Information3

and by letter to Member States and to national and regional pharmacopoeia commissions or other bodies designated by Member States.

i) Notice shall also be sent to the person who submitted the proposal (“the original applicant”) and other persons known to be concerned with a name under consideration.

b) Such notice shall:

i) set forth the name under consideration; ii) identify the person who submitted the proposal for naming the substance, if so requested by such person; iii) identify the substance for which a name is being considered; iv) set forth the time within which comments and objections will be received and the person and place to whom they should be directed; v) state the authority under which WHO is acting and refer to these rules of procedure.

1 See Annex 1 in WHO Technical Report Series, No. 581, 1975. The original text was adopted by the Executive Board in resolution

EB15.R7 and amended in resolutions EB43.R9 and EB115.R4.

2 See Annex 2.

3 Before 1987, lists of international nonproprietary names were published in the Chronicle of the World Health Organization.

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

384

c) In forwarding the notice, the Secretariat shall request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the proposed name during the period it is under consideration by WHO.

Article 4 - Comments on the proposed name may be forwarded by any person to WHO within four months of the date of publication, under article 3, of the name in WHO Drug Information. Article 5 - A formal objection to a proposed name may be filed by any interested person within four months of the date of publication, under article 3, of the name in WHO Drug Information.

Such objection shall:

i) identify the person objecting;

ii) state his or her interest in the name; iii) set forth the reasons for his or her objection to the name proposed. Article 6 - Where there is a formal objection under article 5, WHO may either reconsider the proposed name or use its good offices to attempt to obtain withdrawal of the objection. Without prejudice to the consideration by WHO of a substitute name or names, a name shall not be selected by WHO as a recommended international nonproprietary name while there exists a formal objection thereto filed under article 5 which has not been withdrawn. Article 7 - Where no objection has been filed under article 5, or all objections previously filed have been withdrawn, the Secretariat shall give notice in accordance with subsection (a) of article 3 that the name has been selected by WHO as a recommended international nonproprietary name. Article 8 - In forwarding a recommended international nonproprietary name to Member States under article 7, the Secretariat shall: a) request that it be recognized as the nonproprietary name for the substance; and b) request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the name and to prohibit registration of the name as a trademark or trade name. Article 9 a) In the extraordinary circumstance that a previously recommended international nonproprietary name gives rise to errors in medication, prescription or distribution, or a demonstrable risk thereof, because of similarity with another name in pharmaceutical and/or prescription practices, and it appears that such errors or potential errors cannot readily be resolved through other interventions than a possible substitution of a previously recommended international nonproprietary name, or in the event that a previously recommended international nonproprietary name differs substantially from the nonproprietary name approved in a significant number of Member States, or in other such extraordinary circumstances that justify a substitution of a recommended international nonproprietary name, proposals to that effect may be filed by any interested person. Such proposals shall be submitted on the form provided therefore and shall: i) identify the person making the proposal;

ii) state his or her interest in the proposed substitution; and iii) set forth the reasons for the proposal; and

iv) describe, and provide documentary evidence regarding the other interventions undertaken in an effort to resolve the situation, and the reasons why these other interventions were inadequate.

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

385

Such proposals may include a proposal for a new substitute international nonproprietary name, devised in accordance with the General principles, which takes into account the pharmaceutical substance for which the new substitute international nonproprietary name is being proposed. The Secretariat shall forward a copy of the proposal, for consideration in accordance with the procedure described in subsection (b) below, to the INN Expert Group and the original applicant or its successor (if different from the person bringing the proposal for substitution and provided that the original applicant or its successor is known or can be found through diligent effort, including contacts with industry associations). In addition, the Secretariat shall request comments on the proposal from:

i) Member States and national and regional pharmacopoeia commissions or other bodies designated by Member States (by including a notice to that effect in the letter referred to in article 3(a), and

ii) any other persons known to be concerned by the proposed substitution.

The request for comments shall:

i) state the recommended international nonproprietary name that is being proposed for substitution (and the proposed substitute name, if provided);

ii) identify the person who submitted the proposal for substitution (if so requested by such

person);

iii) identify the substance to which the proposed substitution relates and reasons put forward for substitution;

iv) set forth the time within which comments will be received and the person and place to whom they should be directed; and v) state the authority under which WHO is acting and refer to these rules of procedure.

Comments on the proposed substitution may be forwarded by any person to WHO within four months of the date of the request for comments. b) After the time period for comments referred to above has elapsed, the Secretariat shall forward any comments received to the INN Expert Group, the original applicant or its successor and the person bringing the proposal for substitution. If, after consideration of the proposal for substitution and the comments received, the INN Expert Group, the person bringing the proposal for substitution and the original applicant or its successor all agree that there is a need to substitute the previously recommended international nonproprietary name, the Secretariat shall submit the proposal for substitution to the INN Expert Group for further processing. Notwithstanding the foregoing, the original applicant or its successor shall not be entitled to withhold agreement to a proposal for substitution in the event the original applicant or its successor has no demonstrable continuing interest in the recommended international nonproprietary name proposed for substitution.

In the event that a proposal for substitution shall be submitted to the INN Expert Group for further processing, the INN Expert Group will select a new international nonproprietary name in accordance with the General principles referred to in article 2 and the procedure set forth in articles 3 to 8 inclusive. The notices to be given by the Secretariat under article 3 and article 7, respectively, including to the original applicant or its successor (if not the same as the person proposing the substitution, and provided that the original applicant or its successor is known or can be found through diligent effort, including contacts with industry associations), shall in such event indicate that the new name is a substitute for a previously recommended international nonproprietary name and that Member States may wish to make transitional arrangements in order to accommodate existing products that use the previously recommended international nonproprietary name on their label in accordance with national legislation.

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

386

If, after consideration of the proposal for substitution and the comments received in accordance

with the procedure described above, the INN Expert Group, the original applicant or its successor and the person bringing the proposal for substitution do not agree that there are compelling reasons for substitution of a previously recommended international nonproprietary name, this name shall be retained (provided always that the original applicant or its successor shall not be entitled to withhold agreement to a proposal for substitution in the event that the original applicant or its successor has no demonstrable continuing interest in the recommended international nonproprietary name proposed to be substituted). In such an event, the Secretariat shall advise the person having proposed the substitution, as well as the original applicant or its successor (if not the same as the person proposing the substitution, and provided that the original applicant or its successor is known or can be found through diligent effort, including contacts with industry associations), Member States, national and regional pharmacopoeia commissions, other bodies designated by Member States, and any other persons known to be concerned by the proposed substitution that, despite a proposal for substitution, it has been decided to retain the previously recommended international nonproprietary name (with a description of the reason(s) why the proposal for substitution was not considered sufficiently compelling).

ANNEX 2

GENERAL PRINCIPLES FOR GUIDANCE IN DEVISING INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES1

1. International Nonproprietary Names (INN) should be distinctive in sound and spelling. They should not be inconveniently long and should not be liable to confusion with names in common use. 2. The INN for a substance belonging to a group of pharmacologically related substances should, where appropriate, show this relationship. Names that are likely to convey to a patient an anatomical, physiological, pathological or therapeutic suggestion should be avoided. These primary principles are to be implemented by using the following secondary principles: 3. In devising the INN of the first substance in a new pharmacological group, consideration should be given to the possibility of devising suitable INN for related substances, belonging to the new group. 4. In devising INN for acids, one-word names are preferred; their salts should be named without modifying the acid name, e.g. “oxacillin” and “oxacillin sodium”, “ibufenac” and “ibufenac sodium”. 5. INN for substances which are used as salts should in general apply to the active base or the active acid. Names for different salts or esters of the same active substance should differ only in respect of the name of the inactive acid or the inactive base. For quaternary ammonium substances, the cation and anion should be named appropriately as separate components of a quaternary substance and not in the amine-salt style. 6. The use of an isolated letter or number should be avoided; hyphenated construction is also undesirable. 7. To facilitate the translation and pronunciation of INN, “f” should be used instead of “ph”, “t” instead of “th”, “e” instead of “ae” or “oe”, and “i” instead of “y”; the use of the letters “h” and “k” should be avoided. 1

In its Twentieth report (WHO Technical Report Series, No. 581, 1975), the WHO Expert committee on Nonproprietary Names for Pharmaceutical Substances reviewed the general principles for devising, and the procedures for selecting, INN in the light of developments in pharmaceutical compounds in recent years. The most significant change has been the extension to the naming of synthetic chemical substances of the practice previously used for substances originating in or derived from natural products. This practice involves the use of a characteristic “stem” indicative of a common property of the members of a group. The reason for, and the implications of, the change are fully discussed. The guiding principles were updated during the 13th Consultation on nonproprietary names for pharmaceutical substances (Geneva, 27-29 April 1983) (PHARM S/NOM 928 13 May 1983, revised 18 August 1983).

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

387

8. Provided that the names suggested are in accordance with these principles, names proposed by the person discovering or first developing and marketing a pharmaceutical preparation, or names already officially in use in any country, should receive preferential consideration. 9. Group relationship in INN (see General principle 2) should if possible be shown by using a common stem. The following list contains examples of stems for groups of substances, particularly for new groups. There are many other stems in active use.1 Where a stem is shown without any hyphens it may be used anywhere in the name. Latin English -acum -ac anti-inflammatory agents, ibufenac derivatives -adolum -adol } analgesics -adol- -adol-} -astum -ast antiasthmatic, antiallergic substances not acting primarily

as antihistaminics -astinum -astine antihistaminics -azepamum -azepam diazepam derivatives bol bol steroids, anabolic -cain- -cain- class I antiarrhythmics, procainamide and lidocaine

derivatives -cainum -caine local anaesthetics cef- cef- antibiotics, cefalosporanic acid derivatives -cillinum -cillin antibiotics, 6-aminopenicillanic acid derivatives -conazolum -conazole systemic antifungal agents, miconazole derivatives cort cort corticosteroids, except prednisolone derivatives -coxibum -coxib selective cyclo-oxygenase inhibitors -entanum -entan endothelin receptor antagonists gab gab gabamimetic agents gado- gado- diagnostic agents, gadolinium derivatives -gatranum -gatran thrombin inhibitors, antithrombotic agents gest gest steroids, progestogens gli gli antihyperglycaemics io- io- iodine-containing contrast media -metacinum -metacin anti-inflammatory, indometacin derivatives -mycinum -mycin antibiotics, produced by Streptomyces strains -nidazolum -nidazole antiprotozoal substances, metronidazole derivatives -ololum -olol β-adrenoreceptor antagonists -oxacinum -oxacin antibacterial agents, nalidixic acid derivatives -platinum -platin antineoplastic agents, platinum derivatives -poetinum -poetin erythropoietin type blood factors -pril(at)um -pril(at) angiotensin-converting enzyme inhibitors -profenum -profen anti-inflammatory substances, ibuprofen derivatives prost prost prostaglandins -relinum -relin pituitary hormone release-stimulating peptides -sartanum -sartan angiotensin II receptor antagonists, antihypertensive (non-

peptidic) -vaptanum -vaptan vasopressin receptor antagonists vin- vin- } vinca-type alkaloids -vin- -vin-} 1 A more extensive listing of stems is contained in the working document WHO/EMP/RHT/TSN/2013.1 which is regularly updated and can be requested from the INN Programme, WHO, Geneva.

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

388

ANNEXE 1

PROCEDURE A SUIVRE EN VUE DU CHOIX DE DENOMINATIONS COMMUNES INTERNATIONALES RECOMMANDEES POUR LES

SUBSTANCES PHARMACEUTIQUES1

L’Organisation mondiale de la Santé (également désignée ci-après sous l’appellation « OMS ») observe la procédure exposée ci-dessous pour l’attribution de dénominations communes internationales recommandées pour les substances pharmaceutiques, conformément à la résolution WHA3.11 de l’Assemblée mondiale de la Santé, et pour le remplacement de telles dénominations. Article 1 - Les propositions de dénominations communes internationales recommandées et les propositions de remplacement de telles dénominations sont soumises à l’OMS sur la formule prévue à cet effet. L’examen de telles propositions est soumis au paiement d’une taxe administrative destinée uniquement à couvrir les coûts correspondants assumés par le Secrétariat de l’OMS (« le Secrétariat »). Le montant de cette taxe est déterminé par le Secrétariat et peut être modifié de temps à autre. Article 2 - Ces propositions sont soumises par le Secrétariat aux experts désignés à cette fin parmi les personnalités inscrites au Tableau d’experts de la Pharmacopée internationale et des Préparations pharmaceutiques, ci-après désignés sous l’appellation « le Groupe d’experts des DCI » ; elles sont examinées par les experts conformément aux « Directives générales pour la formation de dénominations communes internationales pour les substances pharmaceutiques » reproduites ci-après2.

La dénomination acceptée est la dénomination employée par la personne qui découvre ou qui, la première, fabrique et lance sur le marché une substance pharmaceutique, à moins que des raisons majeures n’obligent à s’écarter de cette règle. Article 3 - Après l’examen prévu à l’article 2, le Secrétariat notifie qu’un projet de dénomination commune internationale est à l’étude. a) Cette notification est faite par une insertion dans WHO Drug Information3 et par l’envoi d’une lettre aux Etats Membres et aux commissions nationales et régionales de pharmacopée ou autres organismes désignés par les Etats Membres.

i) Notification est également faite à la personne qui a soumis la proposition (« le demandeur initial ») et à d’autres personnes portant à la dénomination mise à l’étude un intérêt notoire.

b) Cette notification contient les indications suivantes :

i) dénomination mise à l’étude;

ii) nom de l’auteur de la proposition tendant à attribuer une dénomination à la substance, si cette personne le demande ;

iii) définition de la substance dont la dénomination est mise à l’étude ;

iv) délai pendant lequel seront reçues les observations et les objections à l’égard de cette dénomination ; nom et adresse de la personne habilitée à recevoir ces observations et objections ;

v) mention des pouvoirs en vertu desquels agit l’OMS et référence au présent règlement.

1 Voir annexe 1 dans OMS, Série de Rapports techniques, N° 581, 1975. Le texte original a été adopté par le Conseil exécutif dans sa résolution EB15.R7 et amendé dans ses résolutions EB43.R9 et EB115.R4.

2 Voir annexe 2. 3

Avant 1987, les listes de dénominations communes internationales étaient publiées dans la Chronique de l’Organisation mondiale de la Santé.

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

389

c) En envoyant cette notification, le Secrétariat demande aux Etats Membres de prendre les mesures nécessaires pour prévenir l’acquisition de droits de propriété sur la dénomination proposée pendant la période au cours de laquelle cette dénomination est mise à l’étude par l’OMS. Article 4 - Des observations sur la dénomination proposée peuvent être adressées à l’OMS par toute personne, dans les quatre mois qui suivent la date de publication de la dénomination dans WHO Drug Information (voir l’article 3). Article 5 - Toute personne intéressée peut formuler une objection formelle contre la dénomination proposée dans les quatre mois qui suivent la date de publication de la dénomination dans WHO Drug Information (voir l’article 3). Cette objection doit s’accompagner des indications suivantes :

i) nom de l’auteur de l’objection ; ii) intérêt qu’il ou elle porte à la dénomination en cause ; iii) raisons motivant l’objection contre la dénomination proposée. Article 6 - Lorsqu’une objection formelle est formulée en vertu de l’article 5, l’OMS peut soit soumettre la dénomination proposée à un nouvel examen, soit intervenir pour tenter d’obtenir le retrait de l’objection. Sans préjudice de l’examen par l’OMS d’une ou de plusieurs appellations de remplacement, l’OMS n’adopte pas d’appellation comme dénomination commune internationale recommandée tant qu’une objection formelle présentée conformément à l’article 5 n’est pas levée. Article 7 - Lorsqu’il n’est formulé aucune objection en vertu de l’article 5, ou que toutes les objections présentées ont été levées, le Secrétariat fait une notification conformément aux dispositions du paragraphe a) de l’article 3, en indiquant que la dénomination a été choisie par l’OMS en tant que dénomination commune internationale recommandée. Article 8 - En communiquant aux Etats Membres, conformément à l’article 7, une dénomination commune internationale recommandée, le Secrétariat : a) demande que cette dénomination soit reconnue comme dénomination commune de la substance considérée ; et b) demande aux Etats Membres de prendre les mesures nécessaires pour prévenir l’acquisition de droits de propriété sur cette dénomination et interdire le dépôt de cette dénomination comme marque ou appellation commerciale. Article 9 - a) Dans le cas exceptionnel où une dénomination commune internationale déjà recommandée donne lieu à des erreurs de médication, de prescription ou de distribution ou en comporte un risque démontrable, en raison d’une similitude avec une autre appellation dans la pratique pharmaceutique et/ou de prescription, et où il apparaît que ces erreurs ou ces risques d’erreur ne peuvent être facilement évités par d’autres interventions que le remplacement éventuel d’une dénomination commune internationale déjà recommandée, ou dans le cas où une dénomination commune internationale déjà recommandée diffère sensiblement de la dénomination commune approuvée dans un nombre important d’Etats Membres, ou dans d’autres circonstances exceptionnelles qui justifient le remplacement d’une dénomination commune internationale recommandée, toute personne intéressée peut formuler une proposition dans ce sens. Cette proposition est présentée sur la formule prévue à cet effet et doit s’accompagner des indications suivantes :

i) nom de l’auteur de la proposition ;

ii) intérêt qu’il ou elle porte au remplacement proposé ;

iii) raisons motivant la proposition ; et

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

390

iv) description, faits à l’appui, des autres interventions entreprises pour tenter de régler le problème et exposé des raisons pour lesquelles ces interventions ont échoué.

Les propositions peuvent comprendre une proposition de nouvelle dénomination commune internationale de remplacement, établie conformément aux Directives générales, compte tenu de la substance pharmaceutique pour laquelle la nouvelle dénomination commune internationale de remplacement est proposée. Le Secrétariat transmet une copie de la proposition pour examen, conformément à la procédure exposée plus loin au paragraphe b), au Groupe d’experts des DCI et au demandeur initial ou à son successeur (s’il s’agit d’une personne différente de celle qui a formulé la proposition de remplacement et pour autant que le demandeur initial ou son successeur soit connu ou puisse être retrouvé moyennant des efforts diligents, notamment des contacts avec les associations industrielles). De plus, le Secrétariat demande aux entités et personnes ci-après de formuler des observations sur la proposition :

i) les Etats Membres et les commissions nationales et régionales de pharmacopée ou d’autres organismes désignés par les Etats Membres (en insérant une note à cet effet dans la lettre mentionnée à l’article 3.a), et

ii) toutes autres personnes portant au remplacement proposé un intérêt notoire. La demande d’observations contient les indications suivantes :

i) dénomination commune internationale recommandée pour laquelle un remplacement est proposé (et la dénomination de remplacement proposée, si elle est fournie) ;

ii) nom de l’auteur de la proposition de remplacement (si cette personne le demande) ;

iii) définition de la substance faisant l’objet du remplacement proposé et raisons avancées pour le remplacement ;

iv) délai pendant lequel seront reçus les commentaires et nom et adresse de la personne habilitée à recevoir ces commentaires ; et

v) mention des pouvoirs en vertu desquels agit l’OMS et référence au présent règlement. Des observations sur la proposition de remplacement peuvent être communiquées par toute personne à l’OMS dans les quatre mois qui suivent la date de la demande d’observations. b) Une fois échu le délai prévu ci-dessus pour la communication d’observations, le Secrétariat transmet les observations reçues au Groupe d’experts des DCI, au demandeur initial ou à son successeur et à l’auteur de la proposition de remplacement. Si, après avoir examiné la proposition de remplacement et les observations reçues, le Groupe d’experts des DCI, l’auteur de la proposition de remplacement et le demandeur initial ou son successeur reconnaissent tous qu’il est nécessaire de remplacer la dénomination commune internationale déjà recommandée, le Secrétariat soumet la proposition de remplacement au Groupe d’experts des DCI pour qu’il y donne suite.

Nonobstant ce qui précède, le demandeur initial ou son successeur n’est pas habilité à refuser son accord à une proposition de remplacement au cas où il ne peut être démontré qu’il porte un intérêt durable à la dénomination commune internationale recommandée qu’il est proposé de remplacer.

Dans le cas où une proposition de remplacement est soumise au Groupe d’experts des DCI pour

qu’il y donne suite, le Groupe choisit une nouvelle dénomination commune internationale conformément aux Directives générales mentionnées à l’article 2 et selon la procédure décrite dans les articles 3 à 8 inclus. La notification faite par le Secrétariat en vertu de l’article 3 et de l’article 7, respectivement, y compris au demandeur initial ou à son successeur (si ce n’est pas la même personne que celle qui a

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

391

proposé le remplacement et pour autant que le demandeur initial ou son successeur soit connu ou puisse être retrouvé moyennant des efforts diligents, notamment des contacts avec les associations industrielles), doit dans un tel cas indiquer que la nouvelle dénomination remplace une dénomination commune internationale déjà recommandée et que les Etats Membres peuvent souhaiter prendre des mesures transitoires pour les produits existants qui utilisent la dénomination commune internationale déjà recommandée sur leur étiquette conformément à la législation nationale.

Si, après examen de la proposition de remplacement et des observations communiquées

conformément à la procédure exposée plus haut, le Groupe d’experts des DCI, le demandeur initial ou son successeur et l’auteur de la proposition de remplacement ne s’accordent pas sur le fait qu’il y a des raisons impératives de remplacer une dénomination commune internationale déjà recommandée, cette dernière est conservée (étant entendu toujours que le demandeur initial ou son successeur n’est pas habilité à refuser son accord à une proposition de remplacement au cas où il ne peut être démontré qu’il porte un intérêt durable à la dénomination commune internationale recommandée qu’il est proposé de remplacer). Dans un tel cas, le Secrétariat informe l’auteur de la proposition de remplacement, ainsi que le demandeur initial ou son successeur (s’il s’agit d’une personne différente de celle qui a formulé la proposition de remplacement et pour autant que le demandeur initial ou son successeur soit connu ou puisse être retrouvé moyennant des efforts diligents, notamment des contacts avec les associations industrielles), les Etats Membres, les commissions nationales et régionales de pharmacopée, les autres organismes désignés par les Etats Membres et toutes autres personnes portant un intérêt notoire au remplacement proposé que, malgré une proposition de remplacement, il a été décidé de conserver la dénomination commune internationale déjà recommandée (avec une brève description de la ou des raisons pour lesquelles la proposition de remplacement n’a pas été jugée suffisamment impérative).

ANNEXE 2

DIRECTIVES GENERALES POUR LA FORMATION DE DENOMINATIONS COMMUNES INTERNATIONALES APPLICABLES AUX SUBSTANCES

PHARMACEUTIQUES1 1. Les dénominations communes internationales (DCI) devront se distinguer les unes des autres par leur consonance et leur orthographe. Elles ne devront pas être d’une longueur excessive, ni prêter à confusion avec des appellations déjà couramment employées. 2. La DCI de chaque substance devra, si possible, indiquer sa parenté pharmacologique. Les dénominations susceptibles d’évoquer pour les malades des considérations anatomiques, physiologiques, pathologiques ou thérapeutiques devront être évitées dans la mesure du possible. Outre ces deux principes fondamentaux, on respectera les principes secondaires suivants : 3. Lorsqu’on formera la DCI de la première substance d’un nouveau groupe pharmacologique, on tiendra compte de la possibilité de former ultérieurement d’autres DCI appropriées pour les substances apparentées du même groupe. 4. Pour former des DCI des acides, on utilisera de préférence un seul mot. Leurs sels devront être désignés par un terme qui ne modifie pas le nom de l’acide d’origine : par exemple «oxacilline» et «oxacilline sodique», «ibufénac» et «ibufénac sodique». 5. Les DCI pour les substances utilisées sous forme de sels devront en général s’appliquer à la base active (ou à l’acide actif). Les dénominations pour différents sels ou esters d’une même substance active ne différeront que par le nom de l’acide inactif (ou de la base inactive). 1

Dans son vingtième rapport (OMS, Série de Rapports techniques, N° 581, 1975), le Comité OMS d’experts des Dénominations communes pour les Substances pharmaceutiques a examiné les directives générales pour la formation des dénominations communes internationales et la procédure à suivre en vue de leur choix, compte tenu de l’évolution du secteur pharmaceutique au cours des dernières années. La modification la plus importante a été l’extension aux substances de synthèse de la pratique normalement suivie pour désigner les substances tirées ou dérivées de produits naturels. Cette pratique consiste à employer des syllabes communes ou groupes de syllabes communes (segments-clés) qui sont caractéristiques et indiquent une propriété commune aux membres du groupe des substances pour lequel ces segments-clés ont été retenus. Les raisons et les conséquences de cette modification ont fait l’objet de discussions approfondies. Les directives ont été mises à jour lors de la treizième consultation sur les dénominations communes pour les substances pharmaceutiques (Genève, 27-29 avril 1983) (PHARM S/NOM 928, 13 mai 1983, révision en date du 18 août 1983).

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

392

En ce qui concerne les substances à base d’ammonium quaternaire, la dénomination s’appliquera de façon appropriée au cation et à l’anion en tant qu’éléments distincts d’une substance quaternaire. On évitera de choisir une désignation évoquant un sel aminé.

6. On évitera d’ajouter une lettre ou un chiffre isolé ; en outre, on renoncera de préférence au trait d’union.

7. Pour simplifier la traduction et la prononciation des DCI, la lettre « f » sera utilisée à la place de « ph », « t » à la place de « th », « e » à la place de « ae » ou « oe », et « i » à la place de « y » ; l’usage des lettres « h » et « k » sera aussi évité.

8. On retiendra de préférence, pour autant qu’elles respectent les principes énoncés ici, les dénominations proposées par les personnes qui ont découvert ou qui, les premières, ont fabriqué et lancé sur le marché les préparations pharmaceutiques considérées, ou les dénominations déjà officiellement adoptées par un pays.

9. La parenté entre substances d’un même groupe (voir Directive générale 2) sera si possible indiquée dans les DCI par l’emploi de segments-clés communs. La liste ci-après contient des exemples de segments-clés pour des groupes de substances, surtout pour des groupes récents. Il y a beaucoup d’autres segments-clés en utilisation active. 1 Les segments-clés indiqués sans trait d’union pourront être insérés n’importe où dans une dénomination.

Latin Français

-acum -ac substances anti-inflammatoires du groupe de l’ibufénac -adolum -adol } analgésiques -adol- -adol- }

-astum -ast antiasthmatiques, antiallergiques n’agissant pas principalement en tant qu’antihistaminiques -astinum -astine antihistaminiques -azepamum -azépam substances du groupe du diazépam bol bol stéroïdes anabolisants -cain- -caïn- antiarythmiques de classe I, dérivés du procaïnamide et de la lidocaïne -cainum -caïne anesthésiques locaux cef- céf- antibiotiques, dérivés de l’acide céphalosporanique -cillinum -cilline antibiotiques, dérivés de l’acide 6-aminopénicillanique -conazolum -conazole agents antifongiques systémiques du groupe du miconazole cort cort corticostéroïdes, autres que les dérivés de la prednisolone -coxibum -coxib inhibiteurs sélectifs de la cyclo-oxygénase -entanum -entan antagonistes du récepteur de l’endothéline gab gab gabamimétiques gado- gado- agents diagnostiques, dérivés du gadolinium -gatranum -gatran antithrombines, antithrombotiques gest gest stéroïdes progestogènes gli gli antihyperglycémiants io- io- produits de contraste iodés -metacinum -métacine substances anti-inflammatoires du groupe de l’indométacine -mycinum -mycine antibiotiques produits par des souches de Streptomyces -nidazolum -nidazole substances antiprotozoaires du groupe du métronidazole -ololum -olol antagonistes des récepteurs β-adrénergiques -oxacinum -oxacine substances antibactériennes du groupe de l’acide nalidixique -platinum -platine antinéoplasiques, dérivés du platine -poetinum -poétine facteurs sanguins de type érythropoïétine -pril(at)um -pril(ate) inhibiteurs de l’enzyme de conversion de l’angiotensine -profenum -profène substances anti-inflammatoires du groupe de l’ibuprofène prost prost prostaglandines

1 Une liste plus complète de segments-clés est contenue dans le document de travail WHO/EMP/RHT/TSN/2013.1 qui est régulièrement mis

à jour et qui peut être demandé auprès du programme des DCI, OMS, Genève.

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

393

-relinum -réline peptides stimulant la libération d’hormones hypophysaires -sartanum -sartan antagonistes d’un récepteur de l’angiotensine II, antihypertenseurs (non peptidiques) -vaptanum -vaptan antagonistes du récepteur de la vasopressine vin- vin- } alcaloïdes du type vinca -vin- -vin- }

ANEXO 1

PROCEDIMIENTO DE SELECCIÓN DE DENOMINACIONES COMUNES INTERNACIONALES RECOMENDADAS PARA SUSTANCIAS FARMACÉUTICAS1

La Organización Mundial de la Salud (OMS) seguirá el procedimiento que se expone a continuación tanto para seleccionar denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas, de conformidad con lo dispuesto en la resolución WHA3.11, como para sustituir esas denominaciones. Artículo 1 - Las propuestas de denominaciones comunes internacionales recomendadas y las propuestas de sustitución de esas denominaciones se presentarán a la OMS en los formularios que se proporcionen a estos efectos. El estudio de estas propuestas estará sujeto al pago de una tasa destinada a sufragar los costos de administración que ello suponga para la Secretaría de la OMS («la Secretaría»). La Secretaría establecerá la cuantía de esa tasa y podrá ajustarla periódicamente. Artículo 2 - Estas propuestas serán sometidas por la Secretaría a los miembros del Cuadro de Expertos en Farmacopea Internacional y Preparaciones Farmacéuticas encargados de su estudio, en adelante de-signados como «el Grupo de Expertos en DCI», para que las examinen de conformidad con los «Principios generales de orientación para formar denominaciones comunes internacionales para sus-tancias farmacéuticas», anexos a este procedimiento.2 A menos que haya poderosas razones en contra, la denominación aceptada será la empleada por la persona que haya descubierto o fabricado y comer-cializado por primera vez esa sustancia farmacéutica. Artículo 3 - Tras el examen al que se refiere el artículo 2, la Secretaría notificará que está en estudio un proyecto de denominación internacional. a) Esa notificación se hará mediante una publicación en Información Farmacéutica OMS3

y el envío de una carta a los Estados Miembros y a las comisiones nacionales y regionales de las farmacopeas u otros organismos designados por los Estados Miembros.

i) La notificación será enviada también a la persona que haya presentado la propuesta («el solicitante inicial») y a otras personas que tengan un interés especial en una denominación objeto de estudio.

b) En esa notificación se incluirán los siguientes datos: i) la denominación sometida a estudio; ii) la identidad de la persona que ha presentado la propuesta de denominación de la sustancia, si lo pide esa persona; iii) la identidad de la sustancia cuya denominación está en estudio;

1 Véase el anexo 1 en OMS, Serie de Informes Técnicos, Nº 581, 1975. El texto vigente fue adoptado por el Consejo Ejecutivo en su resolución EB15.R7 y modificado en las resoluciónes EB43.R9 y EB115.R4..

2 Véase el anexo 2.

3 Hasta 1987 las listas de DCI se publicaban en la Crónica de la Organización Mundial de la Salud.

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

394

iv) el plazo fijado para recibir observaciones y objeciones, así como el nombre y la dirección de la persona a quien deban dirigirse; y v) los poderes conferidos para el caso a la OMS y una referencia al presente procedimiento.

c) Al enviar esa notificación, la Secretaría solicitará de los Estados Miembros la adopción de todas las medidas necesarias para impedir la adquisición de derechos de patente sobre la denominación propuesta, durante el periodo en que la OMS la tenga en estudio. Artículo 4 - Toda persona puede formular a la OMS observaciones sobre la denominación propuesta dentro de los cuatro meses siguientes a su publicación en Información Farmacéutica OMS, conforme a lo dispuesto en el artículo 3. Artículo 5 - Toda persona interesada puede presentar una objeción formal a una denominación propuesta dentro de los cuatro meses siguientes a su publicación en Información Farmacéutica OMS, conforme a lo dispuesto en el artículo 3. Esa objeción deberá acompañarse de los siguientes datos:

i) la identidad de la persona que formula la objeción; ii) las causas que motivan su interés por la denominación; y iii) las causas que motivan su objeción a la denominación propuesta.

Artículo 6 - Cuando se haya presentado una objeción formal en la forma prevista en el artículo 5, la OMS podrá reconsiderar el nombre propuesto o utilizar sus buenos oficios para intentar lograr que se retire la objeción. La OMS no seleccionará como denominación común internacional una denominación a la que se haya hecho una objeción formal, presentada según lo previsto en el artículo 5, que no haya sido retirada, todo ello sin perjuicio de que la Organización examine otra denominación o denominaciones sustitutivas. Artículo 7 - Cuando no se haya formulado ninguna objeción en la forma prevista en el artículo 5, o cuando todas las objeciones presentadas hayan sido retiradas, la Secretaría notificará, conforme a lo dispuesto en el párrafo a) del artículo 3, que la denominación ha sido seleccionada por la OMS como denominación común internacional recomendada. Artículo 8 - Al comunicar a los Estados Miembros una denominación común internacional, conforme a lo previsto en el artículo 7, la Secretaría: a) solicitará que esta denominación sea reconocida como denominación común para la sustancia de que se trate; y b) solicitará a los Estados Miembros que adopten todas las medidas necesarias para impedir la adquisición de derechos de patente sobre la denominación, y prohíban que sea registrada como marca de fábrica o como nombre comercial. Artículo 9 a) En el caso excepcional de que, debido a su semejanza con otra denominación utilizada en las prácticas farmacéuticas y/o de prescripción, una denominación común internacional recomendada anteriormente ocasione errores de medicación, prescripción o distribución, o suponga un riesgo manifiesto de que esto ocurra, y parezca que tales errores o potenciales errores no sean fácilmente subsanables con otras medidas que no sean la posible sustitución de esa denominación común internacional recomendada anteriormente; en el caso de que una denominación común internacional recomendada anteriormente difiera considerablemente de la denominación común aprobada en un número importante de Estados Miembros, o en otras circunstancias excepcionales que justifiquen el cambio de una denominación común internacional recomendada, cualquier persona interesada puede presentar propuestas en este sentido. Esas propuestas se presentarán en los formularios que se proporcionen a estos efectos e incluirán los siguientes datos:

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

395

i) la identidad de la persona que presenta la propuesta; ii) las causas que motivan su interés en la sustitución propuesta;

iii) las causas que motivan la propuesta; y

iv) una descripción, acompañada de pruebas documentales, de las otras medidas que se hayan adoptado con el fin de resolver la situación y de los motivos por los cuales dichas medidas no han sido suficientes.

Entre esas propuestas podrá figurar una relativa a una nueva denominación común

internacional sustitutiva, formulada con arreglo a los Principios generales y que tenga en cuenta la sustancia farmacéutica para la que se proponga la nueva denominación común internacional sustitutiva.

La Secretaría enviará al Grupo de Expertos en DCI y al solicitante inicial o a su sucesor (en el caso de que sea una persona diferente de la que ha presentado la propuesta de sustitución y siempre que el solicitante inicial o su sucesor sean conocidos o puedan ser encontrados mediante esfuerzos diligentes, como el contacto con las asociaciones industriales) una copia de la propuesta, para que sea examinada de conformidad con el procedimiento descrito en el párrafo b) infra. Además, la Secretaría solicitará observaciones sobre la propuesta:

i) a los Estados Miembros y a las comisiones nacionales y regionales de las farmacopeas u otros organismos designados por los Estados Miembros (ello se hará incluyendo una notificación a tal efecto en la carta a la que se refiere el párrafo a) del artículo 3), y

ii) a cualquier persona que tenga un interés especial en la sustitución propuesta.

Al solicitar que se formulen estas observaciones se facilitarán los siguientes datos: i) la denominación común internacional recomendada que se propone sustituir (y la denominación sustitutiva propuesta, si se ha facilitado);

ii) la identidad de la persona que ha presentado la propuesta de sustitución (si lo pide esa persona); iii) la identidad de la sustancia a la que se refiere la sustitución propuesta y las razones para presentar la propuesta de sustitución; iv) el plazo fijado para recibir observaciones, así como el nombre y la dirección de la persona a quien deban dirigirse; y

v) los poderes conferidos para el caso a la OMS y una referencia al presente procedimiento.

Toda persona puede formular a la OMS observaciones sobre la sustitución propuesta dentro de los cuatro meses siguientes a la fecha en que se realizó la solicitud de observaciones. b) Una vez agotado el mencionado plazo para la formulación de observaciones, la Secretaría enviará todos los comentarios recibidos al Grupo de Expertos en DCI, al solicitante inicial o a su sucesor, y a la persona que haya presentado la propuesta de sustitución. Si después de examinar la propuesta de sustitución y las observaciones recibidas, el Grupo de Expertos en DCI, la persona que haya presentado la propuesta de sustitución y el solicitante inicial, o su sucesor, están de acuerdo en la necesidad de sustituir la denominación común internacional recomendada anteriormente, la Secretaría remitirá la propuesta de sustitución al Grupo de Expertos en DCI para que la tramite. No obstante lo anterior, el solicitante inicial o su sucesor no tendrán derecho a impedir el acuerdo sobre una propuesta de sustitución en el caso de que hayan dejado de tener un interés demostrable en la denominación común internacional cuya sustitución se propone.

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

396

En caso de que la propuesta de sustitución sea presentada al Grupo de Expertos en DCI para que la tramite, este grupo seleccionará una nueva denominación común internacional de conformidad con los Principios generales a los que se refiere el artículo 2 y al procedimiento establecido en los artículos 3 a 8 inclusive. En ese caso, en las notificaciones que la Secretaría ha de enviar con arreglo a los artículos 3 y 7, respectivamente, incluida la notificación al solicitante inicial o a su sucesor (en el caso de que no sea la misma persona que propuso la sustitución y siempre que el solicitante inicial o su sucesor sean conocidos o puedan ser encontrados mediante esfuerzos diligentes, como el contacto con las asociaciones industriales), se indicará que la nueva denominación sustituye a una denominación común internacional recomendada anteriormente y que los Estados Miembros podrán, si lo estiman oportuno, adoptar disposiciones transitorias aplicables a los productos existentes en cuya etiqueta se utilice, con arreglo a la legislación nacional, la denominación común internacional recomendada anteriormente que se haya sustituido.

En caso de que, después de haber estudiado la propuesta de sustitución y los comentarios recibidos de conformidad con el procedimiento descrito anteriormente, el Grupo de Expertos en DCI, el solicitante inicial o su sucesor y la persona que haya presentado la propuesta de sustitución no lleguen a un acuerdo sobre la existencia de razones poderosas para sustituir una denominación común internacional recomendada anteriormente, esta denominación se mantendrá (siempre en el entendimiento de que el solicitante inicial o su sucesor no tendrán derecho a impedir el acuerdo sobre una propuesta de sustitución en el caso de que hayan dejado de tener un interés demostrable en la denominación común internacional cuya sustitución se propone). En ese caso, la Secretaría comunicará a la persona que haya propuesto la sustitución, así como al solicitante inicial o a su sucesor (en el caso de que no sea la misma persona que propuso la sustitución y siempre que el solicitante inicial o su sucesor sean conocidos o puedan ser encontrados mediante esfuerzos diligentes, como el contacto con las asociaciones industriales), a los Estados Miembros, a las comisiones nacionales y regionales de las farmacopeas o a otros organismos designados por los Estados Miembros y a cualquier otra persona que tenga interés en la sustitución propuesta, que, pese a la presentación de una propuesta de sustitución, se ha decidido mantener la denominación común internacional recomendada anteriormente (con una descripción de la o las razones por las que se ha considerado que la propuesta de sustitución no estaba respaldada por razones suficientemente poderosas).

ANEXO 2

PRINCIPIOS GENERALES DE ORIENTACIÓN PARA FORMAR DENOMINACIONES COMUNES INTERNACIONALES PARA SUSTANCIAS FARMACÉUTICAS1

1. Las denominaciones comunes internacionales (DCI) deberán diferenciarse tanto fonética como ortográficamente. No deberán ser incómodamente largas, ni dar lugar a confusión con denominaciones de uso común.

2. La DCI de una sustancia que pertenezca a un grupo de sustancias farmacológicamente emparentadas deberá mostrar apropiadamente este parentesco. Deberán evitarse las denominaciones que puedan tener connotaciones anatómicas, fisiológicas, patológicas o terapéuticas para el paciente.

Estos principios primarios se pondrán en práctica utilizando los siguientes principios secundarios:

3. Al idear la DCI de la primera sustancia de un nuevo grupo farmacológico, deberá tenerse en cuenta la posibilidad de poder formar DCI convenientes para las sustancias emparentadas que se agreguen al nuevo grupo.

4. Al idear DCI para ácidos, se preferirán las de una sola palabra; sus sales deberán denominarse sin modificar el nombre del ácido: p. ej. «oxacilina» y «oxacilina sódica», «ibufenaco» y «ibufenaco sódico». 1 En su 20º informe (OMS, Serie de Informes Técnicos, Nº 581, 1975), el Comité de Expertos de la OMS en Denominaciones Comunes para las Sustancias Farmacéuticas revisó los Principios generales para formar denominaciones comunes internacionales (DCI), y su procedimiento de selección, a la luz de las novedades registradas en los últimos años en materia de compuestos farmacéuticos. El cambio más importante había consistido en hacer extensivo a la denominación de sustancias químicas sintéticas el método utilizado hasta entonces para las sustancias originadas en productos naturales o derivadas de éstos. Dicho método conlleva la utilización de una «partícula» característica que indica una propiedad común a los miembros de un grupo. En el citado informe se examinan en detalle las razones y consecuencias de este cambio. Los Principios generales de orientación se actualizaron durante la 13ª consulta sobre denominaciones comunes para sustancias farmacéuticas (Ginebra, 27 a 29 de abril de 1983) (PHARM S/NOM 928, 13 de mayo de 1983, revisado el 18 de agosto de 1983).

WHO Drug Information, Vol. 32, No. 2, 2018 Proposed INN: List 119

397

5. Las DCI para las sustancias que se usan en forma de sal deberán en general aplicarse a la base activa o al ácido activo. Las denominaciones para diferentes sales o esteres de la misma sustancia activa solamente deberán diferir en el nombre del ácido o de la base inactivos. En los compuestos de amonio cuaternario, el catión y el anión deberán denominarse adecuadamente por separado, como componentes independientes de una sustancia cuaternaria y no como sales de una amina.

6. Deberá evitarse el empleo de letras o números aislados; también es indeseable el empleo de guiones. 7. Para facilitar la traducción y la pronunciación, se emplearán de preferencia las letras «f» en lugar de «ph», «t» en lugar de «th», «e» en lugar de «ae» u «oe», e «i» en lugar de «y»; se deberá evitar el empleo de las letras «h» y «k». 8. Siempre que las denominaciones propuestas estén de acuerdo con estos principios, recibirán una consideración preferente las denominaciones propuestas por la persona que haya descubierto las sus-tancias, o que fabrique y comercialice por primera vez una sustancia farmacéutica, así como las deno-minaciones ya adoptadas oficialmente en cualquier país. 9. El parentesco entre sustancias del mismo grupo se pondrá de manifiesto en las DCI (véase el Principio 2) utilizando una partícula común. En la lista que figura a continuación se indican ejemplos de partículas para grupos de sustancias, en particular para grupos nuevos. Existen muchas otras partículas que se usan habitualmente.1 Cuando una partícula aparece sin guión alguno, puede utilizarse en cualquier lugar de la palabra. Latin Español -acum -aco antiinflamatorios derivados del ibufenaco -adolum -adol ) analgésicos -adol- -adol- ) -astum -ast antiasmáticos, sustancias antialérgicas cuya acción principal no es la antihistamínica -astinum -astina antihistamínicos -azepamum -azepam derivados del diazepam bol bol esteroides anabolizantes -cain- -caína- antiarrítmicos de clase I, derivados de procainamida y lidocaína -cainum -caína- anestésicos locales cef- cef- antibióticos, derivados del ácido cefalosporánico -cillinum - cilina antibióticos derivados del ácido 6-aminopenicilánico -conazolum -conazol antifúngicos sistémicos derivados del miconazol cort cort corticosteroides, excepto derivados de prednisolona -coxibum -coxib inhibidores selectivos de ciclooxigenasa -entanum -entán antagonistas del receptor de endotelina gab gab gabamiméticos gado- gado- agentes para diagnóstico derivados de gadolinio -gartranum -gatrán inhibidores de la trombina antitrombóticos gest gest esteroides progestágenos gli gli hipoglucemiantes, antihiperglucémicos io- io- medios de contraste iodados -metacinum -metacina antiinflamatorios derivados de indometacina -mycinum -micina antibióticos producidos por cepas de Streptomyces -nidazolum -nidazol antiprotozoarios derivados de metronidazol -ololum -olol antagonistas de receptores -adrenérgicos -oxacinum -oxacino antibacterianos derivados del ácido nalidíxico -platinum -platino antineoplásicos derivados del platino 1 En el documento de trabajo WHO/EMP/RHT/TSN/2013.1, que se actualiza periódicamente y puede solicitarse al Programa sobre Denominaciones Comunes Internacionales, OMS, Ginebra, figura una lista más amplia de partículas.

Proposed INN: List 119 WHO Drug Information, Vol. 32, No. 2, 2018

398

-poetinum -poetina factores sanguíneos similares a la eritropoyetina -pril(at)um -pril(at) inhibidores de la enzima conversora de la angiotensina -profenum -profeno antiinflamatorios derivados del ibuprofeno prost prost prostaglandinas -relinum -relina péptidos estimulantes de la liberación de hormonas hipofisarias -sartanum -sartán antihipertensivos (no peptídicos) antagonistas del receptor de angiotensina II -vaptanum -vaptán antagonistas del receptor de vasopresina vin- vin- ) alcaloides de la vinca -vin- -vin- )